[
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00001"
      },
      "BIOD00024",
      "BTD00024"
    ],
    "name": "Lepirudin",
    "description": "Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.",
    "cas-number": "120993-53-5",
    "groups": {
      "group": "approved"
    },
    "general-references": "# Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16244762\r\n# Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16690967\r\n# Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16241940\r\n# Askari AT, Lincoff AM: Antithrombotic Drug Therapy in Cardiovascular Disease. 2009 Oct; pp. 440–. ISBN 9781603272346. \"Google books\":http://books.google.com/books?id=iadLoXoQkWEC&pg=PA440. ",
    "synthesis-reference": "",
    "indication": "For the treatment of heparin-induced thrombocytopenia",
    "pharmacodynamics": "Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.",
    "mechanism-of-action": "Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. ",
    "toxicity": "In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.",
    "metabolism": "Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.",
    "absorption": "Bioavailability is 100% following injection.",
    "half-life": "Approximately 1.3 hours",
    "protein-binding": "",
    "route-of-elimination": "Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.",
    "volume-of-distribution": "* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]\r\n* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]\r\n* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]\r\n* 32.1 L [HIT patients (n = 73)]",
    "clearance": "* 164 ml/min [Healthy 18-60 yrs]\r\n* 139 ml/min [Healthy 65-80 yrs]\r\n* 61 ml/min [renal impaired]\r\n* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Hirudin variant-1"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Lepirudin recombinant"
        }
      ]
    },
    "products": {
      "product": {
        "name": "Refludan",
        "ndc-id": "",
        "ndc-product-code": "",
        "dpd-id": "02240996",
        "started-marketing-on": "2000-01-31",
        "ended-marketing-on": "2013-07-26",
        "dosage-form": "powder for solution",
        "strength": "50 mg",
        "route": "intravenous",
        "fda-application-number": "",
        "generic": "false",
        "over-the-counter": "false",
        "approved": "true",
        "country": "Canada",
        "source": "DPD"
      }
    },
    "international-brands": "",
    "mixtures": {
      "mixture": {
        "name": "Refludan",
        "ingredients": "Lepirudin"
      }
    },
    "packagers": {
      "packager": [
        {
          "name": "Bayer Healthcare",
          "url": "http://www.bayerhealthcare.com"
        },
        {
          "name": "Berlex Labs",
          "url": "http://www.berlex.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Bayer healthcare pharmaceuticals inc"
      }
    },
    "prices": {
      "price": {
        "description": "Refludan 50 mg vial",
        "cost": {
          "_currency": "USD",
          "__text": "273.19"
        },
        "unit": "vial"
      }
    },
    "categories": {
      "category": [
        {
          "category": "Antithrombins",
          "mesh-id": "[\"D27.505.519.389.745.800.449\", \"D27.505.954.502.119.500\"]"
        },
        {
          "category": "Fibrinolytic Agents",
          "mesh-id": "[\"D27.505.519.421.750\", \"D27.505.954.411.320\", \"D27.505.954.502.427\"]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": {
        "form": "Powder for solution",
        "route": "intravenous",
        "strength": "50 mg"
      }
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "B",
            "__text": "BLOOD AND BLOOD FORMING ORGANS"
          },
          {
            "_code": "B01",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01A",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01AE",
            "__text": "Direct thrombin inhibitors"
          }
        ],
        "_code": "B01AE02"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "20:12.04.12"
    },
    "patents": {
      "patent": [
        {
          "number": "1339104",
          "country": "Canada",
          "approved": "1997-07-29",
          "expires": "2014-07-29"
        },
        {
          "number": "5180668",
          "country": "United States",
          "approved": "1993-01-19",
          "expires": "2010-01-19"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00001 sequence\nLVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\nEEYLQ"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "65 °C",
          "source": "Otto, A. & Seckler, R. Eur. J. Biochem. 202:67-73 (1991)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.777",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "4.04",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "6963.425",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C287H440N80O110S6",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "11916"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D06880"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA450195"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01050"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Lepirudin"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/lepirudin.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/lepirudin.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000048",
        "name": "Prothrombin",
        "organism": "Human",
        "actions": {
          "action": "inhibitor"
        },
        "references": "# Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10505536\r\n# Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10912644\r\n# Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11055889\r\n# Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11467439\r\n# Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11807012\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Prothrombin",
          "general-function": "Thrombospondin receptor activity",
          "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.",
          "gene-name": "F2",
          "locus": "11p11-q12",
          "cellular-location": "Secreted",
          "transmembrane-regions": "",
          "signal-regions": "1-24",
          "theoretical-pi": "5.7",
          "molecular-weight": "70036.295",
          "chromosome-location": "11",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:3535"
              },
              {
                "resource": "GenAtlas",
                "identifier": "F2"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "M17262"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "339641"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "2362"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P00734"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "THRB_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "3.4.21.5",
              "Coagulation factor II"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00594",
                "name": "Gla"
              },
              {
                "identifier": "PF00051",
                "name": "Kringle"
              },
              {
                "identifier": "PF00089",
                "name": "Trypsin"
              },
              {
                "identifier": "PF09396",
                "name": "Thrombin_light"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "endoplasmic reticulum lumen"
              },
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "extracellular space"
              },
              {
                "category": "component",
                "description": "blood microparticle"
              },
              {
                "category": "component",
                "description": "extracellular matrix"
              },
              {
                "category": "component",
                "description": "Golgi lumen"
              },
              {
                "category": "component",
                "description": "cytosol"
              },
              {
                "category": "component",
                "description": "extracellular exosome"
              },
              {
                "category": "component",
                "description": "extracellular region"
              },
              {
                "category": "function",
                "description": "growth factor activity"
              },
              {
                "category": "function",
                "description": "receptor binding"
              },
              {
                "category": "function",
                "description": "thrombospondin receptor activity"
              },
              {
                "category": "function",
                "description": "calcium ion binding"
              },
              {
                "category": "function",
                "description": "serine-type endopeptidase activity"
              },
              {
                "category": "process",
                "description": "cytosolic calcium ion homeostasis"
              },
              {
                "category": "process",
                "description": "positive regulation of phosphatidylinositol 3-kinase signaling"
              },
              {
                "category": "process",
                "description": "cellular response to mechanical stimulus"
              },
              {
                "category": "process",
                "description": "fibrinolysis"
              },
              {
                "category": "process",
                "description": "positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "leukocyte migration"
              },
              {
                "category": "process",
                "description": "multicellular organismal development"
              },
              {
                "category": "process",
                "description": "positive regulation of reactive oxygen species metabolic process"
              },
              {
                "category": "process",
                "description": "cellular protein metabolic process"
              },
              {
                "category": "process",
                "description": "negative regulation of astrocyte differentiation"
              },
              {
                "category": "process",
                "description": "peptidyl-glutamic acid carboxylation"
              },
              {
                "category": "process",
                "description": "positive regulation of release of sequestered calcium ion into cytosol"
              },
              {
                "category": "process",
                "description": "post-translational protein modification"
              },
              {
                "category": "process",
                "description": "negative regulation of fibrinolysis"
              },
              {
                "category": "process",
                "description": "regulation of blood coagulation"
              },
              {
                "category": "process",
                "description": "negative regulation of platelet activation"
              },
              {
                "category": "process",
                "description": "regulation of cell shape"
              },
              {
                "category": "process",
                "description": "regulation of gene expression"
              },
              {
                "category": "process",
                "description": "blood coagulation"
              },
              {
                "category": "process",
                "description": "negative regulation of proteolysis"
              },
              {
                "category": "process",
                "description": "platelet activation"
              },
              {
                "category": "process",
                "description": "response to inactivity"
              },
              {
                "category": "process",
                "description": "positive regulation of blood coagulation"
              },
              {
                "category": "process",
                "description": "response to wounding"
              },
              {
                "category": "process",
                "description": "acute-phase response"
              },
              {
                "category": "process",
                "description": "positive regulation of cell growth"
              },
              {
                "category": "process",
                "description": "blood coagulation, intrinsic pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of cell proliferation"
              },
              {
                "category": "process",
                "description": "proteolysis"
              },
              {
                "category": "process",
                "description": "positive regulation of protein phosphorylation"
              },
              {
                "category": "process",
                "description": "cell surface receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of collagen biosynthetic process"
              }
            ]
          },
          "_id": "P00734",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-11-27"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00002"
      },
      "BIOD00071",
      "BTD00071"
    ],
    "name": "Cetuximab",
    "description": "Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.",
    "cas-number": "205923-56-4",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.",
    "pharmacodynamics": "Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.",
    "mechanism-of-action": "Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.",
    "toxicity": "Single doses of cetuximab higher than 500 mg/m<sup>2</sup> have not been tested. There is no experience with overdosage in human clinical trials.\r\n\r\n",
    "metabolism": "",
    "absorption": "",
    "half-life": "114 hrs",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Anti EGFR"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "IMC-C225"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Erbitux",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02271249",
          "started-marketing-on": "2008-10-28",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "2 mg",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Erbitux",
          "ndc-id": "",
          "ndc-product-code": "66733-948",
          "dpd-id": "",
          "started-marketing-on": "2004-02-12",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "2 mg/mL",
          "route": "intravenous",
          "fda-application-number": "BLA125084",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Erbitux",
          "ndc-id": "",
          "ndc-product-code": "66733-958",
          "dpd-id": "",
          "started-marketing-on": "2007-10-02",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "2 mg/mL",
          "route": "intravenous",
          "fda-application-number": "BLA125084",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Erbitux",
          "ingredients": "Cetuximab"
        },
        {
          "name": "Erbitux",
          "ingredients": "Cetuximab"
        },
        {
          "name": "Erbitux",
          "ingredients": "Cetuximab"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Cardinal Health",
          "url": "http://www.cardinal.com"
        },
        {
          "name": "Catalent Pharma Solutions",
          "url": "http://www.catalent.com"
        },
        {
          "name": "ImClone Systems Inc.",
          "url": "http://www.imclone.com"
        },
        {
          "name": "Oso Biopharmaceuticals Manufacturing LLC",
          "url": ""
        }
      ]
    },
    "manufacturers": "",
    "prices": "",
    "categories": {
      "category": {
        "category": "Antineoplastic Agents",
        "mesh-id": "[\"D27.505.954.248\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Solution",
          "route": "intravenous",
          "strength": "2 mg/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous",
          "strength": "2 mg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L01",
            "__text": "ANTINEOPLASTIC AGENTS"
          },
          {
            "_code": "L01X",
            "__text": "OTHER ANTINEOPLASTIC AGENTS"
          },
          {
            "_code": "L01XC",
            "__text": "Monoclonal antibodies"
          }
        ],
        "_code": "L01XC06"
      }
    },
    "ahfs-codes": "",
    "patents": {
      "patent": {
        "number": "1340417",
        "country": "Canada",
        "approved": "1999-03-02",
        "expires": "2016-03-02"
      }
    },
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": [
        {
          "_format": "FASTA",
          "__text": ">Cetuximab heavy chain\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\nTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA\nSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG\nLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP\nSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS\nTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL\nTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ\nQGNVFSCSVMHEALHNHYTQKSLSLSPGK"
        },
        {
          "_format": "FASTA",
          "__text": ">Cetuximab light chain\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\nRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"
        }
      ]
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "61 °C (FAB fragment), 71 °C (whole mAb)",
          "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.413",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "8.48",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "145781.6",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C6484H10042N1732O2023S36",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "13175"
        },
        {
          "resource": "GenBank",
          "identifier": "J00228"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA10040"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Cetuximab"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic3/erbitux.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/cetuximab.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": {
      "effect": [
        {
          "protein-name": "Low affinity immunoglobulin gamma Fc region receptor II-a",
          "gene-symbol": "FCGR2A",
          "uniprot-id": "P12318",
          "rs-id": "rs1801274",
          "allele": "",
          "defining-change": "H allelle",
          "description": "Increased progression free survival",
          "pubmed-id": "17704420"
        },
        {
          "protein-name": "Low affinity immunoglobulin gamma Fc region receptor III-A",
          "gene-symbol": "FCGR3A",
          "uniprot-id": "P08637",
          "rs-id": "rs396991",
          "allele": "",
          "defining-change": "A > C",
          "description": "Better response to drug therapy (longer progression free survival) with the F allele",
          "pubmed-id": "17704420"
        }
      ]
    },
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000767",
          "name": "Epidermal growth factor receptor",
          "organism": "Human",
          "actions": {
            "action": "antagonist"
          },
          "references": "# Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10480573\r\n# Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10601294\r\n# Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10628369\r\n# Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11408594\r\n# Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11431346\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Epidermal growth factor receptor",
            "general-function": "Ubiquitin protein ligase binding",
            "specific-function": "Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.",
            "gene-name": "EGFR",
            "locus": "7p12",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "646-668",
            "signal-regions": "1-24",
            "theoretical-pi": "6.67",
            "molecular-weight": "134276.185",
            "chromosome-location": "7",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3236"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "EGFR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X00588"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "757924"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1797"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00533"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "EGFR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "2.7.10.1",
                "ERBB",
                "ERBB1",
                "HER1",
                "Proto-oncogene c-ErbB-1",
                "Receptor tyrosine-protein kinase erbB-1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001530|Epidermal growth factor receptor\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\nVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\nVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\nQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\nTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\nVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\nNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\nENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\nFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\nLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\nGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\nALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\nGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\nCLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\nRNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\nGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\nFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\nQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\nSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\nTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\nAPQSSEFIGA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG\nGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG\nTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG\nGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG\nACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT\nTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA\nGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA\nCAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG\nAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC\nCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG\nGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC\nGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC\nACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC\nAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC\nCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG\nGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA\nGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA\nGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA\nAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC\nTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA\nATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT\nGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC\nGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT\nGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG\nTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG\nGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC\nAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC\nCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA\nGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC\nCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG\nGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC\nCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG\nCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG\nGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG\nAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC\nCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC\nGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT\nCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC\nGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC\nTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC\nTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG\nATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC\nAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA\nCTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG\nATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC\nGGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC\nAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC\nATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG\nTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC\nATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC\nCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG\nCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA\nACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC\nAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC\nAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG\nCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC\nAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC\nACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA\nGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA\nGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC\nGCGCCACAAAGCAGTGAATTTATTGGAGCATGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF07714",
                  "name": "Pkinase_Tyr"
                },
                {
                  "identifier": "PF00757",
                  "name": "Furin-like"
                },
                {
                  "identifier": "PF01030",
                  "name": "Recep_L_domain"
                },
                {
                  "identifier": "PF14843",
                  "name": "GF_recep_IV"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "endosome"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "endocytic vesicle"
                },
                {
                  "category": "component",
                  "description": "receptor complex"
                },
                {
                  "category": "component",
                  "description": "endosome membrane"
                },
                {
                  "category": "component",
                  "description": "nuclear membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "perinuclear region of cytoplasm"
                },
                {
                  "category": "component",
                  "description": "Golgi membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "basolateral plasma membrane"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "multivesicular body, internal vesicle lumen"
                },
                {
                  "category": "component",
                  "description": "Shc-EGFR complex"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "early endosome membrane"
                },
                {
                  "category": "component",
                  "description": "membrane raft"
                },
                {
                  "category": "component",
                  "description": "nucleus"
                },
                {
                  "category": "function",
                  "description": "identical protein binding"
                },
                {
                  "category": "function",
                  "description": "actin filament binding"
                },
                {
                  "category": "function",
                  "description": "ubiquitin protein ligase binding"
                },
                {
                  "category": "function",
                  "description": "chromatin binding"
                },
                {
                  "category": "function",
                  "description": "transmembrane signaling receptor activity"
                },
                {
                  "category": "function",
                  "description": "protein tyrosine kinase activity"
                },
                {
                  "category": "function",
                  "description": "MAP kinase kinase kinase activity"
                },
                {
                  "category": "function",
                  "description": "protein phosphatase binding"
                },
                {
                  "category": "function",
                  "description": "double-stranded DNA binding"
                },
                {
                  "category": "function",
                  "description": "ATP binding"
                },
                {
                  "category": "function",
                  "description": "enzyme binding"
                },
                {
                  "category": "function",
                  "description": "protein heterodimerization activity"
                },
                {
                  "category": "function",
                  "description": "epidermal growth factor-activated receptor activity"
                },
                {
                  "category": "function",
                  "description": "transmembrane receptor protein tyrosine kinase activity"
                },
                {
                  "category": "function",
                  "description": "receptor signaling protein tyrosine kinase activity"
                },
                {
                  "category": "process",
                  "description": "cellular response to estradiol stimulus"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "positive regulation of ERK1 and ERK2 cascade"
                },
                {
                  "category": "process",
                  "description": "morphogenesis of an epithelial fold"
                },
                {
                  "category": "process",
                  "description": "negative regulation of protein catabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular response to amino acid stimulus"
                },
                {
                  "category": "process",
                  "description": "response to UV-A"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "protein autophosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of DNA replication"
                },
                {
                  "category": "process",
                  "description": "cellular response to epidermal growth factor stimulus"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "regulation of peptidyl-tyrosine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of nitric oxide biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of catenin import into nucleus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell migration"
                },
                {
                  "category": "process",
                  "description": "embryonic placenta development"
                },
                {
                  "category": "process",
                  "description": "activation of phospholipase C activity"
                },
                {
                  "category": "process",
                  "description": "salivary gland morphogenesis"
                },
                {
                  "category": "process",
                  "description": "hair follicle development"
                },
                {
                  "category": "process",
                  "description": "ossification"
                },
                {
                  "category": "process",
                  "description": "single organismal cell-cell adhesion"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                },
                {
                  "category": "process",
                  "description": "positive regulation of MAP kinase activity"
                },
                {
                  "category": "process",
                  "description": "protein insertion into membrane"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                },
                {
                  "category": "process",
                  "description": "cerebral cortex cell migration"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of epithelial cell proliferation"
                },
                {
                  "category": "process",
                  "description": "digestive tract morphogenesis"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein kinase B signaling"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "regulation of nitric-oxide synthase activity"
                },
                {
                  "category": "process",
                  "description": "response to stress"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of DNA repair"
                },
                {
                  "category": "process",
                  "description": "peptidyl-tyrosine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "learning or memory"
                },
                {
                  "category": "process",
                  "description": "positive regulation of fibroblast proliferation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein phosphorylation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of phosphorylation"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "phosphatidylinositol-mediated signaling"
                },
                {
                  "category": "process",
                  "description": "activation of phospholipase A2 activity by calcium-mediated signaling"
                }
              ]
            },
            "_id": "P00533",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000901",
          "name": "Low affinity immunoglobulin gamma Fc region receptor III-B",
          "organism": "Human",
          "actions": "",
          "references": "# Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16336752",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor III-B",
            "general-function": "",
            "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.",
            "gene-name": "FCGR3B",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "",
            "signal-regions": "1-16",
            "theoretical-pi": "6.71",
            "molecular-weight": "26215.64",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3620"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR3B"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X16863"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31322"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "O75015"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG3B_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD16B",
                "Fc-gamma RIII",
                "Fc-gamma RIII-beta",
                "Fc-gamma RIIIb",
                "FCG3",
                "FCGR3",
                "FcR-10",
                "FcRIII",
                "FcRIIIb",
                "IGFR3",
                "IgG Fc receptor III-1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "anchored component of membrane"
                },
                {
                  "category": "process",
                  "description": "mitophagy in response to mitochondrial depolarization"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "positive regulation of defense response to virus by host"
                },
                {
                  "category": "process",
                  "description": "xenophagy"
                }
              ]
            },
            "_id": "O75015",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0002093",
          "name": "Complement C1r subcomponent",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1r subcomponent",
            "general-function": "Serine-type peptidase activity",
            "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.",
            "gene-name": "C1R",
            "locus": "12p13",
            "cellular-location": "Cytoplasmic",
            "transmembrane-regions": "",
            "signal-regions": "1-17",
            "theoretical-pi": "6.24",
            "molecular-weight": "80118.04",
            "chromosome-location": "12",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1246"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1R"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X04701"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "29539"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2334"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00736"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1R_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.41",
                "Complement component 1 subcomponent r"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011518|Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDTHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011519|Complement C1r subcomponent (C1R)\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00084",
                  "name": "Sushi"
                },
                {
                  "identifier": "PF00431",
                  "name": "CUB"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "serine-type peptidase activity"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "immune response"
                }
              ]
            },
            "_id": "P00736",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0002094",
          "name": "Complement C1q subcomponent subunit A",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1q subcomponent subunit A",
            "general-function": "",
            "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.",
            "gene-name": "C1QA",
            "locus": "1p36.12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "9.45",
            "molecular-weight": "26016.47",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1241"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1QA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF135157"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "4894854"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02745"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1QA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "Complement C1q subcomponent subunit A precursor"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01391",
                  "name": "Collagen"
                },
                {
                  "identifier": "PF00386",
                  "name": "C1q"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "complement component C1 complex"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "collagen trimer"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "cell-cell signaling"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P02745",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        },
        {
          "id": "BE0002095",
          "name": "Complement C1q subcomponent subunit B",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1q subcomponent subunit B",
            "general-function": "",
            "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.",
            "gene-name": "C1QB",
            "locus": "1p36.12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-27",
            "theoretical-pi": "8.87",
            "molecular-weight": "26721.62",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1242"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1QB"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X03084"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "573114"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02746"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1QB_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "Complement C1q subcomponent subunit B precursor"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\nIFSGFLLFPDMEA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01391",
                  "name": "Collagen"
                },
                {
                  "identifier": "PF00386",
                  "name": "C1q"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "collagen trimer"
                },
                {
                  "category": "component",
                  "description": "complement component C1 complex"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "inner ear development"
                }
              ]
            },
            "_id": "P02746",
            "_source": "Swiss-Prot"
          },
          "_position": "5"
        },
        {
          "id": "BE0002096",
          "name": "Complement C1q subcomponent subunit C",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1q subcomponent subunit C",
            "general-function": "",
            "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.",
            "gene-name": "C1QC",
            "locus": "1p36.11",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-28",
            "theoretical-pi": "8.58",
            "molecular-weight": "25773.56",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1245"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1QC"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF087892"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "33150626"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02747"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1QC_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "C1QG"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011520|Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01391",
                  "name": "Collagen"
                },
                {
                  "identifier": "PF00386",
                  "name": "C1q"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "collagen trimer"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of granulocyte differentiation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of macrophage differentiation"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P02747",
            "_source": "Swiss-Prot"
          },
          "_position": "6"
        },
        {
          "id": "BE0002097",
          "name": "Low affinity immunoglobulin gamma Fc region receptor III-A",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17704420",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor III-A",
            "general-function": "",
            "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.",
            "gene-name": "FCGR3A",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "209-229",
            "signal-regions": "1-16",
            "theoretical-pi": "8.21",
            "molecular-weight": "29088.895",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3619"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR3A"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X52645"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31324"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P08637"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG3A_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD16A",
                "CD16a antigen",
                "Fc-gamma RIII",
                "Fc-gamma RIII-alpha",
                "Fc-gamma RIIIa",
                "FCG3",
                "FCGR3",
                "FcR-10",
                "FcRIII",
                "FcRIIIa",
                "IGFR3",
                "IgG Fc receptor III-2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "process",
                  "description": "regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "Fc-gamma receptor signaling pathway involved in phagocytosis"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P08637",
            "_source": "Swiss-Prot"
          },
          "_position": "7"
        },
        {
          "id": "BE0001529",
          "name": "Complement C1s subcomponent",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1s subcomponent",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.",
            "gene-name": "C1S",
            "locus": "12p13",
            "cellular-location": "Cytoplasmic",
            "transmembrane-regions": "",
            "signal-regions": "1-15",
            "theoretical-pi": "4.59",
            "molecular-weight": "76683.905",
            "chromosome-location": "12",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1247"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1S"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X06596"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "763110"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2335"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P09871"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1S_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.42",
                "C1 esterase",
                "Complement component 1 subcomponent s"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011082|Complement C1s subcomponent\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011083|Complement C1s subcomponent (C1S)\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00084",
                  "name": "Sushi"
                },
                {
                  "identifier": "PF00431",
                  "name": "CUB"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "function",
                  "description": "identical protein binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                }
              ]
            },
            "_id": "P09871",
            "_source": "Swiss-Prot"
          },
          "_position": "8"
        },
        {
          "id": "BE0000710",
          "name": "High affinity immunoglobulin gamma Fc receptor I",
          "organism": "Human",
          "actions": "",
          "references": "# Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7547242",
          "known-action": "unknown",
          "polypeptide": {
            "name": "High affinity immunoglobulin gamma Fc receptor I",
            "general-function": "Receptor signaling protein activity",
            "specific-function": "High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.",
            "gene-name": "FCGR1A",
            "locus": "1q21.2-q21.3",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "293-313",
            "signal-regions": "1-15",
            "theoretical-pi": "8.08",
            "molecular-weight": "42631.525",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3613"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR1A"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X14356"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31332"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P12314"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCGR1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Fc-gamma RI",
                "Fc-gamma RIA",
                "FCG1",
                "FcgammaRIa",
                "FCGR1",
                "FcRI",
                "IGFR1",
                "IgG Fc receptor I"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00047",
                  "name": "ig"
                },
                {
                  "identifier": "PF13895",
                  "name": "Ig_2"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "clathrin-coated endocytic vesicle membrane"
                },
                {
                  "category": "component",
                  "description": "early endosome membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "receptor signaling protein activity"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "phagocytosis, engulfment"
                },
                {
                  "category": "process",
                  "description": "intracellular signal transduction"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "interferon-gamma-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "Fc-gamma receptor signaling pathway involved in phagocytosis"
                }
              ]
            },
            "_id": "P12314",
            "_source": "Swiss-Prot"
          },
          "_position": "9"
        },
        {
          "id": "BE0002098",
          "name": "Low affinity immunoglobulin gamma Fc region receptor II-a",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17704420",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor II-a",
            "general-function": "",
            "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.",
            "gene-name": "FCGR2A",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "218-240",
            "signal-regions": "1-33",
            "theoretical-pi": "6.78",
            "molecular-weight": "35000.42",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3616"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR2A"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M31932"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "182474"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P12318"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG2A_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD32",
                "CDw32",
                "Fc-gamma RII-a",
                "Fc-gamma-RIIa",
                "FCG2",
                "FCGR2A1",
                "FcRII-a",
                "IGFR2",
                "IgG Fc receptor II-a"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "process",
                  "description": "Fc-gamma receptor signaling pathway involved in phagocytosis"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P12318",
            "_source": "Swiss-Prot"
          },
          "_position": "10"
        },
        {
          "id": "BE0002099",
          "name": "Low affinity immunoglobulin gamma Fc region receptor II-b",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor II-b",
            "general-function": "",
            "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.",
            "gene-name": "FCGR2B",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "218-240",
            "signal-regions": "1-42",
            "theoretical-pi": "6.12",
            "molecular-weight": "34043.355",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3618"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR2B"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "U87560"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "4099445"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P31994"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG2B_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD32",
                "CDw32",
                "Fc-gamma RII-b",
                "Fc-gamma-RIIb",
                "FCG2",
                "FcRII-b",
                "IGFR2",
                "IgG Fc receptor II-b"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "viral process"
                }
              ]
            },
            "_id": "P31994",
            "_source": "Swiss-Prot"
          },
          "_position": "11"
        },
        {
          "id": "BE0002100",
          "name": "Low affinity immunoglobulin gamma Fc region receptor II-c",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor II-c",
            "general-function": "Transmembrane signaling receptor activity",
            "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.",
            "gene-name": "FCGR2C",
            "locus": "1q23.3",
            "cellular-location": "Cytoplasm",
            "transmembrane-regions": "224-246",
            "signal-regions": "1-42",
            "theoretical-pi": "6.9",
            "molecular-weight": "35577.96",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:15626"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR2C"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X17652"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "32074"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P31995"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG2C_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD32",
                "CDw32",
                "Fc-gamma RII-c",
                "Fc-gamma-RIIc",
                "FCG2",
                "FcRII-c",
                "IGFR2",
                "IgG Fc receptor II-c"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "transmembrane signaling receptor activity"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "immune response"
                }
              ]
            },
            "_id": "P31995",
            "_source": "Swiss-Prot"
          },
          "_position": "12"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-11-10"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00003"
      },
      "BIOD00001",
      "BTD00001"
    ],
    "name": "Dornase alfa",
    "description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity. ",
    "cas-number": "9003-98-9",
    "groups": {
      "group": "approved"
    },
    "general-references": "# Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8792953 \r\n# Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;3:CD001127. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20238314 \r\n# Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. Epub 2009 Feb 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19255515 \r\n# Roche Products Limited. Pulmozyme. 1st ed. Newmarket, Auckland: N.p., 2014. Web. 11 Nov. 2014.\r\n#Glowm.com,. 'Dornase Alfa'. N.p., 2014. Web. 11 Nov. 2014.",
    "synthesis-reference": "",
    "indication": "Used as adjunct therapy in the treatment of cystic fibrosis. ",
    "pharmacodynamics": "Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals. ",
    "mechanism-of-action": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.",
    "toxicity": "Adverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old. ",
    "metabolism": "While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids. ",
    "absorption": "Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.",
    "clearance": "Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Deoxyribonuclease I"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Deoxyribonuclease-1 precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "DNase"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "DNase I"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "rhDNase"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Pulmozyme",
          "ndc-id": "",
          "ndc-product-code": "50242-100",
          "dpd-id": "",
          "started-marketing-on": "1993-12-30",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "1 mg/mL",
          "route": "respiratory (inhalation)",
          "fda-application-number": "BLA103532",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pulmozyme 1mg/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02046733",
          "started-marketing-on": "1994-12-31",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "1 mg",
          "route": "inhalation",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Viscozyme",
        "company": "Roche (Chile)"
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Pulmozyme",
          "ingredients": "Dornase alfa"
        },
        {
          "name": "Pulmozyme 1mg/ml",
          "ingredients": "Dornase alfa"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Cardinal Health",
          "url": "http://www.cardinal.com"
        },
        {
          "name": "Catalent Pharma Solutions",
          "url": "http://www.catalent.com"
        },
        {
          "name": "F Hoffmann-La Roche Ltd.",
          "url": "http://www.roche.com"
        },
        {
          "name": "Genentech Inc.",
          "url": "http://www.gene.com"
        },
        {
          "name": "Meda AB",
          "url": "http://www.meda.se"
        },
        {
          "name": "Medpointe Pharmaceuticals",
          "url": ""
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Genentech, Inc"
      }
    },
    "prices": {
      "price": [
        {
          "description": "Lufyllin 200 mg tablet",
          "cost": {
            "_currency": "USD",
            "__text": "3.21"
          },
          "unit": "tablet"
        },
        {
          "description": "Lufyllin-gg tablet",
          "cost": {
            "_currency": "USD",
            "__text": "3.84"
          },
          "unit": "tablet"
        },
        {
          "description": "Lufyllin-GG 200-200 mg tablet",
          "cost": {
            "_currency": "USD",
            "__text": "3.99"
          },
          "unit": "tablet"
        },
        {
          "description": "Lufyllin-400 tablet",
          "cost": {
            "_currency": "USD",
            "__text": "4.62"
          },
          "unit": "tablet"
        },
        {
          "description": "Lufyllin 400 mg tablet",
          "cost": {
            "_currency": "USD",
            "__text": "4.81"
          },
          "unit": "tablet"
        },
        {
          "description": "Pulmozyme 1 mg/ml ampul",
          "cost": {
            "_currency": "USD",
            "__text": "37.05"
          },
          "unit": "ml"
        },
        {
          "description": "Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container",
          "cost": {
            "_currency": "USD",
            "__text": "77.06"
          },
          "unit": "plastic"
        },
        {
          "description": "Lufyllin-GG 100-100 mg/15ml Elixir",
          "cost": {
            "_currency": "USD",
            "__text": "0.6"
          },
          "unit": "ml"
        }
      ]
    },
    "categories": {
      "category": {
        "category": "Enzymes",
        "mesh-id": "[\"D08.811\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Solution",
          "route": "respiratory (inhalation)",
          "strength": "1 mg/mL"
        },
        {
          "form": "Solution",
          "route": "inhalation",
          "strength": "1 mg"
        }
      ]
    },
    "atc-codes": "",
    "ahfs-codes": {
      "ahfs-code": "44:00"
    },
    "patents": {
      "patent": [
        {
          "number": "2137237",
          "country": "Canada",
          "approved": "2004-10-26",
          "expires": "2013-05-28"
        },
        {
          "number": "2184581",
          "country": "Canada",
          "approved": "2005-02-22",
          "expires": "2015-02-28"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">Dornase alfa sequence\nLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP\nDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS\nRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ\nWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG\nLSDQLAQAISDHYPVEVMLK"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "67 °C",
          "source": "Chan, H.K. et al., Pharm Res. 13:756-761 (1996)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.083",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "4.58",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "29253.9",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C1321H1999N339O396S9",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "650"
        },
        {
          "resource": "GenBank",
          "identifier": "M55983"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA10318"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P24855"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Dornase_alfa"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/pulmozyme.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/dornase-alfa.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0004796",
        "name": "DNA",
        "organism": "Human",
        "actions": "",
        "references": "# Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8792953",
        "known-action": "yes"
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2014-11-16"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00004"
      },
      "BIOD00084",
      "BTD00084"
    ],
    "name": "Denileukin diftitox",
    "description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.",
    "cas-number": "173146-27-5",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516\r\n# Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17454642",
    "synthesis-reference": "",
    "indication": "For treatment of cutaneous T-cell lymphoma",
    "pharmacodynamics": "Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.",
    "mechanism-of-action": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "70-80 min",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "* 0.06 to 0.09 L/kg",
    "clearance": "* 0.6 - 2.0 mL/min/kg [Lymphoma]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Diphtheria toxin precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "DT"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "NAD(+--diphthamide ADP- ribosyltransferase)"
        }
      ]
    },
    "products": {
      "product": {
        "name": "Ontak",
        "ndc-id": "",
        "ndc-product-code": "62856-603",
        "dpd-id": "",
        "started-marketing-on": "2008-10-15",
        "ended-marketing-on": "",
        "dosage-form": "injection, solution",
        "strength": "150 ug/mL",
        "route": "intravenous",
        "fda-application-number": "BLA103767",
        "generic": "false",
        "over-the-counter": "false",
        "approved": "true",
        "country": "US",
        "source": "FDA NDC"
      }
    },
    "international-brands": "",
    "mixtures": {
      "mixture": {
        "name": "Ontak",
        "ingredients": "Denileukin diftitox"
      }
    },
    "packagers": {
      "packager": [
        {
          "name": "Eisai Inc.",
          "url": "http://www.eisai.com"
        },
        {
          "name": "Hollister-Stier Laboratories LLC",
          "url": "http://www.hollisterstier.com"
        },
        {
          "name": "Ligand Pharmaceuticals Inc.",
          "url": "http://www.ligand.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": {
        "description": "Ontak 150 mcg/ml vial",
        "cost": {
          "_currency": "USD",
          "__text": "878.4"
        },
        "unit": "ml"
      }
    },
    "categories": {
      "category": {
        "category": "Antineoplastic Agents",
        "mesh-id": "[\"D27.505.954.248\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": {
        "form": "Injection, solution",
        "route": "intravenous",
        "strength": "150 ug/mL"
      }
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L01",
            "__text": "ANTINEOPLASTIC AGENTS"
          },
          {
            "_code": "L01X",
            "__text": "OTHER ANTINEOPLASTIC AGENTS"
          },
          {
            "_code": "L01XX",
            "__text": "Other antineoplastic agents"
          }
        ],
        "_code": "L01XX29"
      }
    },
    "ahfs-codes": "",
    "patents": "",
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00004 sequence\nMGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK\nYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG\nTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY\nEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS\nEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK\nTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN\nFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYK\nNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVI\nVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "-0.301",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "5.45",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "57647.3",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C2560H4042N678O799S17",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "GenBank",
          "identifier": "V01536"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164750594"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P00587"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Denileukin_diftitox"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic2/denileukin.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/denileukin-diftitox.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000658",
          "name": "Interleukin-2 receptor subunit alpha",
          "organism": "Human",
          "actions": {
            "action": "binder"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2786749\r\n# Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3124610\r\n# Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18684057\r\n# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interleukin-2 receptor subunit alpha",
            "general-function": "Interleukin-2 receptor activity",
            "specific-function": "Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.",
            "gene-name": "IL2RA",
            "locus": "10p15-p14",
            "cellular-location": "Membrane",
            "transmembrane-regions": "241-259",
            "signal-regions": "1-21",
            "theoretical-pi": "6.49",
            "molecular-weight": "30818.915",
            "chromosome-location": "10",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6008"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IL2RA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X01057"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "33813"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1695"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P01589"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "IL2RA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IL-2 receptor subunit alpha",
                "p55",
                "TAC antigen"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00084",
                "name": "Sushi"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "interleukin-2 binding"
                },
                {
                  "category": "function",
                  "description": "interleukin-2 receptor activity"
                },
                {
                  "category": "function",
                  "description": "drug binding"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "activation-induced cell death of T cells"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "negative regulation of defense response to virus"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of activated T cell proliferation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "regulation of T cell homeostatic proliferation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of inflammatory response"
                },
                {
                  "category": "process",
                  "description": "inflammatory response to antigenic stimulus"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of T cell proliferation"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "regulation of T cell tolerance induction"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "Notch signaling pathway"
                },
                {
                  "category": "process",
                  "description": "apoptotic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "inflammatory response"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of T cell differentiation"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                }
              ]
            },
            "_id": "P01589",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000651",
          "name": "Interleukin-2 receptor subunit beta",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15811959\r\n# Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16516670\r\n# Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18684057\r\n# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interleukin-2 receptor subunit beta",
            "general-function": "Interleukin-2 receptor activity",
            "specific-function": "Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.",
            "gene-name": "IL2RB",
            "locus": "22q13|22q13.1",
            "cellular-location": "Membrane",
            "transmembrane-regions": "241-265",
            "signal-regions": "1-26",
            "theoretical-pi": "4.68",
            "molecular-weight": "61116.59",
            "chromosome-location": "22",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6009"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IL2RB"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M26062"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "307048"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P14784"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "IL2RB_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "High affinity IL-2 receptor subunit beta",
                "IL-2 receptor subunit beta",
                "p70-75",
                "p75"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016166|Interleukin-2 receptor subunit beta\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG"
            },
            "pfams": "\n    ",
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "interleukin-2 binding"
                },
                {
                  "category": "function",
                  "description": "interleukin-2 receptor activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "viral process"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "interleukin-2-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "protein complex assembly"
                }
              ]
            },
            "_id": "P14784",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0002102",
          "name": "Cytokine receptor common subunit gamma",
          "organism": "Human",
          "actions": "",
          "references": "# Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15811959\r\n# Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16516670\r\n# Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11707860",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Cytokine receptor common subunit gamma",
            "general-function": "Interleukin-2 binding",
            "specific-function": "Common subunit for the receptors for a variety of interleukins.",
            "gene-name": "IL2RG",
            "locus": "Xq13.1",
            "cellular-location": "Membrane",
            "transmembrane-regions": "263-283",
            "signal-regions": "1-22",
            "theoretical-pi": "6.31",
            "molecular-weight": "42286.68",
            "chromosome-location": "X",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6010"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IL2RG"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "D11086"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "219890"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P31785"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "IL2RG_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "gammaC",
                "IL-2 receptor subunit gamma",
                "IL-2R subunit gamma",
                "IL-2RG",
                "Interleukin-2 receptor subunit gamma",
                "p64"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004122|Cytokine receptor common subunit gamma\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\nPCYTLKPET"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\nCCATGTTACACCCTAAAGCCTGAAACCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00041",
                  "name": "fn3"
                },
                {
                  "identifier": "PF09240",
                  "name": "IL6Ra-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "cytokine receptor activity"
                },
                {
                  "category": "function",
                  "description": "interleukin-2 binding"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "viral process"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "interleukin-2-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "interleukin-4-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "interleukin-7-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                }
              ]
            },
            "_id": "P31785",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2014-01-14"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00005"
      },
      "BIOD00052",
      "BTD00052"
    ],
    "name": "Etanercept",
    "description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids",
    "cas-number": "185243-69-0",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# http://www.genome.jp/dbget-bin/www_bget?D00742\r\n#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Etanercept; [updated 2014 Sept 24 cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=4&sid=eeea413d-1490-4efa-bf5d-71f40e1986a1%40sessionmgr111&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232781",
    "synthesis-reference": "Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, \"Crystals of etanercept and methods of making thereof.\" U.S. Patent US07276477, issued October 02, 2007.",
    "indication": "For treatment of severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis.",
    "pharmacodynamics": "Tumor necrosis factor TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in tissues and fluids of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis. Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.",
    "mechanism-of-action": "There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "Bioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achieved within 69 hours. ",
    "half-life": "102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "* 160 +/- 80 mL/hr [RA patients]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "CD120b"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "p75"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "p80 TNF-alpha receptor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "TNF-R2"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Tumor necrosis factor receptor 2"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Tumor necrosis factor receptor superfamily member 1B precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Tumor necrosis factor receptor type II"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Enbrel",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242903",
          "started-marketing-on": "2001-03-14",
          "ended-marketing-on": "",
          "dosage-form": "kit; liquid; powder for solution",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Enbrel",
          "ndc-id": "",
          "ndc-product-code": "58406-425",
          "dpd-id": "",
          "started-marketing-on": "2003-01-02",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103795",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Enbrel",
          "ndc-id": "",
          "ndc-product-code": "58406-435",
          "dpd-id": "",
          "started-marketing-on": "2005-10-06",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "50 mg/mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103795",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Enbrel",
          "ndc-id": "",
          "ndc-product-code": "58406-445",
          "dpd-id": "",
          "started-marketing-on": "2005-11-10",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "50 mg/mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103795",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Enbrel",
          "ndc-id": "",
          "ndc-product-code": "58406-455",
          "dpd-id": "",
          "started-marketing-on": "2005-11-10",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "25 mg/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103795",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Enbrel",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02274728",
          "started-marketing-on": "2005-12-21",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "50 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Enbrel Sureclick",
        "company": ""
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Enbrel",
          "ingredients": "Etanercept"
        },
        {
          "name": "Enbrel",
          "ingredients": "Etanercept"
        },
        {
          "name": "Enbrel",
          "ingredients": "Etanercept"
        },
        {
          "name": "Enbrel",
          "ingredients": "Etanercept"
        },
        {
          "name": "Enbrel",
          "ingredients": "Etanercept + Water"
        },
        {
          "name": "Enbrel",
          "ingredients": "Etanercept"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Amgen Inc.",
          "url": "http://www.amgen.com"
        },
        {
          "name": "Boehringer Ingelheim Ltd.",
          "url": "http://www.boehringer-ingelheim.com"
        },
        {
          "name": "DSM Corp.",
          "url": "http://www.dsm.com"
        },
        {
          "name": "Immunex Corp.",
          "url": ""
        },
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        },
        {
          "name": "Vetter Pharma Fertigung GmbH and Co. KG",
          "url": "http://www.vetter-pharma.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Amgen Inc. + Wyeth + Takeda"
      }
    },
    "prices": {
      "price": [
        {
          "description": "Enbrel 25 mg kit",
          "cost": {
            "_currency": "USD",
            "__text": "250.37"
          },
          "unit": "each"
        },
        {
          "description": "Enbrel 50 mg/ml sureclick syr",
          "cost": {
            "_currency": "USD",
            "__text": "488.74"
          },
          "unit": "syringe"
        },
        {
          "description": "Enbrel 4 25 mg Kit (1 Box = 1 Kit = Four 25 mg Vials)",
          "cost": {
            "_currency": "USD",
            "__text": "1016.57"
          },
          "unit": "box"
        },
        {
          "description": "Enbrel (1 Box = 1 Kit = Four 50 mg Syringes) 3.92ml Box",
          "cost": {
            "_currency": "USD",
            "__text": "2033.14"
          },
          "unit": "box"
        },
        {
          "description": "Enbrel SureClick (1 Box Contains Four 50 mg Prefilled Autoinjectors)",
          "cost": {
            "_currency": "USD",
            "__text": "2033.14"
          },
          "unit": "box"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Immunosuppressive Agents",
          "mesh-id": "[\"D27.505.696.477.656\"]"
        },
        {
          "category": "Immunosuppressants",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Kit; liquid; powder for solution",
          "route": "subcutaneous",
          "strength": ""
        },
        {
          "form": "Solution",
          "route": "subcutaneous",
          "strength": "25 mg/.5mL"
        },
        {
          "form": "Solution",
          "route": "subcutaneous",
          "strength": "50 mg/mL"
        },
        {
          "form": "Solution",
          "route": "subcutaneous",
          "strength": "50 mg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L04",
            "__text": "IMMUNOSUPPRESSANTS"
          },
          {
            "_code": "L04A",
            "__text": "IMMUNOSUPPRESSANTS"
          },
          {
            "_code": "L04AB",
            "__text": "Tumor necrosis factor alpha (TNF-α) inhibitors"
          }
        ],
        "_code": "L04AB01"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "92:00.00"
    },
    "patents": {
      "patent": [
        {
          "number": "2123593",
          "country": "Canada",
          "approved": "2000-03-14",
          "expires": "2013-09-14"
        },
        {
          "number": "2476934",
          "country": "Canada",
          "approved": "2009-06-16",
          "expires": "2023-02-27"
        },
        {
          "number": "36755",
          "country": "United States",
          "approved": "2000-06-27",
          "expires": "2012-10-23"
        },
        {
          "number": "7276477",
          "country": "United States",
          "approved": "2007-10-02",
          "expires": "2024-07-29"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB01281",
          "name": "Abatacept",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Abatacept."
        },
        {
          "drugbank-id": "DB00026",
          "name": "Anakinra",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra."
        },
        {
          "drugbank-id": "DB08879",
          "name": "Belimumab",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab."
        },
        {
          "drugbank-id": "DB06168",
          "name": "Canakinumab",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Canakinumab."
        },
        {
          "drugbank-id": "DB08904",
          "name": "Certolizumab pegol",
          "description": "Etanercept may increase the immunosuppressive activities of Certolizumab pegol."
        },
        {
          "drugbank-id": "DB00531",
          "name": "Cyclophosphamide",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide."
        },
        {
          "drugbank-id": "DB06643",
          "name": "Denosumab",
          "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept."
        },
        {
          "drugbank-id": "DB00065",
          "name": "Infliximab",
          "description": "Etanercept may increase the immunosuppressive activities of Infliximab."
        },
        {
          "drugbank-id": "DB01097",
          "name": "Leflunomide",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide."
        },
        {
          "drugbank-id": "DB00108",
          "name": "Natalizumab",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab."
        },
        {
          "drugbank-id": "DB00337",
          "name": "Pimecrolimus",
          "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept."
        },
        {
          "drugbank-id": "DB10283",
          "name": "Rabies vaccine",
          "description": "The therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Etanercept."
        },
        {
          "drugbank-id": "DB06372",
          "name": "Rilonacept",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Rilonacept."
        },
        {
          "drugbank-id": "DB01656",
          "name": "Roflumilast",
          "description": "Roflumilast may increase the immunosuppressive activities of Etanercept."
        },
        {
          "drugbank-id": "DB06688",
          "name": "Sipuleucel-T",
          "description": "The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept."
        },
        {
          "drugbank-id": "DB00864",
          "name": "Tacrolimus",
          "description": "The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etanercept."
        },
        {
          "drugbank-id": "DB06273",
          "name": "Tocilizumab",
          "description": "Tocilizumab may increase the immunosuppressive activities of Etanercept."
        },
        {
          "drugbank-id": "DB08895",
          "name": "Tofacitinib",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Tofacitinib."
        },
        {
          "drugbank-id": "DB00072",
          "name": "Trastuzumab",
          "description": "Trastuzumab may increase the neutropenic activities of Etanercept."
        },
        {
          "drugbank-id": "DB09033",
          "name": "Vedolizumab",
          "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Vedolizumab."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": "> Etanercept Sequence\nLPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDST\nYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRK\nCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTS\nTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSC\nDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD\nGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK\nGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS\nDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "71 °C (whole mAb)",
          "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.529",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "7.89",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "51234.9",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C2224H3475N621O698S36",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "12032"
        },
        {
          "resource": "KEGG Compound",
          "identifier": "C07897"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D00742"
        },
        {
          "resource": "GenBank",
          "identifier": "M32315"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA449515"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P20333"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Etanercept"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/etanercept.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/etanercept.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000704",
          "name": "Tumor necrosis factor",
          "organism": "Human",
          "actions": {
            "action": "antibody"
          },
          "references": "# Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10206649\r\n# Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10338381\r\n# Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10357816\r\n# Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10375846\r\n# Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10405518\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Tumor necrosis factor",
            "general-function": "Tumor necrosis factor receptor binding",
            "specific-function": "Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.",
            "gene-name": "TNF",
            "locus": "6p21.3",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "36-56",
            "signal-regions": "",
            "theoretical-pi": "6.92",
            "molecular-weight": "25644.15",
            "chromosome-location": "6",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:11892"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "TNF"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M16441"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "339741"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2635"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P01375"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "TNFA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Cachectin",
                "TNF-a",
                "TNF-alpha",
                "TNFA",
                "TNFSF2",
                "Tumor necrosis factor ligand superfamily member 2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001404|Tumor necrosis factor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0021837|Tumor necrosis factor (TNF)\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00229",
                "name": "TNF"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "phagocytic cup"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "recycling endosome"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "membrane raft"
                },
                {
                  "category": "function",
                  "description": "transcription regulatory region DNA binding"
                },
                {
                  "category": "function",
                  "description": "cytokine activity"
                },
                {
                  "category": "function",
                  "description": "identical protein binding"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "tumor necrosis factor receptor binding"
                },
                {
                  "category": "process",
                  "description": "positive regulation of NF-kappaB transcription factor activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cytokine secretion"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of chemokine biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "response to glucocorticoid"
                },
                {
                  "category": "process",
                  "description": "negative regulation of alkaline phosphatase activity"
                },
                {
                  "category": "process",
                  "description": "activation of MAPK activity"
                },
                {
                  "category": "process",
                  "description": "sequestering of triglyceride"
                },
                {
                  "category": "process",
                  "description": "inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of extrinsic apoptotic signaling pathway in absence of ligand"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKKK activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "negative regulation of lipid catabolic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of membrane protein ectodomain proteolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cytokine secretion involved in immune response"
                },
                {
                  "category": "process",
                  "description": "positive regulation of hair follicle development"
                },
                {
                  "category": "process",
                  "description": "JNK cascade"
                },
                {
                  "category": "process",
                  "description": "tumor necrosis factor-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "osteoclast differentiation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of ceramide biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "death-inducing signaling complex assembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of fever generation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of vitamin D biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "protein kinase B signaling"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein transport"
                },
                {
                  "category": "process",
                  "description": "positive regulation of chronic inflammatory response to antigenic stimulus"
                },
                {
                  "category": "process",
                  "description": "glucose metabolic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of chemokine production"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell adhesion"
                },
                {
                  "category": "process",
                  "description": "positive regulation of osteoclast differentiation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of podosome assembly"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "negative regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "receptor biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein complex disassembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of humoral immune response mediated by circulating immunoglobulin"
                },
                {
                  "category": "process",
                  "description": "intrinsic apoptotic signaling pathway in response to DNA damage"
                },
                {
                  "category": "process",
                  "description": "positive regulation of gene expression"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cysteine-type endopeptidase activity involved in apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of JUN kinase activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of chemokine (C-X-C motif) ligand 2 production"
                },
                {
                  "category": "process",
                  "description": "positive regulation of peptidyl-serine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of NIK/NF-kappaB signaling"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein kinase B signaling"
                },
                {
                  "category": "process",
                  "description": "positive regulation of MAP kinase activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein localization to cell surface"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cytokine production"
                },
                {
                  "category": "process",
                  "description": "positive regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of gene expression"
                },
                {
                  "category": "process",
                  "description": "leukocyte tethering or rolling"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein kinase activity"
                },
                {
                  "category": "process",
                  "description": "extrinsic apoptotic signaling pathway via death domain receptors"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "negative regulation of glucose import"
                },
                {
                  "category": "process",
                  "description": "negative regulation of growth of symbiont in host"
                },
                {
                  "category": "process",
                  "description": "negative regulation of branching involved in lung morphogenesis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of sequence-specific DNA binding transcription factor activity"
                },
                {
                  "category": "process",
                  "description": "lipopolysaccharide-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of nitric oxide biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "cortical actin cytoskeleton organization"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein phosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-gamma production"
                },
                {
                  "category": "process",
                  "description": "defense response to Gram-positive bacterium"
                },
                {
                  "category": "process",
                  "description": "negative regulation of osteoblast differentiation"
                },
                {
                  "category": "process",
                  "description": "regulation of insulin secretion"
                },
                {
                  "category": "process",
                  "description": "necroptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-8 biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of protein complex disassembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of programmed cell death"
                },
                {
                  "category": "process",
                  "description": "positive regulation of ERK1 and ERK2 cascade"
                },
                {
                  "category": "process",
                  "description": "cellular response to organic cyclic compound"
                },
                {
                  "category": "process",
                  "description": "establishment of protein localization to plasma membrane"
                },
                {
                  "category": "process",
                  "description": "I-kappaB kinase/NF-kappaB signaling"
                },
                {
                  "category": "process",
                  "description": "negative regulation of interleukin-6 production"
                },
                {
                  "category": "process",
                  "description": "response to salt stress"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein complex assembly"
                },
                {
                  "category": "process",
                  "description": "regulation of branching involved in salivary gland morphogenesis"
                },
                {
                  "category": "process",
                  "description": "chronic inflammatory response to antigenic stimulus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of smooth muscle cell proliferation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of I-kappaB kinase/NF-kappaB signaling"
                },
                {
                  "category": "process",
                  "description": "negative regulation of bicellular tight junction assembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of heterotypic cell-cell adhesion"
                },
                {
                  "category": "process",
                  "description": "negative regulation of viral genome replication"
                },
                {
                  "category": "process",
                  "description": "transformed cell apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-6 production"
                },
                {
                  "category": "process",
                  "description": "positive regulation of mononuclear cell migration"
                },
                {
                  "category": "process",
                  "description": "embryonic digestive tract development"
                },
                {
                  "category": "process",
                  "description": "positive regulation of NF-kappaB import into nucleus"
                },
                {
                  "category": "process",
                  "description": "cellular response to nicotine"
                },
                {
                  "category": "process",
                  "description": "negative regulation of myosin-light-chain-phosphatase activity"
                },
                {
                  "category": "process",
                  "description": "activation of cysteine-type endopeptidase activity involved in apoptotic process"
                },
                {
                  "category": "process",
                  "description": "extrinsic apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of lipid storage"
                },
                {
                  "category": "process",
                  "description": "positive regulation of phagocytosis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of myoblast differentiation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of translational initiation by iron"
                },
                {
                  "category": "process",
                  "description": "regulation of establishment of endothelial barrier"
                },
                {
                  "category": "process",
                  "description": "epithelial cell proliferation involved in salivary gland morphogenesis"
                },
                {
                  "category": "process",
                  "description": "regulation of tumor necrosis factor-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular response to amino acid stimulus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of NFAT protein import into nucleus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of calcidiol 1-monooxygenase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fat cell differentiation"
                },
                {
                  "category": "process",
                  "description": "regulation of immunoglobulin secretion"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-8 production"
                },
                {
                  "category": "process",
                  "description": "protein import into nucleus, translocation"
                },
                {
                  "category": "process",
                  "description": "regulation of I-kappaB kinase/NF-kappaB signaling"
                },
                {
                  "category": "process",
                  "description": "humoral immune response"
                }
              ]
            },
            "_id": "P01375",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000949",
          "name": "Tumor necrosis factor receptor superfamily member 1B",
          "organism": "Human",
          "actions": "",
          "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Tumor necrosis factor receptor superfamily member 1B",
            "general-function": "Ubiquitin protein ligase binding",
            "specific-function": "Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.",
            "gene-name": "TNFRSF1B",
            "locus": "1p36.3-p36.2",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "258-287",
            "signal-regions": "1-22",
            "theoretical-pi": "6.22",
            "molecular-weight": "48290.85",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:11917"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "TNFRSF1B"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M32315"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "189186"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P20333"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "TNR1B_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "p75",
                "p80 TNF-alpha receptor",
                "TNF-R2",
                "TNF-RII",
                "TNFBR",
                "TNFR-II",
                "TNFR2",
                "Tumor necrosis factor receptor 2",
                "Tumor necrosis factor receptor type II"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001890|Tumor necrosis factor receptor superfamily member 1B\nMAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPG\nQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTC\nRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICR\nPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTS\nFLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKV\nPHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGE\nARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQ\nVPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016265|Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B)\nATGGCGCCCGTCGCCGTCTGGGCCGCGCTGGCCGTCGGACTGGAGCTCTGGGCTGCGGCG\nCACGCCTTGCCCGCCCAGGTGGCATTTACACCCTACGCCCCGGAGCCCGGGAGCACATGC\nCGGCTCAGAGAATACTATGACCAGACAGCTCAGATGTGCTGCAGCAAATGCTCGCCGGGC\nCAACATGCAAAAGTCTTCTGTACCAAGACCTCGGACACCGTGTGTGACTCCTGTGAGGAC\nAGCACATACACCCAGCTCTGGAACTGGGTTCCCGAGTGCTTGAGCTGTGGCTCCCGCTGT\nAGCTCTGACCAGGTGGAAACTCAAGCCTGCACTCGGGAACAGAACCGCATCTGCACCTGC\nAGGCCCGGCTGGTACTGCGCGCTGAGCAAGCAGGAGGGGTGCCGGCTGTGCGCGCCGCTG\nCGCAAGTGCCGCCCGGGCTTCGGCGTGGCCAGACCAGGAACTGAAACATCAGACGTGGTG\nTGCAAGCCCTGTGCCCCGGGGACGTTCTCCAACACGACTTCATCCACGGATATTTGCAGG\nCCCCACCAGATCTGTAACGTGGTGGCCATCCCTGGGAATGCAAGCATGGATGCAGTCTGC\nACGTCCACGTCCCCCACCCGGAGTATGGCCCCAGGGGCAGTACACTTACCCCAGCCAGTG\nTCCACACGATCCCAACACACGCAGCCAACTCCAGAACCCAGCACTGCTCCAAGCACCTCC\nTTCCTGCTCCCAATGGGCCCCAGCCCCCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTT\nCCAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAAC\nTGTGTCATCATGACCCAGGTGAAAAAGAAGCCCTTGTGCCTGCAGAGAGAAGCCAAGGTG\nCCTCACTTGCCTGCCGATAAGGCCCGGGGTACACAGGGCCCCGAGCAGCAGCACCTGCTG\nATCACAGCGCCGAGCTCCAGCAGCAGCTCCCTGGAGAGCTCGGCCAGTGCGTTGGACAGA\nAGGGCGCCCACTCGGAACCAGCCACAGGCACCAGGCGTGGAGGCCAGTGGGGCCGGGGAG\nGCCCGGGCCAGCACCGGGAGCTCAGATTCTTCCCCTGGTGGCCATGGGACCCAGGTCAAT\nGTCACCTGCATCGTGAACGTCTGTAGCAGCTCTGACCACAGCTCACAGTGCTCCTCCCAA\nGCCAGCTCCACAATGGGAGACACAGATTCCAGCCCCTCGGAGTCCCCGAAGGACGAGCAG\nGTCCCCTTCTCCAAGGAGGAATGTGCCTTTCGGTCACAGCTGGAGACGCCAGAGACCCTG\nCTGGGGAGCACCGAAGAGAAGCCCCTGCCCCTTGGAGTGCCTGATGCTGGGATGAAGCCC\nAGTTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00020",
                "name": "TNFR_c6"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "perinuclear region of cytoplasm"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "membrane raft"
                },
                {
                  "category": "component",
                  "description": "nucleus"
                },
                {
                  "category": "component",
                  "description": "varicosity"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "neuronal cell body"
                },
                {
                  "category": "function",
                  "description": "tumor necrosis factor-activated receptor activity"
                },
                {
                  "category": "function",
                  "description": "ubiquitin protein ligase binding"
                },
                {
                  "category": "process",
                  "description": "apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "aging"
                },
                {
                  "category": "process",
                  "description": "intrinsic apoptotic signaling pathway in response to DNA damage"
                },
                {
                  "category": "process",
                  "description": "positive regulation of MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "cellular response to growth factor stimulus"
                },
                {
                  "category": "process",
                  "description": "tumor necrosis factor-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "multicellular organismal development"
                },
                {
                  "category": "process",
                  "description": "extrinsic apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of membrane protein ectodomain proteolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of inflammatory response"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "cellular response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "RNA destabilization"
                },
                {
                  "category": "process",
                  "description": "inflammatory response"
                },
                {
                  "category": "process",
                  "description": "regulation of apoptotic process"
                }
              ]
            },
            "_id": "P20333",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0000710",
          "name": "High affinity immunoglobulin gamma Fc receptor I",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "High affinity immunoglobulin gamma Fc receptor I",
            "general-function": "Receptor signaling protein activity",
            "specific-function": "High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.",
            "gene-name": "FCGR1A",
            "locus": "1q21.2-q21.3",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "293-313",
            "signal-regions": "1-15",
            "theoretical-pi": "8.08",
            "molecular-weight": "42631.525",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3613"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR1A"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X14356"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31332"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P12314"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCGR1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Fc-gamma RI",
                "Fc-gamma RIA",
                "FCG1",
                "FcgammaRIa",
                "FCGR1",
                "FcRI",
                "IGFR1",
                "IgG Fc receptor I"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00047",
                  "name": "ig"
                },
                {
                  "identifier": "PF13895",
                  "name": "Ig_2"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "clathrin-coated endocytic vesicle membrane"
                },
                {
                  "category": "component",
                  "description": "early endosome membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "receptor signaling protein activity"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "phagocytosis, engulfment"
                },
                {
                  "category": "process",
                  "description": "intracellular signal transduction"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "interferon-gamma-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "Fc-gamma receptor signaling pathway involved in phagocytosis"
                }
              ]
            },
            "_id": "P12314",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0002097",
          "name": "Low affinity immunoglobulin gamma Fc region receptor III-A",
          "organism": "Human",
          "actions": "",
          "references": "# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15457442\r\n# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15526004",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor III-A",
            "general-function": "",
            "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.",
            "gene-name": "FCGR3A",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "209-229",
            "signal-regions": "1-16",
            "theoretical-pi": "8.21",
            "molecular-weight": "29088.895",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3619"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR3A"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X52645"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31324"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P08637"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG3A_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD16A",
                "CD16a antigen",
                "Fc-gamma RIII",
                "Fc-gamma RIII-alpha",
                "Fc-gamma RIIIa",
                "FCG3",
                "FCGR3",
                "FcR-10",
                "FcRIII",
                "FcRIIIa",
                "IGFR3",
                "IgG Fc receptor III-2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "process",
                  "description": "regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "Fc-gamma receptor signaling pathway involved in phagocytosis"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P08637",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        },
        {
          "id": "BE0002098",
          "name": "Low affinity immunoglobulin gamma Fc region receptor II-a",
          "organism": "Human",
          "actions": "",
          "references": "# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15457442\r\n# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15526004",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor II-a",
            "general-function": "",
            "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.",
            "gene-name": "FCGR2A",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "218-240",
            "signal-regions": "1-33",
            "theoretical-pi": "6.78",
            "molecular-weight": "35000.42",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3616"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR2A"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M31932"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "182474"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P12318"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG2A_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD32",
                "CDw32",
                "Fc-gamma RII-a",
                "Fc-gamma-RIIa",
                "FCG2",
                "FCGR2A1",
                "FcRII-a",
                "IGFR2",
                "IgG Fc receptor II-a"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "process",
                  "description": "Fc-gamma receptor signaling pathway involved in phagocytosis"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P12318",
            "_source": "Swiss-Prot"
          },
          "_position": "5"
        },
        {
          "id": "BE0002099",
          "name": "Low affinity immunoglobulin gamma Fc region receptor II-b",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor II-b",
            "general-function": "",
            "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.",
            "gene-name": "FCGR2B",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "218-240",
            "signal-regions": "1-42",
            "theoretical-pi": "6.12",
            "molecular-weight": "34043.355",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3618"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR2B"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "U87560"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "4099445"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P31994"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG2B_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD32",
                "CDw32",
                "Fc-gamma RII-b",
                "Fc-gamma-RIIb",
                "FCG2",
                "FcRII-b",
                "IGFR2",
                "IgG Fc receptor II-b"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "viral process"
                }
              ]
            },
            "_id": "P31994",
            "_source": "Swiss-Prot"
          },
          "_position": "6"
        },
        {
          "id": "BE0002100",
          "name": "Low affinity immunoglobulin gamma Fc region receptor II-c",
          "organism": "Human",
          "actions": "",
          "references": "# Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10800083\r\n# Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7535196",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor II-c",
            "general-function": "Transmembrane signaling receptor activity",
            "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.",
            "gene-name": "FCGR2C",
            "locus": "1q23.3",
            "cellular-location": "Cytoplasm",
            "transmembrane-regions": "224-246",
            "signal-regions": "1-42",
            "theoretical-pi": "6.9",
            "molecular-weight": "35577.96",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:15626"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR2C"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X17652"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "32074"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P31995"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG2C_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD32",
                "CDw32",
                "Fc-gamma RII-c",
                "Fc-gamma-RIIc",
                "FCG2",
                "FcRII-c",
                "IGFR2",
                "IgG Fc receptor II-c"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "transmembrane signaling receptor activity"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "immune response"
                }
              ]
            },
            "_id": "P31995",
            "_source": "Swiss-Prot"
          },
          "_position": "7"
        },
        {
          "id": "BE0001087",
          "name": "Lymphotoxin-alpha",
          "organism": "Human",
          "actions": "",
          "references": "# Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11302411\r\n# Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT, Goeddel DV: Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem. 1992 Oct 15;267(29):21172-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1328224\r\n# Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15005015\r\n# Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15033655\r\n# Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15695296",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Lymphotoxin-alpha",
            "general-function": "Receptor binding",
            "specific-function": "Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.",
            "gene-name": "LTA",
            "locus": "6p21.3",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-34",
            "theoretical-pi": "9.36",
            "molecular-weight": "22296.57",
            "chromosome-location": "6",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6709"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "LTA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X01393"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "34445"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P01374"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "TNFB_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "LT-alpha",
                "TNF-beta",
                "TNFB",
                "TNFSF1",
                "Tumor necrosis factor ligand superfamily member 1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010761|Lymphotoxin-alpha\nMTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST\nLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY\nSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ\nLSTHTDGIPHLVLSPSTVFFGAFAL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010762|Lymphotoxin-alpha (LTA)\nATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC\nCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC\nACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC\nCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA\nGCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG\nGTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC\nTCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC\nCAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG\nGAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG\nCTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT\nGGAGCCTTCGCTCTGTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00229",
                "name": "TNF"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "process",
                  "description": "defense response to Gram-positive bacterium"
                },
                {
                  "category": "process",
                  "description": "cell-cell signaling"
                },
                {
                  "category": "process",
                  "description": "lymph node development"
                },
                {
                  "category": "process",
                  "description": "positive regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of chronic inflammatory response to antigenic stimulus"
                },
                {
                  "category": "process",
                  "description": "apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of glial cell proliferation"
                },
                {
                  "category": "process",
                  "description": "response to hypoxia"
                },
                {
                  "category": "process",
                  "description": "positive regulation of humoral immune response mediated by circulating immunoglobulin"
                },
                {
                  "category": "process",
                  "description": "response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "response to nutrient"
                },
                {
                  "category": "process",
                  "description": "response to drug"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-gamma production"
                },
                {
                  "category": "process",
                  "description": "negative regulation of growth of symbiont in host"
                },
                {
                  "category": "process",
                  "description": "tumor necrosis factor-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibroblast proliferation"
                },
                {
                  "category": "process",
                  "description": "humoral immune response"
                }
              ]
            },
            "_id": "P01374",
            "_source": "Swiss-Prot"
          },
          "_position": "8"
        },
        {
          "id": "BE0000901",
          "name": "Low affinity immunoglobulin gamma Fc region receptor III-B",
          "organism": "Human",
          "actions": "",
          "references": "# Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10800083\r\n# Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17387033\r\n# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15457442\r\n# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15526004",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low affinity immunoglobulin gamma Fc region receptor III-B",
            "general-function": "",
            "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.",
            "gene-name": "FCGR3B",
            "locus": "1q23",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "",
            "signal-regions": "1-16",
            "theoretical-pi": "6.71",
            "molecular-weight": "26215.64",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3620"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FCGR3B"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X16863"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31322"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "O75015"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FCG3B_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CD16B",
                "Fc-gamma RIII",
                "Fc-gamma RIII-beta",
                "Fc-gamma RIIIb",
                "FCG3",
                "FCGR3",
                "FcR-10",
                "FcRIII",
                "FcRIIIb",
                "IGFR3",
                "IgG Fc receptor III-1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13895",
                "name": "Ig_2"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "anchored component of membrane"
                },
                {
                  "category": "process",
                  "description": "mitophagy in response to mitochondrial depolarization"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "positive regulation of defense response to virus by host"
                },
                {
                  "category": "process",
                  "description": "xenophagy"
                }
              ]
            },
            "_id": "O75015",
            "_source": "Swiss-Prot"
          },
          "_position": "9"
        },
        {
          "id": "BE0001529",
          "name": "Complement C1s subcomponent",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1s subcomponent",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.",
            "gene-name": "C1S",
            "locus": "12p13",
            "cellular-location": "Cytoplasmic",
            "transmembrane-regions": "",
            "signal-regions": "1-15",
            "theoretical-pi": "4.59",
            "molecular-weight": "76683.905",
            "chromosome-location": "12",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1247"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1S"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X06596"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "763110"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2335"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P09871"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1S_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.42",
                "C1 esterase",
                "Complement component 1 subcomponent s"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011082|Complement C1s subcomponent\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011083|Complement C1s subcomponent (C1S)\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00084",
                  "name": "Sushi"
                },
                {
                  "identifier": "PF00431",
                  "name": "CUB"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "function",
                  "description": "identical protein binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                }
              ]
            },
            "_id": "P09871",
            "_source": "Swiss-Prot"
          },
          "_position": "10"
        },
        {
          "id": "BE0002093",
          "name": "Complement C1r subcomponent",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1r subcomponent",
            "general-function": "Serine-type peptidase activity",
            "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.",
            "gene-name": "C1R",
            "locus": "12p13",
            "cellular-location": "Cytoplasmic",
            "transmembrane-regions": "",
            "signal-regions": "1-17",
            "theoretical-pi": "6.24",
            "molecular-weight": "80118.04",
            "chromosome-location": "12",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1246"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1R"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X04701"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "29539"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2334"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00736"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1R_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.41",
                "Complement component 1 subcomponent r"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011518|Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDTHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011519|Complement C1r subcomponent (C1R)\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00084",
                  "name": "Sushi"
                },
                {
                  "identifier": "PF00431",
                  "name": "CUB"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "serine-type peptidase activity"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "immune response"
                }
              ]
            },
            "_id": "P00736",
            "_source": "Swiss-Prot"
          },
          "_position": "11"
        },
        {
          "id": "BE0002094",
          "name": "Complement C1q subcomponent subunit A",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1q subcomponent subunit A",
            "general-function": "",
            "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.",
            "gene-name": "C1QA",
            "locus": "1p36.12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "9.45",
            "molecular-weight": "26016.47",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1241"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1QA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF135157"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "4894854"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02745"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1QA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "Complement C1q subcomponent subunit A precursor"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01391",
                  "name": "Collagen"
                },
                {
                  "identifier": "PF00386",
                  "name": "C1q"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "complement component C1 complex"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "collagen trimer"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "cell-cell signaling"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P02745",
            "_source": "Swiss-Prot"
          },
          "_position": "12"
        },
        {
          "id": "BE0002095",
          "name": "Complement C1q subcomponent subunit B",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1q subcomponent subunit B",
            "general-function": "",
            "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.",
            "gene-name": "C1QB",
            "locus": "1p36.12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-27",
            "theoretical-pi": "8.87",
            "molecular-weight": "26721.62",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1242"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1QB"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X03084"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "573114"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02746"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1QB_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "Complement C1q subcomponent subunit B precursor"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\nIFSGFLLFPDMEA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01391",
                  "name": "Collagen"
                },
                {
                  "identifier": "PF00386",
                  "name": "C1q"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "collagen trimer"
                },
                {
                  "category": "component",
                  "description": "complement component C1 complex"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "inner ear development"
                }
              ]
            },
            "_id": "P02746",
            "_source": "Swiss-Prot"
          },
          "_position": "13"
        },
        {
          "id": "BE0002096",
          "name": "Complement C1q subcomponent subunit C",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Complement C1q subcomponent subunit C",
            "general-function": "",
            "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.",
            "gene-name": "C1QC",
            "locus": "1p36.11",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-28",
            "theoretical-pi": "8.58",
            "molecular-weight": "25773.56",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1245"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "C1QC"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF087892"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "33150626"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02747"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "C1QC_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "C1QG"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011520|Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01391",
                  "name": "Collagen"
                },
                {
                  "identifier": "PF00386",
                  "name": "C1q"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "collagen trimer"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "process",
                  "description": "complement activation, classical pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of granulocyte differentiation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of macrophage differentiation"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "complement activation"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                }
              ]
            },
            "_id": "P02747",
            "_source": "Swiss-Prot"
          },
          "_position": "14"
        }
      ]
    },
    "enzymes": {
      "enzyme": {
        "id": "BE0000262",
        "name": "Prostaglandin G/H synthase 2",
        "organism": "Human",
        "actions": {
          "action": "inhibitor"
        },
        "references": "# Bawolak MT, Touzin K, Moreau ME, Desormeaux A, Adam A, Marceau F: Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul Pept. 2008 Feb 7;146(1-3):157-68. Epub 2007 Sep 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17931716\r\n# Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Bramanti P, Cuzzocrea S: Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther. 2006 Mar;316(3):1006-16. Epub 2005 Nov 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16303916",
        "known-action": "unknown",
        "polypeptide": {
          "name": "Prostaglandin G/H synthase 2",
          "general-function": "Prostaglandin-endoperoxide synthase activity",
          "specific-function": "Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.",
          "gene-name": "PTGS2",
          "locus": "1q25.2-q25.3",
          "cellular-location": "Microsome membrane",
          "transmembrane-regions": "",
          "signal-regions": "1-17",
          "theoretical-pi": "7.41",
          "molecular-weight": "68995.625",
          "chromosome-location": "1",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:9605"
              },
              {
                "resource": "GenAtlas",
                "identifier": "PTGS2"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "L15326"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "291988"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "1376"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P35354"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "PGH2_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "1.14.99.1",
              "COX-2",
              "COX2",
              "Cyclooxygenase-2",
              "PGH synthase 2",
              "PGHS-2",
              "PHS II",
              "Prostaglandin H2 synthase 2",
              "Prostaglandin-endoperoxide synthase 2"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0021832|Prostaglandin G/H synthase 2\nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)\nATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT\nTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT\nAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG\nACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC\nTTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT\nTATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT\nGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT\nGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA\nAATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA\nAACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT\nAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC\nGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\nCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC\nTACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG\nGTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT\nGTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA\nATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC\nTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA\nAATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC\nTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG\nCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT\nGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG\nAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC\nTATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC\nTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA\nGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT\nATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG\nGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC\nTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT\nGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT\nTCGACTGAACTGTAG"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF03098",
                "name": "An_peroxidase"
              },
              {
                "identifier": "PF00008",
                "name": "EGF"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "caveola"
              },
              {
                "category": "component",
                "description": "endoplasmic reticulum membrane"
              },
              {
                "category": "component",
                "description": "cytoplasm"
              },
              {
                "category": "component",
                "description": "protein complex"
              },
              {
                "category": "component",
                "description": "neuron projection"
              },
              {
                "category": "component",
                "description": "nucleus"
              },
              {
                "category": "component",
                "description": "endoplasmic reticulum lumen"
              },
              {
                "category": "component",
                "description": "endoplasmic reticulum"
              },
              {
                "category": "function",
                "description": "lipid binding"
              },
              {
                "category": "function",
                "description": "prostaglandin-endoperoxide synthase activity"
              },
              {
                "category": "function",
                "description": "heme binding"
              },
              {
                "category": "function",
                "description": "metal ion binding"
              },
              {
                "category": "function",
                "description": "arachidonate 15-lipoxygenase activity"
              },
              {
                "category": "function",
                "description": "enzyme binding"
              },
              {
                "category": "function",
                "description": "peroxidase activity"
              },
              {
                "category": "process",
                "description": "cellular response to UV"
              },
              {
                "category": "process",
                "description": "cellular response to mechanical stimulus"
              },
              {
                "category": "process",
                "description": "positive regulation of fever generation"
              },
              {
                "category": "process",
                "description": "sensory perception of pain"
              },
              {
                "category": "process",
                "description": "positive regulation of vascular endothelial growth factor production"
              },
              {
                "category": "process",
                "description": "positive regulation of nitric oxide biosynthetic process"
              },
              {
                "category": "process",
                "description": "response to drug"
              },
              {
                "category": "process",
                "description": "negative regulation of smooth muscle contraction"
              },
              {
                "category": "process",
                "description": "response to estradiol"
              },
              {
                "category": "process",
                "description": "brown fat cell differentiation"
              },
              {
                "category": "process",
                "description": "arachidonic acid metabolic process"
              },
              {
                "category": "process",
                "description": "positive regulation of synaptic transmission, glutamatergic"
              },
              {
                "category": "process",
                "description": "negative regulation of cell proliferation"
              },
              {
                "category": "process",
                "description": "negative regulation of calcium ion transport"
              },
              {
                "category": "process",
                "description": "cellular response to ATP"
              },
              {
                "category": "process",
                "description": "response to oxidative stress"
              },
              {
                "category": "process",
                "description": "lipoxygenase pathway"
              },
              {
                "category": "process",
                "description": "cellular response to fluid shear stress"
              },
              {
                "category": "process",
                "description": "positive regulation of brown fat cell differentiation"
              },
              {
                "category": "process",
                "description": "positive regulation of smooth muscle contraction"
              },
              {
                "category": "process",
                "description": "response to vitamin D"
              },
              {
                "category": "process",
                "description": "angiogenesis"
              },
              {
                "category": "process",
                "description": "regulation of blood pressure"
              },
              {
                "category": "process",
                "description": "positive regulation of NF-kappaB import into nucleus"
              },
              {
                "category": "process",
                "description": "maintenance of blood-brain barrier"
              },
              {
                "category": "process",
                "description": "regulation of inflammatory response"
              },
              {
                "category": "process",
                "description": "decidualization"
              },
              {
                "category": "process",
                "description": "movement of cell or subcellular component"
              },
              {
                "category": "process",
                "description": "inflammatory response"
              },
              {
                "category": "process",
                "description": "response to manganese ion"
              },
              {
                "category": "process",
                "description": "response to tumor necrosis factor"
              },
              {
                "category": "process",
                "description": "positive regulation of synaptic plasticity"
              },
              {
                "category": "process",
                "description": "NAD metabolic process"
              },
              {
                "category": "process",
                "description": "cyclooxygenase pathway"
              },
              {
                "category": "process",
                "description": "learning"
              },
              {
                "category": "process",
                "description": "positive regulation of transforming growth factor beta production"
              },
              {
                "category": "process",
                "description": "negative regulation of synaptic transmission, dopaminergic"
              },
              {
                "category": "process",
                "description": "vitamin metabolic process"
              },
              {
                "category": "process",
                "description": "negative regulation of cell cycle"
              },
              {
                "category": "process",
                "description": "positive regulation of prostaglandin biosynthetic process"
              },
              {
                "category": "process",
                "description": "nicotinamide metabolic process"
              },
              {
                "category": "process",
                "description": "bone mineralization"
              },
              {
                "category": "process",
                "description": "hair cycle"
              },
              {
                "category": "process",
                "description": "water-soluble vitamin metabolic process"
              },
              {
                "category": "process",
                "description": "positive regulation of vasoconstriction"
              },
              {
                "category": "process",
                "description": "prostaglandin biosynthetic process"
              },
              {
                "category": "process",
                "description": "small molecule metabolic process"
              },
              {
                "category": "process",
                "description": "embryo implantation"
              },
              {
                "category": "process",
                "description": "positive regulation of fibroblast growth factor production"
              },
              {
                "category": "process",
                "description": "positive regulation of smooth muscle cell proliferation"
              },
              {
                "category": "process",
                "description": "positive regulation of cell migration involved in sprouting angiogenesis"
              },
              {
                "category": "process",
                "description": "positive regulation of apoptotic process"
              },
              {
                "category": "process",
                "description": "response to lithium ion"
              },
              {
                "category": "process",
                "description": "positive regulation of platelet-derived growth factor production"
              },
              {
                "category": "process",
                "description": "response to glucocorticoid"
              },
              {
                "category": "process",
                "description": "cellular response to hypoxia"
              },
              {
                "category": "process",
                "description": "ovulation"
              },
              {
                "category": "process",
                "description": "response to fructose"
              },
              {
                "category": "process",
                "description": "response to fatty acid"
              },
              {
                "category": "process",
                "description": "response to lipopolysaccharide"
              },
              {
                "category": "process",
                "description": "memory"
              },
              {
                "category": "process",
                "description": "prostaglandin metabolic process"
              }
            ]
          },
          "_id": "P35354",
          "_source": "Swiss-Prot"
        },
        "inhibition-strength": "unknown",
        "induction-strength": "unknown",
        "_position": "15"
      }
    },
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2014-11-11"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00006"
      },
      "BIOD00076",
      "BTD00076"
    ],
    "name": "Bivalirudin",
    "description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. ",
    "cas-number": "128270-60-0",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16466327\r\n# Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17381384\r\n# Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16553503\r\n# Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11156732\r\n# Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21108549\r\n# Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16614733\r\n# Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12851152",
    "synthesis-reference": "Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, \"Process for production of Bivalirudin.\" U.S. Patent US20070093423, issued April 26, 2007.",
    "indication": "For treatment of heparin-induced thrombocytopenia and for the\r\nprevention of thrombosis. Bivalirudin is indicated for use in\r\npatients undergoing percutaneous coronary intervention (PCI), in\r\npatients at moderate to high risk acute coronary syndromes due to\r\nunstable angina or non-ST segment elevation in whom a PCI is planned.",
    "pharmacodynamics": "Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin. ",
    "mechanism-of-action": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.",
    "toxicity": "Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
    "metabolism": "80% proteolytic cleavage",
    "absorption": "Following intravenous administration, bivalirudin exhibits linear\r\npharmacokinetics .  The mean steady state concentration is 12.3 +/-\r\n1.7mcg/mL after administration of an intravenous bolus of 1mg/kg\r\nfollowd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.",
    "half-life": "* Normal renal function: 25 min (in normal conditions)\r\n* Creatinine clearance 10-29mL/min: 57min\r\n* Dialysis-dependant patients: 3.5h",
    "protein-binding": "Other than thrombin and red blood cells, bivalirudin does not bind to\r\nplasma proteins.",
    "route-of-elimination": "Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.",
    "volume-of-distribution": "0.2L/kg",
    "clearance": "* 3.4 mL/min/kg [Normal renal function]\r\n* 3.4 mL/min/kg [mild renal function]\r\n* 2.7 mL/min/kg [moderate renal function]\r\n* 2.8 mL/min/kg [severe renal function]\r\n* 1 mL/min/kg [Dialysis-dependent patients]",
    "classification": {
      "description": "This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.",
      "direct-parent": "Polypeptides",
      "kingdom": "Organic compounds",
      "superclass": "Organic Polymers",
      "class": "Polypeptides",
      "subclass": "",
      "alternative-parent": [
        "Alpha amino acid amides",
        "Amino fatty acids",
        "Amphetamines and derivatives",
        "Aralkylamines",
        "Azacyclic compounds",
        "Carbonyl compounds",
        "Carboximidamides",
        "Carboxylic acids",
        "Guanidines",
        "Hexacarboxylic acids and derivatives",
        "Hydrocarbon derivatives",
        "Imines",
        "Monoalkylamines",
        "N-acyl amines",
        "N-acyl-L-alpha-amino acids",
        "N-acyl-aliphatic-alpha amino acids",
        "N-acylpyrrolidines",
        "Peptides",
        "Phenols and derivatives",
        "Phenylpropylamines",
        "Primary carboxylic acid amides",
        "Pyrrolidinecarboxamides",
        "Secondary carboxylic acid amides",
        "Tertiary amines",
        "Tertiary carboxylic acid amides"
      ],
      "substituent": [
        "Alpha peptide",
        "Alpha-amino acid amide",
        "Alpha-amino acid or derivatives",
        "Amine",
        "Amino fatty acid",
        "Amphetamine or derivatives",
        "Aralkylamine",
        "Aromatic heteromonocyclic compound",
        "Azacycle",
        "Benzenoid",
        "Carbonyl group",
        "Carboxamide group",
        "Carboximidamide",
        "Carboxylic acid",
        "Carboxylic acid amide",
        "Carboxylic acid derivative",
        "Fatty acyl",
        "Fatty amide",
        "Guanidine",
        "Hexacarboxylic acid or derivatives",
        "Hydrocarbon derivative",
        "Imine",
        "Monocyclic benzene moiety",
        "N-acyl-aliphatic-alpha amino acid",
        "N-acyl-alpha amino acid or derivatives",
        "N-acyl-alpha-amino acid",
        "N-acyl-amine",
        "N-acyl-l-alpha-amino acid",
        "N-acylpyrrolidine",
        "N-substituted-alpha-amino acid",
        "Organoheterocyclic compound",
        "Organonitrogen compound",
        "Organooxygen compound",
        "Phenol",
        "Phenylpropylamine",
        "Polypeptide",
        "Primary aliphatic amine",
        "Primary amine",
        "Primary carboxylic acid amide",
        "Pyrrolidine",
        "Pyrrolidine carboxylic acid or derivatives",
        "Pyrrolidine-2-carboxamide",
        "Secondary carboxylic acid amide",
        "Tertiary amine",
        "Tertiary carboxylic acid amide"
      ]
    },
    "salts": "",
    "synonyms": "",
    "products": {
      "product": [
        {
          "name": "Angiomax",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246533",
          "started-marketing-on": "2003-05-08",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "250 mg",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Angiomax",
          "ndc-id": "",
          "ndc-product-code": "65293-001",
          "dpd-id": "",
          "started-marketing-on": "2000-12-15",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "250 mg/1",
          "route": "intravenous",
          "fda-application-number": "NDA020873",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Angiomax",
          "ndc-id": "",
          "ndc-product-code": "55154-2275",
          "dpd-id": "",
          "started-marketing-on": "2000-12-15",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "250 mg/1",
          "route": "intravenous",
          "fda-application-number": "NDA020873",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Bivalirudin",
          "ndc-id": "",
          "ndc-product-code": "0781-3158",
          "dpd-id": "",
          "started-marketing-on": "2015-06-15",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "250 mg/1",
          "route": "intravenous",
          "fda-application-number": "NDA020873",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Bivalirudin",
          "ndc-id": "",
          "ndc-product-code": "0409-8300",
          "dpd-id": "",
          "started-marketing-on": "2015-07-14",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "250 mg/1",
          "route": "intravenous",
          "fda-application-number": "ANDA090816",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Bivalirudin",
          "ndc-id": "",
          "ndc-product-code": "0781-9158",
          "dpd-id": "",
          "started-marketing-on": "2015-10-23",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "250 mg/1",
          "route": "intravenous",
          "fda-application-number": "NDA020873",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Bivalirudin for Injection",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02435268",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "250 mg",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Angiox",
        "company": ""
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Bivalirudin",
          "ingredients": "Bivalirudin"
        },
        {
          "name": "Bivalirudin",
          "ingredients": "Bivalirudin"
        },
        {
          "name": "Bivalirudin",
          "ingredients": "Bivalirudin"
        },
        {
          "name": "Angiomax",
          "ingredients": "Bivalirudin"
        },
        {
          "name": "Angiomax",
          "ingredients": "Bivalirudin"
        },
        {
          "name": "Angiomax",
          "ingredients": "Bivalirudin"
        },
        {
          "name": "Bivalirudin for Injection",
          "ingredients": "Bivalirudin"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Ben Venue Laboratories Inc.",
          "url": "http://www.benvenue.com"
        },
        {
          "name": "Oryx Pharmaceuticals Inc.",
          "url": ""
        },
        {
          "name": "Sepracor Pharmaceuticals Inc.",
          "url": "http://www.sepracor.com"
        },
        {
          "name": "The Medicines Co.",
          "url": "http://www.themedicinescompany.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "The medicines co"
      }
    },
    "prices": {
      "price": {
        "description": "Angiomax 250 mg vial",
        "cost": {
          "_currency": "USD",
          "__text": "780.0"
        },
        "unit": "vial"
      }
    },
    "categories": {
      "category": {
        "category": "Antithrombins",
        "mesh-id": "[\"D27.505.519.389.745.800.449\", \"D27.505.954.502.119.500\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "250 mg"
        },
        {
          "form": "Injection, powder, lyophilized, for solution",
          "route": "intravenous",
          "strength": "250 mg/1"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "B",
            "__text": "BLOOD AND BLOOD FORMING ORGANS"
          },
          {
            "_code": "B01",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01A",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01AE",
            "__text": "Direct thrombin inhibitors"
          }
        ],
        "_code": "B01AE06"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "20:12.04.12"
    },
    "patents": {
      "patent": [
        {
          "number": "2065150",
          "country": "Canada",
          "approved": "1999-12-14",
          "expires": "2010-08-17"
        },
        {
          "number": "5196404",
          "country": "United States",
          "approved": "1993-05-23",
          "expires": "2010-05-23"
        },
        {
          "number": "7582727",
          "country": "United States",
          "approved": "2009-01-27",
          "expires": "2029-01-27"
        }
      ]
    },
    "food-interactions": {
      "food-interaction": [
        "Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark",
        "Echinacea"
      ]
    },
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00054",
          "name": "Abciximab",
          "description": "Abciximab may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB01418",
          "name": "Acenocoumarol",
          "description": "Acenocoumarol may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00945",
          "name": "Acetylsalicylic acid",
          "description": "Acetylsalicylic acid may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00009",
          "name": "Alteplase",
          "description": "Alteplase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00029",
          "name": "Anistreplase",
          "description": "Anistreplase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB06605",
          "name": "Apixaban",
          "description": "Apixaban may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00269",
          "name": "Chlorotrianisene",
          "description": "Chlorotrianisene may decrease the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB04272",
          "name": "Citric Acid",
          "description": "Citric Acid may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB11249",
          "name": "Collagenase",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase."
        },
        {
          "drugbank-id": "DB06695",
          "name": "Dabigatran etexilate",
          "description": "Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB06779",
          "name": "Dalteparin",
          "description": "Dalteparin may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB01254",
          "name": "Dasatinib",
          "description": "Dasatinib may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB01609",
          "name": "Deferasirox",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox."
        },
        {
          "drugbank-id": "DB03619",
          "name": "Deoxycholic Acid",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deoxycholic Acid."
        },
        {
          "drugbank-id": "DB00304",
          "name": "Desogestrel",
          "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Desogestrel."
        },
        {
          "drugbank-id": "DB00266",
          "name": "Dicoumarol",
          "description": "Dicoumarol may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00378",
          "name": "Dydrogesterone",
          "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dydrogesterone."
        },
        {
          "drugbank-id": "DB00974",
          "name": "Edetic Acid",
          "description": "Edetic Acid may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB09075",
          "name": "Edoxaban",
          "description": "Edoxaban may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB01225",
          "name": "Enoxaparin",
          "description": "Enoxaparin may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB08794",
          "name": "Ethyl biscoumacetate",
          "description": "Ethyl biscoumacetate may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00569",
          "name": "Fondaparinux sodium",
          "description": "Fondaparinux sodium may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB06730",
          "name": "Gestodene",
          "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestodene."
        },
        {
          "drugbank-id": "DB01109",
          "name": "Heparin",
          "description": "Heparin may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB04865",
          "name": "Homoharringtonine",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Homoharringtonine."
        },
        {
          "drugbank-id": "DB00078",
          "name": "Ibritumomab",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab."
        },
        {
          "drugbank-id": "DB09053",
          "name": "Ibrutinib",
          "description": "The risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin."
        },
        {
          "drugbank-id": "DB00065",
          "name": "Infliximab",
          "description": "Infliximab may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB09211",
          "name": "Limaprost",
          "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Bivalirudin."
        },
        {
          "drugbank-id": "DB09079",
          "name": "Nintedanib",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Nintedanib."
        },
        {
          "drugbank-id": "DB08935",
          "name": "Obinutuzumab",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab."
        },
        {
          "drugbank-id": "DB11133",
          "name": "Omega-3 fatty acids",
          "description": "Omega-3 fatty acids may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00686",
          "name": "Pentosan Polysulfate",
          "description": "Pentosan Polysulfate may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00498",
          "name": "Phenindione",
          "description": "Phenindione may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00946",
          "name": "Phenprocoumon",
          "description": "Phenprocoumon may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00396",
          "name": "Progesterone",
          "description": "The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone."
        },
        {
          "drugbank-id": "DB00015",
          "name": "Reteplase",
          "description": "Reteplase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB01207",
          "name": "Ridogrel",
          "description": "Ridogrel may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB06228",
          "name": "Rivaroxaban",
          "description": "Bivalirudin may increase the anticoagulant activities of Rivaroxaban."
        },
        {
          "drugbank-id": "DB01398",
          "name": "Salicylate-sodium",
          "description": "Salicylate-sodium may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00086",
          "name": "Streptokinase",
          "description": "Streptokinase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB06206",
          "name": "Sugammadex",
          "description": "Sugammadex may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB06271",
          "name": "Sulodexide",
          "description": "Sulodexide may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00031",
          "name": "Tenecteplase",
          "description": "Tenecteplase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB09070",
          "name": "Tibolone",
          "description": "Tibolone may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00932",
          "name": "Tipranavir",
          "description": "Tipranavir may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00081",
          "name": "Tositumomab",
          "description": "The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab."
        },
        {
          "drugbank-id": "DB00374",
          "name": "Treprostinil",
          "description": "Treprostinil may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00013",
          "name": "Urokinase",
          "description": "Urokinase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00163",
          "name": "Vitamin E",
          "description": "Vitamin E may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB09030",
          "name": "Vorapaxar",
          "description": "The risk or severity of adverse effects can be increased when Vorapaxar is combined with Bivalirudin."
        },
        {
          "drugbank-id": "DB00682",
          "name": "Warfarin",
          "description": "Warfarin may increase the anticoagulant activities of Bivalirudin."
        }
      ]
    },
    "calculated-properties": {
      "property": [
        {
          "kind": "logP",
          "value": "-0.76",
          "source": "ALOGPS"
        },
        {
          "kind": "logS",
          "value": "-4.7",
          "source": "ALOGPS"
        },
        {
          "kind": "Water Solubility",
          "value": "4.64e-02 g/l",
          "source": "ALOGPS"
        },
        {
          "kind": "logP",
          "value": "-14",
          "source": "ChemAxon"
        },
        {
          "kind": "IUPAC Name",
          "value": "(4S)-4-[(2S)-2-[(2S)-2-[(2S)-2-{2-[(2S)-2-(2-{2-[2-(2-{[(2S)-1-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-phenylpropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetamido)acetamido]acetamido}acetamido)-3-carbamoylpropanamido]acetamido}-3-carboxypropanamido]-3-phenylpropanamido]-4-carboxybutanamido]-4-{[(2S,3S)-1-[(2S)-2-{[(1S)-3-carboxy-1-{[(1S)-3-carboxy-1-{[(1S)-1-{[(1S)-1-carboxy-3-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}propyl]carbamoyl}propyl]carbamoyl}pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl}butanoic acid",
          "source": "ChemAxon"
        },
        {
          "kind": "Traditional IUPAC Name",
          "value": "bivalirudin",
          "source": "ChemAxon"
        },
        {
          "kind": "Molecular Weight",
          "value": "2180.2853",
          "source": "ChemAxon"
        },
        {
          "kind": "Monoisotopic Weight",
          "value": "2178.985813062",
          "source": "ChemAxon"
        },
        {
          "kind": "SMILES",
          "value": "CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O",
          "source": "ChemAxon"
        },
        {
          "kind": "Molecular Formula",
          "value": "C98H138N24O33",
          "source": "ChemAxon"
        },
        {
          "kind": "InChI",
          "value": "InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1",
          "source": "ChemAxon"
        },
        {
          "kind": "InChIKey",
          "value": "OIRCOABEOLEUMC-GEJPAHFPSA-N",
          "source": "ChemAxon"
        },
        {
          "kind": "Polar Surface Area (PSA)",
          "value": "901.57",
          "source": "ChemAxon"
        },
        {
          "kind": "Refractivity",
          "value": "543.33",
          "source": "ChemAxon"
        },
        {
          "kind": "Polarizability",
          "value": "215.46",
          "source": "ChemAxon"
        },
        {
          "kind": "Rotatable Bond Count",
          "value": "66",
          "source": "ChemAxon"
        },
        {
          "kind": "H Bond Acceptor Count",
          "value": "37",
          "source": "ChemAxon"
        },
        {
          "kind": "H Bond Donor Count",
          "value": "28",
          "source": "ChemAxon"
        },
        {
          "kind": "pKa (strongest acidic)",
          "value": "2.79",
          "source": "ChemAxon"
        },
        {
          "kind": "pKa (strongest basic)",
          "value": "11.88",
          "source": "ChemAxon"
        },
        {
          "kind": "Physiological Charge",
          "value": "-4",
          "source": "ChemAxon"
        },
        {
          "kind": "Number of Rings",
          "value": "6",
          "source": "ChemAxon"
        },
        {
          "kind": "Bioavailability",
          "value": "0",
          "source": "ChemAxon"
        },
        {
          "kind": "Rule of Five",
          "value": "0",
          "source": "ChemAxon"
        },
        {
          "kind": "Ghose Filter",
          "value": "0",
          "source": "ChemAxon"
        },
        {
          "kind": "MDDR-Like Rule",
          "value": "1",
          "source": "ChemAxon"
        }
      ]
    },
    "experimental-properties": "",
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "12945"
        },
        {
          "resource": "ChEBI",
          "identifier": "59173"
        },
        {
          "resource": "PubChem Compound",
          "identifier": "16129704"
        },
        {
          "resource": "PubChem Substance",
          "identifier": "46507415"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D03136"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA10032"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Bivalirudin"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/angiomax.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/bivalirudin.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000048",
        "name": "Prothrombin",
        "organism": "Human",
        "actions": {
          "action": "inhibitor"
        },
        "references": "# Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11060732\r\n# Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11504570\r\n# Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11833835\r\n# Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11923794\r\n# Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11929334\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Prothrombin",
          "general-function": "Thrombospondin receptor activity",
          "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.",
          "gene-name": "F2",
          "locus": "11p11-q12",
          "cellular-location": "Secreted",
          "transmembrane-regions": "",
          "signal-regions": "1-24",
          "theoretical-pi": "5.7",
          "molecular-weight": "70036.295",
          "chromosome-location": "11",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:3535"
              },
              {
                "resource": "GenAtlas",
                "identifier": "F2"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "M17262"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "339641"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "2362"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P00734"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "THRB_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "3.4.21.5",
              "Coagulation factor II"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00594",
                "name": "Gla"
              },
              {
                "identifier": "PF00051",
                "name": "Kringle"
              },
              {
                "identifier": "PF00089",
                "name": "Trypsin"
              },
              {
                "identifier": "PF09396",
                "name": "Thrombin_light"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "endoplasmic reticulum lumen"
              },
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "extracellular space"
              },
              {
                "category": "component",
                "description": "blood microparticle"
              },
              {
                "category": "component",
                "description": "extracellular matrix"
              },
              {
                "category": "component",
                "description": "Golgi lumen"
              },
              {
                "category": "component",
                "description": "cytosol"
              },
              {
                "category": "component",
                "description": "extracellular exosome"
              },
              {
                "category": "component",
                "description": "extracellular region"
              },
              {
                "category": "function",
                "description": "growth factor activity"
              },
              {
                "category": "function",
                "description": "receptor binding"
              },
              {
                "category": "function",
                "description": "thrombospondin receptor activity"
              },
              {
                "category": "function",
                "description": "calcium ion binding"
              },
              {
                "category": "function",
                "description": "serine-type endopeptidase activity"
              },
              {
                "category": "process",
                "description": "cytosolic calcium ion homeostasis"
              },
              {
                "category": "process",
                "description": "positive regulation of phosphatidylinositol 3-kinase signaling"
              },
              {
                "category": "process",
                "description": "cellular response to mechanical stimulus"
              },
              {
                "category": "process",
                "description": "fibrinolysis"
              },
              {
                "category": "process",
                "description": "positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "leukocyte migration"
              },
              {
                "category": "process",
                "description": "multicellular organismal development"
              },
              {
                "category": "process",
                "description": "positive regulation of reactive oxygen species metabolic process"
              },
              {
                "category": "process",
                "description": "cellular protein metabolic process"
              },
              {
                "category": "process",
                "description": "negative regulation of astrocyte differentiation"
              },
              {
                "category": "process",
                "description": "peptidyl-glutamic acid carboxylation"
              },
              {
                "category": "process",
                "description": "positive regulation of release of sequestered calcium ion into cytosol"
              },
              {
                "category": "process",
                "description": "post-translational protein modification"
              },
              {
                "category": "process",
                "description": "negative regulation of fibrinolysis"
              },
              {
                "category": "process",
                "description": "regulation of blood coagulation"
              },
              {
                "category": "process",
                "description": "negative regulation of platelet activation"
              },
              {
                "category": "process",
                "description": "regulation of cell shape"
              },
              {
                "category": "process",
                "description": "regulation of gene expression"
              },
              {
                "category": "process",
                "description": "blood coagulation"
              },
              {
                "category": "process",
                "description": "negative regulation of proteolysis"
              },
              {
                "category": "process",
                "description": "platelet activation"
              },
              {
                "category": "process",
                "description": "response to inactivity"
              },
              {
                "category": "process",
                "description": "positive regulation of blood coagulation"
              },
              {
                "category": "process",
                "description": "response to wounding"
              },
              {
                "category": "process",
                "description": "acute-phase response"
              },
              {
                "category": "process",
                "description": "positive regulation of cell growth"
              },
              {
                "category": "process",
                "description": "blood coagulation, intrinsic pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of cell proliferation"
              },
              {
                "category": "process",
                "description": "proteolysis"
              },
              {
                "category": "process",
                "description": "positive regulation of protein phosphorylation"
              },
              {
                "category": "process",
                "description": "cell surface receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of collagen biosynthetic process"
              }
            ]
          },
          "_id": "P00734",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": {
      "enzyme": {
        "id": "BE0001075",
        "name": "Myeloperoxidase",
        "organism": "Human",
        "actions": {
          "action": "inhibitor"
        },
        "references": "# Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. Epub 2008 Aug 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18701766[",
        "known-action": "unknown",
        "polypeptide": {
          "name": "Myeloperoxidase",
          "general-function": "Peroxidase activity",
          "specific-function": "Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.",
          "gene-name": "MPO",
          "locus": "17q23.1",
          "cellular-location": "Lysosome",
          "transmembrane-regions": "",
          "signal-regions": "1-48",
          "theoretical-pi": "9.14",
          "molecular-weight": "83867.71",
          "chromosome-location": "17",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:7218"
              },
              {
                "resource": "GenAtlas",
                "identifier": "MPO"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "J02694"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "189040"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "2789"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P05164"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "PERM_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "1.11.2.2",
              "MPO"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0002139|Myeloperoxidase\nMGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS\nLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH\nVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC\nNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD\nQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND\nPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL\nGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL\nREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR\nSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE\nGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN\nAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL\nLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS\nNSYPRDFVNCSTLPALNLASWREAS"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016304|Myeloperoxidase (MPO)\nATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT\nGGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG\nGCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG\nTTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG\nCGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC\nTACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC\nGTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC\nACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC\nCAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC\nAACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG\nGCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC\nGGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT\nCAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC\nCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC\nTGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC\nCCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC\nGGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC\nATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG\nGGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC\nAACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG\nGCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT\nCGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG\nAGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG\nGACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT\nTCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC\nGGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA\nCCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA\nGGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG\nAACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG\nCTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT\nGCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG\nCTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC\nGACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC\nCTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG\nGAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC\nCGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC\nAACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC\nTGGAGGGAAGCCTCCTAG"
          },
          "pfams": {
            "pfam": {
              "identifier": "PF03098",
              "name": "An_peroxidase"
            }
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "extracellular space"
              },
              {
                "category": "component",
                "description": "lysosome"
              },
              {
                "category": "component",
                "description": "extracellular exosome"
              },
              {
                "category": "component",
                "description": "azurophil granule"
              },
              {
                "category": "component",
                "description": "mitochondrion"
              },
              {
                "category": "component",
                "description": "secretory granule"
              },
              {
                "category": "component",
                "description": "nucleus"
              },
              {
                "category": "function",
                "description": "heparin binding"
              },
              {
                "category": "function",
                "description": "chromatin binding"
              },
              {
                "category": "function",
                "description": "metal ion binding"
              },
              {
                "category": "function",
                "description": "heme binding"
              },
              {
                "category": "function",
                "description": "peroxidase activity"
              },
              {
                "category": "process",
                "description": "removal of superoxide radicals"
              },
              {
                "category": "process",
                "description": "hydrogen peroxide catabolic process"
              },
              {
                "category": "process",
                "description": "negative regulation of growth of symbiont in host"
              },
              {
                "category": "process",
                "description": "response to yeast"
              },
              {
                "category": "process",
                "description": "defense response to fungus"
              },
              {
                "category": "process",
                "description": "respiratory burst involved in defense response"
              },
              {
                "category": "process",
                "description": "hypochlorous acid biosynthetic process"
              },
              {
                "category": "process",
                "description": "oxidation-reduction process"
              },
              {
                "category": "process",
                "description": "negative regulation of apoptotic process"
              },
              {
                "category": "process",
                "description": "defense response"
              },
              {
                "category": "process",
                "description": "low-density lipoprotein particle remodeling"
              },
              {
                "category": "process",
                "description": "response to oxidative stress"
              }
            ]
          },
          "_id": "P05164",
          "_source": "Swiss-Prot"
        },
        "inhibition-strength": "unknown",
        "induction-strength": "unknown",
        "_position": "1"
      }
    },
    "carriers": "",
    "transporters": "",
    "_type": "small molecule",
    "_created": "2005-06-13",
    "_updated": "2016-01-13"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00007"
      },
      "BIOD00009",
      "BTD00009"
    ],
    "name": "Leuprolide",
    "description": "Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.",
    "cas-number": "53714-56-0",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15568711\r\n# Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15780490\r\n# Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16370917\r\n# Sequence Information \"Link\":http://www.freepatentsonline.com/EP1790656.html\r\n# \"RxMed\":http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html",
    "synthesis-reference": "Daniel Kadzimirzs, Gerhard Jas, Volker Autze, \"Solution-Phase Synthesis of Leuprolide and Its Intermediates.\" U.S. Patent US20090005535, issued January 01, 2009.",
    "indication": "For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty",
    "pharmacodynamics": "Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.",
    "mechanism-of-action": "Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.",
    "toxicity": "In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.",
    "metabolism": "Primarily degraded by peptidase and not by cytochrome P450 enzymes.",
    "absorption": "Bioavailability by subcutaneous administration is comparable to that by intravenous administration.",
    "half-life": "~3 hours",
    "protein-binding": "43% to 49%",
    "route-of-elimination": "Excretion in urine",
    "volume-of-distribution": "* 27 L [intravenous bolus administration to healthy male volunteers]",
    "clearance": "* 8.34 L/h [healthy male receiving a 1-mg IV bolus]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": {
      "salt": {
        "drugbank-id": {
          "_primary": "true",
          "__text": "DBSALT000105"
        },
        "name": "Leuprolide acetate",
        "cas-number": "74381-53-6",
        "inchikey": "InChIKey=RGLRXNKKBLIBQS-XNHQSDQCSA-N"
      }
    },
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Leuprorelin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Leuprorelina"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Leuproreline"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Leuprorelinum"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "0024-0222",
          "dpd-id": "",
          "started-marketing-on": "2002-01-23",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA021379",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "0024-0605",
          "dpd-id": "",
          "started-marketing-on": "2002-01-23",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA021731",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "0024-0610",
          "dpd-id": "",
          "started-marketing-on": "2002-01-23",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA021488",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "0024-0793",
          "dpd-id": "",
          "started-marketing-on": "2002-01-23",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA021343",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-222",
          "dpd-id": "",
          "started-marketing-on": "2002-08-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021379",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-223",
          "dpd-id": "",
          "started-marketing-on": "2002-08-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021379",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-302",
          "dpd-id": "",
          "started-marketing-on": "2003-02-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021488",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-303",
          "dpd-id": "",
          "started-marketing-on": "2003-02-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021488",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-452",
          "dpd-id": "",
          "started-marketing-on": "2005-01-07",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021731",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-453",
          "dpd-id": "",
          "started-marketing-on": "2005-01-07",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021731",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-752",
          "dpd-id": "",
          "started-marketing-on": "2002-05-15",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021343",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard",
          "ndc-id": "",
          "ndc-product-code": "62935-753",
          "dpd-id": "",
          "started-marketing-on": "2002-05-15",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "NDA021343",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Eligard 22.5mg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02248240",
          "started-marketing-on": "2003-12-01",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "28.2 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eligard 30 mg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02248999",
          "started-marketing-on": "2004-04-29",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "35.8 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eligard 45 mg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02268892",
          "started-marketing-on": "2005-08-15",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "58.2 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eligard 7.5mg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02248239",
          "started-marketing-on": "2003-12-01",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "10.2 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Leuprolide Acetate",
          "ndc-id": "",
          "ndc-product-code": "0703-4014",
          "dpd-id": "",
          "started-marketing-on": "2000-11-06",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "ANDA075471",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leuprolide Acetate",
          "ndc-id": "",
          "ndc-product-code": "47335-936",
          "dpd-id": "",
          "started-marketing-on": "2014-12-15",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "ANDA078885",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leuprolide Acetate",
          "ndc-id": "",
          "ndc-product-code": "0185-7400",
          "dpd-id": "",
          "started-marketing-on": "1998-08-04",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "1 mg/.2mL",
          "route": "subcutaneous",
          "fda-application-number": "ANDA074728",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leuprolide Acetate",
          "ndc-id": "",
          "ndc-product-code": "41616-936",
          "dpd-id": "",
          "started-marketing-on": "2009-03-03",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "ANDA078885",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leuprolide Acetate",
          "ndc-id": "",
          "ndc-product-code": "0781-4003",
          "dpd-id": "",
          "started-marketing-on": "1998-08-04",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "ANDA074728",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leuprolide Acetate Injection",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02240264",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "liquid",
          "strength": "5 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupaneta Pack",
          "ndc-id": "",
          "ndc-product-code": "0074-1052",
          "dpd-id": "",
          "started-marketing-on": "2013-07-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA203696",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupaneta Pack",
          "ndc-id": "",
          "ndc-product-code": "0074-1053",
          "dpd-id": "",
          "started-marketing-on": "2013-07-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA203696",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron",
          "ndc-id": "",
          "ndc-product-code": "0074-3663",
          "dpd-id": "",
          "started-marketing-on": "2010-11-08",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020708",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00727695",
          "started-marketing-on": "1985-12-31",
          "ended-marketing-on": "",
          "dosage-form": "liquid",
          "strength": "5 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02230248",
          "started-marketing-on": "1997-01-29",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "22.5 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00884502",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "3.75 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00836273",
          "started-marketing-on": "1989-12-31",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "7.5 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "0074-3346",
          "dpd-id": "",
          "started-marketing-on": "1995-12-22",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020517",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02148722",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "11.25 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "0074-3473",
          "dpd-id": "",
          "started-marketing-on": "1995-12-22",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020517",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02148730",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "15 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "0074-3641",
          "dpd-id": "",
          "started-marketing-on": "1990-10-22",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020011",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "0074-3642",
          "dpd-id": "",
          "started-marketing-on": "1989-01-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA019732",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "0074-3683",
          "dpd-id": "",
          "started-marketing-on": "1995-12-22",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020517",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02239833",
          "started-marketing-on": "1999-09-13",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "30 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02239834",
          "started-marketing-on": "1999-09-13",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release",
          "strength": "11.25 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Lupron Depot-ped",
          "ndc-id": "",
          "ndc-product-code": "0074-2108",
          "dpd-id": "",
          "started-marketing-on": "1993-04-16",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020263",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot-ped",
          "ndc-id": "",
          "ndc-product-code": "0074-2282",
          "dpd-id": "",
          "started-marketing-on": "1993-04-16",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020263",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot-ped",
          "ndc-id": "",
          "ndc-product-code": "0074-2440",
          "dpd-id": "",
          "started-marketing-on": "1993-04-16",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020263",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot-ped",
          "ndc-id": "",
          "ndc-product-code": "0074-3779",
          "dpd-id": "",
          "started-marketing-on": "1993-04-16",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020263",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot-ped",
          "ndc-id": "",
          "ndc-product-code": "0074-9694",
          "dpd-id": "",
          "started-marketing-on": "1993-04-16",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020263",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lupron Depot-ped",
          "ndc-id": "",
          "ndc-product-code": "52125-736",
          "dpd-id": "",
          "started-marketing-on": "2015-07-28",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020263",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Zeulide Depot",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02429977",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for suspension, sustained-release; kit",
          "strength": "5.06 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": [
        {
          "name": "Enantone",
          "company": ""
        },
        {
          "name": "Leuplin",
          "company": "Takeda"
        },
        {
          "name": "LeuProMaxx",
          "company": "Baxter/Teva"
        },
        {
          "name": "Leupromer",
          "company": ""
        },
        {
          "name": "Lutrate",
          "company": ""
        },
        {
          "name": "Memryte",
          "company": "Curaxis"
        },
        {
          "name": "Prostap 3",
          "company": "Takeda UK"
        },
        {
          "name": "Prostap SR",
          "company": "Takeda UK"
        },
        {
          "name": "Viadur",
          "company": "Bayer AG"
        }
      ]
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupaneta Pack",
          "ingredients": "Leuprolide + Norethindrone"
        },
        {
          "name": "Lupaneta Pack",
          "ingredients": "Leuprolide + Norethindrone"
        },
        {
          "name": "Lupron Depot-ped",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot-ped",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot-ped",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot-ped",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot-ped",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Leuprolide Acetate",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Leuprolide Acetate",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Leuprolide Acetate",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Leuprolide Acetate",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Leuprolide Acetate",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot-ped",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard 7.5mg",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard 22.5mg",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard 30 mg",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Eligard 45 mg",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Zeulide Depot",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Leuprolide Acetate Injection",
          "ingredients": "Leuprolide"
        },
        {
          "name": "Lupron",
          "ingredients": "Leuprolide"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Abbott Laboratories Ltd.",
          "url": "http://www.abbott.com"
        },
        {
          "name": "Cardinal Health",
          "url": "http://www.cardinal.com"
        },
        {
          "name": "Eon Labs",
          "url": ""
        },
        {
          "name": "Hospira Inc.",
          "url": "http://www.hospira.com"
        },
        {
          "name": "Oso Biopharmaceuticals Manufacturing LLC",
          "url": ""
        },
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        },
        {
          "name": "Sanofi-Aventis Inc.",
          "url": "http://www.sanofi-aventis.com"
        },
        {
          "name": "Sun Pharmaceutical Industries Ltd.",
          "url": "http://www.sunpharma.com"
        },
        {
          "name": "Takeda Pharmaceutical Co. Ltd.",
          "url": "http://www.takeda.com"
        },
        {
          "name": "Teva Pharmaceutical Industries Ltd.",
          "url": "http://www.tevapharm.com"
        },
        {
          "name": "Tolmar Inc.",
          "url": "http://www.tolmar.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Leuprolide 2wk 1 mg/0.2 ml kit",
          "cost": {
            "_currency": "USD",
            "__text": "385.33"
          },
          "unit": "kit"
        },
        {
          "description": "Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit",
          "cost": {
            "_currency": "USD",
            "__text": "400.74"
          },
          "unit": "box"
        },
        {
          "description": "Eligard 7.5 mg syringe",
          "cost": {
            "_currency": "USD",
            "__text": "493.2"
          },
          "unit": "syringe"
        },
        {
          "description": "Lupron 2-wk 1 mg/0.2 ml kit",
          "cost": {
            "_currency": "USD",
            "__text": "594.37"
          },
          "unit": "kit"
        },
        {
          "description": "Eligard 22.5 mg syringe",
          "cost": {
            "_currency": "USD",
            "__text": "1479.6"
          },
          "unit": "syringe"
        },
        {
          "description": "Eligard 30 mg syringe",
          "cost": {
            "_currency": "USD",
            "__text": "1972.8"
          },
          "unit": "syringe"
        },
        {
          "description": "Eligard 45 mg syringe",
          "cost": {
            "_currency": "USD",
            "__text": "2959.2"
          },
          "unit": "syringe"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Antineoplastic Agents, Hormonal",
          "mesh-id": "[\"D27.505.954.248.169\"]"
        },
        {
          "category": "Fertility Agents, Female",
          "mesh-id": "[\"D27.505.696.875.552.344\", \"D27.505.954.705.552.344\"]"
        },
        {
          "category": "Estrogen Antagonists",
          "mesh-id": "[\"D06.347.295\", \"D27.505.696.399.450.327\"]"
        },
        {
          "category": "Moderate Risk QTc-Prolonging Agents",
          "mesh-id": "[]"
        },
        {
          "category": "Hyperglycemia-Associated Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "subcutaneous",
          "strength": "28.2 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "subcutaneous",
          "strength": "35.8 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "subcutaneous",
          "strength": "58.2 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "subcutaneous",
          "strength": "10.2 mg"
        },
        {
          "form": "Injection, solution",
          "route": "subcutaneous",
          "strength": "1 mg/.2mL"
        },
        {
          "form": "Kit",
          "route": "subcutaneous",
          "strength": ""
        },
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Liquid",
          "route": "subcutaneous",
          "strength": "5 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "intramuscular",
          "strength": "11.25 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "intramuscular",
          "strength": "15 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "intramuscular",
          "strength": "22.5 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "intramuscular",
          "strength": "3.75 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "intramuscular",
          "strength": "30 mg"
        },
        {
          "form": "Powder for suspension, sustained-release",
          "route": "intramuscular",
          "strength": "7.5 mg"
        },
        {
          "form": "Powder for suspension, sustained-release; kit",
          "route": "intramuscular",
          "strength": "5.06 mg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L02",
            "__text": "ENDOCRINE THERAPY"
          },
          {
            "_code": "L02A",
            "__text": "HORMONES AND RELATED AGENTS"
          },
          {
            "_code": "L02AE",
            "__text": "Gonadotropin releasing hormone analogues"
          }
        ],
        "_code": "L02AE02"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "10:00.00"
    },
    "patents": "",
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00284",
          "name": "Acarbose",
          "description": "The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00414",
          "name": "Acetohexamide",
          "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB09043",
          "name": "Albiglutide",
          "description": "The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00346",
          "name": "Alfuzosin",
          "description": "Alfuzosin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06203",
          "name": "Alogliptin",
          "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00915",
          "name": "Amantadine",
          "description": "Amantadine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01118",
          "name": "Amiodarone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Amiodarone."
        },
        {
          "drugbank-id": "DB00321",
          "name": "Amitriptyline",
          "description": "Amitriptyline may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00543",
          "name": "Amoxapine",
          "description": "Amoxapine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00261",
          "name": "Anagrelide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Anagrelide."
        },
        {
          "drugbank-id": "DB00714",
          "name": "Apomorphine",
          "description": "Apomorphine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01274",
          "name": "Arformoterol",
          "description": "Arformoterol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01238",
          "name": "Aripiprazole",
          "description": "Aripiprazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01169",
          "name": "Arsenic trioxide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Arsenic trioxide."
        },
        {
          "drugbank-id": "DB06697",
          "name": "Artemether",
          "description": "Leuprolide may increase the QTc-prolonging activities of Artemether."
        },
        {
          "drugbank-id": "DB06216",
          "name": "Asenapine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Asenapine."
        },
        {
          "drugbank-id": "DB01072",
          "name": "Atazanavir",
          "description": "Atazanavir may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00289",
          "name": "Atomoxetine",
          "description": "Atomoxetine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00207",
          "name": "Azithromycin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Azithromycin."
        },
        {
          "drugbank-id": "DB08903",
          "name": "Bedaquiline",
          "description": "Leuprolide may increase the QTc-prolonging activities of Bedaquiline."
        },
        {
          "drugbank-id": "DB00188",
          "name": "Bortezomib",
          "description": "Bortezomib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06616",
          "name": "Bosutinib",
          "description": "Bosutinib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01200",
          "name": "Bromocriptine",
          "description": "The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB06719",
          "name": "Buserelin",
          "description": "Buserelin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB08907",
          "name": "Canagliflozin",
          "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00089",
          "name": "Capromab",
          "description": "Leuprolide may decrease effectiveness of Capromab as a diagnostic agent."
        },
        {
          "drugbank-id": "DB09063",
          "name": "Ceritinib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Ceritinib."
        },
        {
          "drugbank-id": "DB00608",
          "name": "Chloroquine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Chloroquine."
        },
        {
          "drugbank-id": "DB00477",
          "name": "Chlorpromazine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Chlorpromazine."
        },
        {
          "drugbank-id": "DB00672",
          "name": "Chlorpropamide",
          "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB09277",
          "name": "Choline C 11",
          "description": "The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00537",
          "name": "Ciprofloxacin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin."
        },
        {
          "drugbank-id": "DB00604",
          "name": "Cisapride",
          "description": "Leuprolide may increase the QTc-prolonging activities of Cisapride."
        },
        {
          "drugbank-id": "DB00215",
          "name": "Citalopram",
          "description": "Leuprolide may increase the QTc-prolonging activities of Citalopram."
        },
        {
          "drugbank-id": "DB01211",
          "name": "Clarithromycin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Clarithromycin."
        },
        {
          "drugbank-id": "DB01242",
          "name": "Clomipramine",
          "description": "Clomipramine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00363",
          "name": "Clozapine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Clozapine."
        },
        {
          "drugbank-id": "DB09066",
          "name": "Corifollitropin Alfa",
          "description": "The therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB08865",
          "name": "Crizotinib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Crizotinib."
        },
        {
          "drugbank-id": "DB08912",
          "name": "Dabrafenib",
          "description": "Dabrafenib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06292",
          "name": "Dapagliflozin",
          "description": "The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01254",
          "name": "Dasatinib",
          "description": "Dasatinib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06699",
          "name": "Degarelix",
          "description": "Degarelix may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01189",
          "name": "Desflurane",
          "description": "Desflurane may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01151",
          "name": "Desipramine",
          "description": "Desipramine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01075",
          "name": "Diphenhydramine",
          "description": "Diphenhydramine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00280",
          "name": "Disopyramide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Disopyramide."
        },
        {
          "drugbank-id": "DB00204",
          "name": "Dofetilide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Dofetilide."
        },
        {
          "drugbank-id": "DB00757",
          "name": "Dolasetron",
          "description": "Leuprolide may increase the QTc-prolonging activities of Dolasetron."
        },
        {
          "drugbank-id": "DB01184",
          "name": "Domperidone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Domperidone."
        },
        {
          "drugbank-id": "DB01142",
          "name": "Doxepin",
          "description": "Doxepin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB04855",
          "name": "Dronedarone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Dronedarone."
        },
        {
          "drugbank-id": "DB00450",
          "name": "Droperidol",
          "description": "Leuprolide may increase the QTc-prolonging activities of Droperidol."
        },
        {
          "drugbank-id": "DB09045",
          "name": "Dulaglutide",
          "description": "The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB09039",
          "name": "Eliglustat",
          "description": "Leuprolide may increase the QTc-prolonging activities of Eliglustat."
        },
        {
          "drugbank-id": "DB09038",
          "name": "Empagliflozin",
          "description": "The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB08871",
          "name": "Eribulin",
          "description": "Eribulin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00199",
          "name": "Erythromycin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Erythromycin."
        },
        {
          "drugbank-id": "DB01175",
          "name": "Escitalopram",
          "description": "Leuprolide may increase the QTc-prolonging activities of Escitalopram."
        },
        {
          "drugbank-id": "DB01276",
          "name": "Exenatide",
          "description": "The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB04953",
          "name": "Ezogabine",
          "description": "Ezogabine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00927",
          "name": "Famotidine",
          "description": "Famotidine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00949",
          "name": "Felbamate",
          "description": "Felbamate may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB08868",
          "name": "Fingolimod",
          "description": "Fingolimod may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01195",
          "name": "Flecainide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Flecainide."
        },
        {
          "drugbank-id": "DB00196",
          "name": "Fluconazole",
          "description": "Fluconazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00472",
          "name": "Fluoxetine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Fluoxetine."
        },
        {
          "drugbank-id": "DB00875",
          "name": "Flupentixol",
          "description": "Leuprolide may increase the QTc-prolonging activities of Flupentixol."
        },
        {
          "drugbank-id": "DB00588",
          "name": "Fluticasone Propionate",
          "description": "Fluticasone Propionate may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00983",
          "name": "Formoterol",
          "description": "Formoterol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00529",
          "name": "Foscarnet",
          "description": "Foscarnet may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01320",
          "name": "Fosphenytoin",
          "description": "Fosphenytoin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00743",
          "name": "Gadobenate Dimeglumine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Gadobenate Dimeglumine."
        },
        {
          "drugbank-id": "DB00674",
          "name": "Galantamine",
          "description": "Galantamine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01155",
          "name": "Gemifloxacin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Gemifloxacin."
        },
        {
          "drugbank-id": "DB01120",
          "name": "Gliclazide",
          "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00222",
          "name": "Glimepiride",
          "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01067",
          "name": "Glipizide",
          "description": "The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01251",
          "name": "Gliquidone",
          "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01016",
          "name": "Glyburide",
          "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00014",
          "name": "Goserelin",
          "description": "Goserelin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00889",
          "name": "Granisetron",
          "description": "Leuprolide may increase the QTc-prolonging activities of Granisetron."
        },
        {
          "drugbank-id": "DB00502",
          "name": "Haloperidol",
          "description": "Leuprolide may increase the QTc-prolonging activities of Haloperidol."
        },
        {
          "drugbank-id": "DB06788",
          "name": "Histrelin",
          "description": "Histrelin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00557",
          "name": "Hydroxyzine",
          "description": "Hydroxyzine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00710",
          "name": "Ibandronate",
          "description": "Ibandronate may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00308",
          "name": "Ibutilide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Ibutilide."
        },
        {
          "drugbank-id": "DB04946",
          "name": "Iloperidone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Iloperidone."
        },
        {
          "drugbank-id": "DB00458",
          "name": "Imipramine",
          "description": "Imipramine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB05039",
          "name": "Indacaterol",
          "description": "Indacaterol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00808",
          "name": "Indapamide",
          "description": "Indapamide may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB05278",
          "name": "inhaled insulin",
          "description": "The therapeutic efficacy of inhaled insulin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01306",
          "name": "Insulin Aspart",
          "description": "The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB09564",
          "name": "Insulin degludec",
          "description": "The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01307",
          "name": "Insulin Detemir",
          "description": "The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00047",
          "name": "Insulin Glargine",
          "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01309",
          "name": "Insulin Glulisine",
          "description": "The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00046",
          "name": "Insulin Lispro",
          "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00030",
          "name": "Insulin Regular",
          "description": "The therapeutic efficacy of Insulin Regular can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB08914",
          "name": "Insulin, isophane",
          "description": "The therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00753",
          "name": "Isoflurane",
          "description": "Isoflurane may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00270",
          "name": "Isradipine",
          "description": "Isradipine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01167",
          "name": "Itraconazole",
          "description": "Itraconazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB09083",
          "name": "Ivabradine",
          "description": "Ivabradine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01026",
          "name": "Ketoconazole",
          "description": "Ketoconazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01259",
          "name": "Lapatinib",
          "description": "Lapatinib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB09078",
          "name": "Lenvatinib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Lenvatinib."
        },
        {
          "drugbank-id": "DB01137",
          "name": "Levofloxacin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Levofloxacin."
        },
        {
          "drugbank-id": "DB08882",
          "name": "Linagliptin",
          "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB06655",
          "name": "Liraglutide",
          "description": "The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01356",
          "name": "Lithium",
          "description": "Lithium may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01601",
          "name": "Lopinavir",
          "description": "Leuprolide may increase the QTc-prolonging activities of Lopinavir."
        },
        {
          "drugbank-id": "DB06708",
          "name": "Lumefantrine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Lumefantrine."
        },
        {
          "drugbank-id": "DB00934",
          "name": "Maprotiline",
          "description": "Maprotiline may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00358",
          "name": "Mefloquine",
          "description": "Mefloquine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00331",
          "name": "Metformin",
          "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00333",
          "name": "Methadone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Methadone."
        },
        {
          "drugbank-id": "DB01403",
          "name": "Methotrimeprazine",
          "description": "Methotrimeprazine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01233",
          "name": "Metoclopramide",
          "description": "Metoclopramide may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00916",
          "name": "Metronidazole",
          "description": "Metronidazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00834",
          "name": "Mifepristone",
          "description": "Mifepristone may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00491",
          "name": "Miglitol",
          "description": "The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB08893",
          "name": "Mirabegron",
          "description": "Mirabegron may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00370",
          "name": "Mirtazapine",
          "description": "Mirtazapine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00691",
          "name": "Moexipril",
          "description": "Moexipril may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00218",
          "name": "Moxifloxacin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Moxifloxacin."
        },
        {
          "drugbank-id": "DB00731",
          "name": "Nateglinide",
          "description": "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00220",
          "name": "Nelfinavir",
          "description": "Nelfinavir may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00622",
          "name": "Nicardipine",
          "description": "Nicardipine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB04868",
          "name": "Nilotinib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Nilotinib."
        },
        {
          "drugbank-id": "DB01059",
          "name": "Norfloxacin",
          "description": "Norfloxacin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00540",
          "name": "Nortriptyline",
          "description": "Nortriptyline may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00104",
          "name": "Octreotide",
          "description": "Octreotide may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01165",
          "name": "Ofloxacin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Ofloxacin."
        },
        {
          "drugbank-id": "DB00334",
          "name": "Olanzapine",
          "description": "Olanzapine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB09080",
          "name": "Olodaterol",
          "description": "Olodaterol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00904",
          "name": "Ondansetron",
          "description": "Leuprolide may increase the QTc-prolonging activities of Ondansetron."
        },
        {
          "drugbank-id": "DB09330",
          "name": "Osimertinib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Osimertinib."
        },
        {
          "drugbank-id": "DB00107",
          "name": "Oxytocin",
          "description": "Oxytocin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01267",
          "name": "Paliperidone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Paliperidone."
        },
        {
          "drugbank-id": "DB06603",
          "name": "Panobinostat",
          "description": "Leuprolide may increase the QTc-prolonging activities of Panobinostat."
        },
        {
          "drugbank-id": "DB00715",
          "name": "Paroxetine",
          "description": "Paroxetine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06663",
          "name": "Pasireotide",
          "description": "Pasireotide may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06589",
          "name": "Pazopanib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Pazopanib."
        },
        {
          "drugbank-id": "DB00738",
          "name": "Pentamidine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Pentamidine."
        },
        {
          "drugbank-id": "DB00556",
          "name": "Perflutren",
          "description": "Leuprolide may increase the QTc-prolonging activities of Perflutren."
        },
        {
          "drugbank-id": "DB01100",
          "name": "Pimozide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Pimozide."
        },
        {
          "drugbank-id": "DB01132",
          "name": "Pioglitazone",
          "description": "The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01263",
          "name": "Posaconazole",
          "description": "Posaconazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01278",
          "name": "Pramlintide",
          "description": "The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01087",
          "name": "Primaquine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Primaquine."
        },
        {
          "drugbank-id": "DB01035",
          "name": "Procainamide",
          "description": "Leuprolide may increase the QTc-prolonging activities of Procainamide."
        },
        {
          "drugbank-id": "DB00420",
          "name": "Promazine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Promazine."
        },
        {
          "drugbank-id": "DB01069",
          "name": "Promethazine",
          "description": "Promethazine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01182",
          "name": "Propafenone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Propafenone."
        },
        {
          "drugbank-id": "DB00818",
          "name": "Propofol",
          "description": "Propofol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00344",
          "name": "Protriptyline",
          "description": "Protriptyline may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01224",
          "name": "Quetiapine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Quetiapine."
        },
        {
          "drugbank-id": "DB00908",
          "name": "Quinidine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Quinidine."
        },
        {
          "drugbank-id": "DB00468",
          "name": "Quinine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Quinine."
        },
        {
          "drugbank-id": "DB00243",
          "name": "Ranolazine",
          "description": "Ranolazine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00912",
          "name": "Repaglinide",
          "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB08864",
          "name": "Rilpivirine",
          "description": "Rilpivirine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00734",
          "name": "Risperidone",
          "description": "Risperidone may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00503",
          "name": "Ritonavir",
          "description": "Ritonavir may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00412",
          "name": "Rosiglitazone",
          "description": "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01001",
          "name": "Salbutamol",
          "description": "Salbutamol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00938",
          "name": "Salmeterol",
          "description": "Salmeterol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01232",
          "name": "Saquinavir",
          "description": "Leuprolide may increase the QTc-prolonging activities of Saquinavir."
        },
        {
          "drugbank-id": "DB06335",
          "name": "Saxagliptin",
          "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01104",
          "name": "Sertraline",
          "description": "Sertraline may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01236",
          "name": "Sevoflurane",
          "description": "Sevoflurane may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01261",
          "name": "Sitagliptin",
          "description": "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01591",
          "name": "Solifenacin",
          "description": "Solifenacin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00398",
          "name": "Sorafenib",
          "description": "Sorafenib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00489",
          "name": "Sotalol",
          "description": "Leuprolide may increase the QTc-prolonging activities of Sotalol."
        },
        {
          "drugbank-id": "DB01015",
          "name": "Sulfamethoxazole",
          "description": "Sulfamethoxazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00263",
          "name": "Sulfisoxazole",
          "description": "Leuprolide may increase the QTc-prolonging activities of Sulfisoxazole."
        },
        {
          "drugbank-id": "DB01268",
          "name": "Sunitinib",
          "description": "Sunitinib may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00864",
          "name": "Tacrolimus",
          "description": "Tacrolimus may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00675",
          "name": "Tamoxifen",
          "description": "Tamoxifen may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06402",
          "name": "Telavancin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Telavancin."
        },
        {
          "drugbank-id": "DB00976",
          "name": "Telithromycin",
          "description": "Leuprolide may increase the QTc-prolonging activities of Telithromycin."
        },
        {
          "drugbank-id": "DB00871",
          "name": "Terbutaline",
          "description": "Terbutaline may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB04844",
          "name": "Tetrabenazine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Tetrabenazine."
        },
        {
          "drugbank-id": "DB00679",
          "name": "Thioridazine",
          "description": "Leuprolide may increase the QTc-prolonging activities of Thioridazine."
        },
        {
          "drugbank-id": "DB01623",
          "name": "Thiothixene",
          "description": "Thiothixene may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00697",
          "name": "Tizanidine",
          "description": "Tizanidine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00839",
          "name": "Tolazamide",
          "description": "The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01124",
          "name": "Tolbutamide",
          "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB01036",
          "name": "Tolterodine",
          "description": "Tolterodine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00539",
          "name": "Toremifene",
          "description": "Leuprolide may increase the QTc-prolonging activities of Toremifene."
        },
        {
          "drugbank-id": "DB00656",
          "name": "Trazodone",
          "description": "Trazodone may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00374",
          "name": "Treprostinil",
          "description": "Treprostinil may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00440",
          "name": "Trimethoprim",
          "description": "Trimethoprim may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00726",
          "name": "Trimipramine",
          "description": "Trimipramine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB06825",
          "name": "Triptorelin",
          "description": "Triptorelin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB05294",
          "name": "Vandetanib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Vandetanib."
        },
        {
          "drugbank-id": "DB00862",
          "name": "Vardenafil",
          "description": "Vardenafil may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB08881",
          "name": "Vemurafenib",
          "description": "Leuprolide may increase the QTc-prolonging activities of Vemurafenib."
        },
        {
          "drugbank-id": "DB00285",
          "name": "Venlafaxine",
          "description": "Venlafaxine may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB09082",
          "name": "Vilanterol",
          "description": "Vilanterol may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB04876",
          "name": "Vildagliptin",
          "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide."
        },
        {
          "drugbank-id": "DB00582",
          "name": "Voriconazole",
          "description": "Voriconazole may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB02546",
          "name": "Vorinostat",
          "description": "Vorinostat may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB00246",
          "name": "Ziprasidone",
          "description": "Leuprolide may increase the QTc-prolonging activities of Ziprasidone."
        },
        {
          "drugbank-id": "DB01624",
          "name": "Zuclopenthixol",
          "description": "Leuprolide may increase the QTc-prolonging activities of Zuclopenthixol."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">Leuprolide\nPHWSYLLR"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "0.1",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "1209.3983",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C59H84N16O12",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "1756"
        },
        {
          "resource": "ChEBI",
          "identifier": "6427"
        },
        {
          "resource": "KEGG Compound",
          "identifier": "C07612"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D08113"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA450203"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Leuprolide"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/eligard.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/leuprolide.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000203",
        "name": "Gonadotropin-releasing hormone receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16809153\r\n# Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10687850\r\n# Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9625809\r\n# Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15758569\r\n# Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10394541",
        "known-action": "yes",
        "polypeptide": {
          "name": "Gonadotropin-releasing hormone receptor",
          "general-function": "Peptide binding",
          "specific-function": "Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.",
          "gene-name": "GNRHR",
          "locus": "4q21.2",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326",
          "signal-regions": "",
          "theoretical-pi": "9.93",
          "molecular-weight": "37730.355",
          "chromosome-location": "4",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:4421"
              },
              {
                "resource": "GenAtlas",
                "identifier": "GNRHR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "L03380"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "183422"
              },
              {
                "resource": "IUPHAR",
                "identifier": "256"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "256"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P30968"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "GNRHR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "GnRH receptor",
              "GRHR"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA"
          },
          "pfams": {
            "pfam": {
              "identifier": "PF00001",
              "name": "7tm_1"
            }
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "membrane"
              },
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "integral component of plasma membrane"
              },
              {
                "category": "function",
                "description": "peptide binding"
              },
              {
                "category": "function",
                "description": "gonadotropin-releasing hormone receptor activity"
              },
              {
                "category": "process",
                "description": "cellular response to gonadotropin-releasing hormone"
              },
              {
                "category": "process",
                "description": "G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "multicellular organismal development"
              }
            ]
          },
          "_id": "P30968",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2013-09-13"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00008"
      },
      "BIOD00043",
      "BTD00043"
    ],
    "name": "Peginterferon alfa-2a",
    "description": "Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.",
    "cas-number": "198153-51-4",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.",
    "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.",
    "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "Terminal half life is 80 hours (range 50 to 140 hours).",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": "",
    "products": {
      "product": [
        {
          "name": "Pegasys",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02248077",
          "started-marketing-on": "2003-08-14",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "180 mcg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegasys",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02248078",
          "started-marketing-on": "2003-08-14",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "180 mcg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegasys",
          "ndc-id": "",
          "ndc-product-code": "0004-0350",
          "dpd-id": "",
          "started-marketing-on": "2002-10-16",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "180 ug/mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103964",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegasys",
          "ndc-id": "",
          "ndc-product-code": "0004-0357",
          "dpd-id": "",
          "started-marketing-on": "2011-03-29",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "180 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103964",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegasys",
          "ndc-id": "",
          "ndc-product-code": "0004-0360",
          "dpd-id": "",
          "started-marketing-on": "2011-11-01",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "135 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103964",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegasys",
          "ndc-id": "",
          "ndc-product-code": "0004-0365",
          "dpd-id": "",
          "started-marketing-on": "2011-11-01",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "180 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103964",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegasys Rbv",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02253410",
          "started-marketing-on": "2004-05-26",
          "ended-marketing-on": "",
          "dosage-form": "solution; tablet",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegasys Rbv",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02253429",
          "started-marketing-on": "2004-05-26",
          "ended-marketing-on": "",
          "dosage-form": "solution; tablet",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Pegasys",
          "ingredients": "Peginterferon alfa-2a"
        },
        {
          "name": "Pegasys",
          "ingredients": "Peginterferon alfa-2a"
        },
        {
          "name": "Pegasys",
          "ingredients": "Peginterferon alfa-2a"
        },
        {
          "name": "Pegasys",
          "ingredients": "Peginterferon alfa-2a"
        },
        {
          "name": "Pegasys",
          "ingredients": "Peginterferon alfa-2a"
        },
        {
          "name": "Pegasys",
          "ingredients": "Peginterferon alfa-2a"
        },
        {
          "name": "Pegasys Rbv",
          "ingredients": "Peginterferon alfa-2a + Ribavirin"
        },
        {
          "name": "Pegasys Rbv",
          "ingredients": "Peginterferon alfa-2a + Ribavirin"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "F Hoffmann La Roche Ltd.",
          "url": "http://www.roche.com"
        },
        {
          "name": "F Hoffmann-La Roche Ltd.",
          "url": "http://www.roche.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Pegasys 180 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "642.64"
          },
          "unit": "ml"
        },
        {
          "description": "Pegasys 180 mcg/0.5 ml conv.pk",
          "cost": {
            "_currency": "USD",
            "__text": "2533.2"
          },
          "unit": "each"
        },
        {
          "description": "Pegasys (1 Kit = Four 180 mcg/ml Vials Prefilled Syringes) Box",
          "cost": {
            "_currency": "USD",
            "__text": "2634.53"
          },
          "unit": "box"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Immunosuppressive Agents",
          "mesh-id": "[\"D27.505.696.477.656\"]"
        },
        {
          "category": "Myelosuppressive Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Injection, solution",
          "route": "subcutaneous",
          "strength": "135 ug/.5mL"
        },
        {
          "form": "Injection, solution",
          "route": "subcutaneous",
          "strength": "180 ug/mL"
        },
        {
          "form": "Injection, solution",
          "route": "subcutaneous",
          "strength": "180 ug/.5mL"
        },
        {
          "form": "Solution",
          "route": "subcutaneous",
          "strength": "180 mcg"
        },
        {
          "form": "Solution; tablet",
          "route": "oral; subcutaneous",
          "strength": ""
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L03",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03A",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03AB",
            "__text": "Interferons"
          }
        ],
        "_code": "L03AB11"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "08:18.20"
    },
    "patents": {
      "patent": [
        {
          "number": "2172664",
          "country": "Canada",
          "approved": "2000-10-03",
          "expires": "2016-03-26"
        },
        {
          "number": "2203480",
          "country": "Canada",
          "approved": "2009-06-30",
          "expires": "2017-04-23"
        }
      ]
    },
    "food-interactions": {
      "food-interaction": "Recommended adequate hydration."
    },
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00041",
          "name": "Aldesleukin",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin."
        },
        {
          "drugbank-id": "DB01223",
          "name": "Aminophylline",
          "description": "The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a."
        },
        {
          "drugbank-id": "DB00363",
          "name": "Clozapine",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clozapine."
        },
        {
          "drugbank-id": "DB04817",
          "name": "Metamizole",
          "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2a."
        },
        {
          "drugbank-id": "DB00333",
          "name": "Methadone",
          "description": "The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a."
        },
        {
          "drugbank-id": "DB09208",
          "name": "Pegloticase",
          "description": "The therapeutic efficacy of Peginterferon alfa-2a can be decreased when used in combination with Pegloticase."
        },
        {
          "drugbank-id": "DB00811",
          "name": "Ribavirin",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ribavirin."
        },
        {
          "drugbank-id": "DB01265",
          "name": "Telbivudine",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine."
        },
        {
          "drugbank-id": "DB00277",
          "name": "Theophylline",
          "description": "The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a."
        },
        {
          "drugbank-id": "DB00697",
          "name": "Tizanidine",
          "description": "The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2a."
        },
        {
          "drugbank-id": "DB00495",
          "name": "Zidovudine",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">Peginterferon alfa-2a sequence\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "61 °C",
          "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"
        },
        {
          "kind": "Isoelectric Point",
          "value": "5.99",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "60000.0",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "13246"
        },
        {
          "resource": "GenBank",
          "identifier": "J00207"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164749390"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01563"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Peginterferon_alfa-2a"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic3/pegasys.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/peginterferon-alfa-2a.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000385",
          "name": "Interferon alpha/beta receptor 2",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\r\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\r\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 2",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.",
            "gene-name": "IFNAR2",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "244-264",
            "signal-regions": "1-26",
            "theoretical-pi": "4.11",
            "molecular-weight": "57758.24",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5433"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L42243"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "995300"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P48551"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IFN-R-2",
                "IFNABR",
                "IFNARB",
                "Interferon alpha binding protein",
                "Type I interferon receptor 2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protein kinase binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to interferon-alpha"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                }
              ]
            },
            "_id": "P48551",
            "_source": "Swiss-Prot"
          }
        },
        {
          "id": "BE0000661",
          "name": "Interferon alpha/beta receptor 1",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\r\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\r\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 1",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.",
            "gene-name": "IFNAR1",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "437-457",
            "signal-regions": "1-27",
            "theoretical-pi": "5.56",
            "molecular-weight": "63524.81",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5432"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J03171"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "306914"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1723"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P17181"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CRF2-1",
                "Cytokine receptor class-II member 1",
                "Cytokine receptor family 2 member 1",
                "IFN-R-1",
                "IFNAR",
                "Type I interferon receptor 1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-beta production"
                },
                {
                  "category": "process",
                  "description": "regulation of peptidyl-tyrosine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "type I interferon biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-gamma production"
                },
                {
                  "category": "process",
                  "description": "T cell activation"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "defense response to virus"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-1 beta secretion"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                }
              ]
            },
            "_id": "P17181",
            "_source": "Swiss-Prot"
          }
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2014-01-14"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00009"
      },
      "BIOD00050",
      "BTD00050"
    ],
    "name": "Alteplase",
    "description": "Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells",
    "cas-number": "105857-23-6",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli",
    "pharmacodynamics": "Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.",
    "mechanism-of-action": "Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. ",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "t-PA"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "t-plasminogen activator"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Tissue-type plasminogen activator precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "tPA"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Activase",
          "ndc-id": "",
          "ndc-product-code": "50242-044",
          "dpd-id": "",
          "started-marketing-on": "1987-11-13",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103172",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Activase",
          "ndc-id": "",
          "ndc-product-code": "50242-085",
          "dpd-id": "",
          "started-marketing-on": "1987-11-13",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103172",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Activase RT-PA",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02225689",
          "started-marketing-on": "1998-04-12",
          "ended-marketing-on": "",
          "dosage-form": "liquid; powder for solution",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Activase RT-PA",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02147440",
          "started-marketing-on": "1996-12-31",
          "ended-marketing-on": "",
          "dosage-form": "liquid; powder for solution",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Activase RT-PA Inj",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00771473",
          "started-marketing-on": "1987-12-31",
          "ended-marketing-on": "1998-07-31",
          "dosage-form": "powder for solution",
          "strength": "29 m",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Cathflo",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02245859",
          "started-marketing-on": "2002-09-26",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1 mg",
          "route": "instillation",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Cathflo Activase",
          "ndc-id": "",
          "ndc-product-code": "50242-041",
          "dpd-id": "",
          "started-marketing-on": "2001-09-04",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "2.2 mg/2mL",
          "route": "intravenous",
          "fda-application-number": "BLA103172",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Lysatec RT - Pa",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02009285",
          "started-marketing-on": "1993-12-31",
          "ended-marketing-on": "1997-08-26",
          "dosage-form": "powder for solution",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Cathflo Activase",
          "ingredients": "Alteplase"
        },
        {
          "name": "Activase",
          "ingredients": "Alteplase"
        },
        {
          "name": "Activase",
          "ingredients": "Alteplase"
        },
        {
          "name": "Activase RT-PA",
          "ingredients": "Alteplase + Water"
        },
        {
          "name": "Activase RT-PA",
          "ingredients": "Alteplase + Water"
        },
        {
          "name": "Cathflo",
          "ingredients": "Alteplase"
        },
        {
          "name": "Lysatec RT - Pa",
          "ingredients": "Alteplase + Water"
        },
        {
          "name": "Activase RT-PA Inj",
          "ingredients": "Alteplase"
        }
      ]
    },
    "packagers": {
      "packager": {
        "name": "Genentech Inc.",
        "url": "http://www.gene.com"
      }
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Cathflo activase 2 mg vial",
          "cost": {
            "_currency": "USD",
            "__text": "106.33"
          },
          "unit": "vial"
        },
        {
          "description": "Activase 50 mg vial",
          "cost": {
            "_currency": "USD",
            "__text": "2389.85"
          },
          "unit": "vial"
        },
        {
          "description": "Activase 100 mg vial",
          "cost": {
            "_currency": "USD",
            "__text": "4779.71"
          },
          "unit": "vial"
        }
      ]
    },
    "categories": {
      "category": {
        "category": "Thrombolytic Agents",
        "mesh-id": "[]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Liquid; powder for solution",
          "route": "intravenous",
          "strength": ""
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "29 m"
        },
        {
          "form": "Powder for solution",
          "route": "instillation",
          "strength": "1 mg"
        },
        {
          "form": "Injection, powder, lyophilized, for solution",
          "route": "intravenous",
          "strength": "2.2 mg/2mL"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": ""
        }
      ]
    },
    "atc-codes": {
      "atc-code": [
        {
          "level": [
            {
              "_code": "B",
              "__text": "BLOOD AND BLOOD FORMING ORGANS"
            },
            {
              "_code": "B01",
              "__text": "ANTITHROMBOTIC AGENTS"
            },
            {
              "_code": "B01A",
              "__text": "ANTITHROMBOTIC AGENTS"
            },
            {
              "_code": "B01AD",
              "__text": "Enzymes"
            }
          ],
          "_code": "B01AD02"
        },
        {
          "level": [
            {
              "_code": "S",
              "__text": "SENSORY ORGANS"
            },
            {
              "_code": "S01",
              "__text": "OPHTHALMOLOGICALS"
            },
            {
              "_code": "S01X",
              "__text": "OTHER OPHTHALMOLOGICALS"
            },
            {
              "_code": "S01XA",
              "__text": "Other ophthalmologicals"
            }
          ],
          "_code": "S01XA13"
        }
      ]
    },
    "ahfs-codes": {
      "ahfs-code": "20:12.20"
    },
    "patents": "",
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00054",
          "name": "Abciximab",
          "description": "Alteplase may increase the anticoagulant activities of Abciximab."
        },
        {
          "drugbank-id": "DB01418",
          "name": "Acenocoumarol",
          "description": "Alteplase may increase the anticoagulant activities of Acenocoumarol."
        },
        {
          "drugbank-id": "DB00945",
          "name": "Acetylsalicylic acid",
          "description": "The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alteplase."
        },
        {
          "drugbank-id": "DB00233",
          "name": "Aminosalicylic Acid",
          "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alteplase."
        },
        {
          "drugbank-id": "DB00261",
          "name": "Anagrelide",
          "description": "Anagrelide may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06605",
          "name": "Apixaban",
          "description": "Alteplase may increase the anticoagulant activities of Apixaban."
        },
        {
          "drugbank-id": "DB06692",
          "name": "Aprotinin",
          "description": "The therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin."
        },
        {
          "drugbank-id": "DB00278",
          "name": "Argatroban",
          "description": "Alteplase may increase the anticoagulant activities of Argatroban."
        },
        {
          "drugbank-id": "DB01294",
          "name": "Bismuth Subsalicylate",
          "description": "The risk or severity of adverse effects can be increased when Bismuth Subsalicylate is combined with Alteplase."
        },
        {
          "drugbank-id": "DB00006",
          "name": "Bivalirudin",
          "description": "Alteplase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00201",
          "name": "Caffeine",
          "description": "Caffeine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06441",
          "name": "Cangrelor",
          "description": "Cangrelor may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB01166",
          "name": "Cilostazol",
          "description": "Cilostazol may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00215",
          "name": "Citalopram",
          "description": "Citalopram may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB04272",
          "name": "Citric Acid",
          "description": "Alteplase may increase the anticoagulant activities of Citric Acid."
        },
        {
          "drugbank-id": "DB00758",
          "name": "Clopidogrel",
          "description": "Clopidogrel may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06695",
          "name": "Dabigatran etexilate",
          "description": "Alteplase may increase the anticoagulant activities of Dabigatran etexilate."
        },
        {
          "drugbank-id": "DB06779",
          "name": "Dalteparin",
          "description": "Alteplase may increase the anticoagulant activities of Dalteparin."
        },
        {
          "drugbank-id": "DB06754",
          "name": "Danaparoid",
          "description": "Alteplase may increase the anticoagulant activities of Danaparoid."
        },
        {
          "drugbank-id": "DB11095",
          "name": "Desirudin",
          "description": "Alteplase may increase the anticoagulant activities of Desirudin."
        },
        {
          "drugbank-id": "DB06700",
          "name": "Desvenlafaxine",
          "description": "Desvenlafaxine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00586",
          "name": "Diclofenac",
          "description": "Diclofenac may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00266",
          "name": "Dicoumarol",
          "description": "Alteplase may increase the anticoagulant activities of Dicoumarol."
        },
        {
          "drugbank-id": "DB00861",
          "name": "Diflunisal",
          "description": "Diflunisal may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB01551",
          "name": "Dihydrocodeine",
          "description": "Dihydrocodeine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00975",
          "name": "Dipyridamole",
          "description": "Dipyridamole may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00476",
          "name": "Duloxetine",
          "description": "Duloxetine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00974",
          "name": "Edetic Acid",
          "description": "Alteplase may increase the anticoagulant activities of Edetic Acid."
        },
        {
          "drugbank-id": "DB09075",
          "name": "Edoxaban",
          "description": "Alteplase may increase the anticoagulant activities of Edoxaban."
        },
        {
          "drugbank-id": "DB01225",
          "name": "Enoxaparin",
          "description": "Alteplase may increase the anticoagulant activities of Enoxaparin."
        },
        {
          "drugbank-id": "DB01240",
          "name": "Epoprostenol",
          "description": "The risk or severity of adverse effects can be increased when Alteplase is combined with Epoprostenol."
        },
        {
          "drugbank-id": "DB00063",
          "name": "Eptifibatide",
          "description": "Eptifibatide may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB01175",
          "name": "Escitalopram",
          "description": "Escitalopram may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB08794",
          "name": "Ethyl biscoumacetate",
          "description": "Alteplase may increase the anticoagulant activities of Ethyl biscoumacetate."
        },
        {
          "drugbank-id": "DB00749",
          "name": "Etodolac",
          "description": "Etodolac may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00573",
          "name": "Fenoprofen",
          "description": "Fenoprofen may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB08976",
          "name": "Floctafenine",
          "description": "Floctafenine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00472",
          "name": "Fluoxetine",
          "description": "Fluoxetine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00712",
          "name": "Flurbiprofen",
          "description": "Flurbiprofen may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00176",
          "name": "Fluvoxamine",
          "description": "Fluvoxamine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00569",
          "name": "Fondaparinux sodium",
          "description": "Alteplase may increase the anticoagulant activities of Fondaparinux sodium."
        },
        {
          "drugbank-id": "DB01109",
          "name": "Heparin",
          "description": "Alteplase may increase the anticoagulant activities of Heparin."
        },
        {
          "drugbank-id": "DB01050",
          "name": "Ibuprofen",
          "description": "Ibuprofen may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB01088",
          "name": "Iloprost",
          "description": "The risk or severity of adverse effects can be increased when Alteplase is combined with Iloprost."
        },
        {
          "drugbank-id": "DB00328",
          "name": "Indomethacin",
          "description": "Indomethacin may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB01009",
          "name": "Ketoprofen",
          "description": "Ketoprofen may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00465",
          "name": "Ketorolac",
          "description": "Ketorolac may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB08918",
          "name": "Levomilnacipran",
          "description": "Levomilnacipran may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB09211",
          "name": "Limaprost",
          "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Alteplase."
        },
        {
          "drugbank-id": "DB01397",
          "name": "Magnesium salicylate",
          "description": "The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alteplase."
        },
        {
          "drugbank-id": "DB00784",
          "name": "Mefenamic acid",
          "description": "Mefenamic acid may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00814",
          "name": "Meloxicam",
          "description": "Meloxicam may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB04896",
          "name": "Milnacipran",
          "description": "Milnacipran may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00461",
          "name": "Nabumetone",
          "description": "Nabumetone may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB08813",
          "name": "Nadroparin",
          "description": "Alteplase may increase the anticoagulant activities of Nadroparin."
        },
        {
          "drugbank-id": "DB00788",
          "name": "Naproxen",
          "description": "Naproxen may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00727",
          "name": "Nitroglycerin",
          "description": "The serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin."
        },
        {
          "drugbank-id": "DB00991",
          "name": "Oxaprozin",
          "description": "Oxaprozin may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00715",
          "name": "Paroxetine",
          "description": "Paroxetine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00498",
          "name": "Phenindione",
          "description": "Alteplase may increase the anticoagulant activities of Phenindione."
        },
        {
          "drugbank-id": "DB00946",
          "name": "Phenprocoumon",
          "description": "Alteplase may increase the anticoagulant activities of Phenprocoumon."
        },
        {
          "drugbank-id": "DB00554",
          "name": "Piroxicam",
          "description": "Piroxicam may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06209",
          "name": "Prasugrel",
          "description": "Prasugrel may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06228",
          "name": "Rivaroxaban",
          "description": "Alteplase may increase the anticoagulant activities of Rivaroxaban."
        },
        {
          "drugbank-id": "DB01398",
          "name": "Salicylate-sodium",
          "description": "The risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Alteplase."
        },
        {
          "drugbank-id": "DB01399",
          "name": "Salsalate",
          "description": "The risk or severity of adverse effects can be increased when Salsalate is combined with Alteplase."
        },
        {
          "drugbank-id": "DB01104",
          "name": "Sertraline",
          "description": "Sertraline may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00605",
          "name": "Sulindac",
          "description": "Sulindac may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06271",
          "name": "Sulodexide",
          "description": "Alteplase may increase the anticoagulant activities of Sulodexide."
        },
        {
          "drugbank-id": "DB01600",
          "name": "Tiaprofenic acid",
          "description": "Tiaprofenic acid may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB08816",
          "name": "Ticagrelor",
          "description": "Ticagrelor may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00208",
          "name": "Ticlopidine",
          "description": "Ticlopidine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06822",
          "name": "Tinzaparin",
          "description": "Alteplase may increase the anticoagulant activities of Tinzaparin."
        },
        {
          "drugbank-id": "DB00775",
          "name": "Tirofiban",
          "description": "Tirofiban may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00500",
          "name": "Tolmetin",
          "description": "Tolmetin may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00374",
          "name": "Treprostinil",
          "description": "Alteplase may increase the anticoagulant activities of Treprostinil."
        },
        {
          "drugbank-id": "DB00285",
          "name": "Venlafaxine",
          "description": "Venlafaxine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB06684",
          "name": "Vilazodone",
          "description": "Vilazodone may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB09030",
          "name": "Vorapaxar",
          "description": "Vorapaxar may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB09068",
          "name": "Vortioxetine",
          "description": "Vortioxetine may increase the anticoagulant activities of Alteplase."
        },
        {
          "drugbank-id": "DB00682",
          "name": "Warfarin",
          "description": "Alteplase may increase the anticoagulant activities of Warfarin."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">Alteplase sequence\nSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG\nTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA\nLAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC\nYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK\nPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS\nPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH\nKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL\nSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG\nPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "60 °C",
          "source": "Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.516",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "7.61",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "59042.3",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C2569H3928N746O781S40",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "7297"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D02837"
        },
        {
          "resource": "GenBank",
          "identifier": "L00153"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164776730"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P00750"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Alteplase"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/alteplas.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/alteplase.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000211",
          "name": "Plasminogen",
          "organism": "Human",
          "actions": {
            "action": "activator"
          },
          "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\r\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\r\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Plasminogen",
            "general-function": "Serine-type peptidase activity",
            "specific-function": "Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.",
            "gene-name": "PLG",
            "locus": "6q26",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-19",
            "theoretical-pi": "7.25",
            "molecular-weight": "90568.415",
            "chromosome-location": "6",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9071"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLG"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X05199"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "387026"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2394"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00747"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PLMN_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "3.4.21.7"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00051",
                  "name": "Kringle"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00024",
                  "name": "PAN_1"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "apolipoprotein binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "serine-type peptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix disassembly"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "positive regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell-substrate adhesion"
                },
                {
                  "category": "process",
                  "description": "tissue remodeling"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell-cell adhesion mediated by cadherin"
                }
              ]
            },
            "_id": "P00747",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000538",
          "name": "Fibrinogen alpha chain",
          "organism": "Human",
          "actions": "",
          "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\r\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\r\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464",
          "known-action": "yes",
          "polypeptide": {
            "name": "Fibrinogen alpha chain",
            "general-function": "Structural molecule activity",
            "specific-function": "Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.",
            "gene-name": "FGA",
            "locus": "4q28",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-19",
            "theoretical-pi": "5.87",
            "molecular-weight": "94972.455",
            "chromosome-location": "4",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3661"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FGA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF361104"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "13591824"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02671"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FIBA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "Fibrinogen alpha chain precursor"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001074|Fibrinogen alpha chain\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)\nATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00147",
                  "name": "Fibrinogen_C"
                },
                {
                  "identifier": "PF08702",
                  "name": "Fib_alpha"
                },
                {
                  "identifier": "PF12160",
                  "name": "Fibrinogen_aC"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular vesicle"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "fibrinogen complex"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "rough endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "cell cortex"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "structural molecule activity"
                },
                {
                  "category": "process",
                  "description": "response to estradiol"
                },
                {
                  "category": "process",
                  "description": "induction of bacterial agglutination"
                },
                {
                  "category": "process",
                  "description": "positive regulation of vasoconstriction"
                },
                {
                  "category": "process",
                  "description": "plasminogen activation"
                },
                {
                  "category": "process",
                  "description": "cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, common pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of ERK1 and ERK2 cascade"
                },
                {
                  "category": "process",
                  "description": "cellular response to interleukin-6"
                },
                {
                  "category": "process",
                  "description": "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors"
                },
                {
                  "category": "process",
                  "description": "cellular response to granulocyte colony-stimulating factor"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endothelial cell apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of exocytosis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of blood coagulation, common pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of heterotypic cell-cell adhesion"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "response to morphine"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, fibrin clot formation"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "response to cycloheximide"
                },
                {
                  "category": "process",
                  "description": "protein complex assembly"
                },
                {
                  "category": "process",
                  "description": "cellular protein complex assembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of peptide hormone secretion"
                },
                {
                  "category": "process",
                  "description": "acute-phase response"
                },
                {
                  "category": "process",
                  "description": "protein polymerization"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "positive regulation of substrate adhesion-dependent cell spreading"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "adaptive immune response"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "liver regeneration"
                },
                {
                  "category": "process",
                  "description": "response to calcium ion"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein secretion"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "response to genistein"
                },
                {
                  "category": "process",
                  "description": "platelet aggregation"
                },
                {
                  "category": "process",
                  "description": "cellular response to organic cyclic compound"
                }
              ]
            },
            "_id": "P02671",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0000717",
          "name": "Urokinase plasminogen activator surface receptor",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Urokinase plasminogen activator surface receptor",
            "general-function": "Urokinase plasminogen activator receptor activity",
            "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.",
            "gene-name": "PLAUR",
            "locus": "19q13",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "6.64",
            "molecular-weight": "36977.62",
            "chromosome-location": "19",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9053"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLAUR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X51675"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "37605"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q03405"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "UPAR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "MO3",
                "Monocyte activation antigen Mo3",
                "U-PAR",
                "UPAR"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG\nCCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT\nGTATAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00021",
                "name": "UPAR_LY6"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "invadopodium membrane"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "anchored component of membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "urokinase plasminogen activator receptor activity"
                },
                {
                  "category": "function",
                  "description": "enzyme binding"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "regulation of proteolysis"
                },
                {
                  "category": "process",
                  "description": "chemotaxis"
                },
                {
                  "category": "process",
                  "description": "movement of cell or subcellular component"
                },
                {
                  "category": "process",
                  "description": "attachment of GPI anchor to protein"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "C-terminal protein lipidation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of intrinsic apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "urokinase plasminogen activator signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein phosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of DNA binding"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "positive regulation of epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of release of cytochrome c from mitochondria"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                }
              ]
            },
            "_id": "Q03405",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0000240",
          "name": "Plasminogen activator inhibitor 1",
          "organism": "Human",
          "actions": "",
          "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Plasminogen activator inhibitor 1",
            "general-function": "Serine-type endopeptidase inhibitor activity",
            "specific-function": "Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.",
            "gene-name": "SERPINE1",
            "locus": "7q21.3-q22",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-23",
            "theoretical-pi": "7.22",
            "molecular-weight": "45059.695",
            "chromosome-location": "7",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:8583"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "SERPINE1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X04429"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "35272"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P05121"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PAI1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Endothelial plasminogen activator inhibitor",
                "PAI",
                "PAI1",
                "PLANH1",
                "Serpin E1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00079",
                "name": "Serpin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase inhibitor activity"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of leukotriene production involved in inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell adhesion mediated by integrin"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of monocyte chemotaxis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell migration"
                },
                {
                  "category": "process",
                  "description": "gene expression"
                },
                {
                  "category": "process",
                  "description": "positive regulation of receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endothelial cell apoptotic process"
                },
                {
                  "category": "process",
                  "description": "transcription initiation from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of receptor activity"
                },
                {
                  "category": "process",
                  "description": "circadian rhythm"
                },
                {
                  "category": "process",
                  "description": "negative regulation of plasminogen activation"
                },
                {
                  "category": "process",
                  "description": "transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "angiogenesis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "transforming growth factor beta receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of vascular wound healing"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "negative regulation of wound healing"
                },
                {
                  "category": "process",
                  "description": "chronological cell aging"
                },
                {
                  "category": "process",
                  "description": "positive regulation of angiogenesis"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "defense response to Gram-negative bacterium"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-8 production"
                }
              ]
            },
            "_id": "P05121",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2013-01-09"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00010"
      },
      "BIOD00033",
      "BTD00033"
    ],
    "name": "Sermorelin",
    "description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues",
    "cas-number": "86168-78-7",
    "groups": {
      "group": [
        "approved",
        "withdrawn"
      ]
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For the treatment of dwarfism, prevention of HIV-induced weight loss",
    "pharmacodynamics": "Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.",
    "mechanism-of-action": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "11-12 min",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": {
      "salt": {
        "drugbank-id": {
          "_primary": "true",
          "__text": "DBSALT001439"
        },
        "name": "Sermorelin acetate",
        "cas-number": "",
        "inchikey": ""
      }
    },
    "synonyms": "",
    "products": "",
    "international-brands": {
      "international-brand": {
        "name": "Geref",
        "company": "Serono Pharma"
      }
    },
    "mixtures": "",
    "packagers": {
      "packager": [
        {
          "name": "Chengdu Shengnuo Bio Pharmaceutical Co. Ltd.",
          "url": ""
        },
        {
          "name": "Letco Medical Inc.",
          "url": "http://www.letcomedical.com"
        },
        {
          "name": "Live Well Drugstore LLC",
          "url": "http://www.livewelldrugstore.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Emd serono inc"
      }
    },
    "prices": "",
    "categories": {
      "category": {
        "category": "Hormone Replacement Agents",
        "mesh-id": "[]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": "",
    "atc-codes": {
      "atc-code": [
        {
          "level": [
            {
              "_code": "H",
              "__text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"
            },
            {
              "_code": "H01",
              "__text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"
            },
            {
              "_code": "H01A",
              "__text": "ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES"
            },
            {
              "_code": "H01AC",
              "__text": "Somatropin and somatropin agonists"
            }
          ],
          "_code": "H01AC04"
        },
        {
          "level": [
            {
              "_code": "V",
              "__text": "VARIOUS"
            },
            {
              "_code": "V04",
              "__text": "DIAGNOSTIC AGENTS"
            },
            {
              "_code": "V04C",
              "__text": "OTHER DIAGNOSTIC AGENTS"
            },
            {
              "_code": "V04CD",
              "__text": "Tests for pituitary function"
            }
          ],
          "_code": "V04CD03"
        }
      ]
    },
    "ahfs-codes": "",
    "patents": "",
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00010 sequence\nYADAIFTNSYRKVLGQLSARKLLQDIMSRQ"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "-0.330",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "9.99",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "3357.882",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C149H246N44O42S",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "KEGG Compound",
          "identifier": "C08192"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164749110"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Sermorelin"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic2/sermorelin.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/sermorelin-acetate.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000625",
        "name": "Growth hormone-releasing hormone receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14499707\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Growth hormone-releasing hormone receptor",
          "general-function": "Peptide hormone binding",
          "specific-function": "Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion.",
          "gene-name": "GHRHR",
          "locus": "7p14",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "133-152\n163-181\n205-227\n241-262\n281-304\n330-348\n362-381",
          "signal-regions": "1-22",
          "theoretical-pi": "6.73",
          "molecular-weight": "47401.53",
          "chromosome-location": "7",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:4266"
              },
              {
                "resource": "GenAtlas",
                "identifier": "GHRHR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "L01406"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "183173"
              },
              {
                "resource": "IUPHAR",
                "identifier": "247"
              },
              {
                "resource": "UniProtKB",
                "identifier": "Q02643"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "GHRHR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "GHRH receptor",
              "GRF receptor",
              "GRFR",
              "Growth hormone-releasing factor receptor"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016157|Growth hormone-releasing hormone receptor\nMDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWD\nGLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLA\nEEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVF\nLKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRR\nAFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLF\nLNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPL\nELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLT\nSMC"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016158|Growth hormone-releasing hormone receptor (GHRHR)\nATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTA\nTTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCC\nTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGAT\nGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGAT\nTTCTTCTCTCACTTCAGCTCAGAGTCAGGGGCTGTGAAACGGGATTGTACTATCACTGGC\nTGGTCTGAGCCCTTTCCACCTTACCCTGTGGCCTGCCCTGTGCCTCTGGAGCTGCTGGCT\nGAGGAGGAATCTTACTTCTCCACAGTGAAGATTATCTACACCGTGGGCCATAGCATCTCT\nATTGTAGCCCTCTTCGTGGCCATCACCATCCTGGTTGCTCTCAGGAGGCTCCACTGCCCC\nCGGAACTACGTCCACACCCAGCTGTTCACCACTTTTATCCTCAAGGCGGGAGCTGTGTTC\nCTGAAGGATGCTGCCCTTTTCCACAGCGACGACACTGACCACTGCAGCTTCTCCACTGTT\nCTATGCAAGGTCTCTGTGGCCGCCTCCCATTTCGCCACCATGACCAACTTCAGCTGGCTG\nTTGGCAGAAGCCGTCTACCTGAACTGCCTCCTGGCCTCCACCTCCCCCAGCTCAAGGAGA\nGCCTTCTGGTGGCTGGTTCTCGCTGGCTGGGGGCTGCCCGTGCTCTTCACTGGCACGTGG\nGTGAGCTGCAAACTGGCCTTCGAGGACATCGCGTGCTGGGACCTGGACGACACCTCCCCC\nTACTGGTGGATCATCAAAGGGCCCATTGTCCTCTCGGTCGGGGTGAACTTTGGGCTTTTT\nCTCAATATTATCCGCATCCTGGTGAGGAAACTGGAGCCAGCTCAGGGCAGCCTCCATACC\nCAGTCTCAGTATTGGCGTCTCTCCAAGTCGACACTTTTCCTGATCCCACTCTTTGGAATT\nCACTACATCATCTTCAACTTCCTGCCAGACAATGCTGGCCTGGGCATCCGCCTCCCCCTG\nGAGCTGGGACTGGGTTCCTTCCAGGGCTTCATTGTTGCCATCCTCTACTGCTTCCTCAAC\nCAAGAGGTGAGGACTGAGATCTCACGGAAGTGGCATGGCCATGACCCTGAGCTTCTGCCA\nGCCTGGAGGACCCGTGCTAAGTGGACCACGCCTTCCCGCTCGGCGGCAAAGGTGCTGACA\nTCTATGTGCTAG"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00002",
                "name": "7tm_2"
              },
              {
                "identifier": "PF02793",
                "name": "HRM"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "integral component of membrane"
              },
              {
                "category": "component",
                "description": "secretory granule"
              },
              {
                "category": "component",
                "description": "nuclear inner membrane"
              },
              {
                "category": "component",
                "description": "nuclear outer membrane"
              },
              {
                "category": "component",
                "description": "nuclear matrix"
              },
              {
                "category": "component",
                "description": "cytoplasm"
              },
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "cell surface"
              },
              {
                "category": "function",
                "description": "growth hormone-releasing hormone receptor activity"
              },
              {
                "category": "function",
                "description": "peptide hormone binding"
              },
              {
                "category": "function",
                "description": "G-protein coupled receptor activity"
              },
              {
                "category": "function",
                "description": "growth factor binding"
              },
              {
                "category": "process",
                "description": "positive regulation of cAMP biosynthetic process"
              },
              {
                "category": "process",
                "description": "multicellular organismal reproductive process"
              },
              {
                "category": "process",
                "description": "response to insulin"
              },
              {
                "category": "process",
                "description": "growth hormone secretion"
              },
              {
                "category": "process",
                "description": "adenylate cyclase-activating G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "determination of adult lifespan"
              },
              {
                "category": "process",
                "description": "water homeostasis"
              },
              {
                "category": "process",
                "description": "positive regulation of growth hormone secretion"
              },
              {
                "category": "process",
                "description": "activation of adenylate cyclase activity"
              },
              {
                "category": "process",
                "description": "regulation of intracellular steroid hormone receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "cell surface receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "cell maturation"
              },
              {
                "category": "process",
                "description": "regulation of protein metabolic process"
              },
              {
                "category": "process",
                "description": "positive regulation of cell proliferation"
              },
              {
                "category": "process",
                "description": "hormone metabolic process"
              },
              {
                "category": "process",
                "description": "somatotropin secreting cell development"
              },
              {
                "category": "process",
                "description": "response to estrogen"
              },
              {
                "category": "process",
                "description": "positive regulation of multicellular organism growth"
              },
              {
                "category": "process",
                "description": "response to glucocorticoid"
              },
              {
                "category": "process",
                "description": "cAMP-mediated signaling"
              },
              {
                "category": "process",
                "description": "cellular response to insulin stimulus"
              },
              {
                "category": "process",
                "description": "positive regulation of insulin-like growth factor receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "lactation"
              }
            ]
          },
          "_id": "Q02643",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-11-30"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00011"
      },
      "BIOD00096",
      "BTD00096",
      "DB00084"
    ],
    "name": "Interferon alfa-n1",
    "description": "Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues",
    "cas-number": "74899-72-2",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, \"Method for producing human leukocyte interferon alpha-2.\" U.S. Patent US4680260, issued January, 1982.",
    "indication": "For treatment of venereal or genital warts caused by the Human Papiloma Virus",
    "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.",
    "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "1.2 hours (mammalian reticulocytes, in vitro); >20 hours (yeast, in vivo); >10 hours (Escherichia coli, in vivo).",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Interferon alpha-2"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Interferon alpha-A"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Interferon alpha-n1 (Ins)"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "LeIF A"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Wellferon Inj 10 000 000unit/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "01959069",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "2000-08-01",
          "dosage-form": "liquid",
          "strength": "10000000 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Wellferon Inj 3000000unit/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "01959077",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "2000-08-01",
          "dosage-form": "liquid",
          "strength": "3000000 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Wellferon",
        "company": "GlaxoSmithKline"
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Wellferon Inj 10 000 000unit/ml",
          "ingredients": "Interferon alfa-n1"
        },
        {
          "name": "Wellferon Inj 3000000unit/ml",
          "ingredients": "Interferon alfa-n1"
        }
      ]
    },
    "packagers": "",
    "manufacturers": "",
    "prices": "",
    "categories": {
      "category": [
        {
          "category": "Antiviral Agents",
          "mesh-id": "[\"D27.505.954.122.388\"]"
        },
        {
          "category": "Immunologic Factors",
          "mesh-id": "[\"D27.505.696.477\"]"
        },
        {
          "category": "Immunosuppressive Agents",
          "mesh-id": "[\"D27.505.696.477.656\"]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Liquid",
          "route": "intramuscular; subcutaneous",
          "strength": "10000000 unit"
        },
        {
          "form": "Liquid",
          "route": "intramuscular; subcutaneous",
          "strength": "3000000 unit"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L03",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03A",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03AB",
            "__text": "Interferons"
          }
        ],
        "_code": "L03AB06"
      }
    },
    "ahfs-codes": "",
    "patents": "",
    "food-interactions": {
      "food-interaction": "Avoid alcohol."
    },
    "drug-interactions": "",
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00011 sequence\nCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "61 °C",
          "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.336",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "5.99",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "19241.1",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C860H1353N227O255S9",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "7651"
        },
        {
          "resource": "GenBank",
          "identifier": "J00207"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164746538"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01563"
        }
      ]
    },
    "external-links": "",
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000385",
          "name": "Interferon alpha/beta receptor 2",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10822464\r\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 2",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.",
            "gene-name": "IFNAR2",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "244-264",
            "signal-regions": "1-26",
            "theoretical-pi": "4.11",
            "molecular-weight": "57758.24",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5433"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L42243"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "995300"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P48551"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IFN-R-2",
                "IFNABR",
                "IFNARB",
                "Interferon alpha binding protein",
                "Type I interferon receptor 2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protein kinase binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to interferon-alpha"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                }
              ]
            },
            "_id": "P48551",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000661",
          "name": "Interferon alpha/beta receptor 1",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10822464\r\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 1",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.",
            "gene-name": "IFNAR1",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "437-457",
            "signal-regions": "1-27",
            "theoretical-pi": "5.56",
            "molecular-weight": "63524.81",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5432"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J03171"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "306914"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1723"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P17181"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CRF2-1",
                "Cytokine receptor class-II member 1",
                "Cytokine receptor family 2 member 1",
                "IFN-R-1",
                "IFNAR",
                "Type I interferon receptor 1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-beta production"
                },
                {
                  "category": "process",
                  "description": "regulation of peptidyl-tyrosine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "type I interferon biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-gamma production"
                },
                {
                  "category": "process",
                  "description": "T cell activation"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "defense response to virus"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-1 beta secretion"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                }
              ]
            },
            "_id": "P17181",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-09-23"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00012"
      },
      "BIOD00032",
      "BTD00032"
    ],
    "name": "Darbepoetin alfa",
    "description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.",
    "cas-number": "11096-26-7",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For the treatment of anemia (from renal transplants or certain HIV treatment)",
    "pharmacodynamics": "Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.",
    "mechanism-of-action": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with\r\nprogenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Epoetin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Erythropoietin precursor"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-002",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "25 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-003",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "40 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-004",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "60 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-005",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "100 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-006",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-021",
          "dpd-id": "",
          "started-marketing-on": "2006-08-14",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "40 ug/.4mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-023",
          "dpd-id": "",
          "started-marketing-on": "2006-08-14",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "60 ug/.3mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-025",
          "dpd-id": "",
          "started-marketing-on": "2006-08-14",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "100 ug/.5mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-027",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "150 ug/.3mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-028",
          "dpd-id": "",
          "started-marketing-on": "2006-08-14",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "200 ug/.4mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-032",
          "dpd-id": "",
          "started-marketing-on": "2006-06-07",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "500 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-053",
          "dpd-id": "",
          "started-marketing-on": "2006-09-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "150 ug/.75mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-057",
          "dpd-id": "",
          "started-marketing-on": "2006-08-26",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "25 ug/.42mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-098",
          "dpd-id": "",
          "started-marketing-on": "2006-08-26",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "10 ug/.4mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-110",
          "dpd-id": "",
          "started-marketing-on": "2006-08-14",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "300 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp",
          "ndc-id": "",
          "ndc-product-code": "55513-111",
          "dpd-id": "",
          "started-marketing-on": "2006-08-14",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "300 ug/.6mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103951",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246354",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2015-08-04",
          "dosage-form": "solution",
          "strength": "25 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246355",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2015-08-04",
          "dosage-form": "solution",
          "strength": "40 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246357",
          "started-marketing-on": "2002-08-20",
          "ended-marketing-on": "2015-08-04",
          "dosage-form": "solution",
          "strength": "100 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246358",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2015-08-04",
          "dosage-form": "solution",
          "strength": "200 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246360",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2015-08-04",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391740",
          "started-marketing-on": "2013-12-11",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "100 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391759",
          "started-marketing-on": "2014-05-07",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "100 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391767",
          "started-marketing-on": "2014-01-27",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391775",
          "started-marketing-on": "2014-03-26",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391783",
          "started-marketing-on": "2014-02-10",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391791",
          "started-marketing-on": "2014-04-21",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391805",
          "started-marketing-on": "2014-05-05",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391821",
          "started-marketing-on": "2013-11-04",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02392313",
          "started-marketing-on": "2013-08-16",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "25 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02392321",
          "started-marketing-on": "2014-03-12",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "40 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02392348",
          "started-marketing-on": "2014-03-03",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "100 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02392356",
          "started-marketing-on": "2014-04-03",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02392364",
          "started-marketing-on": "2014-02-24",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246353",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "15 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246356",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "60 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246359",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "325 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391732",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "40 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391813",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02391848",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "500 mcg",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        },
        {
          "name": "Aranesp        -(hsa-free)",
          "ingredients": "Darbepoetin alfa"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Amgen Inc.",
          "url": "http://www.amgen.com"
        },
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Amgen Inc."
      }
    },
    "prices": {
      "price": [
        {
          "description": "Aranesp 25 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "156.36"
          },
          "unit": "ml"
        },
        {
          "description": "Aranesp (Albumin Free) 25 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "162.61"
          },
          "unit": "vial"
        },
        {
          "description": "Aranesp 40 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "250.2"
          },
          "unit": "ml"
        },
        {
          "description": "Aranesp 60 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "375.3"
          },
          "unit": "ml"
        },
        {
          "description": "Aranesp (Albumin Free) 60 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "390.31"
          },
          "unit": "vial"
        },
        {
          "description": "Aranesp 100 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "625.44"
          },
          "unit": "ml"
        },
        {
          "description": "Aranesp 200 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "1250.88"
          },
          "unit": "ml"
        },
        {
          "description": "Aranesp 300 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "1876.32"
          },
          "unit": "ml"
        },
        {
          "description": "Aranesp (Albumin Free) 300 mcg/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "1951.37"
          },
          "unit": "vial"
        },
        {
          "description": "Aranesp (Albumin Free) 100 mcg/0.5ml Solution (1 Box = Four 0.5ml Syringes)",
          "cost": {
            "_currency": "USD",
            "__text": "2601.83"
          },
          "unit": "box"
        },
        {
          "description": "Aranesp (Albumin Free) 100 mcg/ml Solution Four 1ml Vials Per Box",
          "cost": {
            "_currency": "USD",
            "__text": "2601.83"
          },
          "unit": "box"
        },
        {
          "description": "Aranesp (Albumin Free) 150 mcg/0.75ml Solution (1 Box = Four 0.75ml Vials)",
          "cost": {
            "_currency": "USD",
            "__text": "3902.75"
          },
          "unit": "box"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Hematinics",
          "mesh-id": "[\"D27.505.954.502.543\"]"
        },
        {
          "category": "Anti-anemic Agents",
          "mesh-id": "[]"
        },
        {
          "category": "Erythropoiesis-Stimulating Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "10 ug/.4mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "100 ug/.5mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "150 ug/.3mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "200 ug/.4mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "25 ug/.42mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "300 ug/.6mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "40 ug/.4mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "500 ug/mL"
        },
        {
          "form": "Injection, solution",
          "route": "intravenous; subcutaneous",
          "strength": "60 ug/.3mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "100 ug/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "150 ug/.75mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "200 ug/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "25 ug/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "300 ug/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "40 ug/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "60 ug/mL"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "100 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "15 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "200 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "25 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "325 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "40 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "500 mcg"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "60 mcg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "B",
            "__text": "BLOOD AND BLOOD FORMING ORGANS"
          },
          {
            "_code": "B03",
            "__text": "ANTIANEMIC PREPARATIONS"
          },
          {
            "_code": "B03X",
            "__text": "OTHER ANTIANEMIC PREPARATIONS"
          },
          {
            "_code": "B03XA",
            "__text": "Other antianemic preparations"
          }
        ],
        "_code": "B03XA02"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "20:16.00"
    },
    "patents": {
      "patent": [
        {
          "number": "2147124",
          "country": "Canada",
          "approved": "2002-11-05",
          "expires": "2014-08-16"
        },
        {
          "number": "2165694",
          "country": "Canada",
          "approved": "2003-03-18",
          "expires": "2010-10-15"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00480",
          "name": "Lenalidomide",
          "description": "Darbepoetin alfa may increase the thrombogenic activities of Lenalidomide."
        },
        {
          "drugbank-id": "DB00984",
          "name": "Nandrolone phenpropionate",
          "description": "Nandrolone phenpropionate may increase the stimulatory activities of Darbepoetin alfa."
        },
        {
          "drugbank-id": "DB01041",
          "name": "Thalidomide",
          "description": "Darbepoetin alfa may increase the thrombogenic activities of Thalidomide."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00012 sequence\nAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA\nVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS\nPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "53 °C",
          "source": "Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.188",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "8.75",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "18396.1",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C815H1317N233O241S5",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "12550"
        },
        {
          "resource": "GenBank",
          "identifier": "X02158"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164743138"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01588"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Darbepoetin_alfa"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/aranesp.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/darbepoetin-alfa-albumin.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000654",
        "name": "Erythropoietin receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16505108\r\n# Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17575216\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Erythropoietin receptor",
          "general-function": "Identical protein binding",
          "specific-function": "Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.",
          "gene-name": "EPOR",
          "locus": "19p13.3-p13.2",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "251-273",
          "signal-regions": "1-24",
          "theoretical-pi": "4.37",
          "molecular-weight": "55064.725",
          "chromosome-location": "19",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:3416"
              },
              {
                "resource": "GenAtlas",
                "identifier": "EPOR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "M60459"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "182245"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "1718"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P19235"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "EPOR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": "EPO-R"
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0001304|Erythropoietin receptor\nMDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL\nVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL\nELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY\nEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV\nSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH\nKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG\nSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS\nAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL\nSDGPYSNPYENSLIPAAEPLPPSYVACS"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0010455|Erythropoietin receptor (EPOR)\nATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT\nGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC\nTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG\nGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC\nTACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT\nGGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA\nGAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT\nGAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC\nCACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC\nGAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG\nGGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC\nCGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG\nTCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG\nGTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG\nAAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC\nAAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC\nACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG\nACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC\nAGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG\nCCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC\nTCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT\nGCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA\nCTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT\nGACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA\nTCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG\nCCCCCCAGCTATGTGGCTTGCTCTTAG"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00041",
                "name": "fn3"
              },
              {
                "identifier": "PF09067",
                "name": "EpoR_lig-bind"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "extracellular region"
              },
              {
                "category": "component",
                "description": "cytosol"
              },
              {
                "category": "component",
                "description": "integral component of plasma membrane"
              },
              {
                "category": "function",
                "description": "erythropoietin receptor activity"
              },
              {
                "category": "function",
                "description": "identical protein binding"
              },
              {
                "category": "process",
                "description": "heart development"
              },
              {
                "category": "process",
                "description": "brain development"
              },
              {
                "category": "process",
                "description": "negative regulation of neuron apoptotic process"
              },
              {
                "category": "process",
                "description": "decidualization"
              },
              {
                "category": "process",
                "description": "signal transduction"
              },
              {
                "category": "process",
                "description": "erythropoietin-mediated signaling pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of cytosolic calcium ion concentration"
              }
            ]
          },
          "_id": "P19235",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2011-09-03"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00013"
      },
      "BIOD00030",
      "BTD00030"
    ],
    "name": "Urokinase",
    "description": "Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator",
    "cas-number": "9039-53-6",
    "groups": {
      "group": [
        "approved",
        "investigational",
        "withdrawn"
      ]
    },
    "general-references": "# Housley C: Contract purchasing means a buyer's market. Dimens Health Serv. 1976 Apr;53(4):16, 19-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5328",
    "synthesis-reference": "Koji Sasaki, Yasukazu Harada, \"Urokinase preparation for oral administration.\" U.S. Patent US4258030, issued November, 1975.",
    "indication": "Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.",
    "pharmacodynamics": "Urokinase is used for the treatment of pulmonary embolisms. The low molecular weight form of human urokinase consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Urokinase is the low molecular weight form. Urokinase acts on the endogenous fibrinolytic system. It converts plasminogen to the enzyme plasmin. Plasmin degrades fibrin clots as well as fibrinogen and some other plasma proteins.",
    "mechanism-of-action": "Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins.",
    "toxicity": "",
    "metabolism": "Proteolysis",
    "absorption": "",
    "half-life": "12 minutes. Small fractions of the administered dose are excreted in bile and urine",
    "protein-binding": "",
    "route-of-elimination": "Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "U-plasminogen activator"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "uPA"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Urokinase-type plasminogen activator precursor"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Kinlytic (urokinase for Injection)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00749702",
          "started-marketing-on": "1988-12-31",
          "ended-marketing-on": "2009-10-28",
          "dosage-form": "powder for solution",
          "strength": "250000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kinlytic Open-cath",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00886777",
          "started-marketing-on": "1991-12-31",
          "ended-marketing-on": "2009-10-28",
          "dosage-form": "powder for solution",
          "strength": "5000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": [
        {
          "name": "Abbokinase",
          "company": "Abbott Laboratories"
        },
        {
          "name": "Kinlytic",
          "company": "Microbix Biosystems Inc."
        }
      ]
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Kinlytic Open-cath",
          "ingredients": "Urokinase"
        },
        {
          "name": "Kinlytic (urokinase for Injection)",
          "ingredients": "Urokinase"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Hospira Inc.",
          "url": "http://www.hospira.com"
        },
        {
          "name": "ImaRx Therapeutics",
          "url": "http://www.imarx.com"
        },
        {
          "name": "Microbix Biosystems Inc.",
          "url": "http://www.microbix.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Microbix biosystems inc"
      }
    },
    "prices": "",
    "categories": {
      "category": {
        "category": "Thrombolytic Agents",
        "mesh-id": "[]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "250000 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "5000 unit"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "B",
            "__text": "BLOOD AND BLOOD FORMING ORGANS"
          },
          {
            "_code": "B01",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01A",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01AD",
            "__text": "Enzymes"
          }
        ],
        "_code": "B01AD04"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "20:12.20"
    },
    "patents": "",
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00054",
          "name": "Abciximab",
          "description": "Abciximab may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01418",
          "name": "Acenocoumarol",
          "description": "Urokinase may increase the anticoagulant activities of Acenocoumarol."
        },
        {
          "drugbank-id": "DB00945",
          "name": "Acetylsalicylic acid",
          "description": "Acetylsalicylic acid may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00233",
          "name": "Aminosalicylic Acid",
          "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Urokinase."
        },
        {
          "drugbank-id": "DB00261",
          "name": "Anagrelide",
          "description": "Anagrelide may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06605",
          "name": "Apixaban",
          "description": "Urokinase may increase the anticoagulant activities of Apixaban."
        },
        {
          "drugbank-id": "DB06692",
          "name": "Aprotinin",
          "description": "The therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin."
        },
        {
          "drugbank-id": "DB00278",
          "name": "Argatroban",
          "description": "Urokinase may increase the anticoagulant activities of Argatroban."
        },
        {
          "drugbank-id": "DB01294",
          "name": "Bismuth Subsalicylate",
          "description": "The risk or severity of adverse effects can be increased when Bismuth Subsalicylate is combined with Urokinase."
        },
        {
          "drugbank-id": "DB00006",
          "name": "Bivalirudin",
          "description": "Urokinase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00201",
          "name": "Caffeine",
          "description": "Caffeine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06441",
          "name": "Cangrelor",
          "description": "Cangrelor may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01166",
          "name": "Cilostazol",
          "description": "Cilostazol may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00215",
          "name": "Citalopram",
          "description": "Citalopram may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00758",
          "name": "Clopidogrel",
          "description": "Clopidogrel may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06695",
          "name": "Dabigatran etexilate",
          "description": "Urokinase may increase the anticoagulant activities of Dabigatran etexilate."
        },
        {
          "drugbank-id": "DB06779",
          "name": "Dalteparin",
          "description": "Urokinase may increase the anticoagulant activities of Dalteparin."
        },
        {
          "drugbank-id": "DB06754",
          "name": "Danaparoid",
          "description": "Urokinase may increase the anticoagulant activities of Danaparoid."
        },
        {
          "drugbank-id": "DB11095",
          "name": "Desirudin",
          "description": "Urokinase may increase the anticoagulant activities of Desirudin."
        },
        {
          "drugbank-id": "DB06700",
          "name": "Desvenlafaxine",
          "description": "Desvenlafaxine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00586",
          "name": "Diclofenac",
          "description": "Diclofenac may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00861",
          "name": "Diflunisal",
          "description": "Diflunisal may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01551",
          "name": "Dihydrocodeine",
          "description": "Dihydrocodeine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00975",
          "name": "Dipyridamole",
          "description": "Dipyridamole may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00476",
          "name": "Duloxetine",
          "description": "Duloxetine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB09075",
          "name": "Edoxaban",
          "description": "Urokinase may increase the anticoagulant activities of Edoxaban."
        },
        {
          "drugbank-id": "DB01225",
          "name": "Enoxaparin",
          "description": "Urokinase may increase the anticoagulant activities of Enoxaparin."
        },
        {
          "drugbank-id": "DB01240",
          "name": "Epoprostenol",
          "description": "The risk or severity of adverse effects can be increased when Urokinase is combined with Epoprostenol."
        },
        {
          "drugbank-id": "DB00063",
          "name": "Eptifibatide",
          "description": "Eptifibatide may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01175",
          "name": "Escitalopram",
          "description": "Escitalopram may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00749",
          "name": "Etodolac",
          "description": "Etodolac may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00573",
          "name": "Fenoprofen",
          "description": "Fenoprofen may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB08976",
          "name": "Floctafenine",
          "description": "Floctafenine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00472",
          "name": "Fluoxetine",
          "description": "Fluoxetine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00712",
          "name": "Flurbiprofen",
          "description": "Flurbiprofen may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00176",
          "name": "Fluvoxamine",
          "description": "Fluvoxamine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00569",
          "name": "Fondaparinux sodium",
          "description": "Urokinase may increase the anticoagulant activities of Fondaparinux sodium."
        },
        {
          "drugbank-id": "DB01109",
          "name": "Heparin",
          "description": "Urokinase may increase the anticoagulant activities of Heparin."
        },
        {
          "drugbank-id": "DB01050",
          "name": "Ibuprofen",
          "description": "Ibuprofen may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01088",
          "name": "Iloprost",
          "description": "The risk or severity of adverse effects can be increased when Urokinase is combined with Iloprost."
        },
        {
          "drugbank-id": "DB00328",
          "name": "Indomethacin",
          "description": "Indomethacin may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01009",
          "name": "Ketoprofen",
          "description": "Ketoprofen may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00465",
          "name": "Ketorolac",
          "description": "Ketorolac may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB08918",
          "name": "Levomilnacipran",
          "description": "Levomilnacipran may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01397",
          "name": "Magnesium salicylate",
          "description": "The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Urokinase."
        },
        {
          "drugbank-id": "DB00784",
          "name": "Mefenamic acid",
          "description": "Mefenamic acid may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00814",
          "name": "Meloxicam",
          "description": "Meloxicam may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB04896",
          "name": "Milnacipran",
          "description": "Milnacipran may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00461",
          "name": "Nabumetone",
          "description": "Nabumetone may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB08813",
          "name": "Nadroparin",
          "description": "Urokinase may increase the anticoagulant activities of Nadroparin."
        },
        {
          "drugbank-id": "DB00788",
          "name": "Naproxen",
          "description": "Naproxen may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00991",
          "name": "Oxaprozin",
          "description": "Oxaprozin may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00715",
          "name": "Paroxetine",
          "description": "Paroxetine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00554",
          "name": "Piroxicam",
          "description": "Piroxicam may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06209",
          "name": "Prasugrel",
          "description": "Prasugrel may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06228",
          "name": "Rivaroxaban",
          "description": "Urokinase may increase the anticoagulant activities of Rivaroxaban."
        },
        {
          "drugbank-id": "DB01399",
          "name": "Salsalate",
          "description": "The risk or severity of adverse effects can be increased when Salsalate is combined with Urokinase."
        },
        {
          "drugbank-id": "DB01104",
          "name": "Sertraline",
          "description": "Sertraline may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00605",
          "name": "Sulindac",
          "description": "Sulindac may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB01600",
          "name": "Tiaprofenic acid",
          "description": "Tiaprofenic acid may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB08816",
          "name": "Ticagrelor",
          "description": "Ticagrelor may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00208",
          "name": "Ticlopidine",
          "description": "Ticlopidine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06822",
          "name": "Tinzaparin",
          "description": "Urokinase may increase the anticoagulant activities of Tinzaparin."
        },
        {
          "drugbank-id": "DB00775",
          "name": "Tirofiban",
          "description": "Tirofiban may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00500",
          "name": "Tolmetin",
          "description": "Tolmetin may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00374",
          "name": "Treprostinil",
          "description": "The risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil."
        },
        {
          "drugbank-id": "DB00285",
          "name": "Venlafaxine",
          "description": "Venlafaxine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB06684",
          "name": "Vilazodone",
          "description": "Vilazodone may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB09030",
          "name": "Vorapaxar",
          "description": "Vorapaxar may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB09068",
          "name": "Vortioxetine",
          "description": "Vortioxetine may increase the anticoagulant activities of Urokinase."
        },
        {
          "drugbank-id": "DB00682",
          "name": "Warfarin",
          "description": "Urokinase may increase the anticoagulant activities of Warfarin."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00013 sequence\nKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMS\nPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHND\nIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMT\nVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVS\nWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "76 °C at pH 4.5",
          "source": "Nowak, U.K. et al., Biochemistry 33:2951-2960 (1994)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.466",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "8.66",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "31126.5",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C1376H2145N383O406S18",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "2012"
        },
        {
          "resource": "GenBank",
          "identifier": "X02419"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA451836"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P00749"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Urokinase"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/pharmclips2.cgi?keyword=%20Abbokinase%AE"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/mtm/urokinase.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000211",
          "name": "Plasminogen",
          "organism": "Human",
          "actions": {
            "action": "activator"
          },
          "references": "# Zhang X, Zhou H, Shen G, Liu Z, Hu Y, Wei W, Song S: Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):21-3, 76. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12658774\r\n# Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J: Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol. 2003 Apr;72(4):234-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12666133\r\n# Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J: Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thromb Haemost. 2003 May;89(5):820-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12719778\r\n# Guda K, Claffey KP, Dong M, Nambiar PR, Rosenberg DW: Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog. 2003 May;37(1):51-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12720300\r\n# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Plasminogen",
            "general-function": "Serine-type peptidase activity",
            "specific-function": "Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.",
            "gene-name": "PLG",
            "locus": "6q26",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-19",
            "theoretical-pi": "7.25",
            "molecular-weight": "90568.415",
            "chromosome-location": "6",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9071"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLG"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X05199"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "387026"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2394"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00747"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PLMN_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "3.4.21.7"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00051",
                  "name": "Kringle"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00024",
                  "name": "PAN_1"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "apolipoprotein binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "serine-type peptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix disassembly"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "positive regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell-substrate adhesion"
                },
                {
                  "category": "process",
                  "description": "tissue remodeling"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell-cell adhesion mediated by cadherin"
                }
              ]
            },
            "_id": "P00747",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000717",
          "name": "Urokinase plasminogen activator surface receptor",
          "organism": "Human",
          "actions": "",
          "references": "# Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003 Mar 3;160(5):781-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12615913\r\n# Fuchs T, Allgayer H: Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis. Biol Chem. 2003 May;384(5):755-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12817472\r\n# Kanse SM, Chavakis T, Al-Fakhri N, Hersemeyer K, Monard D, Preissner KT: Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. J Cell Sci. 2004 Jan 26;117(Pt 3):477-85. Epub 2003 Dec 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14679304\r\n# Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D: Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004 Jan 1;172(1):540-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14688365\r\n# Guerrero J, Santibanez JF, Gonzalez A, Martinez J: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res. 2004 Jan 1;292(1):201-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14720519\r\n# Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody KS: Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007 Feb 28;2(2):e243. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17327908",
          "known-action": "yes",
          "polypeptide": {
            "name": "Urokinase plasminogen activator surface receptor",
            "general-function": "Urokinase plasminogen activator receptor activity",
            "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.",
            "gene-name": "PLAUR",
            "locus": "19q13",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "6.64",
            "molecular-weight": "36977.62",
            "chromosome-location": "19",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9053"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLAUR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X51675"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "37605"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q03405"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "UPAR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "MO3",
                "Monocyte activation antigen Mo3",
                "U-PAR",
                "UPAR"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG\nCCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT\nGTATAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00021",
                "name": "UPAR_LY6"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "invadopodium membrane"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "anchored component of membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "urokinase plasminogen activator receptor activity"
                },
                {
                  "category": "function",
                  "description": "enzyme binding"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "regulation of proteolysis"
                },
                {
                  "category": "process",
                  "description": "chemotaxis"
                },
                {
                  "category": "process",
                  "description": "movement of cell or subcellular component"
                },
                {
                  "category": "process",
                  "description": "attachment of GPI anchor to protein"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "C-terminal protein lipidation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of intrinsic apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "urokinase plasminogen activator signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein phosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of DNA binding"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "positive regulation of epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of release of cytochrome c from mitochondria"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                }
              ]
            },
            "_id": "Q03405",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0000895",
          "name": "Urokinase-type plasminogen activator",
          "organism": "Human",
          "actions": "",
          "references": "# Bell WR: Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3 Suppl 2:S34-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12556741\r\n# Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12579271\r\n# Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2003 May;14(5):1254-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12707394\r\n# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\r\n# Wielockx B, Libert C: Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor. Cytokine. 2003 Mar 21;21(6):281-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12824001",
          "known-action": "yes",
          "polypeptide": {
            "name": "Urokinase-type plasminogen activator",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.",
            "gene-name": "PLAU",
            "locus": "10q24",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-20",
            "theoretical-pi": "8.48",
            "molecular-weight": "48507.09",
            "chromosome-location": "10",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9052"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLAU"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X02419"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "1834524"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2393"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00749"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "UROK_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.73",
                "U-plasminogen activator"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037097|Urokinase-type plasminogen activator\nMRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ\nHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN\nYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII\nGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLISPCWVISATHCFIDYPKKEDYIVYLG\nRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL\nPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML\nCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR\nSHTKEENGLAL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0021654|Urokinase-type plasminogen activator (PLAU)\nATGGTCTTCCATTTGAGAACTAGATACGAACAGGCGAACTGTGACTGTCTAAATGGAGGA\nACATGTGTGTCCAACAAGTACTTCTCCAACATTCACTGGTGCAACTGCCCAAAGAAATTC\nGGAGGGCAGCACTGTGAAATAGATAAGTCAAAAACCTGCTATGAGGGGAATGGTCACTTT\nTACCGAGGAAAGGCCAGCACTGACACCATGGGCCGGCCCTGCCTGCCCTGGAACTCTGCC\nACTGTCCTTCAGCAAACGTACCATGCCCACAGATCTGATGCTCTTCAGCTGGGCCTGGGG\nAAACATAATTACTGCAGGAACCCAGACAACCGGAGGCGACCCTGGTGCTATGTGCAGGTG\nGGCCTAAAGCCGCTTGTCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAAAGCCC\nTCCTCTCCTCCAGAAGAATTAAAATTTCAGTGTGGCCAAAAGACTCTGAGGCCCCGCTTT\nAAGATTATTGGGGGAGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTAC\nAGGAGGCACCGGGGGGGCTCTGTCACCTACGTGTGTGGAGGCAGCCTCATCAGCCCTTGC\nTGGGTGATCAGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGACTACATCGTC\nTACCTGGGTCGCTCAAGGCTTAACTCCAACACGCAAGGGGAGATGAAGTTTGAGGTGGAA\nAACCTCATCCTACACAAGGACTACAGCGCTGACACGCTTGCTCACCACAACGACATTGCC\nTTGCTGAAGATCCGTTCCAAGGAGGGCAGGTGTGCGCAGCCATCCCGGACTATACAGACC\nATCTGCCTGCCCTCGATGTATAACGATCCCCAGTTTGGCACAAGCTGTGAGATCACTGGC\nTTTGGAAAAGAGAATTCTACCGACTATCTCTATCCGGAGCAGCTGAAAATGACTGTTGTG\nAAGCTGATTTCCCACCGGGAGTGTCAGCAGCCCCACTACTACGGCTCTGAAGTCACCACC\nAAAATGCTGTGTGCTGCTGACCCACAGTGGAAAACAGATTCCTGCCAGGGAGACTCAGGG\nGGACCCCTCGTCTGTTCCCTCCAAGGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGC\nCGTGGATGTGCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCC\nTGGATCCGCAGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00051",
                  "name": "Kringle"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "cellular response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "cellular response to hepatocyte growth factor stimulus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "regulation of cell adhesion mediated by integrin"
                },
                {
                  "category": "process",
                  "description": "chemotaxis"
                },
                {
                  "category": "process",
                  "description": "cellular response to hypoxia"
                },
                {
                  "category": "process",
                  "description": "skeletal muscle tissue regeneration"
                },
                {
                  "category": "process",
                  "description": "regulation of receptor activity"
                },
                {
                  "category": "process",
                  "description": "regulation of smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "response to hyperoxia"
                },
                {
                  "category": "process",
                  "description": "embryo implantation"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "neuron death"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "spermatogenesis"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "cellular response to staurosporine"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "cellular response to glucose stimulus"
                },
                {
                  "category": "process",
                  "description": "positive regulation of ovulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of reactive oxygen species metabolic process"
                },
                {
                  "category": "process",
                  "description": "cellular response to fluid shear stress"
                },
                {
                  "category": "process",
                  "description": "regulation of smooth muscle cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "response to activity"
                },
                {
                  "category": "process",
                  "description": "regulation of hepatocyte proliferation"
                },
                {
                  "category": "process",
                  "description": "regulation of wound healing"
                },
                {
                  "category": "process",
                  "description": "angiogenesis"
                },
                {
                  "category": "process",
                  "description": "plasminogen activation"
                }
              ]
            },
            "_id": "P00749",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0001088",
          "name": "Tissue-type plasminogen activator",
          "organism": "Human",
          "actions": "",
          "references": "# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\r\n# Lindholt JS, Jorgensen B, Shi GP, Henneberg EW: Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003 Jun;25(6):546-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12787697\r\n# Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A, Varela E, Ruiz E, Fernandez de Sevilla T: Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond). 2003 Nov;105(5):601-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12826021\r\n# Wells RG, Havens PL: Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology. 2003 Aug;228(2):370-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12893898\r\n# Stief TW, Bunder R, Richter A, Maisch B, Renz H, Fareed J: In vitro simulation of therapeutic plasmatic fibrinolysis. Clin Appl Thromb Hemost. 2003 Jul;9(3):211-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14507109",
          "known-action": "yes",
          "polypeptide": {
            "name": "Tissue-type plasminogen activator",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration.",
            "gene-name": "PLAT",
            "locus": "8p12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "7.81",
            "molecular-weight": "62916.495",
            "chromosome-location": "8",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9051"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLAT"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L00153"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "339834"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2392"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00750"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "TPA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.68",
                "t-PA"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0002165|Tissue-type plasminogen activator\nMDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPV\nLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCE\nIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCR\nNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWN\nSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCG\nLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQ\nERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCA\nQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQH\nLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQK\nDVPGVYTKVTNYLDWIRDNMRP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010763|Tissue-type plasminogen activator (PLAT)\nATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTT\nTCGCCCAGCCAGGAAATCCATGCCCGATTCAGAAGAGGAGCCAGATCTTACCAAGTGATC\nTGCAGAGATGAAAAAACGCAGATGATATACCAGCAACATCAGTCATGGCTGCGCCCTGTG\nCTCAGAAGCAACCGGGTGGAATATTGCTGGTGCAACAGTGGCAGGGCACAGTGCCACTCA\nGTGCCTGTCAAAAGTTGCAGCGAGCCAAGGTGTTTCAACGGGGGCACCTGCCAGCAGGCC\nCTGTACTTCTCAGATTTCGTGTGCCAGTGCCCCGAAGGATTTGCTGGGAAGTGCTGTGAA\nATAGATACCAGGGCCACGTGCTACGAGGACCAGGGCATCAGCTACAGGGGCACGTGGAGC\nACAGCGGAGAGTGGCGCCGAGTGCACCAACTGGAACAGCAGCGCGTTGGCCCAGAAGCCC\nTACAGCGGGCGGAGGCCAGACGCCATCAGGCTGGGCCTGGGGAACCACAACTACTGCAGA\nAACCCAGATCGAGACTCAAAGCCCTGGTGCTACGTCTTTAAGGCGGGGAAGTACAGCTCA\nGAGTTCTGCAGCACCCCTGCCTGCTCTGAGGGAAACAGTGACTGCTACTTTGGGAATGGG\nTCAGCCTACCGTGGCACGCACAGCCTCACCGAGTCGGGTGCCTCCTGCCTCCCGTGGAAT\nTCCATGATCCTGATAGGCAAGGTTTACACAGCACAGAACCCCAGTGCCCAGGCACTGGGC\nCTGGGCAAACATAATTACTGCCGGAATCCTGATGGGGATGCCAAGCCCTGGTGCCACGTG\nCTGAAGAACCGCAGGCTGACGTGGGAGTACTGTGATGTGCCCTCCTGCTCCACCTGCGGC\nCTGAGACAGTACAGCCAGCCTCAGTTTCGCATCAAAGGAGGGCTCTTCGCCGACATCGCC\nTCCCACCCCTGGCAGGCTGCCATCTTTGCCAAGCACAGGAGGTCGCCCGGAGAGCGGTTC\nCTGTGCGGGGGCATACTCATCAGCTCCTGCTGGATTCTCTCTGCCGCCCACTGCTTCCAG\nGAGAGGTTTCCGCCCCACCACCTGACGGTGATCTTGGGCAGAACATACCGGGTGGTCCCT\nGGCGAGGAGGAGCAGAAATTTGAAGTCGAAAAATACATTGTCCATAAGGAATTCGATGAT\nGACACTTACGACAATGACATTGCGCTGCTGCAGCTGAAATCGGATTCGTCCCGCTGTGCC\nCAGGAGAGCAGCGTGGTCCGCACTGTGTGCCTTCCCCCGGCGGACCTGCAGCTGCCGGAC\nTGGACGGAGTGTGAGCTCTCCGGCTACGGCAAGCATGAGGCCTTGTCTCCTTTCTATTCG\nGAGCGGCTGAAGGAGGCTCATGTCAGACTGTACCCATCCAGCCGCTGCACATCACAACAT\nTTACTTAACAGAACAGTCACCGACAACATGCTGTGTGCTGGAGACACTCGGAGCGGCGGG\nCCCCAGGCAAACTTGCACGACGCCTGCCAGGGCGATTCGGGAGGCCCCCTGGTGTGTCTG\nAACGATGGCCGCATGACTTTGGTGGGCATCATCAGCTGGGGCCTGGGCTGTGGACAGAAG\nGATGTCCCGGGTGTGTACACCAAGGTTACCAACTACCTAGACTGGATTCGTGACAACATG\nCGACCGTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00008",
                  "name": "EGF"
                },
                {
                  "identifier": "PF00051",
                  "name": "Kringle"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00039",
                  "name": "fn1"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "apical part of cell"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "secretory granule"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "glycoprotein binding"
                },
                {
                  "category": "function",
                  "description": "phosphoprotein binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "process",
                  "description": "plasminogen activation"
                },
                {
                  "category": "process",
                  "description": "cellular protein modification process"
                },
                {
                  "category": "process",
                  "description": "smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "platelet-derived growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "response to peptide hormone"
                },
                {
                  "category": "process",
                  "description": "response to hypoxia"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of proteolysis"
                }
              ]
            },
            "_id": "P00750",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        },
        {
          "id": "BE0000240",
          "name": "Plasminogen activator inhibitor 1",
          "organism": "Human",
          "actions": "",
          "references": "# Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12579271\r\n# Shetty S, Bdeir K, Cines DB, Idell S: Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem. 2003 May 16;278(20):18124-31. Epub 2003 Mar 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12642587\r\n# Hellgren M: Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12709915\r\n# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\r\n# Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE: [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer] Vopr Onkol. 2003;49(2):165-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12785198",
          "known-action": "yes",
          "polypeptide": {
            "name": "Plasminogen activator inhibitor 1",
            "general-function": "Serine-type endopeptidase inhibitor activity",
            "specific-function": "Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.",
            "gene-name": "SERPINE1",
            "locus": "7q21.3-q22",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-23",
            "theoretical-pi": "7.22",
            "molecular-weight": "45059.695",
            "chromosome-location": "7",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:8583"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "SERPINE1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X04429"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "35272"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P05121"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PAI1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Endothelial plasminogen activator inhibitor",
                "PAI",
                "PAI1",
                "PLANH1",
                "Serpin E1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00079",
                "name": "Serpin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase inhibitor activity"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of leukotriene production involved in inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell adhesion mediated by integrin"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of monocyte chemotaxis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell migration"
                },
                {
                  "category": "process",
                  "description": "gene expression"
                },
                {
                  "category": "process",
                  "description": "positive regulation of receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endothelial cell apoptotic process"
                },
                {
                  "category": "process",
                  "description": "transcription initiation from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of receptor activity"
                },
                {
                  "category": "process",
                  "description": "circadian rhythm"
                },
                {
                  "category": "process",
                  "description": "negative regulation of plasminogen activation"
                },
                {
                  "category": "process",
                  "description": "transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "angiogenesis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "transforming growth factor beta receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of vascular wound healing"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "negative regulation of wound healing"
                },
                {
                  "category": "process",
                  "description": "chronological cell aging"
                },
                {
                  "category": "process",
                  "description": "positive regulation of angiogenesis"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "defense response to Gram-negative bacterium"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-8 production"
                }
              ]
            },
            "_id": "P05121",
            "_source": "Swiss-Prot"
          },
          "_position": "5"
        },
        {
          "id": "BE0000969",
          "name": "Plasminogen activator inhibitor 2",
          "organism": "Human",
          "actions": "",
          "references": "# Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA, Rosenberg HF: Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol. 2004 Oct;76(4):812-9. Epub 2004 Jul 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15277569\r\n# Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, Grimminger F, Seeger W, Gunther A: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost. 2004 Sep;92(3):529-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15351849\r\n# Iglesias D, Alegre J, Aleman C, Ruiz E, Soriano T, Armadans LI, Segura RM, Angles A, Monasterio J, de Sevilla TF: Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J. 2005 Jan;25(1):104-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15640330\r\n# Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CG, Duffy MJ: Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005 Jul;14(1):235-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15944795\r\n# Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon Y Cajal S: Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006 Jan;28(1):143-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16327990",
          "known-action": "yes",
          "polypeptide": {
            "name": "Plasminogen activator inhibitor 2",
            "general-function": "Serine-type endopeptidase inhibitor activity",
            "specific-function": "Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.",
            "gene-name": "SERPINB2",
            "locus": "18q21.3",
            "cellular-location": "Cytoplasm",
            "transmembrane-regions": "",
            "signal-regions": "1-",
            "theoretical-pi": "5.34",
            "molecular-weight": "46595.84",
            "chromosome-location": "18",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:8584"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "SERPINB2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J02685"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "189545"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P05120"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PAI2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Monocyte Arg-serpin",
                "PAI-2",
                "PAI2",
                "Placental plasminogen activator inhibitor",
                "PLANH2",
                "Serpin B2",
                "Urokinase inhibitor"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016268|Plasminogen activator inhibitor 2\nMEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF\nNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN\nYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK\nIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK\nLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM\nAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV\nDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016269|Plasminogen activator inhibitor 2 (SERPINB2)\nATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA\nAAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC\nATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT\nAATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG\nTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA\nGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT\nTATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA\nTATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA\nTGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA\nATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT\nGCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT\nCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG\nCTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA\nGATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG\nCTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG\nGCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC\nAGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC\nTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG\nGATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA\nACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCTTTTCTTTTTCTTATTATGCAT\nAAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00079",
                "name": "Serpin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase inhibitor activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                }
              ]
            },
            "_id": "P05120",
            "_source": "Swiss-Prot"
          },
          "_position": "6"
        },
        {
          "id": "BE0002112",
          "name": "Plasma serine protease inhibitor",
          "organism": "Human",
          "actions": "",
          "references": "# Uhrin P, Schofer C, Zaujec J, Ryban L, Hilpert M, Weipoltshammer K, Jerabek I, Pirtzkall I, Furtmuller M, Dewerchin M, Binder BR, Geiger M: Male fertility and protein C inhibitor/plasminogen activator inhibitor-3 (PCI): localization of PCI in mouse testis and failure of single plasminogen activator knockout to restore spermatogenesis in PCI-deficient mice. Fertil Steril. 2007 Oct;88(4S):1049-1057. Epub 2007 Apr 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17434507\r\n# Espana F, Navarro S, Medina P, Zorio E, Estelles A: The role of protein C inhibitor in human reproduction. Semin Thromb Hemost. 2007 Feb;33(1):41-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17253188\r\n# Odet F, Guyot R, Leduque P, Le Magueresse-Battistoni B: Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology. 2004 Mar;145(3):1481-9. Epub 2003 Nov 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14645112",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Plasma serine protease inhibitor",
            "general-function": "Serine-type endopeptidase inhibitor activity",
            "specific-function": "Heparin-dependent serine protease inhibitor acting in body fluids and secretions. Inactivates serine proteases by binding irreversibly to their serine activation site. Involved in the regulation of intravascular and extravascular proteolytic activities. Plays hemostatic roles in the blood plasma. Acts as a procoagulant and proinflammatory factor by inhibiting the anticoagulant activated protein C factor as well as the generation of activated protein C factor by the thrombin/thrombomodulin complex. Acts as an anticoagulant factor by inhibiting blood coagulation factors like prothrombin, factor XI, factor Xa, plasma kallikrein and fibrinolytic enzymes such as tissue- and urinary-type plasminogen activators. In seminal plasma, inactivates several serine proteases implicated in the reproductive system. Inhibits the serpin acrosin; indirectly protects component of the male genital tract from being degraded by excessive released acrosin. Inhibits tissue-and urinary-type plasminogen activator, prostate-specific antigen and kallikrein activities; has a control on the sperm motility and fertilization. Inhibits the activated protein C-catalyzed degradation of SEMG1 and SEMG2; regulates the degradation of semenogelin during the process of transfer of spermatozoa from the male reproductive tract into the female tract. In urine, inhibits urinary-type plasminogen activator and kallikrein activities. Inactivates membrane-anchored serine proteases activities such as MPRSS7 and TMPRSS11E. Inhibits urinary-type plasminogen activator-dependent tumor cell invasion and metastasis. May also play a non-inhibitory role in seminal plasma and urine as a hydrophobic hormone carrier by its binding to retinoic acid.",
            "gene-name": "SERPINA5",
            "locus": "14q32.1",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-19",
            "theoretical-pi": "9.76",
            "molecular-weight": "45674.315",
            "chromosome-location": "14",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:8723"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "SERPINA5"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J02639"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "180550"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P05154"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "IPSP_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Acrosomal serine protease inhibitor",
                "PAI-3",
                "PAI3",
                "PCI",
                "PLANH3",
                "Plasminogen activator inhibitor 3",
                "PROCI",
                "Protein C inhibitor",
                "Serpin A5"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011531|Plasma serine protease inhibitor\nMQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA\nPSQSIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ\nPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT\nKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED\nQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE\nLYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT\nRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011532|Plasma serine protease inhibitor (SERPINA5)\nATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC\nCGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG\nGCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC\nCCCAGCCAGAGCATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC\nCTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG\nAAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG\nCCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC\nCTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCTACC\nAACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG\nAAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG\nAATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG\nCAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT\nCAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA\nGGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT\nGGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG\nCTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT\nCTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCGGCATCAGCAACCACTCA\nAATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC\nAGAGCAGCGGCAGCCACGGGGACAATATTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG\nAGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT\nGGCAAAGTGAACCGCCCCTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00079",
                "name": "Serpin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "protein C inhibitor-PLAU complex"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "platelet dense tubular network"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-thrombin complex"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-TMPRSS11E complex"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-TMPRSS7 complex"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "acrosomal membrane"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-coagulation factor V complex"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-coagulation factor Xa complex"
                },
                {
                  "category": "component",
                  "description": "protein complex"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-coagulation factor XI complex"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-KLK3 complex"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-plasma kallikrein complex"
                },
                {
                  "category": "component",
                  "description": "protein C inhibitor-PLAT complex"
                },
                {
                  "category": "function",
                  "description": "retinoic acid binding"
                },
                {
                  "category": "function",
                  "description": "phosphatidylcholine binding"
                },
                {
                  "category": "function",
                  "description": "glycosaminoglycan binding"
                },
                {
                  "category": "function",
                  "description": "acrosin binding"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "heparin binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase inhibitor activity"
                },
                {
                  "category": "process",
                  "description": "fusion of sperm to egg plasma membrane"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "spermatogenesis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of hydrolase activity"
                },
                {
                  "category": "process",
                  "description": "lipid transport"
                }
              ]
            },
            "_id": "P05154",
            "_source": "Swiss-Prot"
          },
          "_position": "7"
        },
        {
          "id": "BE0000942",
          "name": "Low-density lipoprotein receptor-related protein 2",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Kanalas JJ: Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase. Biochim Biophys Acta. 1993 Nov 25;1225(1):101-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8241286\r\n# Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1280065\r\n# Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS: Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1). Genomics. 1994 Jul 1;22(1):88-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7959795",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Low-density lipoprotein receptor-related protein 2",
            "general-function": "Calcium ion binding",
            "specific-function": "Acts together with cubilin to mediate HDL endocytosis (By similarity). May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release.",
            "gene-name": "LRP2",
            "locus": "2q24-q31",
            "cellular-location": "Membrane",
            "transmembrane-regions": "4424-4446",
            "signal-regions": "1-25",
            "theoretical-pi": "4.68",
            "molecular-weight": "521952.77",
            "chromosome-location": "2",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6694"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "LRP2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "U33837"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "1809240"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P98164"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "LRP2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Glycoprotein 330",
                "gp330",
                "LRP-2",
                "Megalin"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010661|Low-density lipoprotein receptor-related protein 2\nMDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI\nGCAVVTCQQGYFKCQSEGQCIPNSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC\nIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT\nEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV\nCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN\nTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ\nKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES\nQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK\nIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER\nAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL\nIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT\nNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR\nGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA\nNRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL\nFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD\nGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL\nKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE\nPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI\nPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE\nKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC\nIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS\nDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL\nGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL\nLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV\nASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR\nRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD\nPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD\nYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM\nYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC\nLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE\nIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL\nIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH\nLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY\nEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL\nFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV\nDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY\nFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL\nDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP\nYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE\nVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS\nLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV\nIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY\nLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL\nTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI\nNTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC\nGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC\nDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR\nTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH\nWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR\nHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC\nGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG\nSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS\nGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP\nGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR\nLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN\nGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII\nSTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI\nYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC\nLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD\nGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ\nCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC\nGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH\nPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH\nYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA\nYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH\nEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL\nGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH\nCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD\nEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY\nVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF\nWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD\nGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI\nFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP\nCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL\nAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI\nDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE\nIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP\nAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010662|Low-density lipoprotein receptor-related protein 2 (LRP2)\nATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA\nGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC\nATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT\nGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC\nATCCCCAACTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT\nCAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT\nATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT\nGACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC\nAGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT\nGAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT\nGTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGACGAACATGCTTGCAACTATCCG\nACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT\nTGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT\nCATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC\nTCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC\nACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG\nTGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC\nAATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG\nAAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG\nCGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT\nGGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT\nCAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG\nACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG\nGTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA\nATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT\nCGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT\nGTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG\nGCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT\nGGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC\nATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC\nATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA\nAAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG\nGCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC\nAATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTCCTCAGCCACAGAACA\nGATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT\nGAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT\nGGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT\nTCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG\nTCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT\nAACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG\nACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA\nGTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA\nTTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC\nCTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT\nGCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT\nGGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC\nATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG\nAAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG\nAAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT\nAACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC\nCCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA\nCCACCCACAGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC\nAATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT\nGGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT\nCCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC\nTGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG\nTGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA\nAAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA\nTGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG\nGTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT\nATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCA\nGGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT\nGGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT\nGATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC\nGGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT\nGATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT\nGGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT\nGGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT\nACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA\nCTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT\nAGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG\nTTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG\nGCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA\nTTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC\nTTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA\nAGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT\nCGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG\nAGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT\nCCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG\nCGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC\nTGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT\nTACATGGACTTTTGTGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG\nATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT\nGCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG\nTATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC\nGTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT\nCATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC\nTTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC\nCTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT\nTTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA\nATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG\nGGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT\nAGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG\nATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT\nGCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC\nGCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC\nCTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA\nGGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGAATGATCCTGGTACACCAGCTT\nTCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT\nGAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT\nGTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT\nGGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG\nTTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA\nTATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG\nTCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG\nGATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT\nGATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT\nGGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT\nTTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC\nCGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG\nAACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT\nGACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA\nGTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG\nATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT\nTATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC\nTTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC\nAACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG\nGTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG\nCCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG\nAATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC\nTTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT\nGTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC\nTCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC\nATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT\nTATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC\nACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC\nCTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC\nTTCCGCGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT\nGAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG\nACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC\nTATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA\nTATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC\nAACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG\nGGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG\nGGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT\nGGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT\nAATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC\nTGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT\nGATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC\nAATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC\nAATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC\nACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT\nTTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC\nACTCACACGTGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT\nTGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT\nCACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA\nAGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG\nCACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT\nCCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC\nGGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT\nGGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC\nTATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG\nAACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA\nTCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC\nAAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT\nTTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT\nGGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT\nTACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT\nTTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA\nGGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT\nCTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC\nCTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA\nTTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC\nAAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT\nTCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT\nGGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT\nGATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG\nGGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC\nTCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC\nTGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC\nACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT\nTATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT\nAGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT\nAGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC\nCTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT\nCAGCTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT\nAACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT\nGGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC\nAGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT\nGGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG\nTGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG\nGATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT\nCGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT\nGGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC\nTTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT\nGGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT\nCCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT\nGGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA\nGAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT\nTACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT\nGAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC\nGCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA\nTACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA\nTGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT\nGTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT\nGAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT\nAGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC\nATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG\nGGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC\nCAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT\nGACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC\nTGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT\nGACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC\nAATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT\nGAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT\nGTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC\nCCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC\nGTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT\nGTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT\nTCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC\nTGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC\nAACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC\nAATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT\nGGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT\nGAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT\nGGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC\nTTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC\nCTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA\nGAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA\nTGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG\nTGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA\nGGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG\nGCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG\nCTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA\nTCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT\nGACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA\nTTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG\nGTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG\nATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG\nAATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG\nATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT\nGCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC\nACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF07645",
                  "name": "EGF_CA"
                },
                {
                  "identifier": "PF00057",
                  "name": "Ldl_recept_a"
                },
                {
                  "identifier": "PF00058",
                  "name": "Ldl_recept_b"
                },
                {
                  "identifier": "PF12662",
                  "name": "cEGF"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "apical plasma membrane"
                },
                {
                  "category": "component",
                  "description": "brush border membrane"
                },
                {
                  "category": "component",
                  "description": "Golgi apparatus"
                },
                {
                  "category": "component",
                  "description": "endocytic vesicle"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "lysosomal membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "receptor complex"
                },
                {
                  "category": "component",
                  "description": "endosome"
                },
                {
                  "category": "component",
                  "description": "lysosome"
                },
                {
                  "category": "component",
                  "description": "coated pit"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "small molecule metabolic process"
                },
                {
                  "category": "process",
                  "description": "protein glycosylation"
                },
                {
                  "category": "process",
                  "description": "retinoid metabolic process"
                },
                {
                  "category": "process",
                  "description": "receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "forebrain development"
                },
                {
                  "category": "process",
                  "description": "steroid metabolic process"
                },
                {
                  "category": "process",
                  "description": "endocytosis"
                },
                {
                  "category": "process",
                  "description": "lipid metabolic process"
                },
                {
                  "category": "process",
                  "description": "vitamin D metabolic process"
                },
                {
                  "category": "process",
                  "description": "phototransduction, visible light"
                }
              ]
            },
            "_id": "P98164",
            "_source": "Swiss-Prot"
          },
          "_position": "8"
        },
        {
          "id": "BE0001656",
          "name": "Suppressor of tumorigenicity 14 protein",
          "organism": "Human",
          "actions": "",
          "references": "# Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem. 2004 Apr 9;279(15):14899-908. Epub 2004 Jan 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14747469\r\n# Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P: Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 2003 Sep 19;278(38):36341-9. Epub 2003 Jun 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12815039",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Suppressor of tumorigenicity 14 protein",
            "general-function": "Serine-type peptidase activity",
            "specific-function": "Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing.",
            "gene-name": "ST14",
            "locus": "11q24-q25",
            "cellular-location": "Membrane",
            "transmembrane-regions": "56-76",
            "signal-regions": "",
            "theoretical-pi": "6.53",
            "molecular-weight": "94769.01",
            "chromosome-location": "11",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:11344"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "ST14"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF118224"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "6647302"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2418"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q9Y5Y6"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "ST14_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.109",
                "Matriptase",
                "Membrane-type serine protease 1",
                "MT-SP1",
                "Prostamin",
                "PRSS14",
                "Serine protease 14",
                "Serine protease TADG-15",
                "SNC19",
                "TADG15",
                "Tumor-associated differentially-expressed gene 15 protein"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016512|Suppressor of tumorigenicity 14 protein\nMGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA\nVLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKV\nKDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVM\nLPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPA\nHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPS\nYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHY\nPPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTS\nNSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDH\nSDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSK\nSQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEK\nDCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYID\nDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKP\nAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLL\nPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYT\nRLPLFRDWIKENTGV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016513|Suppressor of tumorigenicity 14 protein (ST14)\nATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTC\nAAGTACAACTCCCGGCACGAGAAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCA\nGTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCC\nGTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAG\nTACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAAT\nTTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTG\nAAGGACGCGCTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAG\nTCGGCTGTGACGGCCTTCAGCGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGC\nATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATG\nCTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCCCC\nACGGACTCCAAAACAGTACAGAGGACCCAGGACAACAGCTGCAGCTTTGGCCTGCACGCC\nCGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCT\nCATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTC\nCGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGGCAGCGACCTGGTGACGGTGTACAAC\nACCCTGAGCCCCATGGAGCCCCACGCCCTGGTGCAGTTGTGTGGCACCTACCCTCCCTCC\nTACAACCTGACCTTCCACTCCTCCCAGAACGTCCTGCTCATCACACTGATAACCAACACT\nGAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCAGCTGT\nGGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCCTACTACCCAGGCCACTAC\nCCACCCAACATTGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTG\nCGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGAC\nTACGTGGAGATCAACGGGGAGAAATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGC\nAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTC\nTTAGCTGAATACCTCTCCTACGACTCCAGTGACCCATGCCCGGGGCAGTTCACGTGCCGC\nACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCAC\nAGCGATGAGCTCAACTGCAGTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTC\nTGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAG\nCAGGGGTGCAGTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAA\nAGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCC\nAAGGTGAACGTCGTCACTTGTACCAAACACACCTACCGCTGCCTCAATGGGCTCTGCTTG\nAGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAG\nGACTGCGACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGAT\nGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATC\nTGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGAT\nGACAGAGGATTCAGGTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGAC\nCAGAGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCAC\nCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCG\nGCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGTCTTCCCT\nGCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAGGCACTGGCGCG\nCTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTG\nCCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCC\nTGCCAGGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAG\nGCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACA\nAGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00057",
                  "name": "Ldl_recept_a"
                },
                {
                  "identifier": "PF00431",
                  "name": "CUB"
                },
                {
                  "identifier": "PF01390",
                  "name": "SEA"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "basolateral plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "serine-type peptidase activity"
                },
                {
                  "category": "process",
                  "description": "neural tube closure"
                },
                {
                  "category": "process",
                  "description": "keratinocyte differentiation"
                },
                {
                  "category": "process",
                  "description": "cell morphogenesis"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "epithelial cell morphogenesis involved in placental branching"
                }
              ]
            },
            "_id": "Q9Y5Y6",
            "_source": "Swiss-Prot"
          },
          "_position": "9"
        },
        {
          "id": "BE0002113",
          "name": "Nidogen-1",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Stephens RW, Aumailley M, Timpl R, Reisberg T, Tapiovaara H, Myohanen H, Murphy-Ullrich J, Vaheri A: Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin. Eur J Biochem. 1992 Aug 1;207(3):937-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1499567",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Nidogen-1",
            "general-function": "Proteoglycan binding",
            "specific-function": "Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell-extracellular matrix interactions.",
            "gene-name": "NID1",
            "locus": "1q43",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-28",
            "theoretical-pi": "4.96",
            "molecular-weight": "136375.93",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:7821"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "NID1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M30269"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "189209"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P14543"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "NID1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Entactin",
                "NID",
                "NID-1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037160|Nidogen-1\nMLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDLELEDGDDFVSPALELS\nGALRFYDRSDIDAVYVTTNGIIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKV\nYYREDLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESVAPYQGPSRDPDQKGKRNTFQ\nAVLASSDSSSYAIFLYPEDGLQFHTTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA\nNDRESVENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTEDGAEYDDEDEDYDLAT\nTRLGLEDVGTTPFSYKALRRGGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETF\nHQQHPQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVHAECRDYATGFCCSCVAGYTG\nNGRQCVAEGSPQRVNGKVKGRIFVGSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV\nGYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTFVGHPGNLVIKQRFSGI\nDEHGHLTIDTELEGRVPQIPFGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGAS\nPSRIYTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFVLYNQEEKILRYALSNSIGPV\nREGSPDALQNPCYIGTHGCDTNAACRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV\nCGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCETGLHNCDIPQRAQCIYT\nGGSSYTCSCLPGFSGDGQACQDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCV\nPGEVEKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDAHGHYAPTQCHGSTGYCWCVD\nRDGREVEGTRTRPGMTPPCLSTVAPPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE\nGNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGRASLHGGEPTTIIRQDL\nGSPEGIAVDHLGRNIFWTDSNLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYW\nTDWNRDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFSSQLCWVDAGTNRAECLNPSQ\nPSRRKALEGLQYPFAVTSYGKNLYFTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT\nALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCIEQK"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016685|Nidogen-1 (NID1)\nATGTTGGCCTCGAGCAGCCGGATCCGGGCTGCGTGGACGCGGGCGCTGCTGCTGCCGCTG\nCTGCTGGCGGGGCCTGTGGGCTGCCTGAGCCGCCAGGAGCTCTTTCCCTTCGGCCCCGGA\nCAGGGGGACCTGGAGCTGGAGGACGGGGATGACTTCGTCTCTCCTGCCCTGGAGCTGAGT\nGGGGCGCTCCGCTTCTACGACAGATCCGACATCGACGCAGTCTACGTCACCACAAATGGC\nATCATTGCTACGAGTGAACCCCCGGCCAAAGAATCCCATCCCGGGCTCTTCCCACCAACA\nTTCGGTGCAGTCGCCCCTTTCCTGGCGGACTTGGACACGACCGATGGCCTGGGGAAGGTT\nTATTATCGAGAAGACTTATCCCCCTCCATCACTCAGCGAGCAGCAGAGTGTGTCCACAGA\nGGGTTCCCGGAGATCTCTTTCCAGCCTAGTAGCGCGGTGGTTGTCACTTGGGAATCCGTG\nGCCCCCTACCAAGGGCCCAGCAGGGACCCAGACCAGAAAGGCAAGAGAAACACGTTCCAG\nGCTGTTCTAGCCTCCTCTGATTCCAGCTCCTATGCCATTTTCCTTTATCCTGAGGATGGT\nCTGCAGTTCCATACGACATTCTCAAAGAAGGAAAACAACCAAGTTCCTGCCGTGGTTGCA\nTTCAGTCAAGGTTCAGTGGGATTCTTATGGAAGAGCAACGGAGCTTATAACATATTTGCT\nAATGACAGGGAATCAGTTGAAAATTTGGCCAAGAGTAGTAACTCTGGGCAGCAGGGTGTC\nTGGGTGTTTGAGATTGGGAGTCCAGCCACCACCAATGGCGTGGTGCCTGCAGACGTGATC\nCTCGGAACTGAAGATGGGGCAGAGTATGATGATGAGGATGAAGATTATGACCTGGCGACC\nACTCGTCTGGGCCTGGAGGATGTGGGCACCACGCCCTTCTCCTACAAGGCTCTGAGAAGG\nGGAGGTGCTGACACATACAGTGTGCCCAGCGTCCTCTCCCCGCGCCGGGCAGCTACCGAA\nAGGCCCCTTGGACCTCCCACAGAGAGAACCAGGTCTTTCCAGTTGGCAGTGGAGACTTTT\nCACCAGCAGCACCCTCAGGTCATAGATGTGGATGAAGTTGAGGAAACAGGAGTTGTTTTC\nAGCTATAACACGGATTCCCGCCAGACGTGTGCTAACAACAGACACCAGTGCTCGGTGCAC\nGCAGAGTGCAGGGACTACGCCACGGGCTTCTGCTGCAGCTGTGTCGCTGGCTATACGGGC\nAATGGCAGGCAATGTGTTGCAGAAGGTTCCCCCCAGCGAGTCAATGGCAAGGTGAAAGGA\nAGGATCTTTGTGGGGAGCAGCCAGGTCCCCATTGTCTTTGAGAACACTGACCTCCACTCT\nTACGTAGTAATGAACCACGGGCGCTCCTACACAGCCATCAGCACCATTCCCGAGACCGTT\nGGATATTCTCTGCTTCCACTGGCCCCAGTTGGAGGCATCATTGGATGGATGTTTGCAGTG\nGAGCAGGACGGATTCAAGAATGGGTTCAGCATCACCGGGGGTGAGTTCACTCGCCAGGCT\nGAGGTGACCTTCGTGGGGCACCCGGGCAATCTGGTCATTAAGCAGCGGTTCAGCGGCATC\nGATGAGCATGGGCACCTGACCATCGACACGGAGCTGGAGGGCCGCGTGCCGCAGATTCCG\nTTCGGCTCCTCCGTGCACATTGAGCCCTACACGGAGCTGTACCACTACTCCACCTCAGTG\nATCACTTCCTCCTCCACCCGGGAGTACACGGTGACTGAGCCCGAGCGAGATGGGGCATCT\nCCTTCACGCATCTACACTTACCAGTGGCGCCAGACCATCACCTTCCAGGAATGCGTCCAC\nGATGACTCCCGGCCAGCCCTGCCCAGCACCCAGCAGCTCTCGGTGGACAGCGTGTTCGTC\nCTGTACAACCAGGAGGAGAAGATCTTGCGCTATGCTCTCAGCAACTCCATTGGGCCTGTG\nAGGGAAGGCTCCCCTGATGCTCTTCAGAATCCCTGCTACATCGGCACTCATGGGTGTGAC\nACCAACGCGGCCTGTCGCCCTGGTCCCAGGACACAGTTCACCTGCGAGTGCTCCATCGGC\nTTCCGAGGAGACGGGCGAACCTGCTATGATATTGATGAATGTTCAGAACAACCCTCAGTG\nTGTGGGAGCCACACAATCTGCAATAATCACCCAGGAACCTTCCGCTGCGAGTGTGTGGAG\nGGCTACCAGTTTTCAGATGAGGGAACGTGTGTGGCTGTCGTGGACCAGCGCCCCATCAAC\nTACTGTGAAACTGGCCTTCATAACTGCGACATACCCCAGCGGGCCCAGTGTATCTACACA\nGGAGGCTCCTCCTACACCTGTTCCTGCTTGCCAGGCTTTTCTGGGGATGGCCAAGCCTGC\nCAAGATGTAGATGAATGCCAGCCAAGCCGATGTCACCCTGACGCCTTCTGCTACAACACT\nCCAGGCTCTTTCACGTGCCAGTGCAAACCTGGTTATCAGGGAGACGGCTTCCGTTGCGTG\nCCCGGAGAGGTGGAGAAAACCCGGTGCCAGCACGAGCGAGAACACATTCTCGGGGCAGCG\nGGGGCGACAGACCCACAGCGACCCATTCCTCCGGGGCTGTTCGTTCCTGAGTGCGATGCG\nCACGGGCACTACGCGCCCACCCAGTGCCACGGCAGCACCGGCTACTGCTGGTGCGTGGAT\nCGCGACGGCCGCGAGGTGGAGGGCACCAGGACCAGGCCCGGGATGACGCCCCCGTGTCTG\nAGTACAGTGGCTCCCCCGATTCACCAAGGACCTGCGGTGCCTACCGCCGTGATCCCCTTG\nCCTCCTGGGACCCATTTACTCTTTGCCCAGACTGGGAAGATTGAGCGCCTGCCCCTGGAG\nGGAAATACCATGAGGAAGACAGAAGCAAAGGCGTTCCTTCATGTCCCGGCTAAAGTCATC\nATTGGACTGGCCTTTGACTGCGTGGACAAGATGGTTTACTGGACGGACATCACTGAGCCT\nTCCATTGGGAGAGCTAGTCTACATGGTGGAGAGCCAACCACCATCATTAGACAAGATCTT\nGGAAGTCCAGAAGGTATCGCTGTTGATCACCTTGGCCGCAACATCTTCTGGACAGACTCT\nAACCTGGATCGAATAGAAGTGGCGAAGCTGGACGGCACGCAGCGCCGGGTGCTCTTTGAG\nACTGACTTGGTGAATCCCAGAGGCATTGTAACGGATTCCGTGAGAGGGAACCTTTACTGG\nACAGACTGGAACAGAGATAACCCCAAGATTGAAACTTCCTACATGGACGGCACGAACCGG\nAGGATCCTTGTGCAGGATGACCTGGGCTTGCCCAATGGACTGACCTTCGATGCGTTCTCA\nTCTCAGCTCTGCTGGGTGGATGCAGGCACCAATCGGGCGGAATGCCTGAACCCCAGTCAG\nCCCAGCAGACGCAAGGCTCTCGAAGGGCTCCAGTATCCTTTTGCTGTGACGAGCTACGGG\nAAGAATCTGTATTTCACAGACTGGAAGATGAATTCCGTGGTTGCTCTCGATCTTGCAATT\nTCCAAGGAGACGGATGCTTTCCAACCCCACAAGCAGACCCGGCTGTATGGCATCACCACG\nGCCCTGTCTCAGTGTCCGCAAGGCCATAACTACTGCTCAGTGAACAATGGCGGCTGCACC\nCACCTATGCTTGGCCACCCCAGGGAGCAGGACCTGCCGTTGCCCTGACAACACCTTGGGA\nGTTGACTGTATCGAACAGAAATGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF07645",
                  "name": "EGF_CA"
                },
                {
                  "identifier": "PF00058",
                  "name": "Ldl_recept_b"
                },
                {
                  "identifier": "PF00086",
                  "name": "Thyroglobulin_1"
                },
                {
                  "identifier": "PF06119",
                  "name": "NIDO"
                },
                {
                  "identifier": "PF07474",
                  "name": "G2F"
                },
                {
                  "identifier": "PF12662",
                  "name": "cEGF"
                },
                {
                  "identifier": "PF12947",
                  "name": "EGF_3"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "basal lamina"
                },
                {
                  "category": "component",
                  "description": "extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "cell periphery"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "basement membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "function",
                  "description": "collagen binding"
                },
                {
                  "category": "function",
                  "description": "laminin binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "proteoglycan binding"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix disassembly"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell-substrate adhesion"
                },
                {
                  "category": "process",
                  "description": "cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "glomerular basement membrane development"
                },
                {
                  "category": "process",
                  "description": "basement membrane organization"
                }
              ]
            },
            "_id": "P14543",
            "_source": "Swiss-Prot"
          },
          "_position": "10"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2014-01-20"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00014"
      },
      "BIOD00113",
      "BTD00113"
    ],
    "name": "Goserelin",
    "description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.",
    "cas-number": "65807-02-5",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "Kripa S. Srivastava, Matthew R. Davis, \"Solid Phase Peptide for the Production of Goserelin.\" U.S. Patent US20100311946, issued December 09, 2010.",
    "indication": "Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.",
    "pharmacodynamics": "The pharmacokinetics of goserelin have been determined in both male and female healthy volunteers and patients. In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.",
    "mechanism-of-action": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.",
    "toxicity": "No experience of overdosage from clinical trials.",
    "metabolism": "Hepatic",
    "absorption": "Inactive orally, rapidly absorbed following subcutaneous administration.",
    "half-life": "4-5 hours",
    "protein-binding": "27.3%",
    "route-of-elimination": "Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.",
    "volume-of-distribution": "* 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]",
    "clearance": "* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]",
    "classification": {
      "description": "This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.",
      "direct-parent": "Peptides",
      "kingdom": "Organic compounds",
      "superclass": "Organic acids and derivatives",
      "class": "Carboxylic acids and derivatives",
      "subclass": "Amino acids, peptides, and analogues",
      "alternative-parent": [
        "Alpha amino acid amides",
        "Amphetamines and derivatives",
        "Azacyclic compounds",
        "Carbonyl compounds",
        "Carboximidamides",
        "Carboxylic acid hydrazides",
        "Dialkyl ethers",
        "Guanidines",
        "Heteroaromatic compounds",
        "Hydrazinecarboxamides",
        "Hydrocarbon derivatives",
        "Imidazoles",
        "Indoles",
        "Lactams",
        "N-acyl amines",
        "N-acyl-alpha amino acids and derivatives",
        "N-acylpyrrolidines",
        "Phenols and derivatives",
        "Phenylpropylamines",
        "Primary alcohols",
        "Propargyl-type 1,3-dipolar organic compounds",
        "Pyrrolidine-2-ones",
        "Pyrrolidinecarboxamides",
        "Secondary carboxylic acid amides",
        "Semicarbazides",
        "Substituted pyrroles",
        "Tertiary amines",
        "Tertiary carboxylic acid amides",
        "Tryptamines and derivatives"
      ],
      "substituent": [
        "2-pyrrolidone",
        "Alcohol",
        "Alpha peptide",
        "Alpha-amino acid amide",
        "Amine",
        "Amphetamine or derivatives",
        "Aromatic heteropolycyclic compound",
        "Azacycle",
        "Azole",
        "Benzenoid",
        "Carbonyl group",
        "Carboxamide group",
        "Carboximidamide",
        "Carboxylic acid amide",
        "Carboxylic acid hydrazide",
        "Dialkyl ether",
        "Ether",
        "Fatty acyl",
        "Fatty amide",
        "Guanidine",
        "Heteroaromatic compound",
        "Hydrazinecarboxamide",
        "Hydrocarbon derivative",
        "Imidazole",
        "Indole",
        "Indole or derivatives",
        "Lactam",
        "Monocyclic benzene moiety",
        "N-acyl-alpha amino acid or derivatives",
        "N-acyl-amine",
        "N-acylpyrrolidine",
        "N-substituted-alpha-amino acid",
        "Organic 1,3-dipolar compound",
        "Organoheterocyclic compound",
        "Organonitrogen compound",
        "Organooxygen compound",
        "Phenol",
        "Phenylpropylamine",
        "Primary alcohol",
        "Propargyl-type 1,3-dipolar organic compound",
        "Pyrrole",
        "Pyrrolidine",
        "Pyrrolidine carboxylic acid or derivatives",
        "Pyrrolidine-2-carboxamide",
        "Pyrrolidone",
        "Secondary carboxylic acid amide",
        "Semicarbazide",
        "Substituted pyrrole",
        "Tertiary amine",
        "Tertiary carboxylic acid amide",
        "Triptan"
      ]
    },
    "salts": {
      "salt": {
        "drugbank-id": {
          "_primary": "true",
          "__text": "DBSALT000093"
        },
        "name": "Goserelin acetate",
        "cas-number": "",
        "inchikey": "InChIKey=IKDXDQDKCZPQSZ-JHYYTBFNSA-N"
      }
    },
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Goserelin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Goserelin acetate"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "ICI-118630"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Zoladex"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Zoladex",
          "ndc-id": "",
          "ndc-product-code": "0310-0950",
          "dpd-id": "",
          "started-marketing-on": "2003-05-05",
          "ended-marketing-on": "",
          "dosage-form": "implant",
          "strength": "3.6 mg/1",
          "route": "subcutaneous",
          "fda-application-number": "NDA019726",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Zoladex",
          "ndc-id": "",
          "ndc-product-code": "0310-0951",
          "dpd-id": "",
          "started-marketing-on": "2003-05-05",
          "ended-marketing-on": "",
          "dosage-form": "implant",
          "strength": "10.8 mg/1",
          "route": "subcutaneous",
          "fda-application-number": "NDA020578",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Zoladex Inj Depot 3.6mg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02049325",
          "started-marketing-on": "1994-12-31",
          "ended-marketing-on": "",
          "dosage-form": "implant",
          "strength": "3.6 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Zoladex LA Inj Depot 10.8mg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02225905",
          "started-marketing-on": "1996-08-28",
          "ended-marketing-on": "",
          "dosage-form": "implant",
          "strength": "10.8 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Zoladex",
          "ingredients": "Goserelin"
        },
        {
          "name": "Zoladex",
          "ingredients": "Goserelin"
        },
        {
          "name": "Zoladex Inj Depot 3.6mg",
          "ingredients": "Goserelin"
        },
        {
          "name": "Zoladex LA Inj Depot 10.8mg",
          "ingredients": "Goserelin"
        }
      ]
    },
    "packagers": {
      "packager": {
        "name": "AstraZeneca Inc.",
        "url": "http://www.astrazeneca.ca"
      }
    },
    "manufacturers": {
      "manufacturer": {
        "_generic": "false",
        "__text": "Astrazeneca uk ltd"
      }
    },
    "prices": {
      "price": [
        {
          "description": "Zoladex 3.6 mg implant syringe",
          "cost": {
            "_currency": "USD",
            "__text": "451.19"
          },
          "unit": "syringe"
        },
        {
          "description": "Zoladex 10.8 mg implant syringe",
          "cost": {
            "_currency": "USD",
            "__text": "1380.65"
          },
          "unit": "syringe"
        }
      ]
    },
    "categories": {
      "category": {
        "category": "Moderate Risk QTc-Prolonging Agents",
        "mesh-id": "[]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Implant",
          "route": "subcutaneous",
          "strength": "10.8 mg/1"
        },
        {
          "form": "Implant",
          "route": "subcutaneous",
          "strength": "3.6 mg/1"
        },
        {
          "form": "Implant",
          "route": "subcutaneous",
          "strength": "3.6 mg"
        },
        {
          "form": "Implant",
          "route": "subcutaneous",
          "strength": "10.8 mg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L02",
            "__text": "ENDOCRINE THERAPY"
          },
          {
            "_code": "L02A",
            "__text": "HORMONES AND RELATED AGENTS"
          },
          {
            "_code": "L02AE",
            "__text": "Gonadotropin releasing hormone analogues"
          }
        ],
        "_code": "L02AE03"
      }
    },
    "ahfs-codes": {
      "ahfs-code": [
        "68:18.00",
        "92:00.00"
      ]
    },
    "patents": {
      "patent": [
        {
          "number": "7118552",
          "country": "United States",
          "approved": "2002-04-13",
          "expires": "2022-04-13"
        },
        {
          "number": "7500964",
          "country": "United States",
          "approved": "2001-02-26",
          "expires": "2021-02-26"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00414",
          "name": "Acetohexamide",
          "description": "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00346",
          "name": "Alfuzosin",
          "description": "Alfuzosin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06203",
          "name": "Alogliptin",
          "description": "The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00915",
          "name": "Amantadine",
          "description": "Amantadine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01118",
          "name": "Amiodarone",
          "description": "Goserelin may increase the QTc-prolonging activities of Amiodarone."
        },
        {
          "drugbank-id": "DB00321",
          "name": "Amitriptyline",
          "description": "Amitriptyline may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00543",
          "name": "Amoxapine",
          "description": "Amoxapine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00261",
          "name": "Anagrelide",
          "description": "Goserelin may increase the QTc-prolonging activities of Anagrelide."
        },
        {
          "drugbank-id": "DB00714",
          "name": "Apomorphine",
          "description": "Apomorphine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01274",
          "name": "Arformoterol",
          "description": "Arformoterol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01238",
          "name": "Aripiprazole",
          "description": "Aripiprazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01169",
          "name": "Arsenic trioxide",
          "description": "Goserelin may increase the QTc-prolonging activities of Arsenic trioxide."
        },
        {
          "drugbank-id": "DB06697",
          "name": "Artemether",
          "description": "Goserelin may increase the QTc-prolonging activities of Artemether."
        },
        {
          "drugbank-id": "DB06216",
          "name": "Asenapine",
          "description": "Goserelin may increase the QTc-prolonging activities of Asenapine."
        },
        {
          "drugbank-id": "DB01072",
          "name": "Atazanavir",
          "description": "Atazanavir may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00289",
          "name": "Atomoxetine",
          "description": "Atomoxetine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00207",
          "name": "Azithromycin",
          "description": "Goserelin may increase the QTc-prolonging activities of Azithromycin."
        },
        {
          "drugbank-id": "DB08903",
          "name": "Bedaquiline",
          "description": "Goserelin may increase the QTc-prolonging activities of Bedaquiline."
        },
        {
          "drugbank-id": "DB00188",
          "name": "Bortezomib",
          "description": "Bortezomib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06616",
          "name": "Bosutinib",
          "description": "Bosutinib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06719",
          "name": "Buserelin",
          "description": "Buserelin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB08907",
          "name": "Canagliflozin",
          "description": "The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00089",
          "name": "Capromab",
          "description": "Goserelin may decrease effectiveness of Capromab as a diagnostic agent."
        },
        {
          "drugbank-id": "DB09063",
          "name": "Ceritinib",
          "description": "Goserelin may increase the QTc-prolonging activities of Ceritinib."
        },
        {
          "drugbank-id": "DB00608",
          "name": "Chloroquine",
          "description": "Goserelin may increase the QTc-prolonging activities of Chloroquine."
        },
        {
          "drugbank-id": "DB00477",
          "name": "Chlorpromazine",
          "description": "Goserelin may increase the QTc-prolonging activities of Chlorpromazine."
        },
        {
          "drugbank-id": "DB00672",
          "name": "Chlorpropamide",
          "description": "The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB09277",
          "name": "Choline C 11",
          "description": "The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00537",
          "name": "Ciprofloxacin",
          "description": "Goserelin may increase the QTc-prolonging activities of Ciprofloxacin."
        },
        {
          "drugbank-id": "DB00604",
          "name": "Cisapride",
          "description": "Goserelin may increase the QTc-prolonging activities of Cisapride."
        },
        {
          "drugbank-id": "DB00215",
          "name": "Citalopram",
          "description": "Goserelin may increase the QTc-prolonging activities of Citalopram."
        },
        {
          "drugbank-id": "DB01211",
          "name": "Clarithromycin",
          "description": "Goserelin may increase the QTc-prolonging activities of Clarithromycin."
        },
        {
          "drugbank-id": "DB01242",
          "name": "Clomipramine",
          "description": "Clomipramine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00363",
          "name": "Clozapine",
          "description": "Goserelin may increase the QTc-prolonging activities of Clozapine."
        },
        {
          "drugbank-id": "DB09066",
          "name": "Corifollitropin Alfa",
          "description": "The therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB08865",
          "name": "Crizotinib",
          "description": "Goserelin may increase the QTc-prolonging activities of Crizotinib."
        },
        {
          "drugbank-id": "DB08912",
          "name": "Dabrafenib",
          "description": "Dabrafenib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01254",
          "name": "Dasatinib",
          "description": "Dasatinib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06699",
          "name": "Degarelix",
          "description": "Degarelix may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01189",
          "name": "Desflurane",
          "description": "Desflurane may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01151",
          "name": "Desipramine",
          "description": "Desipramine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01075",
          "name": "Diphenhydramine",
          "description": "Diphenhydramine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00280",
          "name": "Disopyramide",
          "description": "Goserelin may increase the QTc-prolonging activities of Disopyramide."
        },
        {
          "drugbank-id": "DB00204",
          "name": "Dofetilide",
          "description": "Goserelin may increase the QTc-prolonging activities of Dofetilide."
        },
        {
          "drugbank-id": "DB00757",
          "name": "Dolasetron",
          "description": "Goserelin may increase the QTc-prolonging activities of Dolasetron."
        },
        {
          "drugbank-id": "DB01184",
          "name": "Domperidone",
          "description": "Goserelin may increase the QTc-prolonging activities of Domperidone."
        },
        {
          "drugbank-id": "DB01142",
          "name": "Doxepin",
          "description": "Doxepin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB04855",
          "name": "Dronedarone",
          "description": "Goserelin may increase the QTc-prolonging activities of Dronedarone."
        },
        {
          "drugbank-id": "DB00450",
          "name": "Droperidol",
          "description": "Goserelin may increase the QTc-prolonging activities of Droperidol."
        },
        {
          "drugbank-id": "DB09039",
          "name": "Eliglustat",
          "description": "Goserelin may increase the QTc-prolonging activities of Eliglustat."
        },
        {
          "drugbank-id": "DB08871",
          "name": "Eribulin",
          "description": "Eribulin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00199",
          "name": "Erythromycin",
          "description": "Goserelin may increase the QTc-prolonging activities of Erythromycin."
        },
        {
          "drugbank-id": "DB01175",
          "name": "Escitalopram",
          "description": "Goserelin may increase the QTc-prolonging activities of Escitalopram."
        },
        {
          "drugbank-id": "DB04953",
          "name": "Ezogabine",
          "description": "Ezogabine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00927",
          "name": "Famotidine",
          "description": "Famotidine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00949",
          "name": "Felbamate",
          "description": "Felbamate may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB08868",
          "name": "Fingolimod",
          "description": "Fingolimod may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01195",
          "name": "Flecainide",
          "description": "Goserelin may increase the QTc-prolonging activities of Flecainide."
        },
        {
          "drugbank-id": "DB00196",
          "name": "Fluconazole",
          "description": "Fluconazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00472",
          "name": "Fluoxetine",
          "description": "Goserelin may increase the QTc-prolonging activities of Fluoxetine."
        },
        {
          "drugbank-id": "DB00875",
          "name": "Flupentixol",
          "description": "Goserelin may increase the QTc-prolonging activities of Flupentixol."
        },
        {
          "drugbank-id": "DB00588",
          "name": "Fluticasone Propionate",
          "description": "Fluticasone Propionate may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00983",
          "name": "Formoterol",
          "description": "Formoterol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00529",
          "name": "Foscarnet",
          "description": "Foscarnet may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01320",
          "name": "Fosphenytoin",
          "description": "Fosphenytoin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00743",
          "name": "Gadobenate Dimeglumine",
          "description": "Goserelin may increase the QTc-prolonging activities of Gadobenate Dimeglumine."
        },
        {
          "drugbank-id": "DB00674",
          "name": "Galantamine",
          "description": "Galantamine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01155",
          "name": "Gemifloxacin",
          "description": "Goserelin may increase the QTc-prolonging activities of Gemifloxacin."
        },
        {
          "drugbank-id": "DB01120",
          "name": "Gliclazide",
          "description": "The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00222",
          "name": "Glimepiride",
          "description": "The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01251",
          "name": "Gliquidone",
          "description": "The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01016",
          "name": "Glyburide",
          "description": "The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00889",
          "name": "Granisetron",
          "description": "Goserelin may increase the QTc-prolonging activities of Granisetron."
        },
        {
          "drugbank-id": "DB00502",
          "name": "Haloperidol",
          "description": "Goserelin may increase the QTc-prolonging activities of Haloperidol."
        },
        {
          "drugbank-id": "DB06788",
          "name": "Histrelin",
          "description": "Histrelin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00557",
          "name": "Hydroxyzine",
          "description": "Hydroxyzine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00710",
          "name": "Ibandronate",
          "description": "Ibandronate may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00308",
          "name": "Ibutilide",
          "description": "Goserelin may increase the QTc-prolonging activities of Ibutilide."
        },
        {
          "drugbank-id": "DB04946",
          "name": "Iloperidone",
          "description": "Goserelin may increase the QTc-prolonging activities of Iloperidone."
        },
        {
          "drugbank-id": "DB00458",
          "name": "Imipramine",
          "description": "Imipramine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB05039",
          "name": "Indacaterol",
          "description": "Indacaterol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00808",
          "name": "Indapamide",
          "description": "Indapamide may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01306",
          "name": "Insulin Aspart",
          "description": "The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01307",
          "name": "Insulin Detemir",
          "description": "The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00047",
          "name": "Insulin Glargine",
          "description": "The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01309",
          "name": "Insulin Glulisine",
          "description": "The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00046",
          "name": "Insulin Lispro",
          "description": "The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00030",
          "name": "Insulin Regular",
          "description": "The therapeutic efficacy of Insulin Regular can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB08914",
          "name": "Insulin, isophane",
          "description": "The therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00753",
          "name": "Isoflurane",
          "description": "Isoflurane may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00270",
          "name": "Isradipine",
          "description": "Isradipine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01167",
          "name": "Itraconazole",
          "description": "Itraconazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB09083",
          "name": "Ivabradine",
          "description": "Ivabradine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01026",
          "name": "Ketoconazole",
          "description": "Ketoconazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01259",
          "name": "Lapatinib",
          "description": "Lapatinib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB09078",
          "name": "Lenvatinib",
          "description": "Goserelin may increase the QTc-prolonging activities of Lenvatinib."
        },
        {
          "drugbank-id": "DB00007",
          "name": "Leuprolide",
          "description": "Goserelin may increase the QTc-prolonging activities of Leuprolide."
        },
        {
          "drugbank-id": "DB01137",
          "name": "Levofloxacin",
          "description": "Goserelin may increase the QTc-prolonging activities of Levofloxacin."
        },
        {
          "drugbank-id": "DB08882",
          "name": "Linagliptin",
          "description": "The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01356",
          "name": "Lithium",
          "description": "Lithium may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01601",
          "name": "Lopinavir",
          "description": "Goserelin may increase the QTc-prolonging activities of Lopinavir."
        },
        {
          "drugbank-id": "DB06708",
          "name": "Lumefantrine",
          "description": "Goserelin may increase the QTc-prolonging activities of Lumefantrine."
        },
        {
          "drugbank-id": "DB00934",
          "name": "Maprotiline",
          "description": "Maprotiline may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00358",
          "name": "Mefloquine",
          "description": "Mefloquine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00331",
          "name": "Metformin",
          "description": "The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00333",
          "name": "Methadone",
          "description": "Goserelin may increase the QTc-prolonging activities of Methadone."
        },
        {
          "drugbank-id": "DB01403",
          "name": "Methotrimeprazine",
          "description": "Methotrimeprazine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01233",
          "name": "Metoclopramide",
          "description": "Metoclopramide may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00916",
          "name": "Metronidazole",
          "description": "Metronidazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00834",
          "name": "Mifepristone",
          "description": "Mifepristone may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB08893",
          "name": "Mirabegron",
          "description": "Mirabegron may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00370",
          "name": "Mirtazapine",
          "description": "Mirtazapine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00691",
          "name": "Moexipril",
          "description": "Moexipril may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00218",
          "name": "Moxifloxacin",
          "description": "Goserelin may increase the QTc-prolonging activities of Moxifloxacin."
        },
        {
          "drugbank-id": "DB00220",
          "name": "Nelfinavir",
          "description": "Nelfinavir may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00622",
          "name": "Nicardipine",
          "description": "Nicardipine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB04868",
          "name": "Nilotinib",
          "description": "Goserelin may increase the QTc-prolonging activities of Nilotinib."
        },
        {
          "drugbank-id": "DB01059",
          "name": "Norfloxacin",
          "description": "Norfloxacin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00540",
          "name": "Nortriptyline",
          "description": "Nortriptyline may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00104",
          "name": "Octreotide",
          "description": "Octreotide may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01165",
          "name": "Ofloxacin",
          "description": "Goserelin may increase the QTc-prolonging activities of Ofloxacin."
        },
        {
          "drugbank-id": "DB00334",
          "name": "Olanzapine",
          "description": "Olanzapine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB09080",
          "name": "Olodaterol",
          "description": "Olodaterol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00904",
          "name": "Ondansetron",
          "description": "Goserelin may increase the QTc-prolonging activities of Ondansetron."
        },
        {
          "drugbank-id": "DB09330",
          "name": "Osimertinib",
          "description": "Goserelin may increase the QTc-prolonging activities of Osimertinib."
        },
        {
          "drugbank-id": "DB00107",
          "name": "Oxytocin",
          "description": "Oxytocin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01267",
          "name": "Paliperidone",
          "description": "Goserelin may increase the QTc-prolonging activities of Paliperidone."
        },
        {
          "drugbank-id": "DB06603",
          "name": "Panobinostat",
          "description": "Goserelin may increase the QTc-prolonging activities of Panobinostat."
        },
        {
          "drugbank-id": "DB00715",
          "name": "Paroxetine",
          "description": "Paroxetine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06663",
          "name": "Pasireotide",
          "description": "Pasireotide may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06589",
          "name": "Pazopanib",
          "description": "Goserelin may increase the QTc-prolonging activities of Pazopanib."
        },
        {
          "drugbank-id": "DB00738",
          "name": "Pentamidine",
          "description": "Goserelin may increase the QTc-prolonging activities of Pentamidine."
        },
        {
          "drugbank-id": "DB00556",
          "name": "Perflutren",
          "description": "Goserelin may increase the QTc-prolonging activities of Perflutren."
        },
        {
          "drugbank-id": "DB01100",
          "name": "Pimozide",
          "description": "Goserelin may increase the QTc-prolonging activities of Pimozide."
        },
        {
          "drugbank-id": "DB01263",
          "name": "Posaconazole",
          "description": "Posaconazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01087",
          "name": "Primaquine",
          "description": "Goserelin may increase the QTc-prolonging activities of Primaquine."
        },
        {
          "drugbank-id": "DB01035",
          "name": "Procainamide",
          "description": "Goserelin may increase the QTc-prolonging activities of Procainamide."
        },
        {
          "drugbank-id": "DB00420",
          "name": "Promazine",
          "description": "Goserelin may increase the QTc-prolonging activities of Promazine."
        },
        {
          "drugbank-id": "DB01069",
          "name": "Promethazine",
          "description": "Promethazine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01182",
          "name": "Propafenone",
          "description": "Goserelin may increase the QTc-prolonging activities of Propafenone."
        },
        {
          "drugbank-id": "DB00818",
          "name": "Propofol",
          "description": "Propofol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00344",
          "name": "Protriptyline",
          "description": "Protriptyline may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01224",
          "name": "Quetiapine",
          "description": "Goserelin may increase the QTc-prolonging activities of Quetiapine."
        },
        {
          "drugbank-id": "DB00908",
          "name": "Quinidine",
          "description": "Goserelin may increase the QTc-prolonging activities of Quinidine."
        },
        {
          "drugbank-id": "DB00468",
          "name": "Quinine",
          "description": "Goserelin may increase the QTc-prolonging activities of Quinine."
        },
        {
          "drugbank-id": "DB00243",
          "name": "Ranolazine",
          "description": "Ranolazine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00912",
          "name": "Repaglinide",
          "description": "The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB08864",
          "name": "Rilpivirine",
          "description": "Rilpivirine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00734",
          "name": "Risperidone",
          "description": "Risperidone may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00503",
          "name": "Ritonavir",
          "description": "Ritonavir may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01001",
          "name": "Salbutamol",
          "description": "Salbutamol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00938",
          "name": "Salmeterol",
          "description": "Salmeterol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01232",
          "name": "Saquinavir",
          "description": "Goserelin may increase the QTc-prolonging activities of Saquinavir."
        },
        {
          "drugbank-id": "DB06335",
          "name": "Saxagliptin",
          "description": "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01104",
          "name": "Sertraline",
          "description": "Sertraline may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01236",
          "name": "Sevoflurane",
          "description": "Sevoflurane may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01591",
          "name": "Solifenacin",
          "description": "Solifenacin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00398",
          "name": "Sorafenib",
          "description": "Sorafenib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00489",
          "name": "Sotalol",
          "description": "Goserelin may increase the QTc-prolonging activities of Sotalol."
        },
        {
          "drugbank-id": "DB01015",
          "name": "Sulfamethoxazole",
          "description": "Sulfamethoxazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00263",
          "name": "Sulfisoxazole",
          "description": "Goserelin may increase the QTc-prolonging activities of Sulfisoxazole."
        },
        {
          "drugbank-id": "DB01268",
          "name": "Sunitinib",
          "description": "Sunitinib may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00864",
          "name": "Tacrolimus",
          "description": "Tacrolimus may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00675",
          "name": "Tamoxifen",
          "description": "Tamoxifen may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06402",
          "name": "Telavancin",
          "description": "Goserelin may increase the QTc-prolonging activities of Telavancin."
        },
        {
          "drugbank-id": "DB00976",
          "name": "Telithromycin",
          "description": "Goserelin may increase the QTc-prolonging activities of Telithromycin."
        },
        {
          "drugbank-id": "DB00871",
          "name": "Terbutaline",
          "description": "Terbutaline may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB04844",
          "name": "Tetrabenazine",
          "description": "Goserelin may increase the QTc-prolonging activities of Tetrabenazine."
        },
        {
          "drugbank-id": "DB00679",
          "name": "Thioridazine",
          "description": "Goserelin may increase the QTc-prolonging activities of Thioridazine."
        },
        {
          "drugbank-id": "DB01623",
          "name": "Thiothixene",
          "description": "Thiothixene may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00697",
          "name": "Tizanidine",
          "description": "Tizanidine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB01124",
          "name": "Tolbutamide",
          "description": "The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB01036",
          "name": "Tolterodine",
          "description": "Tolterodine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00539",
          "name": "Toremifene",
          "description": "Goserelin may increase the QTc-prolonging activities of Toremifene."
        },
        {
          "drugbank-id": "DB00656",
          "name": "Trazodone",
          "description": "Trazodone may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00374",
          "name": "Treprostinil",
          "description": "Treprostinil may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00440",
          "name": "Trimethoprim",
          "description": "Trimethoprim may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00726",
          "name": "Trimipramine",
          "description": "Trimipramine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB06825",
          "name": "Triptorelin",
          "description": "Triptorelin may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB05294",
          "name": "Vandetanib",
          "description": "Goserelin may increase the QTc-prolonging activities of Vandetanib."
        },
        {
          "drugbank-id": "DB00862",
          "name": "Vardenafil",
          "description": "Vardenafil may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB08881",
          "name": "Vemurafenib",
          "description": "Goserelin may increase the QTc-prolonging activities of Vemurafenib."
        },
        {
          "drugbank-id": "DB00285",
          "name": "Venlafaxine",
          "description": "Venlafaxine may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB09082",
          "name": "Vilanterol",
          "description": "Vilanterol may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB04876",
          "name": "Vildagliptin",
          "description": "The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin."
        },
        {
          "drugbank-id": "DB00582",
          "name": "Voriconazole",
          "description": "Voriconazole may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB02546",
          "name": "Vorinostat",
          "description": "Vorinostat may increase the QTc-prolonging activities of Goserelin."
        },
        {
          "drugbank-id": "DB00246",
          "name": "Ziprasidone",
          "description": "Goserelin may increase the QTc-prolonging activities of Ziprasidone."
        },
        {
          "drugbank-id": "DB01624",
          "name": "Zuclopenthixol",
          "description": "Goserelin may increase the QTc-prolonging activities of Zuclopenthixol."
        }
      ]
    },
    "calculated-properties": {
      "property": [
        {
          "kind": "logP",
          "value": "0.3",
          "source": "ALOGPS"
        },
        {
          "kind": "logS",
          "value": "-4.7",
          "source": "ALOGPS"
        },
        {
          "kind": "Water Solubility",
          "value": "2.83e-02 g/l",
          "source": "ALOGPS"
        },
        {
          "kind": "logP",
          "value": "-5.2",
          "source": "ChemAxon"
        },
        {
          "kind": "IUPAC Name",
          "value": "(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide",
          "source": "ChemAxon"
        },
        {
          "kind": "Traditional IUPAC Name",
          "value": "(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(3H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide",
          "source": "ChemAxon"
        },
        {
          "kind": "Molecular Weight",
          "value": "1269.4105",
          "source": "ChemAxon"
        },
        {
          "kind": "Monoisotopic Weight",
          "value": "1268.641439486",
          "source": "ChemAxon"
        },
        {
          "kind": "SMILES",
          "value": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O",
          "source": "ChemAxon"
        },
        {
          "kind": "Molecular Formula",
          "value": "C59H84N18O14",
          "source": "ChemAxon"
        },
        {
          "kind": "InChI",
          "value": "InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1",
          "source": "ChemAxon"
        },
        {
          "kind": "InChIKey",
          "value": "InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N",
          "source": "ChemAxon"
        },
        {
          "kind": "Polar Surface Area (PSA)",
          "value": "495.89",
          "source": "ChemAxon"
        },
        {
          "kind": "Refractivity",
          "value": "325.84",
          "source": "ChemAxon"
        },
        {
          "kind": "Polarizability",
          "value": "131.22",
          "source": "ChemAxon"
        },
        {
          "kind": "Rotatable Bond Count",
          "value": "33",
          "source": "ChemAxon"
        },
        {
          "kind": "H Bond Acceptor Count",
          "value": "18",
          "source": "ChemAxon"
        },
        {
          "kind": "H Bond Donor Count",
          "value": "17",
          "source": "ChemAxon"
        },
        {
          "kind": "pKa (strongest acidic)",
          "value": "9.27",
          "source": "ChemAxon"
        },
        {
          "kind": "pKa (strongest basic)",
          "value": "10.82",
          "source": "ChemAxon"
        },
        {
          "kind": "Physiological Charge",
          "value": "2",
          "source": "ChemAxon"
        },
        {
          "kind": "Number of Rings",
          "value": "6",
          "source": "ChemAxon"
        },
        {
          "kind": "Bioavailability",
          "value": "0",
          "source": "ChemAxon"
        },
        {
          "kind": "Rule of Five",
          "value": "0",
          "source": "ChemAxon"
        },
        {
          "kind": "Ghose Filter",
          "value": "0",
          "source": "ChemAxon"
        },
        {
          "kind": "MDDR-Like Rule",
          "value": "1",
          "source": "ChemAxon"
        }
      ]
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Water Solubility",
          "value": "Soluble",
          "source": ""
        },
        {
          "kind": "logP",
          "value": "-2",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "11167"
        },
        {
          "resource": "PubChem Compound",
          "identifier": "5311128"
        },
        {
          "resource": "PubChem Substance",
          "identifier": "46507336"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D00573"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164747674"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Goserelin"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/goserel.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/goserelin.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000134",
          "name": "Lutropin-choriogonadotropic hormone receptor",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20053189",
          "known-action": "yes",
          "polypeptide": {
            "name": "Lutropin-choriogonadotropic hormone receptor",
            "general-function": "Luteinizing hormone receptor activity",
            "specific-function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.",
            "gene-name": "LHCGR",
            "locus": "2p21",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627",
            "signal-regions": "1-26",
            "theoretical-pi": "8.58",
            "molecular-weight": "78642.01",
            "chromosome-location": "2",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6585"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "LHCGR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M73746"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "903746"
                },
                {
                  "resource": "IUPHAR",
                  "identifier": "254"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "254"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P22888"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "LSHR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "LCGR",
                "LGR2",
                "LH/CG-R",
                "LHR",
                "LHRHR",
                "LSH-R",
                "Luteinizing hormone receptor"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0036957|Lutropin-choriogonadotropic hormone receptor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVNNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010174|Lutropin-choriogonadotropic hormone receptor (LHCGR)\nATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCG\nCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGC\nGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCT\nGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATC\nTCTCAGATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTG\nTCTGAAATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATA\nAATCTTCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGAT\nGTTACGAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACAC\nATAACCACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAA\nCTATATGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACT\nTCACTGGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGG\nGCCACAGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTAT\nGGCCTAGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCA\nTCAAGAGAAACATTTGTCAATCTCCTGGAGGCCACGTTGACTTACCCCAGCCACTGCTGT\nGCTTTTAGAAACTTGCCAACAAAAGAACAGAATTTTTCACATTCCATTTCTGAAAACTTT\nTCCAAACAATGTGAAAGCACAGTAAGGAAAGTGAATAACAAAACACTTTATTCTTCCATG\nCTTGCTGAGAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTCTGCTTACCCAAGACA\nCCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGATATTATGGGCTATGAC\nTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATGGGAAACATGACTGTT\nCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGTTTTCTCATGTGCAAT\nCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATAGCCTCAGTTGATTCC\nCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACAGGGAGTGGGTGCAGC\nACTGCTGGCTTTTTCACTGTATTCGCAAGTGAACTTTCTGTCTACACCCTCACCGTCATC\nACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGACCAAAAGCTGCGATTA\nAGACATGCCATTCTGATTATGCTTGGAGGATGGCTCTTTTCTTCTCTAATTGCTATGTTG\nCCCCTTGTCGGTGTCAGCAATTACATGAAGGTCAGTATTTGCTTCCCCATGGATGTGGAA\nACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAATGTGGTGGCCTTCTTC\nATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAACCCAGAATTAATGGCT\nACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATCTTCACCGATTTCACC\nTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAAGTACCTCTTATCACA\nGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAATTCTTGTGCCAATCCA\nTTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTTCTTTTGCTGAGCAAA\nTTTGGCTGCTGTAAACGTCGGGCTGAACTTTATAGAAGGAAAGATTTTTCAGCTTACACC\nTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCTCAATCCACCTTGAAGTTG\nTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACTCGCTACACAGAGTGTTAA\n"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00001",
                  "name": "7tm_1"
                },
                {
                  "identifier": "PF13306",
                  "name": "LRR_5"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "endosome"
                },
                {
                  "category": "function",
                  "description": "G-protein coupled peptide receptor activity"
                },
                {
                  "category": "function",
                  "description": "choriogonadotropin hormone binding"
                },
                {
                  "category": "function",
                  "description": "choriogonadotropin hormone receptor activity"
                },
                {
                  "category": "function",
                  "description": "luteinizing hormone receptor activity"
                },
                {
                  "category": "process",
                  "description": "cellular response to gonadotropin stimulus"
                },
                {
                  "category": "process",
                  "description": "G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger"
                },
                {
                  "category": "process",
                  "description": "female gonad development"
                },
                {
                  "category": "process",
                  "description": "cognition"
                },
                {
                  "category": "process",
                  "description": "luteinizing hormone signaling pathway"
                },
                {
                  "category": "process",
                  "description": "adenylate cyclase-activating G-protein coupled receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "male genitalia development"
                },
                {
                  "category": "process",
                  "description": "hormone-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "ovulation cycle process"
                },
                {
                  "category": "process",
                  "description": "male gonad development"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cAMP-mediated signaling"
                },
                {
                  "category": "process",
                  "description": "spermatogenesis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of inositol trisphosphate biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "uterus development"
                },
                {
                  "category": "process",
                  "description": "activation of adenylate cyclase activity"
                },
                {
                  "category": "process",
                  "description": "G-protein coupled receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "phospholipase C-activating G-protein coupled receptor signaling pathway"
                }
              ]
            },
            "_id": "P22888",
            "_source": "Swiss-Prot"
          }
        },
        {
          "id": "BE0000203",
          "name": "Gonadotropin-releasing hormone receptor",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20053189",
          "known-action": "yes",
          "polypeptide": {
            "name": "Gonadotropin-releasing hormone receptor",
            "general-function": "Peptide binding",
            "specific-function": "Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.",
            "gene-name": "GNRHR",
            "locus": "4q21.2",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326",
            "signal-regions": "",
            "theoretical-pi": "9.93",
            "molecular-weight": "37730.355",
            "chromosome-location": "4",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:4421"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "GNRHR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L03380"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "183422"
                },
                {
                  "resource": "IUPHAR",
                  "identifier": "256"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "256"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P30968"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "GNRHR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "GnRH receptor",
                "GRHR"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00001",
                "name": "7tm_1"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "peptide binding"
                },
                {
                  "category": "function",
                  "description": "gonadotropin-releasing hormone receptor activity"
                },
                {
                  "category": "process",
                  "description": "cellular response to gonadotropin-releasing hormone"
                },
                {
                  "category": "process",
                  "description": "G-protein coupled receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "multicellular organismal development"
                }
              ]
            },
            "_id": "P30968",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "small molecule",
    "_created": "2005-06-13",
    "_updated": "2013-09-16"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00015"
      },
      "BIOD00013",
      "BTD00013"
    ],
    "name": "Reteplase",
    "description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).",
    "cas-number": "133652-38-7",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction",
    "pharmacodynamics": "Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.",
    "mechanism-of-action": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. ",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "t- PA"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "t-plasminogen activator"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Tissue-type plasminogen activator precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "tPA"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Retavase",
          "ndc-id": "",
          "ndc-product-code": "24477-040",
          "dpd-id": "",
          "started-marketing-on": "1996-10-30",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103786",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Retavase",
          "ndc-id": "",
          "ndc-product-code": "24477-041",
          "dpd-id": "",
          "started-marketing-on": "1996-10-30",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103786",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Retavase",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02233013",
          "started-marketing-on": "1999-02-19",
          "ended-marketing-on": "2013-08-29",
          "dosage-form": "powder for solution",
          "strength": "10.4 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Retavase",
          "ingredients": "Reteplase"
        },
        {
          "name": "Retavase",
          "ingredients": "Reteplase"
        },
        {
          "name": "Retavase",
          "ingredients": "Reteplase"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "EKR Therapeutics Inc.",
          "url": "http://www.ekrtx.com"
        },
        {
          "name": "Hospira Inc.",
          "url": "http://www.hospira.com"
        },
        {
          "name": "PDL BioPharma Inc.",
          "url": "http://www.pdl.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": {
        "description": "Retavase vial half-kit",
        "cost": {
          "_currency": "USD",
          "__text": "2605.93"
        },
        "unit": "vial"
      }
    },
    "categories": {
      "category": [
        {
          "category": "Fibrinolytic Agents",
          "mesh-id": "[\"D27.505.519.421.750\", \"D27.505.954.411.320\", \"D27.505.954.502.427\"]"
        },
        {
          "category": "Thrombolytic Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "10.4 unit"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "B",
            "__text": "BLOOD AND BLOOD FORMING ORGANS"
          },
          {
            "_code": "B01",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01A",
            "__text": "ANTITHROMBOTIC AGENTS"
          },
          {
            "_code": "B01AD",
            "__text": "Enzymes"
          }
        ],
        "_code": "B01AD07"
      }
    },
    "ahfs-codes": "",
    "patents": {
      "patent": {
        "number": "2107476",
        "country": "Canada",
        "approved": "2007-12-18",
        "expires": "2012-04-15"
      }
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00054",
          "name": "Abciximab",
          "description": "Reteplase may increase the anticoagulant activities of Abciximab."
        },
        {
          "drugbank-id": "DB01418",
          "name": "Acenocoumarol",
          "description": "Reteplase may increase the anticoagulant activities of Acenocoumarol."
        },
        {
          "drugbank-id": "DB00945",
          "name": "Acetylsalicylic acid",
          "description": "The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Reteplase."
        },
        {
          "drugbank-id": "DB00233",
          "name": "Aminosalicylic Acid",
          "description": "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Reteplase."
        },
        {
          "drugbank-id": "DB00261",
          "name": "Anagrelide",
          "description": "Anagrelide may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06605",
          "name": "Apixaban",
          "description": "Reteplase may increase the anticoagulant activities of Apixaban."
        },
        {
          "drugbank-id": "DB06692",
          "name": "Aprotinin",
          "description": "The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin."
        },
        {
          "drugbank-id": "DB00278",
          "name": "Argatroban",
          "description": "Reteplase may increase the anticoagulant activities of Argatroban."
        },
        {
          "drugbank-id": "DB01294",
          "name": "Bismuth Subsalicylate",
          "description": "The risk or severity of adverse effects can be increased when Bismuth Subsalicylate is combined with Reteplase."
        },
        {
          "drugbank-id": "DB00006",
          "name": "Bivalirudin",
          "description": "Reteplase may increase the anticoagulant activities of Bivalirudin."
        },
        {
          "drugbank-id": "DB00201",
          "name": "Caffeine",
          "description": "Caffeine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06441",
          "name": "Cangrelor",
          "description": "Cangrelor may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB01166",
          "name": "Cilostazol",
          "description": "Cilostazol may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00215",
          "name": "Citalopram",
          "description": "Citalopram may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB04272",
          "name": "Citric Acid",
          "description": "Reteplase may increase the anticoagulant activities of Citric Acid."
        },
        {
          "drugbank-id": "DB00758",
          "name": "Clopidogrel",
          "description": "Clopidogrel may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06695",
          "name": "Dabigatran etexilate",
          "description": "Reteplase may increase the anticoagulant activities of Dabigatran etexilate."
        },
        {
          "drugbank-id": "DB06779",
          "name": "Dalteparin",
          "description": "Reteplase may increase the anticoagulant activities of Dalteparin."
        },
        {
          "drugbank-id": "DB06754",
          "name": "Danaparoid",
          "description": "Reteplase may increase the anticoagulant activities of Danaparoid."
        },
        {
          "drugbank-id": "DB11095",
          "name": "Desirudin",
          "description": "Reteplase may increase the anticoagulant activities of Desirudin."
        },
        {
          "drugbank-id": "DB06700",
          "name": "Desvenlafaxine",
          "description": "Desvenlafaxine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00586",
          "name": "Diclofenac",
          "description": "Diclofenac may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00266",
          "name": "Dicoumarol",
          "description": "Reteplase may increase the anticoagulant activities of Dicoumarol."
        },
        {
          "drugbank-id": "DB00861",
          "name": "Diflunisal",
          "description": "Diflunisal may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB01551",
          "name": "Dihydrocodeine",
          "description": "Dihydrocodeine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00975",
          "name": "Dipyridamole",
          "description": "Dipyridamole may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00476",
          "name": "Duloxetine",
          "description": "Duloxetine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00974",
          "name": "Edetic Acid",
          "description": "Reteplase may increase the anticoagulant activities of Edetic Acid."
        },
        {
          "drugbank-id": "DB09075",
          "name": "Edoxaban",
          "description": "Reteplase may increase the anticoagulant activities of Edoxaban."
        },
        {
          "drugbank-id": "DB01225",
          "name": "Enoxaparin",
          "description": "Reteplase may increase the anticoagulant activities of Enoxaparin."
        },
        {
          "drugbank-id": "DB01240",
          "name": "Epoprostenol",
          "description": "The risk or severity of adverse effects can be increased when Reteplase is combined with Epoprostenol."
        },
        {
          "drugbank-id": "DB00063",
          "name": "Eptifibatide",
          "description": "Eptifibatide may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB01175",
          "name": "Escitalopram",
          "description": "Escitalopram may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB08794",
          "name": "Ethyl biscoumacetate",
          "description": "Reteplase may increase the anticoagulant activities of Ethyl biscoumacetate."
        },
        {
          "drugbank-id": "DB00749",
          "name": "Etodolac",
          "description": "Etodolac may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00573",
          "name": "Fenoprofen",
          "description": "Fenoprofen may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB08976",
          "name": "Floctafenine",
          "description": "Floctafenine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00472",
          "name": "Fluoxetine",
          "description": "Fluoxetine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00712",
          "name": "Flurbiprofen",
          "description": "Flurbiprofen may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00176",
          "name": "Fluvoxamine",
          "description": "Fluvoxamine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00569",
          "name": "Fondaparinux sodium",
          "description": "Reteplase may increase the anticoagulant activities of Fondaparinux sodium."
        },
        {
          "drugbank-id": "DB01109",
          "name": "Heparin",
          "description": "Reteplase may increase the anticoagulant activities of Heparin."
        },
        {
          "drugbank-id": "DB01050",
          "name": "Ibuprofen",
          "description": "Ibuprofen may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB01088",
          "name": "Iloprost",
          "description": "The risk or severity of adverse effects can be increased when Reteplase is combined with Iloprost."
        },
        {
          "drugbank-id": "DB00328",
          "name": "Indomethacin",
          "description": "Indomethacin may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB01009",
          "name": "Ketoprofen",
          "description": "Ketoprofen may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00465",
          "name": "Ketorolac",
          "description": "Ketorolac may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB08918",
          "name": "Levomilnacipran",
          "description": "Levomilnacipran may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB09211",
          "name": "Limaprost",
          "description": "The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase."
        },
        {
          "drugbank-id": "DB01397",
          "name": "Magnesium salicylate",
          "description": "The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Reteplase."
        },
        {
          "drugbank-id": "DB00784",
          "name": "Mefenamic acid",
          "description": "Mefenamic acid may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00814",
          "name": "Meloxicam",
          "description": "Meloxicam may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB04896",
          "name": "Milnacipran",
          "description": "Milnacipran may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00461",
          "name": "Nabumetone",
          "description": "Nabumetone may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB08813",
          "name": "Nadroparin",
          "description": "Reteplase may increase the anticoagulant activities of Nadroparin."
        },
        {
          "drugbank-id": "DB00788",
          "name": "Naproxen",
          "description": "Naproxen may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00991",
          "name": "Oxaprozin",
          "description": "Oxaprozin may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00715",
          "name": "Paroxetine",
          "description": "Paroxetine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00498",
          "name": "Phenindione",
          "description": "Reteplase may increase the anticoagulant activities of Phenindione."
        },
        {
          "drugbank-id": "DB00946",
          "name": "Phenprocoumon",
          "description": "Reteplase may increase the anticoagulant activities of Phenprocoumon."
        },
        {
          "drugbank-id": "DB00554",
          "name": "Piroxicam",
          "description": "Piroxicam may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06209",
          "name": "Prasugrel",
          "description": "Prasugrel may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06228",
          "name": "Rivaroxaban",
          "description": "Reteplase may increase the anticoagulant activities of Rivaroxaban."
        },
        {
          "drugbank-id": "DB01398",
          "name": "Salicylate-sodium",
          "description": "The risk or severity of adverse effects can be increased when Salicylate-sodium is combined with Reteplase."
        },
        {
          "drugbank-id": "DB01399",
          "name": "Salsalate",
          "description": "The risk or severity of adverse effects can be increased when Salsalate is combined with Reteplase."
        },
        {
          "drugbank-id": "DB01104",
          "name": "Sertraline",
          "description": "Sertraline may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00605",
          "name": "Sulindac",
          "description": "Sulindac may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06271",
          "name": "Sulodexide",
          "description": "Reteplase may increase the anticoagulant activities of Sulodexide."
        },
        {
          "drugbank-id": "DB01600",
          "name": "Tiaprofenic acid",
          "description": "Tiaprofenic acid may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB08816",
          "name": "Ticagrelor",
          "description": "Ticagrelor may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00208",
          "name": "Ticlopidine",
          "description": "Ticlopidine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06822",
          "name": "Tinzaparin",
          "description": "Reteplase may increase the anticoagulant activities of Tinzaparin."
        },
        {
          "drugbank-id": "DB00775",
          "name": "Tirofiban",
          "description": "Tirofiban may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00500",
          "name": "Tolmetin",
          "description": "Tolmetin may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00374",
          "name": "Treprostinil",
          "description": "Reteplase may increase the anticoagulant activities of Treprostinil."
        },
        {
          "drugbank-id": "DB00285",
          "name": "Venlafaxine",
          "description": "Venlafaxine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB06684",
          "name": "Vilazodone",
          "description": "Vilazodone may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB09030",
          "name": "Vorapaxar",
          "description": "Vorapaxar may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB09068",
          "name": "Vortioxetine",
          "description": "Vortioxetine may increase the anticoagulant activities of Reteplase."
        },
        {
          "drugbank-id": "DB00682",
          "name": "Warfarin",
          "description": "Reteplase may increase the anticoagulant activities of Warfarin."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00015 sequence\nSYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYC\nRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAA\nIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKF\nEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELS\nGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHD\nACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "60 °C",
          "source": "Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.435",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "6.86",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "39589.6",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C1736H2671N499O522S22",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "11534"
        },
        {
          "resource": "GenBank",
          "identifier": "L00153"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164743728"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P00750"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Reteplase"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic2/reteplase.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/reteplase.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000211",
          "name": "Plasminogen",
          "organism": "Human",
          "actions": {
            "action": "activator"
          },
          "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464\n# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Plasminogen",
            "general-function": "Serine-type peptidase activity",
            "specific-function": "Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.",
            "gene-name": "PLG",
            "locus": "6q26",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-19",
            "theoretical-pi": "7.25",
            "molecular-weight": "90568.415",
            "chromosome-location": "6",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9071"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLG"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X05199"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "387026"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2394"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00747"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PLMN_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "3.4.21.7"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016037|Plasminogen\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016038|Plasminogen (PLG)\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAACTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGTGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTCCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAGATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGTCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00051",
                  "name": "Kringle"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF00024",
                  "name": "PAN_1"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "apolipoprotein binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "serine-type peptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix disassembly"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "positive regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell-substrate adhesion"
                },
                {
                  "category": "process",
                  "description": "tissue remodeling"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell-cell adhesion mediated by cadherin"
                }
              ]
            },
            "_id": "P00747",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000538",
          "name": "Fibrinogen alpha chain",
          "organism": "Human",
          "actions": "",
          "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464",
          "known-action": "yes",
          "polypeptide": {
            "name": "Fibrinogen alpha chain",
            "general-function": "Structural molecule activity",
            "specific-function": "Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function in hemostasis as one of the primary components of blood clots. In addition, functions during the early stages of wound repair to stabilize the lesion and guide cell migration during re-epithelialization. Was originally thought to be essential for platelet aggregation, based on in vitro studies using anticoagulated blood. However, subsequent studies have shown that it is not absolutely required for thrombus formation in vivo. Enhances expression of SELP in activated platelets via an ITGB3-dependent pathway. Maternal fibrinogen is essential for successful pregnancy. Fibrin deposition is also associated with infection, where it protects against IFNG-mediated hemorrhage. May also facilitate the immune response via both innate and T-cell mediated pathways.",
            "gene-name": "FGA",
            "locus": "4q28",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-19",
            "theoretical-pi": "5.87",
            "molecular-weight": "94972.455",
            "chromosome-location": "4",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3661"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "FGA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF361104"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "13591824"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P02671"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FIBA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": "Fibrinogen alpha chain precursor"
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001074|Fibrinogen alpha chain\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0021267|Fibrinogen alpha chain (FGA)\nATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00147",
                  "name": "Fibrinogen_C"
                },
                {
                  "identifier": "PF08702",
                  "name": "Fib_alpha"
                },
                {
                  "identifier": "PF12160",
                  "name": "Fibrinogen_aC"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular vesicle"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "fibrinogen complex"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "rough endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "cell cortex"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "structural molecule activity"
                },
                {
                  "category": "process",
                  "description": "response to estradiol"
                },
                {
                  "category": "process",
                  "description": "induction of bacterial agglutination"
                },
                {
                  "category": "process",
                  "description": "positive regulation of vasoconstriction"
                },
                {
                  "category": "process",
                  "description": "plasminogen activation"
                },
                {
                  "category": "process",
                  "description": "cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, common pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of ERK1 and ERK2 cascade"
                },
                {
                  "category": "process",
                  "description": "cellular response to interleukin-6"
                },
                {
                  "category": "process",
                  "description": "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors"
                },
                {
                  "category": "process",
                  "description": "cellular response to granulocyte colony-stimulating factor"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endothelial cell apoptotic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of exocytosis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of blood coagulation, common pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of heterotypic cell-cell adhesion"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "response to morphine"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, fibrin clot formation"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "response to cycloheximide"
                },
                {
                  "category": "process",
                  "description": "protein complex assembly"
                },
                {
                  "category": "process",
                  "description": "cellular protein complex assembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of peptide hormone secretion"
                },
                {
                  "category": "process",
                  "description": "acute-phase response"
                },
                {
                  "category": "process",
                  "description": "protein polymerization"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "positive regulation of substrate adhesion-dependent cell spreading"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "adaptive immune response"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "liver regeneration"
                },
                {
                  "category": "process",
                  "description": "response to calcium ion"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein secretion"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "response to genistein"
                },
                {
                  "category": "process",
                  "description": "platelet aggregation"
                },
                {
                  "category": "process",
                  "description": "cellular response to organic cyclic compound"
                }
              ]
            },
            "_id": "P02671",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0000717",
          "name": "Urokinase plasminogen activator surface receptor",
          "organism": "Human",
          "actions": "",
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Urokinase plasminogen activator surface receptor",
            "general-function": "Urokinase plasminogen activator receptor activity",
            "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.",
            "gene-name": "PLAUR",
            "locus": "19q13",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "6.64",
            "molecular-weight": "36977.62",
            "chromosome-location": "19",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9053"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PLAUR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X51675"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "37605"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q03405"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "UPAR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "MO3",
                "Monocyte activation antigen Mo3",
                "U-PAR",
                "UPAR"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001430|Urokinase plasminogen activator surface receptor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016188|Urokinase plasminogen activator surface receptor (PLAUR)\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACGCTCACTCTGGGGAAGCTGGTTG\nCCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCAT\nGTATAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00021",
                "name": "UPAR_LY6"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "invadopodium membrane"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "anchored component of membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extrinsic component of membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "urokinase plasminogen activator receptor activity"
                },
                {
                  "category": "function",
                  "description": "enzyme binding"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "regulation of proteolysis"
                },
                {
                  "category": "process",
                  "description": "chemotaxis"
                },
                {
                  "category": "process",
                  "description": "movement of cell or subcellular component"
                },
                {
                  "category": "process",
                  "description": "attachment of GPI anchor to protein"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "C-terminal protein lipidation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of intrinsic apoptotic signaling pathway"
                },
                {
                  "category": "process",
                  "description": "urokinase plasminogen activator signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein phosphorylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of DNA binding"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "positive regulation of epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of release of cytochrome c from mitochondria"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                }
              ]
            },
            "_id": "Q03405",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0000240",
          "name": "Plasminogen activator inhibitor 1",
          "organism": "Human",
          "actions": "",
          "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Plasminogen activator inhibitor 1",
            "general-function": "Serine-type endopeptidase inhibitor activity",
            "specific-function": "Serine protease inhibitor. This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, protein C and matriptase-3/TMPRSS7. Its rapid interaction with PLAT may function as a major control point in the regulation of fibrinolysis.",
            "gene-name": "SERPINE1",
            "locus": "7q21.3-q22",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-23",
            "theoretical-pi": "7.22",
            "molecular-weight": "45059.695",
            "chromosome-location": "7",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:8583"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "SERPINE1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X04429"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "35272"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P05121"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PAI1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Endothelial plasminogen activator inhibitor",
                "PAI",
                "PAI1",
                "PLANH1",
                "Serpin E1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000479|Plasminogen activator inhibitor 1\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010214|Plasminogen activator inhibitor 1 (SERPINE1)\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGATGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00079",
                "name": "Serpin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase inhibitor activity"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of leukotriene production involved in inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell adhesion mediated by integrin"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of monocyte chemotaxis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of cell migration"
                },
                {
                  "category": "process",
                  "description": "gene expression"
                },
                {
                  "category": "process",
                  "description": "positive regulation of receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of inflammatory response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endothelial cell apoptotic process"
                },
                {
                  "category": "process",
                  "description": "transcription initiation from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of receptor activity"
                },
                {
                  "category": "process",
                  "description": "circadian rhythm"
                },
                {
                  "category": "process",
                  "description": "negative regulation of plasminogen activation"
                },
                {
                  "category": "process",
                  "description": "transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "angiogenesis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "transforming growth factor beta receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell-matrix adhesion"
                },
                {
                  "category": "process",
                  "description": "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors"
                },
                {
                  "category": "process",
                  "description": "negative regulation of endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of vascular wound healing"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "negative regulation of wound healing"
                },
                {
                  "category": "process",
                  "description": "chronological cell aging"
                },
                {
                  "category": "process",
                  "description": "positive regulation of angiogenesis"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "defense response to Gram-negative bacterium"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-8 production"
                }
              ]
            },
            "_id": "P05121",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2010-09-29"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00016"
      },
      "BIOD00103",
      "BTD00103"
    ],
    "name": "Epoetin alfa",
    "description": "Human erythropoietin (recombinant), produced by CHO cells.",
    "cas-number": "113427-24-0",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For treatment of anemia (from renal transplants or certain HIV treatment)",
    "pharmacodynamics": "Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.",
    "mechanism-of-action": "Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "* 20.2 +/- 15.9 mL/h/kg [150 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]\r\n* 23.6 +/- 9.5 mL/h/kg [150 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]\r\n* 9.2 +/- 4.7 mL/h/kg [40,000 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]\r\n* 13.9 +/- 7.6 mL/h/kg [40,000 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": {
        "_language": "",
        "_coder": "",
        "__text": "Erythropoietin precursor"
      }
    },
    "products": {
      "product": [
        {
          "name": "Eprex Sterile Solution",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02288680",
          "started-marketing-on": "2007-11-19",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "30000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243239",
          "started-marketing-on": "2005-08-24",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "20000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 10000iu/1.0ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02231587",
          "started-marketing-on": "1997-09-19",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "10000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 10000iu/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02126591",
          "started-marketing-on": "1990-12-31",
          "ended-marketing-on": "2014-10-09",
          "dosage-form": "solution",
          "strength": "10000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 1000iu/0.5ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02231583",
          "started-marketing-on": "1997-09-19",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "1000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 20000iu/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02206072",
          "started-marketing-on": "1996-10-02",
          "ended-marketing-on": "2010-04-29",
          "dosage-form": "solution",
          "strength": "20000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 2000iu/0.5ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02231584",
          "started-marketing-on": "1997-09-19",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "2000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 2000iu/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02126575",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "2014-09-25",
          "dosage-form": "solution",
          "strength": "2000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 3000iu/0.3ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02231585",
          "started-marketing-on": "1997-09-19",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "3000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 40000iu/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02240722",
          "started-marketing-on": "1999-12-21",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "40000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 4000iu/0.4ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02231586",
          "started-marketing-on": "1997-09-19",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "4000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 4000iu/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02126583",
          "started-marketing-on": "1990-12-31",
          "ended-marketing-on": "2014-10-09",
          "dosage-form": "solution",
          "strength": "4000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 5000iu/0.5ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243400",
          "started-marketing-on": "2002-07-01",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "5000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 6000 Iu/0.6 Ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243401",
          "started-marketing-on": "2001-02-20",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "6000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Eprex Sterile Solution 8000 Iu/0.8 Ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243403",
          "started-marketing-on": "2001-02-20",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "8000 unit",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": [
        {
          "name": "Binocrit",
          "company": "Sandoz"
        },
        {
          "name": "Epocept",
          "company": "Lupin pharma"
        },
        {
          "name": "Epofit",
          "company": "Intas pharma"
        },
        {
          "name": "Epogin",
          "company": "Chugai"
        },
        {
          "name": "Eprex",
          "company": "Janssen-Cilag. Ortho Biologics LLC"
        },
        {
          "name": "Nanokine",
          "company": "Nanogen Pharmaceutical biotechnology, Vietnam)"
        }
      ]
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Eprex Sterile Solution 1000iu/0.5ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 2000iu/0.5ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 3000iu/0.3ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 4000iu/0.4ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 10000iu/1.0ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 40000iu/ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 5000iu/0.5ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 6000 Iu/0.6 Ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 8000 Iu/0.8 Ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 10000iu/ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 4000iu/ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 2000iu/ml",
          "ingredients": "Epoetin alfa"
        },
        {
          "name": "Eprex Sterile Solution 20000iu/ml",
          "ingredients": "Epoetin alfa"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Amgen Inc.",
          "url": "http://www.amgen.com"
        },
        {
          "name": "Centocor Ortho Biotech Inc.",
          "url": "http://www.centocororthobiotech.com"
        },
        {
          "name": "DSM Corp.",
          "url": "http://www.dsm.com"
        },
        {
          "name": "Janssen-Ortho Inc.",
          "url": "http://www.janssen-ortho.com"
        },
        {
          "name": "JHP Pharmaceuticals LLC",
          "url": "http://www.jhppharma.com"
        },
        {
          "name": "Ortho-McNeil-Janssen Pharmaceuticals Inc.",
          "url": "http://www.ortho-mcneil.com"
        },
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Epogen 2000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "34.14"
          },
          "unit": "vial"
        },
        {
          "description": "Procrit 2000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "37.09"
          },
          "unit": "vial"
        },
        {
          "description": "Epogen 3000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "47.53"
          },
          "unit": "vial"
        },
        {
          "description": "Procrit 3000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "55.63"
          },
          "unit": "vial"
        },
        {
          "description": "Epogen 4000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "61.34"
          },
          "unit": "vial"
        },
        {
          "description": "Procrit 4000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "74.17"
          },
          "unit": "vial"
        },
        {
          "description": "Epogen 10000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "151.8"
          },
          "unit": "ml"
        },
        {
          "description": "Epogen 20000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "303.6"
          },
          "unit": "ml"
        },
        {
          "description": "Epogen 10000 unit/ml Solution 2ml Vial",
          "cost": {
            "_currency": "USD",
            "__text": "315.74"
          },
          "unit": "vial"
        },
        {
          "description": "Procrit 10000 unit/ml Solution 2ml Vial",
          "cost": {
            "_currency": "USD",
            "__text": "358.02"
          },
          "unit": "vial"
        },
        {
          "description": "Procrit 20000 unit/ml Solution",
          "cost": {
            "_currency": "USD",
            "__text": "378.14"
          },
          "unit": "ml"
        },
        {
          "description": "Procrit 20000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "388.97"
          },
          "unit": "ml"
        },
        {
          "description": "Epogen 40000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "640.37"
          },
          "unit": "ml"
        },
        {
          "description": "Procrit 10000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "710.87"
          },
          "unit": "vial"
        },
        {
          "description": "Procrit 40000 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "767.03"
          },
          "unit": "vial"
        },
        {
          "description": "Epogen 10000 unit/ml Solution 1 Box Contains Ten 1ml Vials",
          "cost": {
            "_currency": "USD",
            "__text": "1578.72"
          },
          "unit": "box"
        },
        {
          "description": "Epogen 20000 unit/ml Solution 1 Box Contains Ten 1ml Vials",
          "cost": {
            "_currency": "USD",
            "__text": "3157.44"
          },
          "unit": "box"
        },
        {
          "description": "Epogen 40000 unit/ml Solution 1 Box Contains Ten 1ml Vials",
          "cost": {
            "_currency": "USD",
            "__text": "6852.3"
          },
          "unit": "box"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Hematinics",
          "mesh-id": "[\"D27.505.954.502.543\"]"
        },
        {
          "category": "Anti-anemic Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "20000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "30000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "10000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "1000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "2000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "3000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "40000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "4000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "5000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "6000 unit"
        },
        {
          "form": "Solution",
          "route": "intravenous; subcutaneous",
          "strength": "8000 unit"
        }
      ]
    },
    "atc-codes": "",
    "ahfs-codes": {
      "ahfs-code": "20:16.00"
    },
    "patents": {
      "patent": {
        "number": "1339047",
        "country": "Canada",
        "approved": "1997-05-27",
        "expires": "2014-05-27"
      }
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00480",
          "name": "Lenalidomide",
          "description": "Epoetin alfa may increase the thrombogenic activities of Lenalidomide."
        },
        {
          "drugbank-id": "DB00984",
          "name": "Nandrolone phenpropionate",
          "description": "Nandrolone phenpropionate may increase the stimulatory activities of Epoetin alfa."
        },
        {
          "drugbank-id": "DB01041",
          "name": "Thalidomide",
          "description": "Epoetin alfa may increase the thrombogenic activities of Thalidomide."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00016 sequence\nAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA\nVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS\nPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "53 °C",
          "source": "Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)"
        },
        {
          "kind": "Isoelectric Point",
          "value": "8.75",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "18396.1",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C815H1317N233O241S5",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "299"
        },
        {
          "resource": "GenBank",
          "identifier": "X02158"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA10072"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01588"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Epoetin_alfa"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/epoetin.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/epoetin-alfa.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000654",
        "name": "Erythropoietin receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16505108\r\n# Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17575216\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Erythropoietin receptor",
          "general-function": "Identical protein binding",
          "specific-function": "Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.",
          "gene-name": "EPOR",
          "locus": "19p13.3-p13.2",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "251-273",
          "signal-regions": "1-24",
          "theoretical-pi": "4.37",
          "molecular-weight": "55064.725",
          "chromosome-location": "19",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:3416"
              },
              {
                "resource": "GenAtlas",
                "identifier": "EPOR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "M60459"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "182245"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "1718"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P19235"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "EPOR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": "EPO-R"
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0001304|Erythropoietin receptor\nMDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL\nVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL\nELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY\nEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV\nSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH\nKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG\nSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS\nAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL\nSDGPYSNPYENSLIPAAEPLPPSYVACS"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0010455|Erythropoietin receptor (EPOR)\nATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT\nGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC\nTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG\nGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC\nTACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT\nGGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA\nGAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT\nGAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC\nCACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC\nGAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG\nGGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC\nCGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG\nTCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG\nGTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG\nAAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC\nAAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC\nACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG\nACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC\nAGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG\nCCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC\nTCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT\nGCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA\nCTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT\nGACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA\nTCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG\nCCCCCCAGCTATGTGGCTTGCTCTTAG"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00041",
                "name": "fn3"
              },
              {
                "identifier": "PF09067",
                "name": "EpoR_lig-bind"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "extracellular region"
              },
              {
                "category": "component",
                "description": "cytosol"
              },
              {
                "category": "component",
                "description": "integral component of plasma membrane"
              },
              {
                "category": "function",
                "description": "erythropoietin receptor activity"
              },
              {
                "category": "function",
                "description": "identical protein binding"
              },
              {
                "category": "process",
                "description": "heart development"
              },
              {
                "category": "process",
                "description": "brain development"
              },
              {
                "category": "process",
                "description": "negative regulation of neuron apoptotic process"
              },
              {
                "category": "process",
                "description": "decidualization"
              },
              {
                "category": "process",
                "description": "signal transduction"
              },
              {
                "category": "process",
                "description": "erythropoietin-mediated signaling pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of cytosolic calcium ion concentration"
              }
            ]
          },
          "_id": "P19235",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2011-08-02"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00017"
      },
      "BIOD00025",
      "BTD00025"
    ],
    "name": "Salmon Calcitonin",
    "description": "Synthetic peptide, 32 residues long formulated as a nasal spray.",
    "cas-number": "47931-85-1",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# Sanofi-Aventis Canada Inc. Calcimar Solution. Laval, Quebec: N.p., 2014. \r\n#Lexicomp. Calcitonin. N.p., 2014. Web. 11 Nov. 2014.",
    "synthesis-reference": "Marcos C. Poblet, Berta P. Obiols, Gemma J. Farres, \"Procedure for preparing salmon calcitonin.\" U.S. Patent US5527881, issued October, 1991.",
    "indication": "Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.  ",
    "pharmacodynamics": "Calcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass and a reduction in plasma calcium levels. It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.",
    "mechanism-of-action": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.",
    "toxicity": "Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans. It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks. Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response. The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo. The same may apply to IV, IM and SC routes since the systemic exposure is higher in those cases.\r\nNausea is noticeable in some patients but tends to decrease with continued administration. Rhinitis, headaches and back pain have also been reported among others. ",
    "metabolism": "Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. It is also metabolized in the blood and the peripheral tissue. ",
    "absorption": "Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.",
    "half-life": "Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes ",
    "protein-binding": "30 to 40%",
    "route-of-elimination": "Urine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.",
    "volume-of-distribution": "0.15 to 0.3 L/kg",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcimar"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcitonin (Salmon Synthetic)"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcitonin 1 precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcitonin Salmon"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcitonin salmon recombinant"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcitonin-salmon"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Calcitonin, salmon"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Cibacalcin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Fortical"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Miacalcin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Salmon calcitonin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Salmotonin"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Apo-calcitonin Injectable",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246058",
          "started-marketing-on": "2003-05-01",
          "ended-marketing-on": "2013-08-02",
          "dosage-form": "liquid",
          "strength": "200 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Apo-calcitonin Nasal Spray",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02247585",
          "started-marketing-on": "2003-09-12",
          "ended-marketing-on": "2013-10-01",
          "dosage-form": "solution",
          "strength": "200 unit",
          "route": "nasal",
          "fda-application-number": "",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Calcimar Solution Inj 200unit/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "01926691",
          "started-marketing-on": "1983-12-31",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Calcitonin (salmon) Injection, BP",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02383233",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "200 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Calcitonin Salmon",
          "ndc-id": "",
          "ndc-product-code": "49884-161",
          "dpd-id": "",
          "started-marketing-on": "2009-06-08",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "200 [iU]/.09mL",
          "route": "nasal",
          "fda-application-number": "ANDA076979",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Calcitonin Salmon",
          "ndc-id": "",
          "ndc-product-code": "54868-6323",
          "dpd-id": "",
          "started-marketing-on": "2011-12-09",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "200 [iU]/.09mL",
          "route": "nasal",
          "fda-application-number": "ANDA076979",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Calcitonin Salmon",
          "ndc-id": "",
          "ndc-product-code": "0781-6320",
          "dpd-id": "",
          "started-marketing-on": "1995-08-01",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "200 [iU]/1",
          "route": "nasal",
          "fda-application-number": "NDA020313",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Calcitonin Salmon",
          "ndc-id": "",
          "ndc-product-code": "60505-0823",
          "dpd-id": "",
          "started-marketing-on": "2008-12-09",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "200 [iU]/1",
          "route": "nasal",
          "fda-application-number": "ANDA076396",
          "generic": "true",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Caltine Inj 100 Unit/ml (1ml Amp)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02007134",
          "started-marketing-on": "1993-12-31",
          "ended-marketing-on": "2014-07-25",
          "dosage-form": "liquid",
          "strength": "100 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Caltine Inj 100unit/ml (0.5ml Amp)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "01940376",
          "started-marketing-on": "1993-12-31",
          "ended-marketing-on": "2002-01-30",
          "dosage-form": "liquid",
          "strength": "100 unit",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Fortical",
          "ndc-id": "",
          "ndc-product-code": "54868-5499",
          "dpd-id": "",
          "started-marketing-on": "2005-12-30",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "2200 [iU]/mL",
          "route": "nasal",
          "fda-application-number": "NDA021406",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Fortical",
          "ndc-id": "",
          "ndc-product-code": "0245-0008",
          "dpd-id": "",
          "started-marketing-on": "2005-08-12",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "2200 [iU]/mL",
          "route": "nasal",
          "fda-application-number": "NDA021406",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Miacalcin",
          "ndc-id": "",
          "ndc-product-code": "54766-149",
          "dpd-id": "",
          "started-marketing-on": "1986-07-03",
          "ended-marketing-on": "2018-03-31",
          "dosage-form": "injection, solution",
          "strength": "200 [iU]/mL",
          "route": "intramuscular",
          "fda-application-number": "NDA017808",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Miacalcin",
          "ndc-id": "",
          "ndc-product-code": "0078-0149",
          "dpd-id": "",
          "started-marketing-on": "1986-07-03",
          "ended-marketing-on": "",
          "dosage-form": "injection, solution",
          "strength": "200 [iU]/mL",
          "route": "intramuscular; subcutaneous",
          "fda-application-number": "NDA017808",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Miacalcin",
          "ndc-id": "",
          "ndc-product-code": "0078-0311",
          "dpd-id": "",
          "started-marketing-on": "1995-08-01",
          "ended-marketing-on": "",
          "dosage-form": "spray, metered",
          "strength": "200 [iU]/1",
          "route": "nasal",
          "fda-application-number": "NDA020313",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Miacalcin Injection 200iu/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02144301",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "liquid",
          "strength": "200 unit",
          "route": "intramuscular; intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Miacalcin Nasal Spray 200 Iu",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02240775",
          "started-marketing-on": "1999-09-08",
          "ended-marketing-on": "2013-10-01",
          "dosage-form": "spray",
          "strength": "200 unit",
          "route": "nasal",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pro-calcitonin - 200",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02311046",
          "started-marketing-on": "2008-07-04",
          "ended-marketing-on": "2011-07-27",
          "dosage-form": "solution",
          "strength": "200 unit",
          "route": "nasal",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Sandoz-calcitonin NS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02261766",
          "started-marketing-on": "2004-12-01",
          "ended-marketing-on": "2013-10-01",
          "dosage-form": "liquid",
          "strength": "200 unit",
          "route": "nasal",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Calcimar",
        "company": ""
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Miacalcin",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Miacalcin",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Fortical",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Calcitonin Salmon",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Calcitonin Salmon",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Miacalcin",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Fortical",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Calcitonin Salmon",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Calcitonin Salmon",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Calcimar Solution Inj 200unit/ml",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Caltine Inj 100 Unit/ml (1ml Amp)",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Caltine Inj 100unit/ml (0.5ml Amp)",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Miacalcin Nasal Spray 200 Iu",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Apo-calcitonin Injectable",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Apo-calcitonin Nasal Spray",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Sandoz-calcitonin NS",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Pro-calcitonin - 200",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Miacalcin Injection 200iu/ml",
          "ingredients": "Salmon Calcitonin"
        },
        {
          "name": "Calcitonin (salmon) Injection, BP",
          "ingredients": "Salmon Calcitonin"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Apotex Inc.",
          "url": "http://www.apotex.com"
        },
        {
          "name": "Novartis AG",
          "url": "http://www.novartis.com"
        },
        {
          "name": "Par Pharmaceuticals",
          "url": "http://www.parpharm.com"
        },
        {
          "name": "Sandoz",
          "url": "http://www.sandoz.ca"
        },
        {
          "name": "Upsher Smith Laboratories",
          "url": "http://www.upsher-smith.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": [
        {
          "_generic": "false",
          "__text": "Sanofi aventis us llc"
        },
        {
          "_generic": "false",
          "__text": "Astrazeneca lp"
        },
        {
          "_generic": "false",
          "__text": "Novartis pharmaceuticals corp"
        },
        {
          "_generic": "false",
          "__text": "Apotex inc"
        },
        {
          "_generic": "false",
          "__text": "Par pharmaceutical inc"
        },
        {
          "_generic": "false",
          "__text": "Upsher smith laboratories inc"
        }
      ]
    },
    "prices": {
      "price": [
        {
          "description": "Caltine 100 (100 Iu/Ml) 100 iu/ml",
          "cost": {
            "_currency": "USD",
            "__text": "8.81"
          },
          "unit": "ml"
        },
        {
          "description": "Calcimar 200 iu/ml",
          "cost": {
            "_currency": "USD",
            "__text": "29.94"
          },
          "unit": "ml"
        },
        {
          "description": "Miacalcin 200 unit/ml vial",
          "cost": {
            "_currency": "USD",
            "__text": "30.73"
          },
          "unit": "ml"
        },
        {
          "description": "Fortical 200 unit nasal spray",
          "cost": {
            "_currency": "USD",
            "__text": "34.3"
          },
          "unit": "ml"
        },
        {
          "description": "Calcitonin-salmon 200 unit sp",
          "cost": {
            "_currency": "USD",
            "__text": "39.51"
          },
          "unit": "ml"
        },
        {
          "description": "Miacalcin 200 unit nasal spray",
          "cost": {
            "_currency": "USD",
            "__text": "44.68"
          },
          "unit": "ml"
        },
        {
          "description": "Miacalcin For Inj, 2 unit = 1 Box 2ml Vial",
          "cost": {
            "_currency": "USD",
            "__text": "63.59"
          },
          "unit": "vial"
        },
        {
          "description": "Calcitonin (Salmon) 200 unit/act Solution 3.7ml Bottle",
          "cost": {
            "_currency": "USD",
            "__text": "123.28"
          },
          "unit": "bottle"
        },
        {
          "description": "Miacalcin 200 unit/act Solution 3.7ml Bottle",
          "cost": {
            "_currency": "USD",
            "__text": "139.39"
          },
          "unit": "bottle"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Bone Density Conservation Agents",
          "mesh-id": "[\"D27.505.696.242\"]"
        },
        {
          "category": "Antihypercalcemic Agents",
          "mesh-id": "[]"
        },
        {
          "category": "Anti-Osteporotic Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Liquid",
          "route": "intramuscular; subcutaneous",
          "strength": "200 unit"
        },
        {
          "form": "Solution",
          "route": "nasal",
          "strength": "200 unit"
        },
        {
          "form": "Solution",
          "route": "intramuscular; subcutaneous",
          "strength": "200 unit"
        },
        {
          "form": "Spray, metered",
          "route": "nasal",
          "strength": "200 [iU]/.09mL"
        },
        {
          "form": "Liquid",
          "route": "intramuscular; subcutaneous",
          "strength": "100 unit"
        },
        {
          "form": "Spray, metered",
          "route": "nasal",
          "strength": "2200 [iU]/mL"
        },
        {
          "form": "Injection, solution",
          "route": "intramuscular",
          "strength": "200 [iU]/mL"
        },
        {
          "form": "Injection, solution",
          "route": "intramuscular; subcutaneous",
          "strength": "200 [iU]/mL"
        },
        {
          "form": "Spray, metered",
          "route": "nasal",
          "strength": "200 [iU]/1"
        },
        {
          "form": "Liquid",
          "route": "intramuscular; intravenous; subcutaneous",
          "strength": "200 unit"
        },
        {
          "form": "Spray",
          "route": "nasal",
          "strength": "200 unit"
        },
        {
          "form": "Liquid",
          "route": "nasal",
          "strength": "200 unit"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "H",
            "__text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"
          },
          {
            "_code": "H05",
            "__text": "CALCIUM HOMEOSTASIS"
          },
          {
            "_code": "H05B",
            "__text": "ANTI-PARATHYROID AGENTS"
          },
          {
            "_code": "H05BA",
            "__text": "Calcitonin preparations"
          }
        ],
        "_code": "H05BA01"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "68:24.00"
    },
    "patents": {
      "patent": [
        {
          "number": "5733569",
          "country": "United States",
          "approved": "1995-03-31",
          "expires": "2015-03-31"
        },
        {
          "number": "6440392",
          "country": "United States",
          "approved": "2001-02-02",
          "expires": "2021-02-02"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB01356",
          "name": "Lithium",
          "description": "The serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin."
        },
        {
          "drugbank-id": "DB00399",
          "name": "Zoledronate",
          "description": "Salmon Calcitonin may increase the  activities of Zoledronate."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00017 sequence\nCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "-0.537",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "8.86",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "3431.853",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C145H240N44O48S2",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "13186"
        },
        {
          "resource": "KEGG Compound",
          "identifier": "C06865"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D00249"
        },
        {
          "resource": "GenBank",
          "identifier": "Y00765"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA448715"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01263"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Calcitonin"
        }
      ]
    },
    "external-links": {
      "external-link": {
        "resource": "RxList",
        "url": "http://www.rxlist.com/cgi/generic2/calcit.htm"
      }
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000431",
        "name": "Calcitonin receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# Bouizar Z, Fouchereau-Peron M, Taboulet J, Moukhtar MS, Milhaud G: Purification and characterization of calcitonin receptors in rat kidney membranes by covalent cross-linking techniques. Eur J Biochem. 1986 Feb 17;155(1):141-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3004987\r\n# Stroop SD, Moore EE: Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res. 1995 Apr;10(4):524-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7610922\r\n# Sarkar A, Dickerson IM: Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain. J Neurochem. 1997 Aug;69(2):455-64. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9231703\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "unknown",
        "polypeptide": {
          "name": "Calcitonin receptor",
          "general-function": "Receptor activity",
          "specific-function": "This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin.",
          "gene-name": "CALCR",
          "locus": "7q21.3",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "172-191\n215-234\n255-277\n295-314\n331-354\n378-395\n408-429",
          "signal-regions": "1-42",
          "theoretical-pi": "8.71",
          "molecular-weight": "59351.865",
          "chromosome-location": "7",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:1440"
              },
              {
                "resource": "GenAtlas",
                "identifier": "CALCR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "L00587"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "179880"
              },
              {
                "resource": "IUPHAR",
                "identifier": "43"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "43"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P30988"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "CALCR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": "CT-R"
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0037016|Calcitonin receptor\nMQFSGEKISGQRDLQKSKMRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYV\nVGRKKMMDAQYKCYDRMQQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDF\nDPSEKVTKYCDEKGVWFKHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFT\nLVISLGIFVFFRKLTTIFPLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVV\nPNGELVRRDPVSCKILHFFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLG\nWGFPLVPTTIHAITRAVYFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTK\nMRETHEAESHMYLKAVKATMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFF\nVATIYCFCNNEVQTTVKRQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQE\nPRNEPANNQGEESAEIIPLNIIEQESSA"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0010301|Calcitonin receptor (CALCR)\nATGCAATTTTCTGGAGAGAAGATTAGTGGACAAAGAGATCTTCAAAAATCAAAAATGAGG\nTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACCCCAATT\nCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTTTACGTC\nGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAGCAGTTA\nCCCGCATACCAAGGAGAAGGTCCATATTGCAATCGCACCTGGGATGGATGGCTGTGCTGG\nGATGACACACCGGCTGGAGTATTGTCCTATCAGTTCTGCCCAGATTATTTTCCGGATTTT\nGATCCATCAGAAAAGGTTACAAAATACTGTGATGAAAAAGGTGTTTGGTTTAAACATCCT\nGAAAACAATCGAACCTGGTCCAACTATACTATGTGCAATGCTTTCACTCCTGAGAAACTG\nAAGAATGCATATGTTCTGTACTATTTGGCTATTGTGGGTCATTCTTTGTCAATTTTCACC\nCTAGTGATTTCCCTGGGGATTTTCGTGTTTTTCAGAAAATTGACAACTATTTTTCCTTTG\nAATTGGAAATATAGGAAGGCATTGAGCCTTGGCTGCCAAAGGGTAACCCTGCACAAGAAC\nATGTTTCTTACTTACATTCTGAATTCTATGATTATCATCATCCACCTGGTTGAAGTAGTA\nCCCAATGGAGAGCTCGTGCGAAGGGACCCGGTGAGCTGCAAGATTTTGCATTTTTTCCAC\nCAGTACATGATGGCCTGCAACTATTTCTGGATGCTCTGTGAAGGGATCTATCTTCATACA\nCTCATTGTCGTGGCTGTGTTTACTGAGAAGCAACGCTTGCGGTGGTATTATCTCTTGGGC\nTGGGGGTTCCCGCTGGTGCCAACCACTATCCATGCTATTACCAGGGCCGTGTACTTCAAT\nGACAACTGCTGGCTGAGTGTGGAAACCCATTTGCTTTACATAATCCATGGACCTGTCATG\nGCGGCACTTGTGGTCAATTTCTTCTTTTTGCTCAACATTGTCCGGGTGCTTGTGACCAAA\nATGAGGGAAACCCATGAGGCGGAATCCCACATGTACCTGAAGGCTGTGAAGGCCACCATG\nATCCTTGTGCCCCTGCTGGGAATCCAGTTTGTCGTCTTTCCCTGGAGACCTTCCAACAAG\nATGCTTGGGAAGATATATGATTACGTGATGCACTCTCTGATTCATTTCCAGGGCTTCTTT\nGTTGCGACCATCTACTGCTTCTGCAACAATGAGGTCCAAACCACCGTGAAGCGCCAATGG\nGCCCAATTCAAAATTCAGTGGAACCAGCGTTGGGGGAGGCGCCCCTCCAACCGCTCTGCT\nCGCGCTGCAGCCGCTGCTGCGGAGGCTGGCGACATCCCAATTTACATCTGCCATCAGGAG\nCTGAGGAATGAACCAGCCAACAACCAAGGCGAGGAGAGTGCTGAGATCATCCCTTTGAAT\nATCATAGAGCAAGAGTCATCTGCTTGA"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00002",
                "name": "7tm_2"
              },
              {
                "identifier": "PF02793",
                "name": "HRM"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "integral component of plasma membrane"
              },
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "cytosol"
              },
              {
                "category": "function",
                "description": "calcitonin binding"
              },
              {
                "category": "function",
                "description": "receptor activity"
              },
              {
                "category": "function",
                "description": "calcitonin receptor activity"
              },
              {
                "category": "function",
                "description": "protein transporter activity"
              },
              {
                "category": "process",
                "description": "positive regulation of cytosolic calcium ion concentration"
              },
              {
                "category": "process",
                "description": "receptor internalization"
              },
              {
                "category": "process",
                "description": "G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "cell surface receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "protein localization to plasma membrane"
              },
              {
                "category": "process",
                "description": "protein transport"
              },
              {
                "category": "process",
                "description": "response to glucocorticoid"
              },
              {
                "category": "process",
                "description": "positive regulation of cAMP biosynthetic process"
              },
              {
                "category": "process",
                "description": "adenylate cyclase-activating G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "positive regulation of adenylate cyclase activity"
              }
            ]
          },
          "_id": "P30988",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-11-27"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00018"
      },
      "BIOD00023",
      "BTD00023"
    ],
    "name": "Interferon alfa-n3",
    "description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).",
    "cas-number": "",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# Sturgill MG, Rashidbaigi A, Liao MJ, Zhao XX, Hua J, Trout R, Knill JR, Grasing KW: Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity. J Clin Pharmacol. 2000 Jun;40(6):606-15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10868311",
    "synthesis-reference": "",
    "indication": "For the intralesional treatment of refractory or recurring external condylomata acuminata.",
    "pharmacodynamics": "Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.",
    "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": "",
    "products": {
      "product": {
        "name": "Alferon",
        "ndc-id": "",
        "ndc-product-code": "54746-001",
        "dpd-id": "",
        "started-marketing-on": "1989-10-10",
        "ended-marketing-on": "",
        "dosage-form": "injection",
        "strength": "5000000 [arb'U]/mL",
        "route": "subcutaneous",
        "fda-application-number": "BLA103158",
        "generic": "false",
        "over-the-counter": "false",
        "approved": "true",
        "country": "US",
        "source": "FDA NDC"
      }
    },
    "international-brands": {
      "international-brand": [
        {
          "name": "Alferon",
          "company": "Interferon Sciences Inc."
        },
        {
          "name": "Alferon LDO",
          "company": ""
        },
        {
          "name": "Alferon N Injection",
          "company": ""
        }
      ]
    },
    "mixtures": {
      "mixture": {
        "name": "Alferon",
        "ingredients": "Interferon alfa-n3"
      }
    },
    "packagers": {
      "packager": {
        "name": "Hemispherx Biopharma Inc.",
        "url": "http://www.hemispherx.net"
      }
    },
    "manufacturers": "",
    "prices": {
      "price": {
        "description": "Alferon n 5 million unit vial",
        "cost": {
          "_currency": "USD",
          "__text": "412.87"
        },
        "unit": "ml"
      }
    },
    "categories": {
      "category": {
        "category": "Immunosuppressive Agents",
        "mesh-id": "[\"D27.505.696.477.656\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": {
        "form": "Injection",
        "route": "subcutaneous",
        "strength": "5000000 [arb'U]/mL"
      }
    },
    "atc-codes": "",
    "ahfs-codes": "",
    "patents": "",
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00041",
          "name": "Aldesleukin",
          "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin."
        },
        {
          "drugbank-id": "DB00363",
          "name": "Clozapine",
          "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clozapine."
        },
        {
          "drugbank-id": "DB04817",
          "name": "Metamizole",
          "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Interferon alfa-n3."
        },
        {
          "drugbank-id": "DB00333",
          "name": "Methadone",
          "description": "The serum concentration of Methadone can be increased when it is combined with Interferon alfa-n3."
        },
        {
          "drugbank-id": "DB00811",
          "name": "Ribavirin",
          "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ribavirin."
        },
        {
          "drugbank-id": "DB00277",
          "name": "Theophylline",
          "description": "The metabolism of Theophylline can be decreased when combined with Interferon alfa-n3."
        },
        {
          "drugbank-id": "DB00495",
          "name": "Zidovudine",
          "description": "The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Zidovudine."
        }
      ]
    },
    "sequences": {
      "sequence": [
        {
          "_format": "FASTA",
          "__text": ">DB00018 sequence (alpha-2A)\nCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"
        },
        {
          "_format": "FASTA",
          "__text": ">DB00018 sequence (alpha-2B)\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"
        },
        {
          "_format": "FASTA",
          "__text": ">DB00018 sequence (alpha-2C)\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"
        }
      ]
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "61 °C",
          "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"
        },
        {
          "kind": "Isoelectric Point",
          "value": "5.99",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": {
        "resource": "PharmGKB",
        "identifier": "PA164746228"
      }
    },
    "external-links": {
      "external-link": {
        "resource": "Drugs.com",
        "url": "http://www.drugs.com/cdi/interferon-alfa-n3-solution.html"
      }
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000661",
          "name": "Interferon alpha/beta receptor 1",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 1",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.",
            "gene-name": "IFNAR1",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "437-457",
            "signal-regions": "1-27",
            "theoretical-pi": "5.56",
            "molecular-weight": "63524.81",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5432"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J03171"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "306914"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1723"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P17181"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CRF2-1",
                "Cytokine receptor class-II member 1",
                "Cytokine receptor family 2 member 1",
                "IFN-R-1",
                "IFNAR",
                "Type I interferon receptor 1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-beta production"
                },
                {
                  "category": "process",
                  "description": "regulation of peptidyl-tyrosine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "type I interferon biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-gamma production"
                },
                {
                  "category": "process",
                  "description": "T cell activation"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "defense response to virus"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-1 beta secretion"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                }
              ]
            },
            "_id": "P17181",
            "_source": "Swiss-Prot"
          }
        },
        {
          "id": "BE0000385",
          "name": "Interferon alpha/beta receptor 2",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 2",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.",
            "gene-name": "IFNAR2",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "244-264",
            "signal-regions": "1-26",
            "theoretical-pi": "4.11",
            "molecular-weight": "57758.24",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5433"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L42243"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "995300"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P48551"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IFN-R-2",
                "IFNABR",
                "IFNARB",
                "Interferon alpha binding protein",
                "Type I interferon receptor 2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protein kinase binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to interferon-alpha"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                }
              ]
            },
            "_id": "P48551",
            "_source": "Swiss-Prot"
          }
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2010-09-29"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00019"
      },
      "BIOD00094",
      "BTD00094"
    ],
    "name": "Pegfilgrastim",
    "description": "PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation.",
    "cas-number": "208265-92-3",
    "groups": {
      "group": "approved"
    },
    "general-references": "# Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May 1;50(5):295-306. doi: 10.2165/11586040-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21456630",
    "synthesis-reference": "",
    "indication": "Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant",
    "pharmacodynamics": "Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.",
    "mechanism-of-action": "Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "15-80 hrs",
    "protein-binding": "",
    "route-of-elimination": "Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. Pegylation of filgrastim renders renal clearance insignificant, which was demonstrated in bilaterally nephrectomized rats and confirmed in subjects with renal impairment. As a result, the neutrophil-mediated clearance is the predominant elimination pathway for pegfilgrastim. During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery.",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "G-CSF"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Granulocyte colony-stimulating factor precursor"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Lenograstim"
        },
        {
          "_language": "",
          "_coder": "IUPAC",
          "__text": "N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Pluripoietin"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Neulasta",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02249790",
          "started-marketing-on": "2004-03-12",
          "ended-marketing-on": "",
          "dosage-form": "solution",
          "strength": "10 mg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Neulasta",
          "ndc-id": "",
          "ndc-product-code": "55513-190",
          "dpd-id": "",
          "started-marketing-on": "2002-04-01",
          "ended-marketing-on": "",
          "dosage-form": "injection",
          "strength": "6 mg/.6mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA125031",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Neulasta",
          "ndc-id": "",
          "ndc-product-code": "55513-192",
          "dpd-id": "",
          "started-marketing-on": "2002-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "subcutaneous",
          "fda-application-number": "BLA125031",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Neulasta",
          "ingredients": "Pegfilgrastim"
        },
        {
          "name": "Neulasta",
          "ingredients": "Pegfilgrastim"
        },
        {
          "name": "Neulasta",
          "ingredients": "Pegfilgrastim"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Amgen Inc.",
          "url": "http://www.amgen.com"
        },
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Neulasta 6 mg/0.6ml Solution 0.6ml Syringe",
          "cost": {
            "_currency": "USD",
            "__text": "4026.05"
          },
          "unit": "syringe"
        },
        {
          "description": "Neulasta 6 mg/0.6 ml syringe",
          "cost": {
            "_currency": "USD",
            "__text": "4102.37"
          },
          "unit": "syringe"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Immunosuppressive Agents",
          "mesh-id": "[\"D27.505.696.477.656\"]"
        },
        {
          "category": "Antineutropenic Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": "",
    "dosages": {
      "dosage": [
        {
          "form": "Injection",
          "route": "subcutaneous",
          "strength": "6 mg/.6mL"
        },
        {
          "form": "Kit",
          "route": "subcutaneous",
          "strength": ""
        },
        {
          "form": "Solution",
          "route": "subcutaneous",
          "strength": "10 mg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L03",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03A",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03AA",
            "__text": "Colony stimulating factors"
          }
        ],
        "_code": "L03AA13"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "20:16.00"
    },
    "patents": {
      "patent": [
        {
          "number": "1339071",
          "country": "Canada",
          "approved": "1997-07-29",
          "expires": "2014-07-29"
        },
        {
          "number": "1341537",
          "country": "Canada",
          "approved": "2007-07-31",
          "expires": "2024-07-31"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": {
        "drugbank-id": "DB09208",
        "name": "Pegloticase",
        "description": "The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Pegloticase."
      }
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": "> Pegfilgrastim sequence\nMTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA\nPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ\nQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "60 °C",
          "source": "Luo, P., Protein Science 11:1218-1226 (2002)"
        },
        {
          "kind": "Hydrophobicity",
          "value": "0.209",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "5.65",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "18802.8",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C845H1343N223O243S9",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "12313"
        },
        {
          "resource": "KEGG Drug",
          "identifier": "D06889"
        },
        {
          "resource": "GenBank",
          "identifier": "X03438"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164781387"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P09919"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Pegfilgrastim"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic3/neulasta.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/pegfilgrastim.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000793",
          "name": "Granulocyte colony-stimulating factor receptor",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17001306\r\n# Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G: The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003 Aug 28;22(36):5646-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12944913\r\n# Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17127322\r\n# Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16033816\r\n# Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients] Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15949269\r\n# Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15082029",
          "known-action": "yes",
          "polypeptide": {
            "name": "Granulocyte colony-stimulating factor receptor",
            "general-function": "Receptor activity",
            "specific-function": "Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differientation and survival of cells along the neutrophilic lineage. In addition it may function in some adhesion or recognition events at the cell surface.",
            "gene-name": "CSF3R",
            "locus": "1p35-p34.3",
            "cellular-location": "Secreted",
            "transmembrane-regions": "628-650",
            "signal-regions": "1-24",
            "theoretical-pi": "6.14",
            "molecular-weight": "92155.615",
            "chromosome-location": "1",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:2439"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "CSF3R"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X55721"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "31697"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q99062"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "CSF3R_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "G-CSF receptor",
                "GCSFR"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001582|Granulocyte colony-stimulating factor receptor\nMARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ\nILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG\nYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK\nDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE\nAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA\nTAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP\nLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT\nPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME\nQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK\nTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL\nMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP\nSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL\nPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL\nTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010560|Granulocyte colony-stimulating factor receptor (CSF3R)\nATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC\nGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT\nCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG\nATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT\nGGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC\nTGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC\nTACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC\nATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT\nTTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG\nGACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC\nATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT\nCCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA\nGCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG\nCACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA\nCTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC\nACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC\nTGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA\nTGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC\nCTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG\nGCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT\nTCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGTCCCACT\nCCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA\nGACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG\nATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA\nCAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT\nGAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC\nTACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG\nACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC\nCACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC\nTCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC\nATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC\nCCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC\nTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA\nAGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG\nGATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG\nGAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC\nCCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC\nCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA\nAGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC\nACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG\nGTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC\nCTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00041",
                  "name": "fn3"
                },
                {
                  "identifier": "PF06328",
                  "name": "Lep_receptor_Ig"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "cytokine receptor activity"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "process",
                  "description": "neutrophil chemotaxis"
                },
                {
                  "category": "process",
                  "description": "amelogenesis"
                },
                {
                  "category": "process",
                  "description": "regulation of myeloid cell differentiation"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "cell adhesion"
                },
                {
                  "category": "process",
                  "description": "defense response"
                }
              ]
            },
            "_id": "Q99062",
            "_source": "Swiss-Prot"
          }
        },
        {
          "id": "BE0000394",
          "name": "Neutrophil elastase",
          "organism": "Human",
          "actions": "",
          "references": "# Carter CR, Whitmore KM, Thorpe R: The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14657210\r\n# Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K: Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats. Inflammation. 2004 Dec;28(6):327-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16245075\r\n# Pelus LM, Bian H, King AG, Fukuda S: Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004 Jan 1;103(1):110-9. Epub 2003 Sep 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12958067\r\n# Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR: Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005 Jan 15;105(2):584-91. Epub 2004 Sep 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15353486\r\n# Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ: Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17475913",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Neutrophil elastase",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis.",
            "gene-name": "ELANE",
            "locus": "19p13.3",
            "cellular-location": "Cytoplasmic",
            "transmembrane-regions": "",
            "signal-regions": "1-27",
            "theoretical-pi": "9.41",
            "molecular-weight": "28517.81",
            "chromosome-location": "19",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3309"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "ELA2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "Y00477"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "296665"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2358"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P08246"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "ELNE_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.37",
                "Bone marrow serine protease",
                "ELA2",
                "Elastase-2",
                "HLE",
                "Human leukocyte elastase",
                "Medullasin",
                "PMN elastase"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000785|Neutrophil elastase\nMTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI\nAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI\nLQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL\nCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN\nWIDSIIQRSEDNPCPHPRDPDPASRTH"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010273|Neutrophil elastase (ELANE)\nATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG\nCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG\nTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT\nGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG\nCGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC\nGTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT\nCTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT\nCAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC\nAGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC\nTGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG\nGACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG\nGGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC\nTGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG\nGACCCGGCCAGCAGGACCCACTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00089",
                "name": "Trypsin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "secretory granule"
                },
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "transcriptional repressor complex"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "cytokine binding"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "peptidase activity"
                },
                {
                  "category": "function",
                  "description": "heparin binding"
                },
                {
                  "category": "function",
                  "description": "endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "RNA polymerase II transcription corepressor activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of inflammatory response"
                },
                {
                  "category": "process",
                  "description": "acute inflammatory response to antigenic stimulus"
                },
                {
                  "category": "process",
                  "description": "response to lipopolysaccharide"
                },
                {
                  "category": "process",
                  "description": "negative regulation of chemokine biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "negative regulation of chemotaxis"
                },
                {
                  "category": "process",
                  "description": "cellular calcium ion homeostasis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of growth of symbiont in host"
                },
                {
                  "category": "process",
                  "description": "positive regulation of MAP kinase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of interleukin-8 biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of smooth muscle cell proliferation"
                },
                {
                  "category": "process",
                  "description": "neutrophil mediated killing of fungus"
                },
                {
                  "category": "process",
                  "description": "collagen catabolic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of immune response"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix disassembly"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-8 biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "phagocytosis"
                },
                {
                  "category": "process",
                  "description": "protein catabolic process"
                },
                {
                  "category": "process",
                  "description": "leukocyte migration"
                },
                {
                  "category": "process",
                  "description": "response to UV"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "defense response to bacterium"
                },
                {
                  "category": "process",
                  "description": "response to yeast"
                }
              ]
            },
            "_id": "P08246",
            "_source": "Swiss-Prot"
          }
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2011-12-20"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00020"
      },
      "BIOD00035",
      "BTD00035"
    ],
    "name": "Sargramostim",
    "description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.",
    "cas-number": "83869-56-1",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "",
    "synthesis-reference": "Kaname Sugimoto, \"Process for the production of human colony-stimulating factor.\" U.S. Patent US4621050, issued May, 1983.",
    "indication": "For the treatment of cancer and bone marrow transplant",
    "pharmacodynamics": "Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.",
    "mechanism-of-action": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "* 420 mL/min/m2 [Normal people with liquid LEUKINE (IV)]\r\n* 431 mL/min/m2 [Normal people with lyophilized LEUKINE (IV)]\r\n* 549 mL/min/m2 [Normal people with liquid LEUKINE (SC)]\r\n* 529 mL/min/m2 [Normal people with lyophilized LEUKINE (SC)]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": {
        "_language": "",
        "_coder": "",
        "__text": "GM-CSF"
      }
    },
    "products": {
      "product": [
        {
          "name": "Leukine",
          "ndc-id": "",
          "ndc-product-code": "0024-5843",
          "dpd-id": "",
          "started-marketing-on": "1991-05-01",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, for solution",
          "strength": "250 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103362",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leukine",
          "ndc-id": "",
          "ndc-product-code": "0024-5844",
          "dpd-id": "",
          "started-marketing-on": "1996-12-01",
          "ended-marketing-on": "",
          "dosage-form": "liquid",
          "strength": "500 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103362",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Leukine",
          "ndc-id": "",
          "ndc-product-code": "58468-0180",
          "dpd-id": "",
          "started-marketing-on": "2010-03-15",
          "ended-marketing-on": "2016-06-30",
          "dosage-form": "injection, powder, for solution",
          "strength": "250 ug/mL",
          "route": "intravenous; subcutaneous",
          "fda-application-number": "BLA103362",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Leucomax",
        "company": "Novartis"
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Leukine",
          "ingredients": "Sargramostim"
        },
        {
          "name": "Leukine",
          "ingredients": "Sargramostim"
        },
        {
          "name": "Leukine",
          "ingredients": "Sargramostim"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Bayer Healthcare",
          "url": "http://www.bayerhealthcare.com"
        },
        {
          "name": "Genzyme Inc.",
          "url": "http://www.genzyme.ca"
        },
        {
          "name": "Hospira Inc.",
          "url": "http://www.hospira.com"
        },
        {
          "name": "Kramer-Novis",
          "url": "http://www.kramernovis.com"
        },
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        },
        {
          "name": "Wyeth Pharmaceuticals",
          "url": "http://www.wyeth.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Leukine 250 mcg vial",
          "cost": {
            "_currency": "USD",
            "__text": "204.79"
          },
          "unit": "vial"
        },
        {
          "description": "Bio-immunex capsule",
          "cost": {
            "_currency": "USD",
            "__text": "0.42"
          },
          "unit": "capsule"
        }
      ]
    },
    "categories": {
      "category": {
        "category": "Immunosuppressive Agents",
        "mesh-id": "[\"D27.505.696.477.656\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Injection, powder, for solution",
          "route": "intravenous; subcutaneous",
          "strength": "250 ug/mL"
        },
        {
          "form": "Liquid",
          "route": "intravenous; subcutaneous",
          "strength": "500 ug/mL"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L03",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03A",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03AA",
            "__text": "Colony stimulating factors"
          }
        ],
        "_code": "L03AA09"
      }
    },
    "ahfs-codes": "",
    "patents": {
      "patent": {
        "number": "1341150",
        "country": "Canada",
        "approved": "2000-12-05",
        "expires": "2017-12-05"
      }
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB00290",
          "name": "Bleomycin",
          "description": "The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin."
        },
        {
          "drugbank-id": "DB00531",
          "name": "Cyclophosphamide",
          "description": "The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00020 sequence\nAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE\nLYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFD\nCWEPVQE"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Isoelectric Point",
          "value": "5.05",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "14434.5",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C639H1006N168O196S8",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "GenBank",
          "identifier": "M13207"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164748631"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P04141"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Sargramostim"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic/sargramostim.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/sargramostim.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000628",
          "name": "Granulocyte-macrophage colony-stimulating factor receptor subunit alpha",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17090651\r\n# Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem. 2006 Aug 4;281(31):22421-6. Epub 2006 Jun 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16760463\r\n# Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17522711\r\n# Xiao R, Zhang R, Wang YL, Zhu ZL, Chen T, Yang JH: [Expression of soluble GM-CSF-Ralpha in patients with acute myeloid leukemia] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):225-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16638185\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Granulocyte-macrophage colony-stimulating factor receptor subunit alpha",
            "general-function": "Receptor activity",
            "specific-function": "Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells.",
            "gene-name": "CSF2RA",
            "locus": "Xp22.32 and Yp11.3",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "321-346",
            "signal-regions": "1-22",
            "theoretical-pi": "7.81",
            "molecular-weight": "46206.185",
            "chromosome-location": "X, Y",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:2435"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "CSF2RA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X17648"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "32089"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1707"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P15509"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "CSF2R_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CDw116",
                "CSF2R",
                "CSF2RY",
                "GM-CSF-R-alpha"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001252|Granulocyte-macrophage colony-stimulating factor receptor subunit alpha\nMLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKC\nFLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTA\nAQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHL\nDNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQP\nRTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAAD\nVRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVP\nQIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016159|Granulocyte-macrophage colony-stimulating factor receptor subunit alpha (CSF2RA)\nATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTG\nATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTT\nGACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGT\nTTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCG\nTGCACATTTCGTGAAATTTGTCTGCATGAAGGAGTCACATTTGAGGTTCACGTGAATACT\nAGTCAAAGAGGATTTCAACAGAAACTGCTTTATCCAAATTCAGGAAGGGAGGGTACCGCT\nGCTCAGAATTTCTCCTGTTTCATCTACAATGCGGATTTAATGAACTGTACCTGGGCGAGG\nGGTCCGACGGCCCCCCGTGACGTCCAGTATTTTTTGTACATACGAAACTCAAAGAGAAGG\nAGGGAGATCCGGTGTCCTTATTACATACAAGACTCAGGAACCCATGTGGGATGTCACCTG\nGATAACCTGTCAGGATTAACGTCTCGCAATTACTTTCTGGTTAACGGAACCAGCCGAGAA\nATTGGCATCCAATTCTTTGATTCACTTTTGGACACAAAGAAAATAGAACGATTCAACCCT\nCCCAGCAATGTCACCGTACGTTGCAACACGACGCACTGCCTCGTACGGTGGAAACAGCCC\nAGGACCTATCAGAAGCTGTCGTACCTGGACTTTCAGTACCAGCTGGACGTCCACAGAAAG\nAATACCCAGCCTGGCACGGAAAACCTACTGATTAATGTTTCTGGTGATTTGGAAAATAGA\nTACAACTTTCCAAGCTCTGAGCCCAGAGCAAAACACAGTGTGAAGATCAGAGCTGCAGAC\nGTCCGCATCTTGAATTGGAGCTCCTGGAGTGAAGCCATTGAATTTGGTTCTGACGACGGG\nAACCTCGGCTCTGTGTACATTTATGTGCTCCTAATCGTGGGAACCCTTGTCTGTGGCATC\nGTCCTCGGCTTCCTCTTTAAAAGGTTCCTTAGGATACAGCGGCTGTTCCCGCCAGTTCCA\nCAGATCAAAGACAAACTGAATGATAACCATGAGGTGGAAGACGAGATCATCTGGGAGGAA\nTTCACCCCAGAGGAAGGGAAAGGCTACCGCGAAGAGGTCTTGACCGTGAAGGAAATTACC\nTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF09240",
                "name": "IL6Ra-bind"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "granulocyte colony-stimulating factor receptor activity"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "cellular response to granulocyte macrophage colony-stimulating factor stimulus"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                }
              ]
            },
            "_id": "P15509",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0001036",
          "name": "Interleukin-3 receptor subunit alpha",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007 Aug;35(8):1163-71. Epub 2007 Jun 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17562355\r\n# Sakhno LV, Leplina OIu, Tikhonova MA, Raspai ZhM, Gileva IP, Nikonov SD, Zhdanov OA, Ostanin AA, Chernykh ER: [Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis] Probl Tuberk Bolezn Legk. 2007;(3):42-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17500228\r\n# Ward KA, Stewart LA, Schwarer AP: CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy. 2006;8(2):130-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16698686\r\n# Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17522711",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interleukin-3 receptor subunit alpha",
            "general-function": "Interleukin-3 receptor activity",
            "specific-function": "This is a receptor for interleukin-3.",
            "gene-name": "IL3RA",
            "locus": "Xp22.3 or Yp11.3",
            "cellular-location": "Membrane",
            "transmembrane-regions": "306-325",
            "signal-regions": "1-18",
            "theoretical-pi": "8.32",
            "molecular-weight": "43329.585",
            "chromosome-location": "X, Y",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6012"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IL3RA"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M74782"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "186331"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P26951"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "IL3RA_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IL-3 receptor subunit alpha",
                "IL3R"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0002063|Interleukin-3 receptor subunit alpha\nMVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM\nPAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL\nSCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS\nHILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL\nQIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN\nTRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG\nKAGLEECLVTEVQVVQKT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0020503|Interleukin-3 receptor subunit alpha (IL3RA)\nATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAG\nGAAGGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGAT\nTTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTG\nTACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCT\nCAGGGAACACGTATCGGGTGTCGTTTCGATGACATCTCTCGACTCTCCAGCGGTTCTCAA\nAGTTCCCACATCCTGGTGCGGGGCAGGAGCGCAGCCTTCGGTATCCCCTGCACAGATAAG\nTTTGTCGTCTTTTCACAGATTGAGATATTAACTCCACCCAACATGACTGCAAAGTGTAAT\nAAGACACATTCCTTTATGCACTGGAAAATGAGAAGTCATTTCAATCGCAAATTTCGCTAT\nGAGCTTCAGATACAAAAGAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACC\nTCCTTCCAGCTACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGGAAAGAGTG\nTATGAATTCTTGAGCGCCTGGAGCACCCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGGC\nGCAAACACACGTGCCTGGCGGACGTCGCTGCTGATCGCGCTGGGGACGCTGCTGGCCCTG\nGTCTGTGTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTCTTTCCCCGCATC\nCCTCACATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACAAGCTGGTGGTCTGGGAG\nGCGGGCAAAGCCGGCCTGGAGGAGTGTCTGGTGACTGAAGTACAGGTCGTGCAGAAAACT\nTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF09240",
                "name": "IL6Ra-bind"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "interleukin-3 receptor activity"
                },
                {
                  "category": "process",
                  "description": "interleukin-3-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                },
                {
                  "category": "process",
                  "description": "cellular response to interleukin-3"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                }
              ]
            },
            "_id": "P26951",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0002115",
          "name": "Cytokine receptor common subunit beta",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Shen Y, Baker E, Callen DF, Sutherland GR, Willson TA, Rakar S, Gough NM: Localization of the human GM-CSF receptor beta chain gene (CSF2RB) to chromosome 22q12.2-->q13.1. Cytogenet Cell Genet. 1992;61(3):175-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1424804",
          "known-action": "yes",
          "polypeptide": {
            "name": "Cytokine receptor common subunit beta",
            "general-function": "Receptor activity",
            "specific-function": "High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor.",
            "gene-name": "CSF2RB",
            "locus": "22q13.1",
            "cellular-location": "Membrane",
            "transmembrane-regions": "444-460",
            "signal-regions": "1-16",
            "theoretical-pi": "5.21",
            "molecular-weight": "97334.89",
            "chromosome-location": "22",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:2436"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "CSF2RB"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M59941"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "487425"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P32927"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "IL3RB_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CDw131",
                "GM-CSF/IL-3/IL-5 receptor common beta subunit",
                "IL3RB",
                "IL5RB"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004148|Cytokine receptor common subunit beta\nMVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVT\nLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLG\nTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQD\nSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPG\nDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSL\nHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWET\nMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTG\nYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPN\nPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIE\nDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSR\nSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQ\nGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFT\nPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSP\nRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPS\nSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011533|Cytokine receptor common subunit beta (CSF2RB)\nATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGC\nCTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACC\nAGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACC\nCTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGAC\nATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCAGGAGATGTGTCATTCCCTGC\nCAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAGGCCTCTGGGC\nACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG\nATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAG\nAGCCACTGGTTGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGAC\nTCTTGGGAGGACGCAGCCATCCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAG\nCACCTCATGCCCAGCAGCACCTACGTGGCCCGAGTACGGACCCGCCTGGCCCCAGGTTCT\nCGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTTGCTGGGACTCCCAGCCAGGG\nGATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGTGCTCAGCTGC\nTCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC\nAGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTC\nCACACCAGGCACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATC\nGTCTCTGTTCAGCCAAGGAGGGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATG\nGCCCCTCCATCCCTCAACGTGACCAAGGATGGAGACAGCTACAGCCTGCGCTGGGAAACA\nATGAAAATGCGATACGAACACATAGACCACACATTTGAGATCCAGTACAGGAAAGACACG\nGCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCATGGCCCTGCCA\nGCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC\nTACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG\nCCTATGTGGGTGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTC\nCGCTTCTGTGGCATCTACGGGTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAAC\nCCCAGCAAGAGCCACCTGTTCCAGAACGGGAGCGCAGAGCTTTGGCCCCCAGGCAGCATG\nTCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGTGGGGCAGCCGCTTCCCTGAG\nCTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCTCACCATAGAG\nGACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT\nCTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCT\nGAGAAACAGGCTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGC\nTCCCTACCTGACATCCTGGGCCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCC\nCCACCTCCAGGGTCCCTGGAGTACCTGTGTCTGCCTGCTGGGGGGCAGGTGCAACTGGTC\nCCTCTGGCCCAGGCGATGGGACCAGGACAGGCCGTGGAAGTGGAGAGAAGGCCGAGCCAG\nGGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCCTGCTCTTGGG\nCCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG\nGACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACC\nCCAAACTCAGGGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAG\nACCCCCAGCTTATGTCCTGGGCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAG\nTCAGGGTTTGAGGGCTATGTGGAGCTCCCTCCAATTGAGGGCCGGTCCCCCAGGTCACCA\nAGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCCTGAACCCAGGGGAACGCCCG\nGCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCAGCAAGTGGGC\nGACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT\nTCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCC\nCCAGGCCAGGCTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAG\nGACTACCTGTCTCTGCCCCCTTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00041",
                  "name": "fn3"
                },
                {
                  "identifier": "PF09240",
                  "name": "IL6Ra-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "granulocyte macrophage colony-stimulating factor receptor complex"
                },
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "cytokine receptor activity"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "process",
                  "description": "Ras protein signal transduction"
                },
                {
                  "category": "process",
                  "description": "epidermal growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "vascular endothelial growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "innate immune response"
                },
                {
                  "category": "process",
                  "description": "respiratory gaseous exchange"
                },
                {
                  "category": "process",
                  "description": "Fc-epsilon receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "cellular response to interleukin-3"
                },
                {
                  "category": "process",
                  "description": "activation of MAPKK activity"
                },
                {
                  "category": "process",
                  "description": "interleukin-3-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "fibroblast growth factor receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "interleukin-5-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "signal transduction"
                },
                {
                  "category": "process",
                  "description": "insulin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "MAPK cascade"
                },
                {
                  "category": "process",
                  "description": "small GTPase mediated signal transduction"
                },
                {
                  "category": "process",
                  "description": "neurotrophin TRK receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                }
              ]
            },
            "_id": "P32927",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0002116",
          "name": "Syndecan-2",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Modrowski D, Basle M, Lomri A, Marie PJ: Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem. 2000 Mar 31;275(13):9178-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10734053",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Syndecan-2",
            "general-function": "Pdz domain binding",
            "specific-function": "Cell surface proteoglycan that bears heparan sulfate. Regulates dendritic arbor morphogenesis (By similarity).",
            "gene-name": "SDC2",
            "locus": "8q22-q23",
            "cellular-location": "Membrane",
            "transmembrane-regions": "145-169",
            "signal-regions": "1-18",
            "theoretical-pi": "4.48",
            "molecular-weight": "22159.62",
            "chromosome-location": "8",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:10659"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "SDC2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J04621"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "386787"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P34741"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "SDC2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Fibroglycan",
                "Heparan sulfate proteoglycan core protein",
                "HSPG",
                "HSPG1",
                "SYND2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037162|Syndecan-2\nMRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGAD\nEDVESPELTTSRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERK\nMDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYD\nLGERKPSSAAYQKAPTKEFYA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011534|Syndecan-2 (SDC2)\nATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCG\nAGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCT\nTCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGAT\nGAGGATGTAGAGAGTCCAGAGCTGACAACATCTCGACCACTTCCAAAGATACTGTTGACT\nAGTGCTGCTCCAAAAGTGGAAACCACGACGCTGAATATACAGAACAAGATACCTGCTCAG\nACAAAGTCACCTGAAGAAACTGATAAAGAGAAAGTTCACCTCTCTGACTCAGAAAGGAAA\nATGGACCCAGCCGAAGAGGATACAAATGTGTATACTGAGAAACACTCAGACAGTCTGTTT\nAAACGGACAGAAGTCCTAGCAGCTGTCATTGCTGGTGGAGTTATTGGCTTTCTCTTTGCA\nATTTTTCTTATCCTGCTGTTGGTGTATCGCATGAGAAAGAAGGATGAAGGAAGCTATGAC\nCTTGGAGAACGCAAACCATCCAGTGCTGCTTATCAGAAGGCACCTACTAAGGAGTTTTAT\nGCGTAA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF01034",
                "name": "Syndecan"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "Golgi lumen"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "lysosomal lumen"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "PDZ domain binding"
                },
                {
                  "category": "process",
                  "description": "glycosaminoglycan metabolic process"
                },
                {
                  "category": "process",
                  "description": "cell migration"
                },
                {
                  "category": "process",
                  "description": "regulation of dendrite morphogenesis"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "glycosaminoglycan catabolic process"
                },
                {
                  "category": "process",
                  "description": "chondroitin sulfate metabolic process"
                },
                {
                  "category": "process",
                  "description": "dendrite morphogenesis"
                },
                {
                  "category": "process",
                  "description": "bioluminescence"
                },
                {
                  "category": "process",
                  "description": "phototransduction, visible light"
                },
                {
                  "category": "process",
                  "description": "glycosaminoglycan biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "small molecule metabolic process"
                },
                {
                  "category": "process",
                  "description": "retinoid metabolic process"
                },
                {
                  "category": "process",
                  "description": "carbohydrate metabolic process"
                },
                {
                  "category": "process",
                  "description": "ephrin receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "axon guidance"
                }
              ]
            },
            "_id": "P34741",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        },
        {
          "id": "BE0002114",
          "name": "Bone marrow proteoglycan",
          "organism": "Human",
          "actions": "",
          "references": "# Menon K, Wu Y, Haas J, Sahu SK, Yang B, Zaheer A: Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice. Neurosci Res. 2007 Jun;58(2):156-63. Epub 2007 Feb 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17383764\r\n# Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006 Mar;117(3):590-6. Epub 2006 Feb 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16522458\r\n# Kang JH, Lee DH, Seo HM, Park JS, Nam KH, Shin SY, Park CS, Chung IY: Regulation of Functional Phenotypes of Cord-blood-derived Eosinophils by {gamma}-secretase Inhibitor. Am J Respir Cell Mol Biol. 2007 Jun 28;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17600316",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Bone marrow proteoglycan",
            "general-function": "Heparin binding",
            "specific-function": "Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA.",
            "gene-name": "PRG2",
            "locus": "11q12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-16",
            "theoretical-pi": "6.64",
            "molecular-weight": "25205.345",
            "chromosome-location": "11",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9362"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PRG2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "Y00809"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "34476"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P13727"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PRG2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "BMPG",
                "MBP",
                "Proteoglycan 2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037161|Bone marrow proteoglycan\nMKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEW\nGSGSEDASKKDGAVESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ\nAWFTCRRCYRGNLVSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRW\nNFAYWAAHQPWSRGGHCVALCTRGGHWRRAHCLRRLPFICSY"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019238|Bone marrow proteoglycan (PRG2)\nATGAAACTCCCCTTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGG\nTCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAG\nACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGG\nGGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCA\nGATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC\nATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGTTTACTTGCCGGAGGTGCTACAGGGGC\nAACCTGGTTTCCATCCACAACTTCAATATTAATTATCGAATCCAGTGTTCTGTCAGCGCG\nCTCAACCAGGGTCAAGTCTGGATTGGAGGCAGGATCACAGGCTCGGGTCGCTGCAGACGC\nTTTCAGTGGGTTGACGGCAGCCGCTGGAACTTTGCGTACTGGGCTGCTCACCAGCCCTGG\nTCCCGCGGTGGTCACTGCGTGGCCCTGTGTACCCGAGGAGGCCACTGGCGTCGAGCCCAC\nTGCCTCAGAAGACTTCCTTTCATCTGTTCCTACTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00059",
                "name": "Lectin_C"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "transport vesicle"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "function",
                  "description": "heparin binding"
                },
                {
                  "category": "function",
                  "description": "carbohydrate binding"
                },
                {
                  "category": "process",
                  "description": "negative regulation of interleukin-10 production"
                },
                {
                  "category": "process",
                  "description": "defense response to nematode"
                },
                {
                  "category": "process",
                  "description": "regulation of cytokine biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "immune response"
                },
                {
                  "category": "process",
                  "description": "defense response to bacterium"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-4 production"
                }
              ]
            },
            "_id": "P13727",
            "_source": "Swiss-Prot"
          },
          "_position": "5"
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2013-10-03"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00021"
      },
      "BIOD00039",
      "BTD00039"
    ],
    "name": "Secretin",
    "description": "This drug is the synthetic form of natural secretin.  It is prepared using solid phase peptide synthesis.  Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small  intestine’s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.",
    "cas-number": "",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "",
    "synthesis-reference": "Martin Bickel, Rolf Geiger, Richard Leeb, Walter Petri, \"Secretin preparations with intensified and protracted action, process for their manufacture, their use as well as dihydroxybenzoyl-L-tyrosine.\" U.S. Patent US4302448, issued August, 1964.",
    "indication": "For diagnosis of pancreatic exocrine dysfunction and gastrinoma",
    "pharmacodynamics": "Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.",
    "mechanism-of-action": "Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": "",
    "products": {
      "product": {
        "name": "Secretin Inj 75unit/vial",
        "ndc-id": "",
        "ndc-product-code": "",
        "dpd-id": "00874000",
        "started-marketing-on": "1990-12-31",
        "ended-marketing-on": "1999-08-04",
        "dosage-form": "powder for solution",
        "strength": "75 unit",
        "route": "intravenous",
        "fda-application-number": "",
        "generic": "false",
        "over-the-counter": "false",
        "approved": "true",
        "country": "Canada",
        "source": "DPD"
      }
    },
    "international-brands": {
      "international-brand": [
        {
          "name": "SecreFlo",
          "company": "Repligen Corp"
        },
        {
          "name": "Secremax",
          "company": "Repligen Corp"
        }
      ]
    },
    "mixtures": {
      "mixture": {
        "name": "Secretin Inj 75unit/vial",
        "ingredients": "Secretin"
      }
    },
    "packagers": {
      "packager": {
        "name": "Professional Co.",
        "url": ""
      }
    },
    "manufacturers": {
      "manufacturer": [
        {
          "_generic": "false",
          "__text": "Ferring pharmaceuticals inc"
        },
        {
          "_generic": "false",
          "__text": "Chirhoclin inc"
        }
      ]
    },
    "prices": {
      "price": {
        "description": "Secretin-mannitol powder",
        "cost": {
          "_currency": "USD",
          "__text": "1.43"
        },
        "unit": "g"
      }
    },
    "categories": {
      "category": {
        "category": "Diagnostic Agents",
        "mesh-id": "[]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": {
        "form": "Powder for solution",
        "route": "intravenous",
        "strength": "75 unit"
      }
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "V",
            "__text": "VARIOUS"
          },
          {
            "_code": "V04",
            "__text": "DIAGNOSTIC AGENTS"
          },
          {
            "_code": "V04C",
            "__text": "OTHER DIAGNOSTIC AGENTS"
          },
          {
            "_code": "V04CK",
            "__text": "Tests for pancreatic function"
          }
        ],
        "_code": "V04CK01"
      }
    },
    "ahfs-codes": "",
    "patents": "",
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB08897",
          "name": "Aclidinium",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium."
        },
        {
          "drugbank-id": "DB00321",
          "name": "Amitriptyline",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Amitriptyline."
        },
        {
          "drugbank-id": "DB00543",
          "name": "Amoxapine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Amoxapine."
        },
        {
          "drugbank-id": "DB00572",
          "name": "Atropine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Atropine."
        },
        {
          "drugbank-id": "DB00972",
          "name": "Azelastine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Azelastine."
        },
        {
          "drugbank-id": "DB00245",
          "name": "Benzatropine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Benzatropine."
        },
        {
          "drugbank-id": "DB00835",
          "name": "Brompheniramine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Brompheniramine."
        },
        {
          "drugbank-id": "DB00748",
          "name": "Carbinoxamine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Carbinoxamine."
        },
        {
          "drugbank-id": "DB00341",
          "name": "Cetirizine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Cetirizine."
        },
        {
          "drugbank-id": "DB01114",
          "name": "Chlorphenamine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Chlorphenamine."
        },
        {
          "drugbank-id": "DB00477",
          "name": "Chlorpromazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Chlorpromazine."
        },
        {
          "drugbank-id": "DB00283",
          "name": "Clemastine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Clemastine."
        },
        {
          "drugbank-id": "DB01242",
          "name": "Clomipramine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Clomipramine."
        },
        {
          "drugbank-id": "DB00363",
          "name": "Clozapine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Clozapine."
        },
        {
          "drugbank-id": "DB01176",
          "name": "Cyclizine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Cyclizine."
        },
        {
          "drugbank-id": "DB00924",
          "name": "Cyclobenzaprine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Cyclobenzaprine."
        },
        {
          "drugbank-id": "DB00979",
          "name": "Cyclopentolate",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Cyclopentolate."
        },
        {
          "drugbank-id": "DB00434",
          "name": "Cyproheptadine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Cyproheptadine."
        },
        {
          "drugbank-id": "DB00496",
          "name": "Darifenacin",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin."
        },
        {
          "drugbank-id": "DB01151",
          "name": "Desipramine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Desipramine."
        },
        {
          "drugbank-id": "DB00967",
          "name": "Desloratadine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine."
        },
        {
          "drugbank-id": "DB09555",
          "name": "Dexchlorpheniramine maleate",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Dexchlorpheniramine maleate."
        },
        {
          "drugbank-id": "DB00804",
          "name": "Dicyclomine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine."
        },
        {
          "drugbank-id": "DB00985",
          "name": "Dimenhydrinate",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Dimenhydrinate."
        },
        {
          "drugbank-id": "DB01075",
          "name": "Diphenhydramine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Diphenhydramine."
        },
        {
          "drugbank-id": "DB00280",
          "name": "Disopyramide",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Disopyramide."
        },
        {
          "drugbank-id": "DB01142",
          "name": "Doxepin",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Doxepin."
        },
        {
          "drugbank-id": "DB00366",
          "name": "Doxylamine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Doxylamine."
        },
        {
          "drugbank-id": "DB00450",
          "name": "Droperidol",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Droperidol."
        },
        {
          "drugbank-id": "DB06702",
          "name": "Fesoterodine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine."
        },
        {
          "drugbank-id": "DB00950",
          "name": "Fexofenadine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Fexofenadine."
        },
        {
          "drugbank-id": "DB01148",
          "name": "Flavoxate",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Flavoxate."
        },
        {
          "drugbank-id": "DB00875",
          "name": "Flupentixol",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Flupentixol."
        },
        {
          "drugbank-id": "DB00623",
          "name": "Fluphenazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Fluphenazine."
        },
        {
          "drugbank-id": "DB00986",
          "name": "Glycopyrrolate",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Glycopyrrolate."
        },
        {
          "drugbank-id": "DB00502",
          "name": "Haloperidol",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Haloperidol."
        },
        {
          "drugbank-id": "DB11181",
          "name": "Homatropine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine."
        },
        {
          "drugbank-id": "DB00557",
          "name": "Hydroxyzine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Hydroxyzine."
        },
        {
          "drugbank-id": "DB00424",
          "name": "Hyoscyamine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Hyoscyamine."
        },
        {
          "drugbank-id": "DB00458",
          "name": "Imipramine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Imipramine."
        },
        {
          "drugbank-id": "DB00332",
          "name": "Ipratropium bromide",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide."
        },
        {
          "drugbank-id": "DB01247",
          "name": "Isocarboxazid",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Isocarboxazid."
        },
        {
          "drugbank-id": "DB01106",
          "name": "Levocabastine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Levocabastine."
        },
        {
          "drugbank-id": "DB06282",
          "name": "Levocetirizine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Levocetirizine."
        },
        {
          "drugbank-id": "DB00455",
          "name": "Loratadine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Loratadine."
        },
        {
          "drugbank-id": "DB00408",
          "name": "Loxapine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Loxapine."
        },
        {
          "drugbank-id": "DB00934",
          "name": "Maprotiline",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Maprotiline."
        },
        {
          "drugbank-id": "DB00737",
          "name": "Meclizine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Meclizine."
        },
        {
          "drugbank-id": "DB04843",
          "name": "Mepenzolate",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Mepenzolate."
        },
        {
          "drugbank-id": "DB01403",
          "name": "Methotrimeprazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Methotrimeprazine."
        },
        {
          "drugbank-id": "DB11315",
          "name": "Methscopolamine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Methscopolamine."
        },
        {
          "drugbank-id": "DB01171",
          "name": "Moclobemide",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Moclobemide."
        },
        {
          "drugbank-id": "DB00540",
          "name": "Nortriptyline",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Nortriptyline."
        },
        {
          "drugbank-id": "DB00334",
          "name": "Olanzapine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Olanzapine."
        },
        {
          "drugbank-id": "DB00768",
          "name": "Olopatadine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Olopatadine."
        },
        {
          "drugbank-id": "DB01173",
          "name": "Orphenadrine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine."
        },
        {
          "drugbank-id": "DB01062",
          "name": "Oxybutynin",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin."
        },
        {
          "drugbank-id": "DB00850",
          "name": "Perphenazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Perphenazine."
        },
        {
          "drugbank-id": "DB00780",
          "name": "Phenelzine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Phenelzine."
        },
        {
          "drugbank-id": "DB01100",
          "name": "Pimozide",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Pimozide."
        },
        {
          "drugbank-id": "DB06153",
          "name": "Pizotifen",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Pizotifen."
        },
        {
          "drugbank-id": "DB00433",
          "name": "Prochlorperazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Prochlorperazine."
        },
        {
          "drugbank-id": "DB00387",
          "name": "Procyclidine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine."
        },
        {
          "drugbank-id": "DB00420",
          "name": "Promazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Promazine."
        },
        {
          "drugbank-id": "DB01069",
          "name": "Promethazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Promethazine."
        },
        {
          "drugbank-id": "DB00782",
          "name": "Propantheline",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Propantheline."
        },
        {
          "drugbank-id": "DB00344",
          "name": "Protriptyline",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Protriptyline."
        },
        {
          "drugbank-id": "DB01224",
          "name": "Quetiapine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Quetiapine."
        },
        {
          "drugbank-id": "DB00734",
          "name": "Risperidone",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Risperidone."
        },
        {
          "drugbank-id": "DB00747",
          "name": "Scopolamine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine."
        },
        {
          "drugbank-id": "DB09300",
          "name": "Scopolamine butylbromide",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine butylbromide."
        },
        {
          "drugbank-id": "DB01591",
          "name": "Solifenacin",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Solifenacin."
        },
        {
          "drugbank-id": "DB00679",
          "name": "Thioridazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Thioridazine."
        },
        {
          "drugbank-id": "DB01623",
          "name": "Thiothixene",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Thiothixene."
        },
        {
          "drugbank-id": "DB01409",
          "name": "Tiotropium",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tiotropium."
        },
        {
          "drugbank-id": "DB01036",
          "name": "Tolterodine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tolterodine."
        },
        {
          "drugbank-id": "DB00752",
          "name": "Tranylcypromine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Tranylcypromine."
        },
        {
          "drugbank-id": "DB00831",
          "name": "Trifluoperazine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trifluoperazine."
        },
        {
          "drugbank-id": "DB00376",
          "name": "Trihexyphenidyl",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trihexyphenidyl."
        },
        {
          "drugbank-id": "DB00662",
          "name": "Trimethobenzamide",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trimethobenzamide."
        },
        {
          "drugbank-id": "DB00726",
          "name": "Trimipramine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trimipramine."
        },
        {
          "drugbank-id": "DB00427",
          "name": "Triprolidine",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Triprolidine."
        },
        {
          "drugbank-id": "DB00209",
          "name": "Trospium",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Trospium."
        },
        {
          "drugbank-id": "DB09076",
          "name": "Umeclidinium",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Umeclidinium."
        },
        {
          "drugbank-id": "DB01624",
          "name": "Zuclopenthixol",
          "description": "The therapeutic efficacy of Secretin can be decreased when used in combination with Zuclopenthixol."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00021 sequence\nHSDGTFTSELSRLRDSARLQRLLQGLV"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "-0.463",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "9.45",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "3056.4",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C130H219N43O42",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "2067"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164760844"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Secretin"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic3/secretin.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/human_secretin.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000318",
        "name": "Secretin receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Secretin receptor",
          "general-function": "Secretin receptor activity",
          "specific-function": "This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.",
          "gene-name": "SCTR",
          "locus": "2q14.1",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "144-167\n175-194\n217-240\n255-276\n295-317\n344-362\n370-392",
          "signal-regions": "1-22",
          "theoretical-pi": "7.77",
          "molecular-weight": "50206.135",
          "chromosome-location": "2",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:10608"
              },
              {
                "resource": "GenAtlas",
                "identifier": "SCTR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "U20178"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "662796"
              },
              {
                "resource": "IUPHAR",
                "identifier": "252"
              },
              {
                "resource": "Guide to Pharmacology",
                "identifier": "252"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P47872"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "SCTR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": "SCT-R"
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016064|Secretin receptor\nMRPHLSPPLQQLLLPVLLACAAHSTGALPRLCDVLQVLWEEQDQCLQELSREQTGDLGTE\nQPVPGCEGMWDNISCWPSSVPGRMVEVECPRFLRMLTSRNGSLFRNCTQDGWSETFPRPN\nLACGVNVNDSSNEKRHSYLLKLKVMYTVGYSSSLVMLLVALGILCAFRRLHCTRNYIHMH\nLFVSFILRALSNFIKDAVLFSSDDVTYCDAHRAGCKLVMVLFQYCIMANYSWLLVEGLYL\nHTLLAISFFSERKYLQGFVAFGWGSPAIFVALWAIARHFLEDVGCWDINANASIWWIIRG\nPVILSILINFILFINILRILMRKLRTQETRGNEVSHYKRLARSTLLLIPLFGIHYIVFAF\nSPEDAMEIQLFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQWHLREFPLHPVASFS\nNSTKASHLEQSQGTCRTSII"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0016065|Secretin receptor (SCTR)\nATGCGTCCCCACCTGTCGCCGCCGCTGCAGCAGCTACTACTGCCGGTGCTGCTCGCCTGC\nGCCGCGCACTCGACTGGAGCCCTTCCCCGACTATGTGACGTGCTACAAGTGCTGTGGGAA\nGAGCAAGACCAGTGCCTGCAGGAACTCTCCAGAGAGCAGACAGGAGACCTGGGCACGGAG\nCAGCCAGTGCCAGGTTGTGAGGGGATGTGGGACAACATAAGCTGCTGGCCCTCTTCTGTG\nCCGGGCCGGATGGTGGAGGTGGAATGCCCGAGATTCCTCCGGATGCTCACCAGCAGAAAT\nGGTTCCTTGTTCCGAAACTGCACACAGGATGGCTGGTCAGAAACCTTCCCCAGGCCTAAT\nCTGGCCTGTGGCGTTAATGTGAACGACTCTTCCAACGAGAAGCGGCACTCCTACCTGCTG\nAAGCTGAAAGTCATGTACACCGTGGGCTACAGCTCCTCCCTGGTCATGCTCCTGGTCGCC\nCTTGGCATCCTCTGTGCTTTCCGGAGGCTCCACTGCACTCGCAACTACATCCACATGCAC\nCTGTTCGTGTCCTTCATCCTTCGTGCCCTGTCCAACTTCATCAAGGACGCCGTGCTCTTC\nTCCTCAGATGATGTCACCTACTGCGATGCCCACAGGGCGGGCTGCAAGCTGGTCATGGTG\nCTGTTCCAGTACTGCATCATGGCCAACTACTCCTGGCTGCTGGTGGAAGGCCTCTACCTT\nCACACACTCCTCGCCATCTCCTTCTTCTCTGAAAGAAAGTACCTCCAGGGATTTGTGGCA\nTTCGGATGGGGTTCTCCAGCCATTTTTGTTGCTTTGTGGGCTATTGCCAGACACTTTCTG\nGAAGATGTTGGGTGCTGGGACATCAATGCCAACGCATCCATCTGGTGGATCATTCGTGGT\nCCTGTGATCCTCTCCATCCTGATTAATTTCATCCTTTTCATAAACATTCTAAGAATCCTG\nATGAGAAAACTTAGAACCCAAGAAACAAGAGGAAATGAAGTCAGCCATTATAAGCGCCTG\nGCCAGGTCCACTCTCCTGCTGATCCCCCTCTTTGGCATCCACTACATCGTCTTCGCCTTC\nTCCCCAGAGGACGCTATGGAGATCCAGCTGTTTTTTGAACTAGCCCTTGGCTCATTCCAG\nGGACTGGTGGTGGCCGTCCTCTACTGCTTCCTCAATGGGGAGGTGCAGCTGGAGGTTCAG\nAAGAAGTGGCAGCAATGGCACCTCCGTGAGTTCCCACTGCACCCCGTGGCCTCCTTCAGC\nAACAGCACCAAGGCCAGCCACTTGGAGCAGAGCCAGGGCACCTGCAGGACCAGCATCATC\nTGA"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00002",
                "name": "7tm_2"
              },
              {
                "identifier": "PF02793",
                "name": "HRM"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "cytoplasmic microtubule"
              },
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "integral component of plasma membrane"
              },
              {
                "category": "function",
                "description": "secretin receptor activity"
              },
              {
                "category": "process",
                "description": "digestion"
              },
              {
                "category": "process",
                "description": "G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "cell surface receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "excretion"
              }
            ]
          },
          "_id": "P47872",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2013-09-13"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00022"
      },
      "BIOD00048",
      "BTD00048"
    ],
    "name": "Peginterferon alfa-2b",
    "description": "Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.",
    "cas-number": "99210-65-8",
    "groups": {
      "group": "approved"
    },
    "general-references": "",
    "synthesis-reference": "",
    "indication": "For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.",
    "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.",
    "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&frac12; k<sub>a</sub>) was 4.6 hours.\r\n",
    "half-life": "The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.\r\n\r\n",
    "protein-binding": "",
    "route-of-elimination": "Renal elimination accounts for 30% of the clearance.",
    "volume-of-distribution": "",
    "clearance": "* Oral cl=22 mL/hr∙kg [patients with HCV infection]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": "",
    "products": {
      "product": [
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246026",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246030",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254581",
          "started-marketing-on": "2004-09-17",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254603",
          "started-marketing-on": "2004-09-17",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254638",
          "started-marketing-on": "2004-09-17",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254646",
          "started-marketing-on": "2004-09-17",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246027",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2013-01-23",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246028",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2013-01-23",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegetron",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246029",
          "started-marketing-on": "2002-08-13",
          "ended-marketing-on": "2013-01-23",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1279",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1291",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1297",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "120 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1304",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1316",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "80 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1323",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "50 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1368",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-1370",
          "dpd-id": "",
          "started-marketing-on": "2001-01-19",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, lyophilized, for solution",
          "strength": "150 ug/.5mL",
          "route": "subcutaneous",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-4353",
          "dpd-id": "",
          "started-marketing-on": "2014-08-11",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-4354",
          "dpd-id": "",
          "started-marketing-on": "2014-08-11",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-4355",
          "dpd-id": "",
          "started-marketing-on": "2014-08-11",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Pegintron",
          "ndc-id": "",
          "ndc-product-code": "0085-4356",
          "dpd-id": "",
          "started-marketing-on": "2014-08-11",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Sylatron",
          "ndc-id": "",
          "ndc-product-code": "0085-1287",
          "dpd-id": "",
          "started-marketing-on": "2011-03-29",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Sylatron",
          "ndc-id": "",
          "ndc-product-code": "0085-1312",
          "dpd-id": "",
          "started-marketing-on": "2011-03-29",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Sylatron",
          "ndc-id": "",
          "ndc-product-code": "0085-1388",
          "dpd-id": "",
          "started-marketing-on": "2011-03-29",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Sylatron",
          "ndc-id": "",
          "ndc-product-code": "0085-4347",
          "dpd-id": "",
          "started-marketing-on": "2014-08-30",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Sylatron",
          "ndc-id": "",
          "ndc-product-code": "0085-4348",
          "dpd-id": "",
          "started-marketing-on": "2011-03-29",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Sylatron",
          "ndc-id": "",
          "ndc-product-code": "0085-4349",
          "dpd-id": "",
          "started-marketing-on": "2011-03-29",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103949",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Unitron Peg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242966",
          "started-marketing-on": "2001-03-27",
          "ended-marketing-on": "2012-02-01",
          "dosage-form": "powder for solution",
          "strength": "74 mcg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Unitron Peg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242967",
          "started-marketing-on": "2001-03-27",
          "ended-marketing-on": "2012-02-01",
          "dosage-form": "powder for solution",
          "strength": "118.4 mcg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Unitron Peg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242968",
          "started-marketing-on": "2001-03-27",
          "ended-marketing-on": "2012-02-01",
          "dosage-form": "powder for solution",
          "strength": "177.6 mcg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Unitron Peg",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242969",
          "started-marketing-on": "2001-03-27",
          "ended-marketing-on": "2012-02-01",
          "dosage-form": "powder for solution",
          "strength": "222 mcg",
          "route": "subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Victrelis Triple",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02371448",
          "started-marketing-on": "2011-08-16",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Victrelis Triple",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02371456",
          "started-marketing-on": "2011-08-16",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Victrelis Triple",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02371464",
          "started-marketing-on": "2011-08-16",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Victrelis Triple",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02371472",
          "started-marketing-on": "2011-08-16",
          "ended-marketing-on": "",
          "dosage-form": "capsule; powder for solution",
          "strength": "",
          "route": "oral; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "PEG-Intron",
        "company": "Schering Corp"
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Sylatron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Sylatron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Sylatron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Sylatron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Sylatron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Sylatron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegintron",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Victrelis Triple",
          "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"
        },
        {
          "name": "Victrelis Triple",
          "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"
        },
        {
          "name": "Victrelis Triple",
          "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"
        },
        {
          "name": "Victrelis Triple",
          "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"
        },
        {
          "name": "Unitron Peg",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Unitron Peg",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Unitron Peg",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Unitron Peg",
          "ingredients": "Peginterferon alfa-2b"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        },
        {
          "name": "Pegetron",
          "ingredients": "Peginterferon alfa-2b + Ribavirin"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Physicians Total Care Inc.",
          "url": "http://www.physicianstotalcare.com"
        },
        {
          "name": "Schering Corp.",
          "url": "http://www.schering.de"
        },
        {
          "name": "Schering-Plough Inc.",
          "url": "http://www.schering-plough.ca"
        },
        {
          "name": "Vetter Pharma Fertigung GmbH and Co. KG",
          "url": "http://www.vetter-pharma.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Peg-Intron 50 mcg kit",
          "cost": {
            "_currency": "USD",
            "__text": "553.4"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron redipen 50 mcg",
          "cost": {
            "_currency": "USD",
            "__text": "553.4"
          },
          "unit": "redipen"
        },
        {
          "description": "Peg-Intron redipen 80 mcg",
          "cost": {
            "_currency": "USD",
            "__text": "581.02"
          },
          "unit": "redipen"
        },
        {
          "description": "Peg-Intron 50 mcg/0.5ml Kit",
          "cost": {
            "_currency": "USD",
            "__text": "607.19"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron 80 mcg Kit",
          "cost": {
            "_currency": "USD",
            "__text": "609.26"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron redipen 120 mcg",
          "cost": {
            "_currency": "USD",
            "__text": "610.09"
          },
          "unit": "redipen"
        },
        {
          "description": "Peg-Intron Redipen 80 mcg/0.5ml Kit",
          "cost": {
            "_currency": "USD",
            "__text": "637.49"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron 120 mcg Kit",
          "cost": {
            "_currency": "USD",
            "__text": "639.74"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron redipen 150 mcg 4pk",
          "cost": {
            "_currency": "USD",
            "__text": "640.6"
          },
          "unit": "redipen"
        },
        {
          "description": "Peg-Intron redipen 150 mcg",
          "cost": {
            "_currency": "USD",
            "__text": "640.61"
          },
          "unit": "redipen"
        },
        {
          "description": "Peg-Intron Redipen 120 mcg/0.5ml Kit",
          "cost": {
            "_currency": "USD",
            "__text": "669.39"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron 150 mcg Kit",
          "cost": {
            "_currency": "USD",
            "__text": "671.74"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron Redipen 150 mcg/0.5ml Kit",
          "cost": {
            "_currency": "USD",
            "__text": "702.87"
          },
          "unit": "kit"
        },
        {
          "description": "Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box",
          "cost": {
            "_currency": "USD",
            "__text": "2428.8"
          },
          "unit": "kit"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Immunosuppressive Agents",
          "mesh-id": "[\"D27.505.696.477.656\"]"
        },
        {
          "category": "CYP2D6 Inhibitors (Weak)",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Capsule; powder for solution",
          "route": "oral; subcutaneous",
          "strength": ""
        },
        {
          "form": "Injection, powder, lyophilized, for solution",
          "route": "subcutaneous",
          "strength": "120 ug/.5mL"
        },
        {
          "form": "Injection, powder, lyophilized, for solution",
          "route": "subcutaneous",
          "strength": "150 ug/.5mL"
        },
        {
          "form": "Injection, powder, lyophilized, for solution",
          "route": "subcutaneous",
          "strength": "50 ug/.5mL"
        },
        {
          "form": "Injection, powder, lyophilized, for solution",
          "route": "subcutaneous",
          "strength": "80 ug/.5mL"
        },
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Powder for solution",
          "route": "subcutaneous",
          "strength": "118.4 mcg"
        },
        {
          "form": "Powder for solution",
          "route": "subcutaneous",
          "strength": "177.6 mcg"
        },
        {
          "form": "Powder for solution",
          "route": "subcutaneous",
          "strength": "222 mcg"
        },
        {
          "form": "Powder for solution",
          "route": "subcutaneous",
          "strength": "74 mcg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L03",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03A",
            "__text": "IMMUNOSTIMULANTS"
          },
          {
            "_code": "L03AB",
            "__text": "Interferons"
          }
        ],
        "_code": "L03AB10"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "08:18.20"
    },
    "patents": {
      "patent": [
        {
          "number": "1341567",
          "country": "Canada",
          "approved": "2008-02-19",
          "expires": "2025-02-19"
        },
        {
          "number": "2329474",
          "country": "Canada",
          "approved": "0002-02-26",
          "expires": "2016-10-31"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": [
        {
          "drugbank-id": "DB01418",
          "name": "Acenocoumarol",
          "description": "The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00041",
          "name": "Aldesleukin",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin."
        },
        {
          "drugbank-id": "DB00969",
          "name": "Alosetron",
          "description": "The serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01223",
          "name": "Aminophylline",
          "description": "The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00321",
          "name": "Amitriptyline",
          "description": "The serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00543",
          "name": "Amoxapine",
          "description": "The serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01238",
          "name": "Aripiprazole",
          "description": "The serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB06216",
          "name": "Asenapine",
          "description": "The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00289",
          "name": "Atomoxetine",
          "description": "The serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00195",
          "name": "Betaxolol",
          "description": "The serum concentration of Betaxolol can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00188",
          "name": "Bortezomib",
          "description": "The serum concentration of Bortezomib can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB09128",
          "name": "Brexpiprazole",
          "description": "The serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01558",
          "name": "Bromazepam",
          "description": "The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00201",
          "name": "Caffeine",
          "description": "The serum concentration of Caffeine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01197",
          "name": "Captopril",
          "description": "The serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01136",
          "name": "Carvedilol",
          "description": "The serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00608",
          "name": "Chloroquine",
          "description": "The serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01114",
          "name": "Chlorphenamine",
          "description": "The serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00477",
          "name": "Chlorpromazine",
          "description": "The serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01242",
          "name": "Clomipramine",
          "description": "The serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00363",
          "name": "Clozapine",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clozapine."
        },
        {
          "drugbank-id": "DB00924",
          "name": "Cyclobenzaprine",
          "description": "The serum concentration of Cyclobenzaprine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00851",
          "name": "Dacarbazine",
          "description": "The serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01151",
          "name": "Desipramine",
          "description": "The serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00514",
          "name": "Dextromethorphan",
          "description": "The serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01142",
          "name": "Doxepin",
          "description": "The serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00997",
          "name": "Doxorubicin",
          "description": "The serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00476",
          "name": "Duloxetine",
          "description": "The serum concentration of Duloxetine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB09039",
          "name": "Eliglustat",
          "description": "The serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01195",
          "name": "Flecainide",
          "description": "The serum concentration of Flecainide can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00472",
          "name": "Fluoxetine",
          "description": "The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00623",
          "name": "Fluphenazine",
          "description": "The serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00499",
          "name": "Flutamide",
          "description": "The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00176",
          "name": "Fluvoxamine",
          "description": "The serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00317",
          "name": "Gefitinib",
          "description": "The serum concentration of Gefitinib can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00502",
          "name": "Haloperidol",
          "description": "The serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB04946",
          "name": "Iloperidone",
          "description": "The serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00458",
          "name": "Imipramine",
          "description": "The serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00281",
          "name": "Lidocaine",
          "description": "The serum concentration of Lidocaine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00934",
          "name": "Maprotiline",
          "description": "The serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB04817",
          "name": "Metamizole",
          "description": "The risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00333",
          "name": "Methadone",
          "description": "The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01577",
          "name": "Methamphetamine",
          "description": "The serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00264",
          "name": "Metoprolol",
          "description": "The serum concentration of Metoprolol can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00379",
          "name": "Mexiletine",
          "description": "The serum concentration of Mexiletine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00370",
          "name": "Mirtazapine",
          "description": "The serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01149",
          "name": "Nefazodone",
          "description": "The serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00540",
          "name": "Nortriptyline",
          "description": "The serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00334",
          "name": "Olanzapine",
          "description": "The serum concentration of Olanzapine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00715",
          "name": "Paroxetine",
          "description": "The serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB09208",
          "name": "Pegloticase",
          "description": "The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegloticase."
        },
        {
          "drugbank-id": "DB00850",
          "name": "Perphenazine",
          "description": "The serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01100",
          "name": "Pimozide",
          "description": "The serum concentration of Pimozide can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01621",
          "name": "Pipotiazine",
          "description": "The serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB08910",
          "name": "Pomalidomide",
          "description": "The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01087",
          "name": "Primaquine",
          "description": "The serum concentration of Primaquine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01035",
          "name": "Procainamide",
          "description": "The serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00420",
          "name": "Promazine",
          "description": "The serum concentration of Promazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01069",
          "name": "Promethazine",
          "description": "The serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00571",
          "name": "Propranolol",
          "description": "The serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00344",
          "name": "Protriptyline",
          "description": "The serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00980",
          "name": "Ramelteon",
          "description": "The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01367",
          "name": "Rasagiline",
          "description": "The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00811",
          "name": "Ribavirin",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ribavirin."
        },
        {
          "drugbank-id": "DB00734",
          "name": "Risperidone",
          "description": "The serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00268",
          "name": "Ropinirole",
          "description": "The serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00296",
          "name": "Ropivacaine",
          "description": "The serum concentration of Ropivacaine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB09118",
          "name": "Stiripentol",
          "description": "The serum concentration of Stiripentol can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00675",
          "name": "Tamoxifen",
          "description": "The serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB09071",
          "name": "Tasimelteon",
          "description": "The serum concentration of Tasimelteon can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01265",
          "name": "Telbivudine",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine."
        },
        {
          "drugbank-id": "DB04844",
          "name": "Tetrabenazine",
          "description": "The serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00277",
          "name": "Theophylline",
          "description": "The serum concentration of Theophylline can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00679",
          "name": "Thioridazine",
          "description": "The serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01623",
          "name": "Thiothixene",
          "description": "The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00373",
          "name": "Timolol",
          "description": "The serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00697",
          "name": "Tizanidine",
          "description": "The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB01036",
          "name": "Tolterodine",
          "description": "The serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00831",
          "name": "Trifluoperazine",
          "description": "The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00726",
          "name": "Trimipramine",
          "description": "The serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00285",
          "name": "Venlafaxine",
          "description": "The serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB09068",
          "name": "Vortioxetine",
          "description": "The serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b."
        },
        {
          "drugbank-id": "DB00495",
          "name": "Zidovudine",
          "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine."
        },
        {
          "drugbank-id": "DB01624",
          "name": "Zuclopenthixol",
          "description": "The serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b."
        }
      ]
    },
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00022 sequence\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "61 °C",
          "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"
        },
        {
          "kind": "Isoelectric Point",
          "value": "5.99",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "31000.0",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "12036"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164784024"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01563"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Peginterferon_alfa-2b"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic2/peginterferon.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/peginterferon-alfa-2b.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000661",
          "name": "Interferon alpha/beta receptor 1",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 1",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.",
            "gene-name": "IFNAR1",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "437-457",
            "signal-regions": "1-27",
            "theoretical-pi": "5.56",
            "molecular-weight": "63524.81",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5432"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "J03171"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "306914"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "1723"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P17181"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "CRF2-1",
                "Cytokine receptor class-II member 1",
                "Cytokine receptor family 2 member 1",
                "IFN-R-1",
                "IFNAR",
                "Type I interferon receptor 1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0001318|Interferon alpha/beta receptor 1\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018987|Interferon alpha/beta receptor 1 (IFNAR1)\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTAGTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-beta production"
                },
                {
                  "category": "process",
                  "description": "regulation of peptidyl-tyrosine phosphorylation"
                },
                {
                  "category": "process",
                  "description": "type I interferon biosynthetic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interferon-gamma production"
                },
                {
                  "category": "process",
                  "description": "T cell activation"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "defense response to virus"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of interleukin-1 beta secretion"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                }
              ]
            },
            "_id": "P17181",
            "_source": "Swiss-Prot"
          }
        },
        {
          "id": "BE0000385",
          "name": "Interferon alpha/beta receptor 2",
          "organism": "Human",
          "actions": {
            "action": "agonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
          "known-action": "yes",
          "polypeptide": {
            "name": "Interferon alpha/beta receptor 2",
            "general-function": "Type i interferon receptor activity",
            "specific-function": "Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.",
            "gene-name": "IFNAR2",
            "locus": "",
            "cellular-location": "Membrane",
            "transmembrane-regions": "244-264",
            "signal-regions": "1-26",
            "theoretical-pi": "4.11",
            "molecular-weight": "57758.24",
            "chromosome-location": "21",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5433"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "IFNAR2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L42243"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "995300"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P48551"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "INAR2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IFN-R-2",
                "IFNABR",
                "IFNARB",
                "Interferon alpha binding protein",
                "Type I interferon receptor 2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000767|Interferon alpha/beta receptor 2\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0018941|Interferon alpha/beta receptor 2 (IFNAR2)\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAGGCAAGGTCTCGCTAAGGGCTGGAATGCAGTGGCTATTCACAGGTGCAGTCATAATGCA\nCTACAGTCTGAAACTCCTGAGCTCAAACAGTCGTCCTGCCTAAGCTTCCCCAGTAGCTGG\nGATTACAAGCGTGCATCCCTGTGCCCCAGTGATTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF01108",
                  "name": "Tissue_fac"
                },
                {
                  "identifier": "PF09294",
                  "name": "Interfer-bind"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "function",
                  "description": "protein kinase binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon binding"
                },
                {
                  "category": "function",
                  "description": "type I interferon receptor activity"
                },
                {
                  "category": "process",
                  "description": "type I interferon signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cytokine-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "JAK-STAT cascade"
                },
                {
                  "category": "process",
                  "description": "regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "regulation of type I interferon-mediated signaling pathway"
                },
                {
                  "category": "process",
                  "description": "response to interferon-alpha"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "response to virus"
                }
              ]
            },
            "_id": "P48551",
            "_source": "Swiss-Prot"
          }
        }
      ]
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2010-09-29"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00023"
      },
      "BIOD00011",
      "BTD00011"
    ],
    "name": "Asparaginase",
    "description": "L-asparagine amidohydrolase from E. coli",
    "cas-number": "9015-68-3",
    "groups": {
      "group": "approved"
    },
    "general-references": "# Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R: Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007 Jun 7;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17554375\r\n# http://www.google.com/patents/EP2046369A2",
    "synthesis-reference": "Masao Nambu, \"Process for producing immobilized L-asparaginase preparations for the therapy of leukemia.\" U.S. Patent US4617271, issued January, 1977.",
    "indication": "For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma",
    "pharmacodynamics": "In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.",
    "mechanism-of-action": "Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "8-30 hrs",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Asparaginase (E. coli)"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "L-asparagine amidohydrolase"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Putative L-asparaginase precursor"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Erwinase",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02237815",
          "started-marketing-on": "2009-07-01",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "10000 unit",
          "route": "intramuscular; intravenous; subcutaneous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kidrolase",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "01926438",
          "started-marketing-on": "1974-12-31",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "10000 unit",
          "route": "intramuscular; intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        }
      ]
    },
    "international-brands": {
      "international-brand": {
        "name": "Elspar",
        "company": "Merck & Co. Inc"
      }
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Kidrolase",
          "ingredients": "Asparaginase"
        },
        {
          "name": "Erwinase",
          "ingredients": "Asparaginase"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Lundbeck Inc.",
          "url": "http://www.lundbeckinc.com"
        },
        {
          "name": "Merck & Co.",
          "url": "http://www.merck.com"
        },
        {
          "name": "Prescript Pharmaceuticals",
          "url": "http://www.prescript.net"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": {
        "description": "Elspar 10000 unit vial",
        "cost": {
          "_currency": "USD",
          "__text": "74.6"
        },
        "unit": "vial"
      }
    },
    "categories": {
      "category": {
        "category": "Antineoplastic Agents",
        "mesh-id": "[\"D27.505.954.248\"]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Powder for solution",
          "route": "intramuscular; intravenous; subcutaneous",
          "strength": "10000 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intramuscular; intravenous",
          "strength": "10000 unit"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "L",
            "__text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"
          },
          {
            "_code": "L01",
            "__text": "ANTINEOPLASTIC AGENTS"
          },
          {
            "_code": "L01X",
            "__text": "OTHER ANTINEOPLASTIC AGENTS"
          },
          {
            "_code": "L01XX",
            "__text": "Other antineoplastic agents"
          }
        ],
        "_code": "L01XX02"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "10:00.00"
    },
    "patents": "",
    "food-interactions": "",
    "drug-interactions": {
      "drug-interaction": {
        "drugbank-id": "DB01234",
        "name": "Dexamethasone",
        "description": "The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase."
      }
    },
    "sequences": {
      "sequence": [
        {
          "_format": "FASTA",
          "__text": "> Elspar Sequence\nQMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDE\nTHELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMER\nVSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTG\nGMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAE\nACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTV\nATQ"
        },
        {
          "_format": "FASTA",
          "__text": ">sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2\nMEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNA\nVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYF\nLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGR\nDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVY\nNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGAT\nTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY"
        }
      ]
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "0.059",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "4.67",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "31731.9",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C1377H2208N382O442S17",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "2433"
        },
        {
          "resource": "GenBank",
          "identifier": "U00096"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA448492"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P37595"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Asparaginase"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic3/asparaginase.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/asparaginase.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0004798",
        "name": "L-asparagine",
        "organism": "Human",
        "actions": {
          "action": "other/unknown"
        },
        "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17264295\r\n# Wenner KA, Vieira Pinheiro JP, Escherich G, Wessalowski R, Jorch N, Wolff J, Stehn M, Kohlschutter A, Boos J, Janka-Schaub GE: Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005 Nov-Dec;217(6):321-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16307417\r\n# Appel IM, Pinheiro JP, den Boer ML, Lanvers C, Reniers NC, Boos J, Pieters R: Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003 Nov;17(11):2254-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14523472",
        "known-action": "yes"
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-11-13"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00024"
      },
      "BIOD00020",
      "BTD00020"
    ],
    "name": "Thyrotropin Alfa",
    "description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit is nearly identical to that of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The alpha subunit is thought to be the effector region responsible for stimulation of adenylate cyclase (involved the generation of cAMP). The beta subunit (TSHB) is unique to TSH, and therefore determines its receptor specificity. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.",
    "cas-number": "9002-71-5",
    "groups": {
      "group": "approved"
    },
    "general-references": "# Lexicomp\r\n#Product label ",
    "synthesis-reference": "19366632",
    "indication": "For detection of residueal or recurrent thyroid cancer",
    "pharmacodynamics": "Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyrogen is an exogenous source of human TSH that offers an additional diagnostic tool in the follow-up of patients with a history of well-differentiated thyroid cancer.",
    "mechanism-of-action": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.",
    "toxicity": "No difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised. ",
    "metabolism": "",
    "absorption": "Time to peak: Median: 10 hours (range: 3-24 hours)\r\nAfter a single intramuscular injection of 0.9 mg of thyrotropin alfa: Cmax= 116+38mU/L, Tmax=22+8.5 hours. AUC=5088+1728 mU·hr/L.",
    "half-life": "25 ± 10 hours",
    "protein-binding": "",
    "route-of-elimination": "kidney and liver",
    "volume-of-distribution": "",
    "clearance": "",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "rTSH"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thyroid stimulating hormone"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thyrotrophin-alfa"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thyrotrophin-alpha"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thyrotropin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thyrotropin-a"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thyrotropin-alpha"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Thytrophin"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "TSH"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Thyrogen",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02246016",
          "started-marketing-on": "2002-08-12",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "0.9 mg",
          "route": "intramuscular",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Thyrogen",
          "ndc-id": "",
          "ndc-product-code": "58468-0030",
          "dpd-id": "",
          "started-marketing-on": "1998-11-30",
          "ended-marketing-on": "",
          "dosage-form": "injection, powder, for solution",
          "strength": ".9 mg/mL",
          "route": "intramuscular",
          "fda-application-number": "NDA020898",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Thyrogen",
          "ndc-id": "",
          "ndc-product-code": "58468-1849",
          "dpd-id": "",
          "started-marketing-on": "1998-11-30",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "NDA020898",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        }
      ]
    },
    "international-brands": "",
    "mixtures": {
      "mixture": [
        {
          "name": "Thyrogen",
          "ingredients": "Thyrotropin Alfa"
        },
        {
          "name": "Thyrogen",
          "ingredients": "Thyrotropin Alfa"
        },
        {
          "name": "Thyrogen",
          "ingredients": "Thyrotropin Alfa"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Genzyme Inc.",
          "url": "http://www.genzyme.ca"
        },
        {
          "name": "Organon Pharmaceuticals",
          "url": "http://www.organonshop.com"
        }
      ]
    },
    "manufacturers": {
      "manufacturer": [
        {
          "_generic": "false",
          "__text": "Sanofi aventis us llc"
        },
        {
          "_generic": "false",
          "__text": "Genzyme corp"
        }
      ]
    },
    "prices": {
      "price": {
        "description": "Thyrogen 1.1 mg vial",
        "cost": {
          "_currency": "USD",
          "__text": "1196.4"
        },
        "unit": "vial"
      }
    },
    "categories": {
      "category": {
        "category": "Diagnostic Agents",
        "mesh-id": "[]"
      }
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Injection, powder, for solution",
          "route": "intramuscular",
          "strength": ".9 mg/mL"
        },
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Powder for solution",
          "route": "intramuscular",
          "strength": "0.9 mg"
        }
      ]
    },
    "atc-codes": {
      "atc-code": {
        "level": [
          {
            "_code": "H",
            "__text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"
          },
          {
            "_code": "H01",
            "__text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"
          },
          {
            "_code": "H01A",
            "__text": "ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES"
          },
          {
            "_code": "H01AB",
            "__text": "Thyrotropin"
          }
        ],
        "_code": "H01AB01"
      }
    },
    "ahfs-codes": {
      "ahfs-code": "36:60.00"
    },
    "patents": {
      "patent": {
        "number": "5840566",
        "country": "United States",
        "approved": "1995-11-24",
        "expires": "2015-11-24"
      }
    },
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": [
        {
          "_format": "FASTA",
          "__text": ">Alpha chain\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"
        },
        {
          "_format": "FASTA",
          "__text": ">Beta chain\nFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYR\nTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY"
        }
      ]
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Melting Point",
          "value": "55 °C",
          "source": ""
        },
        {
          "kind": "Hydrophobicity",
          "value": "-0.330",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "7.50",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "22672.9",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C975H1513N267O304S26",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "12790"
        },
        {
          "resource": "GenBank",
          "identifier": "M16647"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164746560"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P01225"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic2/thyrotropin.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/thyrotropin-alfa.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": {
        "id": "BE0000490",
        "name": "Thyrotropin receptor",
        "organism": "Human",
        "actions": {
          "action": "agonist"
        },
        "references": "# Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15571461\r\n# Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9039330\r\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352",
        "known-action": "yes",
        "polypeptide": {
          "name": "Thyrotropin receptor",
          "general-function": "Thyroid-stimulating hormone receptor activity",
          "specific-function": "Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5).",
          "gene-name": "TSHR",
          "locus": "14q31",
          "cellular-location": "Cell membrane",
          "transmembrane-regions": "414-441\n451-473\n495-517\n538-560\n581-602\n626-649\n661-682",
          "signal-regions": "1-20",
          "theoretical-pi": "6.98",
          "molecular-weight": "86828.965",
          "chromosome-location": "14",
          "organism": {
            "_ncbi-taxonomy-id": "9606",
            "__text": "Human"
          },
          "external-identifiers": {
            "external-identifier": [
              {
                "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                "identifier": "HGNC:12373"
              },
              {
                "resource": "GenAtlas",
                "identifier": "TSHR"
              },
              {
                "resource": "GenBank Gene Database",
                "identifier": "M73747"
              },
              {
                "resource": "GenBank Protein Database",
                "identifier": "903760"
              },
              {
                "resource": "IUPHAR",
                "identifier": "255"
              },
              {
                "resource": "UniProtKB",
                "identifier": "P16473"
              },
              {
                "resource": "UniProt Accession",
                "identifier": "TSHR_HUMAN"
              }
            ]
          },
          "synonyms": {
            "synonym": [
              "LGR3",
              "Thyroid-stimulating hormone receptor",
              "TSH-R"
            ]
          },
          "amino-acid-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0000978|Thyrotropin receptor\nMRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI\nETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD\nALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL\nTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA\nLPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM\nCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE\nDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIV\nVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSE\nYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACA\nIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCC\nYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSK\nILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQ\nVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL"
          },
          "gene-sequence": {
            "_format": "FASTA",
            "__text": ">lcl|BSEQ0010345|Thyrotropin receptor (TSHR)\nATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGC\nGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACC\nTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATT\nGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGA\nATCTACGTATCTATAGATGTGACTCTGCAGCAGCTGGAATCACACTCCTTCTACAATTTG\nAGTAAAGTGACTCACATAGAAATTCGGAATACCAGGAACTTAACTTACATAGACCCTGAT\nGCCCTCAAAGAGCTCCCCCTCCTAAAGTTCCTTGGCATTTTCAACACTGGACTTAAAATG\nTTCCCTGACCTGACCAAAGTTTATTCCACTGATATATTCTTTATACTTGAAATTACAGAC\nAACCCTTACATGACGTCAATCCCTGTGAATGCTTTTCAGGGACTATGCAATGAAACCTTG\nACACTGAAGCTGTACAACAATGGCTTTACTTCAGTCCAAGGATATGCTTTCAATGGGACA\nAAGCTGGATGCTGTTTACCTAAACAAGAATAAATACCTGACAGTTATTGACAAAGATGCA\nTTTGGAGGAGTATACAGTGGACCAAGCTTGCTGGACGTGTCTCAAACCAGTGTCACTGCC\nCTTCCATCCAAAGGCCTGGAGCACCTGAAGGAACTGATAGCAAGAAACACCTGGACTCTT\nAAGAAACTTCCACTTTCCTTGAGTTTCCTTCACCTCACACGGGCTGACCTTTCTTACCCA\nAGCCACTGCTGTGCTTTTAAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTTGATG\nTGTAATGAGAGCAGTATGCAGAGCTTGCGCCAGAGAAAATCTGTGAATGCCTTGAATAGC\nCCCCTCCACCAGGAATATGAAGAGAATCTGGGTGACAGCATTGTTGGGTACAAGGAAAAG\nTCCAAGTTCCAGGATACTCATAACAACGCTCATTATTACGTCTTCTTTGAAGAACAAGAG\nGATGAGATCATTGGTTTTGGCCAGGAGCTCAAAAACCCCCAGGAAGAGACTCTACAAGCT\nTTTGACAGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGTACCCCC\nAAGTCCGATGAGTTCAACCCGTGTGAAGACATAATGGGCTACAAGTTCCTGAGAATTGTG\nGTGTGGTTCGTTAGTCTGCTGGCTCTCCTGGGCAATGTCTTTGTCCTGCTTATTCTCCTC\nACCAGCCACTACAAACTGAACGTCCCCCGCTTTCTCATGTGCAACCTGGCCTTTGCGGAT\nTTCTGCATGGGGATGTACCTGCTCCTCATCGCCTCTGTAGACCTCTACACTCACTCTGAG\nTACTACAACCATGCCATCGACTGGCAGACAGGCCCTGGGTGCAACACGGCTGGTTTCTTC\nACTGTCTTTGCAAGCGAGTTATCGGTGTATACGCTGACGGTCATCACCCTGGAGCGCTGG\nTATGCCATCACCTTCGCCATGCGCCTGGACCGGAAGATCCGCCTCAGGCACGCATGTGCC\nATCATGGTTGGGGGCTGGGTTTGCTGCTTCCTTCTCGCCCTGCTTCCTTTGGTGGGAATA\nAGTAGCTATGCCAAAGTCAGTATCTGCCTGCCCATGGACACCGAGACCCCTCTTGCTCTG\nGCATATATTGTTTTTGTTCTGACGCTCAACATAGTTGCCTTCGTCATCGTCTGCTGCTGT\nTATGTGAAGATCTACATCACAGTCCGAAATCCGCAGTACAACCCAGGGGACAAAGATACC\nAAAATTGCCAAGAGGATGGCTGTGTTGATCTTCACCGACTTCATATGCATGGCCCCAATC\nTCATTCTATGCTCTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCAAA\nATCTTGCTGGTACTCTTCTATCCACTTAACTCCTGTGCCAATCCATTCCTCTATGCTATT\nTTCACCAAGGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTTGGCATCTGTAAA\nCGCCAGGCTCAGGCATACCGGGGGCAGAGGGTTCCTCCAAAGAACAGCACTGATATTCAG\nGTTCAAAAGGTTACCCACGAGATGAGGCAGGGTCTCCACAACATGGAAGATGTCTATGAA\nCTGATTGAAAACTCCCATCTAACCCCAAAGAAGCAAGGCCAAATCTCAGAAGAGTATATG\nCAAACGGTTTTGTAA"
          },
          "pfams": {
            "pfam": [
              {
                "identifier": "PF00001",
                "name": "7tm_1"
              },
              {
                "identifier": "PF13306",
                "name": "LRR_5"
              }
            ]
          },
          "go-classifiers": {
            "go-classifier": [
              {
                "category": "component",
                "description": "plasma membrane"
              },
              {
                "category": "component",
                "description": "receptor complex"
              },
              {
                "category": "component",
                "description": "integral component of plasma membrane"
              },
              {
                "category": "function",
                "description": "G-protein coupled peptide receptor activity"
              },
              {
                "category": "function",
                "description": "thyroid-stimulating hormone receptor activity"
              },
              {
                "category": "process",
                "description": "positive regulation of cell proliferation"
              },
              {
                "category": "process",
                "description": "G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger"
              },
              {
                "category": "process",
                "description": "adenylate cyclase-activating G-protein coupled receptor signaling pathway"
              },
              {
                "category": "process",
                "description": "hormone-mediated signaling pathway"
              },
              {
                "category": "process",
                "description": "thyroid-stimulating hormone signaling pathway"
              },
              {
                "category": "process",
                "description": "cell-cell signaling"
              },
              {
                "category": "process",
                "description": "activation of adenylate cyclase activity"
              },
              {
                "category": "process",
                "description": "G-protein coupled receptor signaling pathway"
              }
            ]
          },
          "_id": "P16473",
          "_source": "Swiss-Prot"
        }
      }
    },
    "enzymes": "",
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2014-10-14"
  },
  {
    "drugbank-id": [
      {
        "_primary": "true",
        "__text": "DB00025"
      },
      "BIOD00029",
      "BTD00029"
    ],
    "name": "Antihemophilic Factor (Recombinant)",
    "description": "Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells",
    "cas-number": "",
    "groups": {
      "group": [
        "approved",
        "investigational"
      ]
    },
    "general-references": "# Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an \"inhibitor-stop\" technique. Biochem J. 1975 Sep;150(3):553-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2157",
    "synthesis-reference": "James W. Bloom, \"Warm ethanol method for preparation of low fibrinogen antihemophilic factor.\" U.S. Patent US4478825, issued June, 1955.",
    "indication": "For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.",
    "pharmacodynamics": "Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.",
    "mechanism-of-action": "Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).",
    "toxicity": "",
    "metabolism": "",
    "absorption": "",
    "half-life": "8.4-19.3 hrs",
    "protein-binding": "",
    "route-of-elimination": "",
    "volume-of-distribution": "",
    "clearance": "* 4.1 mL/h•kg [Previously treated pediatric patients]",
    "classification": {
      "description": "",
      "direct-parent": "Peptides",
      "kingdom": "Organic Compounds",
      "superclass": "Organic Acids",
      "class": "Carboxylic Acids and Derivatives",
      "subclass": "Amino Acids, Peptides, and Analogues"
    },
    "salts": "",
    "synonyms": {
      "synonym": [
        {
          "_language": "",
          "_coder": "",
          "__text": "Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Antihemophilic Factor, Human Recombinant"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Factor VIII (Recombinant)"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "Human Factor VIII (Recombinant)"
        },
        {
          "_language": "",
          "_coder": "",
          "__text": "rAHF"
        }
      ]
    },
    "products": {
      "product": [
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02284138",
          "started-marketing-on": "2006-10-06",
          "ended-marketing-on": "2013-10-08",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02284146",
          "started-marketing-on": "2006-10-06",
          "ended-marketing-on": "2013-10-08",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02365979",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02365987",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02284154",
          "started-marketing-on": "2006-10-06",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02313111",
          "started-marketing-on": "2008-09-04",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "2000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02365952",
          "started-marketing-on": "2012-03-05",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02365944",
          "started-marketing-on": "2012-01-16",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02337193",
          "started-marketing-on": "2010-01-05",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "3000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Advate",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02284162",
          "started-marketing-on": "2006-10-06",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Factorate Inj 15unit/ml",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00611131",
          "started-marketing-on": "1984-12-31",
          "ended-marketing-on": "1999-12-15",
          "dosage-form": "powder for solution",
          "strength": "15 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Helixate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02342723",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "3000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Helixate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243186",
          "started-marketing-on": "2008-04-24",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Helixate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243187",
          "started-marketing-on": "2008-04-24",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Helixate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02243188",
          "started-marketing-on": "2008-04-24",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Helixate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02308592",
          "started-marketing-on": "2009-09-07",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "2000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Hemofil M",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00808709",
          "started-marketing-on": "1988-12-31",
          "ended-marketing-on": "2006-05-19",
          "dosage-form": "powder for solution",
          "strength": "1700 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Hyate C Inj Vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00738859",
          "started-marketing-on": "1986-12-31",
          "ended-marketing-on": "1996-09-25",
          "dosage-form": "powder for solution",
          "strength": "700 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Koate-HP - Pws IV 1000iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02187841",
          "started-marketing-on": "1997-01-23",
          "ended-marketing-on": "2000-08-01",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Koate-HP Unj",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00836419",
          "started-marketing-on": "1989-12-31",
          "ended-marketing-on": "1998-09-25",
          "dosage-form": "liquid",
          "strength": "1800 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate - Pws IV 1000I.U./vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02178834",
          "started-marketing-on": "1996-07-09",
          "ended-marketing-on": "2002-08-01",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate - Pws IV 250I.U./vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02178818",
          "started-marketing-on": "1996-11-20",
          "ended-marketing-on": "2002-08-01",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate - Pws IV 500I.U./vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02178826",
          "started-marketing-on": "1996-11-20",
          "ended-marketing-on": "2002-08-01",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242489",
          "started-marketing-on": "2004-03-31",
          "ended-marketing-on": "2009-08-06",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242490",
          "started-marketing-on": "2000-09-29",
          "ended-marketing-on": "2009-08-06",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02242491",
          "started-marketing-on": "2000-09-29",
          "ended-marketing-on": "2009-08-06",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3782",
          "dpd-id": "",
          "started-marketing-on": "2000-06-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3783",
          "dpd-id": "",
          "started-marketing-on": "2000-06-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3785",
          "dpd-id": "",
          "started-marketing-on": "2000-06-26",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3786",
          "dpd-id": "",
          "started-marketing-on": "2007-06-07",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3787",
          "dpd-id": "",
          "started-marketing-on": "2009-07-31",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3792",
          "dpd-id": "",
          "started-marketing-on": "2005-11-17",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3793",
          "dpd-id": "",
          "started-marketing-on": "2005-11-17",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3795",
          "dpd-id": "",
          "started-marketing-on": "2005-11-17",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3796",
          "dpd-id": "",
          "started-marketing-on": "2008-07-04",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "0026-3797",
          "dpd-id": "",
          "started-marketing-on": "2009-07-31",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA103332",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254484",
          "started-marketing-on": "2005-09-26",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254492",
          "started-marketing-on": "2005-09-26",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02291517",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02254476",
          "started-marketing-on": "2006-08-04",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS     -(with Bio-set)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02302225",
          "started-marketing-on": "2008-08-06",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "2000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS     -(with Bio-set)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02342758",
          "started-marketing-on": "2010-05-11",
          "ended-marketing-on": "2015-07-07",
          "dosage-form": "powder for solution",
          "strength": "3000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02342731",
          "started-marketing-on": "2015-07-07",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "3000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02291525",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02291533",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02302217",
          "started-marketing-on": "",
          "ended-marketing-on": "",
          "dosage-form": "powder for solution",
          "strength": "2000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate Pws 1000iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02042517",
          "started-marketing-on": "1993-12-31",
          "ended-marketing-on": "1998-09-25",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate Pws 250iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02042495",
          "started-marketing-on": "1993-12-31",
          "ended-marketing-on": "1998-09-25",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kogenate Pws 500iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02042509",
          "started-marketing-on": "1993-12-31",
          "ended-marketing-on": "1998-09-25",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kryobulin Vh 1000 Unit/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00719838",
          "started-marketing-on": "1988-12-31",
          "ended-marketing-on": "1998-08-13",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Kryobulin Vh 500 Unit/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00719811",
          "started-marketing-on": "1987-12-31",
          "ended-marketing-on": "1998-08-13",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Monoclate-P  -  200-350iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02215144",
          "started-marketing-on": "2001-06-27",
          "ended-marketing-on": "2008-10-16",
          "dosage-form": "solution; kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Monoclate-P  -  400-700iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02215152",
          "started-marketing-on": "2001-06-27",
          "ended-marketing-on": "2008-10-16",
          "dosage-form": "solution; kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Monoclate-P  -  800-1500iu/vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02215160",
          "started-marketing-on": "2001-06-27",
          "ended-marketing-on": "2008-10-16",
          "dosage-form": "solution; kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Novoeight",
          "ndc-id": "",
          "ndc-product-code": "0169-7810",
          "dpd-id": "",
          "started-marketing-on": "2015-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125466",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Novoeight",
          "ndc-id": "",
          "ndc-product-code": "0169-7815",
          "dpd-id": "",
          "started-marketing-on": "2015-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125466",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Novoeight",
          "ndc-id": "",
          "ndc-product-code": "0169-7820",
          "dpd-id": "",
          "started-marketing-on": "2015-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125466",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Novoeight",
          "ndc-id": "",
          "ndc-product-code": "0169-7825",
          "dpd-id": "",
          "started-marketing-on": "2015-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125466",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Novoeight",
          "ndc-id": "",
          "ndc-product-code": "0169-7830",
          "dpd-id": "",
          "started-marketing-on": "2015-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125466",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Novoeight",
          "ndc-id": "",
          "ndc-product-code": "0169-7850",
          "dpd-id": "",
          "started-marketing-on": "2015-04-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125466",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Nuwiq",
          "ndc-id": "",
          "ndc-product-code": "68982-139",
          "dpd-id": "",
          "started-marketing-on": "2016-01-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "BLA125555",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Nuwiq",
          "ndc-id": "",
          "ndc-product-code": "68982-141",
          "dpd-id": "",
          "started-marketing-on": "2016-01-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "BLA125555",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Nuwiq",
          "ndc-id": "",
          "ndc-product-code": "68982-143",
          "dpd-id": "",
          "started-marketing-on": "2016-01-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "BLA125555",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Nuwiq",
          "ndc-id": "",
          "ndc-product-code": "68982-145",
          "dpd-id": "",
          "started-marketing-on": "2016-01-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "intravenous",
          "fda-application-number": "BLA125555",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Profilate Heat Treated-wet Method Inj",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "00740780",
          "started-marketing-on": "1988-12-31",
          "ended-marketing-on": "1997-11-12",
          "dosage-form": "liquid",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Recombinate Pws Inj 1000I.U./vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02015137",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "2009-02-12",
          "dosage-form": "powder for solution",
          "strength": "1000 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Recombinate Pws Inj 250I.U./vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02015129",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "2009-02-12",
          "dosage-form": "powder for solution",
          "strength": "250 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Recombinate Pws Inj 500I.U./vial",
          "ndc-id": "",
          "ndc-product-code": "",
          "dpd-id": "02015145",
          "started-marketing-on": "1992-12-31",
          "ended-marketing-on": "2009-02-12",
          "dosage-form": "powder for solution",
          "strength": "500 unit",
          "route": "intravenous",
          "fda-application-number": "",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "Canada",
          "source": "DPD"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-012",
          "dpd-id": "",
          "started-marketing-on": "2008-08-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-013",
          "dpd-id": "",
          "started-marketing-on": "2008-08-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-014",
          "dpd-id": "",
          "started-marketing-on": "2008-08-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-015",
          "dpd-id": "",
          "started-marketing-on": "2008-08-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-016",
          "dpd-id": "",
          "started-marketing-on": "2010-08-13",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-022",
          "dpd-id": "",
          "started-marketing-on": "2011-12-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-023",
          "dpd-id": "",
          "started-marketing-on": "2011-12-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-024",
          "dpd-id": "",
          "started-marketing-on": "2011-08-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        },
        {
          "name": "Xyntha",
          "ndc-id": "",
          "ndc-product-code": "58394-025",
          "dpd-id": "",
          "started-marketing-on": "2011-08-01",
          "ended-marketing-on": "",
          "dosage-form": "kit",
          "strength": "",
          "route": "",
          "fda-application-number": "BLA125264",
          "generic": "false",
          "over-the-counter": "false",
          "approved": "true",
          "country": "US",
          "source": "FDA NDC"
        }
      ]
    },
    "international-brands": {
      "international-brand": [
        {
          "name": "Bioclate",
          "company": ""
        },
        {
          "name": "Helixate",
          "company": ""
        },
        {
          "name": "Hyate:C",
          "company": ""
        },
        {
          "name": "Koate-HP",
          "company": ""
        },
        {
          "name": "Kogenate",
          "company": ""
        },
        {
          "name": "Monarc-M",
          "company": ""
        },
        {
          "name": "ReFacto",
          "company": ""
        }
      ]
    },
    "mixtures": {
      "mixture": [
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Novoeight",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Novoeight",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Novoeight",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Novoeight",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Novoeight",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Novoeight",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Xyntha",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Nuwiq",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Nuwiq",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Nuwiq",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Nuwiq",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Helixate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Helixate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Helixate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS     -(with Bio-set)",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Helixate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Koate-HP Unj",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kryobulin Vh 1000 Unit/vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Hyate C Inj Vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Recombinate Pws Inj 250I.U./vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Recombinate Pws Inj 1000I.U./vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Recombinate Pws Inj 500I.U./vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate Pws 250iu/vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate Pws 500iu/vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate Pws 1000iu/vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Koate-HP - Pws IV 1000iu/vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Monoclate-P  -  200-350iu/vial",
          "ingredients": "Water + Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Monoclate-P  -  400-700iu/vial",
          "ingredients": "Water + Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Monoclate-P  -  800-1500iu/vial",
          "ingredients": "Water + Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate - Pws IV 250I.U./vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate - Pws IV 500I.U./vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate - Pws IV 1000I.U./vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Factorate Inj 15unit/ml",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kryobulin Vh 500 Unit/vial",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS     -(with Bio-set)",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Profilate Heat Treated-wet Method Inj",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Hemofil M",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS     -(with Vial Adapter)",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Helixate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Advate",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        },
        {
          "name": "Kogenate FS",
          "ingredients": "Antihemophilic Factor (Recombinant)"
        }
      ]
    },
    "packagers": {
      "packager": [
        {
          "name": "Baxter International Inc.",
          "url": "http://www.baxter.com"
        },
        {
          "name": "Bayer Healthcare",
          "url": "http://www.bayerhealthcare.com"
        },
        {
          "name": "CSL Behring LLC",
          "url": "http://www.cslbehring.com"
        },
        {
          "name": "GlaxoSmithKline Inc.",
          "url": "http://www.gsk.com"
        },
        {
          "name": "Grifols SA",
          "url": "http://www.grifols.com"
        },
        {
          "name": "Ipsen Pharmaceuticals Inc.",
          "url": "http://www.ipsen.com"
        },
        {
          "name": "Octapharma USA",
          "url": "http://www.octapharma.com"
        },
        {
          "name": "Talecris Biotherapeutics",
          "url": "http://www.talecris.com"
        },
        {
          "name": "Wyeth Pharmaceuticals",
          "url": "http://www.wyeth.com"
        }
      ]
    },
    "manufacturers": "",
    "prices": {
      "price": [
        {
          "description": "Monoclate-p 1000 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.01"
          },
          "unit": "kit"
        },
        {
          "description": "Monoclate-p 1500 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.01"
          },
          "unit": "kit"
        },
        {
          "description": "Monoclate-p 250 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.01"
          },
          "unit": "kit"
        },
        {
          "description": "Monoclate-p 500ahfu kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.01"
          },
          "unit": "kit"
        },
        {
          "description": "Alphanate 1000-1500 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "vial"
        },
        {
          "description": "Alphanate 250-500 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "vial"
        },
        {
          "description": "Humate-p 1000 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "kit"
        },
        {
          "description": "Humate-p 1200 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "kit"
        },
        {
          "description": "Humate-p 2000 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "kit"
        },
        {
          "description": "Humate-p 2400 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "kit"
        },
        {
          "description": "Humate-p 500 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "kit"
        },
        {
          "description": "Humate-p 600 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.2"
          },
          "unit": "kit"
        },
        {
          "description": "Koate-dvi 1000 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "kit"
        },
        {
          "description": "Koate-dvi 250 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "kit"
        },
        {
          "description": "Koate-dvi 500 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "kit"
        },
        {
          "description": "Refacto 1000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "vial"
        },
        {
          "description": "Refacto 2000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "vial"
        },
        {
          "description": "Refacto 250 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "vial"
        },
        {
          "description": "Refacto 500 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.31"
          },
          "unit": "vial"
        },
        {
          "description": "Hemofil m 1701-2000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.34"
          },
          "unit": "vial"
        },
        {
          "description": "Hemofil m 220-400 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.34"
          },
          "unit": "vial"
        },
        {
          "description": "Hemofil m 401-800 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.34"
          },
          "unit": "vial"
        },
        {
          "description": "Hemofil m 801-1700 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.34"
          },
          "unit": "vial"
        },
        {
          "description": "Wilate 450-450 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.38"
          },
          "unit": "kit"
        },
        {
          "description": "Wilate 900-900 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.38"
          },
          "unit": "kit"
        },
        {
          "description": "Helixate fs 1000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.56"
          },
          "unit": "vial"
        },
        {
          "description": "Helixate fs 250 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.56"
          },
          "unit": "vial"
        },
        {
          "description": "Helixate fs 3000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.56"
          },
          "unit": "vial"
        },
        {
          "description": "Helixate fs 500 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.56"
          },
          "unit": "vial"
        },
        {
          "description": "Xyntha 1000 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.66"
          },
          "unit": "kit"
        },
        {
          "description": "Xyntha 2000 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.66"
          },
          "unit": "kit"
        },
        {
          "description": "Xyntha 250 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.66"
          },
          "unit": "kit"
        },
        {
          "description": "Xyntha 500 unit kit",
          "cost": {
            "_currency": "USD",
            "__text": "1.66"
          },
          "unit": "kit"
        },
        {
          "description": "Advate 1201-1800 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Advate 1801-2400 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Advate 200-400 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Advate 2400-3600 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Advate 401-800 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Advate 801-1200 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Kogenate fs 1000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Kogenate fs 250 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Kogenate fs 3000 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        },
        {
          "description": "Kogenate fs 500 unit vial",
          "cost": {
            "_currency": "USD",
            "__text": "1.68"
          },
          "unit": "vial"
        }
      ]
    },
    "categories": {
      "category": [
        {
          "category": "Coagulants",
          "mesh-id": "[\"D27.505.954.502.270\"]"
        },
        {
          "category": "Thrombotic Agents",
          "mesh-id": "[]"
        }
      ]
    },
    "affected-organisms": {
      "affected-organism": "Humans and other mammals"
    },
    "dosages": {
      "dosage": [
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "1500 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "3000 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "15 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "1000 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "250 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "500 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "1700 unit"
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "700 unit"
        },
        {
          "form": "Liquid",
          "route": "intravenous",
          "strength": "1800 unit"
        },
        {
          "form": "Kit",
          "route": "",
          "strength": ""
        },
        {
          "form": "Powder for solution",
          "route": "intravenous",
          "strength": "2000 unit"
        },
        {
          "form": "Solution; kit",
          "route": "intravenous",
          "strength": ""
        },
        {
          "form": "Kit",
          "route": "intravenous",
          "strength": ""
        },
        {
          "form": "Liquid",
          "route": "intravenous",
          "strength": "1000 unit"
        }
      ]
    },
    "atc-codes": "",
    "ahfs-codes": {
      "ahfs-code": "20:28.16"
    },
    "patents": {
      "patent": [
        {
          "number": "1339477",
          "country": "Canada",
          "approved": "1997-09-23",
          "expires": "2014-09-23"
        },
        {
          "number": "2124690",
          "country": "Canada",
          "approved": "2007-09-11",
          "expires": "2013-10-01"
        }
      ]
    },
    "food-interactions": "",
    "drug-interactions": "",
    "sequences": {
      "sequence": {
        "_format": "FASTA",
        "__text": ">DB00025 sequence\nATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFN\nIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ\nREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR\nEGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNR\nSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL\nMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF\nDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG\nRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI\nTDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNME\nRDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAG\nVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKH\nKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYE\nDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMP\nKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQ\nLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDN\nTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSW\nGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSL\nLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQK\nKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEG\nQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEK\nKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNR\nTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRL\nPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI\nPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKK\nNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHI\nYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSK\nLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKP\nEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIY\nDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD\nGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGA\nEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHT\nNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHA\nINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYP\nGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS\nGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQ\nFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRS\nTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWR\nPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKV\nKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY"
      }
    },
    "experimental-properties": {
      "property": [
        {
          "kind": "Hydrophobicity",
          "value": "-0.533",
          "source": ""
        },
        {
          "kind": "Isoelectric Point",
          "value": "6.97",
          "source": ""
        },
        {
          "kind": "Molecular Weight",
          "value": "264725.5",
          "source": ""
        },
        {
          "kind": "Molecular Formula",
          "value": "C11794H18314N3220O3553S83",
          "source": ""
        }
      ]
    },
    "external-identifiers": {
      "external-identifier": [
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "745"
        },
        {
          "resource": "Drugs Product Database (DPD)",
          "identifier": "9847"
        },
        {
          "resource": "GenBank",
          "identifier": "M14113"
        },
        {
          "resource": "PharmGKB",
          "identifier": "PA164750168"
        },
        {
          "resource": "UniProtKB",
          "identifier": "P00451"
        },
        {
          "resource": "Wikipedia",
          "identifier": "Antihemophilic_Factor"
        }
      ]
    },
    "external-links": {
      "external-link": [
        {
          "resource": "RxList",
          "url": "http://www.rxlist.com/cgi/generic2/hemofilm.htm"
        },
        {
          "resource": "Drugs.com",
          "url": "http://www.drugs.com/cdi/antihemophilic-factor-human.html"
        }
      ]
    },
    "pathways": "",
    "reactions": "",
    "snp-effects": "",
    "snp-adverse-drug-reactions": "",
    "targets": {
      "target": [
        {
          "id": "BE0000216",
          "name": "Coagulation factor X",
          "organism": "Human",
          "actions": {
            "action": "activator"
          },
          "references": "# BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)] Pathol Biol (Paris). 1959 Dec;7:2477-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13801371\r\n# LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF STUART FACTOR (FACTOR X) BY ACTIVATED ANTIHEMOPHILIC FACTOR (ACTIVATED FACTOR 8). Biochemistry. 1965 Jan;4:113-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14285227\r\n# Radnoff OD, Saito H: Inhibition of Hageman factor, plasma thromboplastin antecedent, thrombin and other clotting factors by phenylglyoxal hydrate (38500). Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/236567\r\n# Orthner CL: Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography. J Lab Clin Med. 1984 Nov;104(5):816-28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6436416\r\n# Freedman J, Mody M, Lazarus AH, Dewar L, Song S, Blanchette VS, Garvey MB, Ofosu FA: Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol. 2002 Mar;69(3):192-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11891806",
          "known-action": "yes",
          "polypeptide": {
            "name": "Coagulation factor X",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.",
            "gene-name": "F10",
            "locus": "13q34",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-31",
            "theoretical-pi": "5.74",
            "molecular-weight": "54731.255",
            "chromosome-location": "13",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3528"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "F10"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "K03194"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "182841"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2359"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00742"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FA10_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.6",
                "Stuart factor",
                "Stuart-Prower factor"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010204|Coagulation factor X\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010205|Coagulation factor X (F10)\nATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTC\nGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGG\nGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAG\nACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTC\nTGGAATAAATACAAAGATGGCGACCAGTGTGAGACCAGTCCTTGCCAGAACCAGGGCAAA\nTGTAAAGACGGCCTCGGGGAATACACCTGCACCTGTTTAGAAGGATTCGAAGGCAAAAAC\nTGTGAATTATTCACACGGAAGCTCTGCAGCCTGGACAACGGGGACTGTGACCAGTTCTGC\nCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCGCCCGCGGGTACACCCTGGCTGACAAC\nGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCTGTGGGAAACAGACCCTGGAACGCAGG\nAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCGGGGAGGCCCCTGACAGCATCACATGG\nAAGCCATATGATGCAGCCGACCTGGACCCCACCGAGAACCCCTTCGACCTGCTTGACTTC\nAACCAGACGCAGCCTGAGAGGGGCGACAACAACCTCACCAGGATCGTGGGAGGCCAGGAA\nTGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGCTCATCAATGAGGAAAACGAGGGTTTC\nTGTGGTGGAACCATTCTGAGCGAGTTCTACATCCTAACGGCAGCCCACTGTCTCTACCAA\nGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGAACACGGAGCAGGAGGAGGGCGGTGAG\nGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACAACCGGTTCACAAAGGAGACCTATGAC\nTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCATCACCTTCCGCATGAACGTGGCGCCT\nGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCACGCTGATGACGCAGAAGACGGGGATT\nGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCCGGCAGTCCACCAGGCTCAAGATGCTG\nGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGCTGTCCAGCAGCTTCATCATCACCCAG\nAACATGTTCTGTGCCGGCTACGACACCAAGCAGGAGGATGCCTGCCAGGGGGACAGCGGG\nGGCCCGCACGTCACCCGCTTCAAGGACACCTACTTCGTGACAGGCATCGTCAGCTGGGGA\nGAGGGCTGTGCCCGTAAGGGGAAGTACGGGATCTACACCAAGGTCACCGCCTTCCTCAAG\nTGGATCGACAGGTCCATGAAAACCAGGGGCTTGCCCAAGGCCAAGAGCCATGCCCCGGAG\nGTCATAACGTCCTCTCCATTAAAGTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00008",
                  "name": "EGF"
                },
                {
                  "identifier": "PF00594",
                  "name": "Gla"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "Golgi lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "intrinsic component of external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "function",
                  "description": "phospholipid binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, extrinsic pathway"
                },
                {
                  "category": "process",
                  "description": "peptidyl-glutamic acid carboxylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein kinase B signaling"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell migration"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, intrinsic pathway"
                }
              ]
            },
            "_id": "P00742",
            "_source": "Swiss-Prot"
          },
          "_position": "1"
        },
        {
          "id": "BE0000364",
          "name": "Coagulation factor IX",
          "organism": "Human",
          "actions": {
            "action": "cofactor"
          },
          "references": "# Hule V: [Factor IX inhibitor (antihemophilic factor B, PTC) in a woman] Vnitr Lek. 1975 Mar;21(3):274-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1119107\r\n# Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2994716\r\n# LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF ANTIHEMOPHILIC FACTOR (FACTOR 8) BY ACTIVATED CHRISTMAS FACTOR (ACTIVATED FACTOR9 9). Biochemistry. 1964 Nov;3:1720-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14240634\r\n# Hoofnagle JH, Gerety RJ, Thiel J, Barker LF: The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med. 1976 Jul;88(1):102-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/932529\r\n# Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang. 1984;46(1):36-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6422634",
          "known-action": "yes",
          "polypeptide": {
            "name": "Coagulation factor IX",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.",
            "gene-name": "F9",
            "locus": "Xq27.1-q27.2",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-28",
            "theoretical-pi": "5.16",
            "molecular-weight": "51778.11",
            "chromosome-location": "X",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3551"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "F9"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "K02402"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "182609"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2364"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00740"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "FA9_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.22",
                "Christmas factor",
                "Plasma thromboplastin component",
                "PTC"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000725|Coagulation factor IX\nMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNL\nERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCP\nFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGR\nVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPW\nQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRII\nPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVF\nHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVE\nGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0010262|Coagulation factor IX (F9)\nATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTA\nGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATT\nCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTT\nGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAAC\nACTGAAAGAACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAAT\nCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCC\nTTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGA\nTGCGAGCAGTTTTGTAAAAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGA\nTATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGA\nGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGAC\nTATGTAAATTCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCA\nTTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGG\nCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAA\nTGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGT\nGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATT\nCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAA\nCTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAA\nTACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTC\nCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCC\nACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCAT\nGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAA\nGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAA\nTATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTC\nACTTAA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00008",
                  "name": "EGF"
                },
                {
                  "identifier": "PF00594",
                  "name": "Gla"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "Golgi lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "endopeptidase activity"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "zymogen activation"
                },
                {
                  "category": "process",
                  "description": "peptidyl-glutamic acid carboxylation"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, intrinsic pathway"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, extrinsic pathway"
                }
              ]
            },
            "_id": "P00740",
            "_source": "Swiss-Prot"
          },
          "_position": "2"
        },
        {
          "id": "BE0001043",
          "name": "von Willebrand factor",
          "organism": "Human",
          "actions": {
            "action": "binder"
          },
          "references": "# Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10938981\r\n# Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11858481\r\n# Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA: Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14750934\r\n# Smith KJ, Lusher JM, Cohen AR, Salzman P: Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol. 1990 Apr;27(2 Suppl 2):25-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2128855\r\n# Altieri DC, Capitanio AM, Mannucci PM: von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol. 1986 Aug;63(4):703-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2942172",
          "known-action": "yes",
          "polypeptide": {
            "name": "von Willebrand factor",
            "general-function": "Protein n-terminus binding",
            "specific-function": "Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.",
            "gene-name": "VWF",
            "locus": "12p13.3",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-22",
            "theoretical-pi": "5.21",
            "molecular-weight": "309261.83",
            "chromosome-location": "12",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:12726"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "VWF"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X04385"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "37947"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P04275"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "VWF_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "F8VWF",
                "vWF"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037116|von Willebrand factor\nMIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYL\nLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYL\nETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTL\nTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL\nVDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGME\nYRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPG\nTSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQD\nHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDVQLPLLKGDL\nRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSG\nLAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVS\nPLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQ\nCGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPED\nIFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADN\nLRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGE\nTVKIGCNTCVCQDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGS\nNPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGR\nYIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVD\nFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPY\nLDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGY\nECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCE\nVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVE\nDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVE\nYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRI\nTLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVL\nSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPDMAQVTVGPGLLGVSTLGPKRNSMVLDVA\nFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGD\nILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLP\nGDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTL\nSPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITT\nIDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILV\nTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTM\nVTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCD\nRGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNK\nEQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEV\nNVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRD\nGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFY\nAICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHC\nDGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQI\nCTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHC\nERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVN\nSTVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAV\nMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQ\nWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERME\nACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGEC\nCGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHK\nCLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMY\nSIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016295|von Willebrand factor (VWF)\nATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACC\nCTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGT\nGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTC\nCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAG\nAGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCATTTGTTTGTCAATGGT\nACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTATGCCTCCAAAGGGCTGTATCTA\nGAAACTGAGGCTGGGTACTACAAGCTGTCCGGTGAGGCCTATGGCTTTGTGGCCAGGATC\nGATGGCAGCGGCAACTTTCAAGTCCTGCTGTCAGACAGATACTTCAACAAGACCTGCGGG\nCTGTGTGGCAACTTTAACATCTTTGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTG\nACCTCGGACCCTTATGACTTTGCCAACTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGT\nGAACGGGCATCTCCTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGC\nCTGTGGGAGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTG\nGTGGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGGGGG\nCTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGGAGGGAATG\nGTGCTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCCCTGCTGGTATGGAG\nTATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAGCCTGCACATCAATGAAATG\nTGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCTGAGGGACAGCTCCTGGATGAAGGC\nCTCTGCGTGGAGAGCACCGAGTGTCCCTGCGTGCATTCCGGAAAGCGCTACCCTCCCGGC\nACCTCCCTCTCTCGAGACTGCAACACCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGC\nAATGAAGAATGTCCAGGGGAGTGCCTTGTCACAGGTCAATCACACTTCAAGAGCTTTGAC\nAACAGATACTTCACCTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGAC\nCACTCCTTCTCCATTGTCATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGC\nACCCGCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAAACTGAAGCAT\nGGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGGTGACCTC\nCGCATCCAGCATACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAGGACCTGCAGATG\nGACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCCGTCTATGCCGGGAAGACC\nTGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGCGACGACTTCCTTACCCCCTCTGGG\nCTGGCGGAGCCCCGGGTGGAGGACTTCGGGAACGCCTGGAAGCTGCACGGGGACTGCCAG\nGACCTGCAGAAGCAGCACAGCGATCCCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCC\nGAGGAGGCGTGCGCGGTCCTGACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTCAGC\nCCGCTGCCCTACCTGCGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAG\nTGCCTGTGCGGCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTC\nGCGTGGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCGAAAGGCCAGGTGTACCTGCAG\nTGCGGGACCCCCTGCAACCTGACCTGCCGCTCTCTCTCTTACCCGGATGAGGAATGCAAT\nGAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCCAGGGCTCTACATGGATGAGAGGGGGGAC\nTGCGTGCCCAAGGCCCAGTGCCCCTGTTACTATGACGGTGAGATCTTCCAGCCAGAAGAC\nATCTTCTCAGACCATCACACCATGTGCTACTGTGAGGATGGCTTCATGCACTGTACCATG\nAGTGGAGTCCCCGGAAGCTTGCTGCCTGACGCTGTCCTCAGCAGTCCCCTGTCTCATCGC\nAGCAAAAGGAGCCTATCCTGTCGGCCCCCCATGGTCAAGCTGGTGTGTCCCGCTGACAAC\nCTGCGGGCTGAAGGGCTCGAGTGTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATG\nAGCATGGGCTGTGTCTCTGGCTGCCTCTGCCCCCCGGGCATGGTCCGGCATGAGAACAGA\nTGTGTGGCCCTGGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCCTGGAGAA\nACAGTGAAGATTGGCTGCAACACTTGTGTCTGTCGGGACCGGAAGTGGAACTGCACAGAC\nCATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTCGACGGG\nCTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATTACTGCGGCAGT\nAACCCTGGGACCTTTCGGATCCTAGTGGGGAATAAGGGATGCAGCCACCCCTCAGTGAAA\nTGCAAGAAACGGGTCACCATCCTGGTGGAGGGAGGAGAGATTGAGCTGTTTGACGGGGAG\nGTGAATGTGAAGAGGCCCATGAAGGATGAGACTCACTTTGAGGTGGTGGAGTCTGGCCGG\nTACATCATTCTGCTGCTGGGCAAAGCCCTCTCCGTGGTCTGGGACCGCCACCTGAGCATC\nTCCGTGGTCCTGAAGCAGACATACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGAT\nGGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGAC\nTTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGAC\nTCATCCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGT\nAGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAGCCATAT\nCTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTC\nTGCGACACCATTGCTGCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGG\nAGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTAT\nGAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCCT\nGAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGGG\nAAAATCCTGGATGAGCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAG\nGTGGCTGGCCGGCGTTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAG\nCACTGCCAGATTTGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCG\nGGAGGCCTGGTGGTGCCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAG\nGACATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTC\nCTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTG\nGTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAG\nTACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTG\nCGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTC\nTTGAAATACACACTGTTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATC\nACCCTGCTCCTGATGGCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTAC\nGTCCAGGGCCTGAAGAAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCC\nAACCTCAAGCAGATCCGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTG\nAGCAGTGTGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTT\nGCCCCTGAAGCCCCTCCTCCTACTCTGCCCCCCGACATGGCACAAGTCACTGTGGGCCCG\nGGGCTCTTGGGGGTTTCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCG\nTTCGTCCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTC\nATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTG\nCAGTACTCCTACATGGTGACTGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGAC\nATCCTGCAGCGGGTGCGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTG\nGCCCTGCGGTACCTCTCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCG\nCCCAACCTGGTCTACATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCT\nGGAGACATCCAGGTGGTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAG\nAGGATTGGCTGGCCCAATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAG\nGCTCCTGACCTGGTGCTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTC\nTCCCCTGCACCTGACTGCAGCCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCC\nAGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAA\nGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTATGGAAGCATCACCACC\nATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTGAGCCTTGTGGACGTC\nATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGCTTTGCTGTGCGATAC\nTTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTC\nACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTG\nACAGTGTTCCCTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCA\nGGCCCAGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATG\nGTCACCTTGGGCAATTCCTTCCTCCACAAACTGTGCTCTGGATTTGTTAGGATTTGCATG\nGATGAGGATGGGAATGAGAAGAGGCCCGGGGACGTCTGGACCTTGCCAGACCAGTGCCAC\nACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGAGTCATCGGGTCAACTGTGAC\nCGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCCTGTTAAAGTGGAAGAGACCTGT\nGGCTGCCGCTGGACCTGCCCCTGCGTGTGCACAGGCAGCTCCACTCGGCACATCGTGACC\nTTTGATGGGCAGAATTTCAAGCTGACTGGCAGCTGTTCTTATGTCCTATTTCAAAACAAG\nGAGCAGGACCTGGAGGTGATTCTCCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGC\nTGCATGAAATCCATCGAGGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATG\nGAGGTGACGGTGAATGGGAGACTGGTCTCTGTTCCTTACGTGGGTGGGAACATGGAAGTC\nAACGTTTATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACA\nTTCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTCAAAG\nACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCATGCTGAGGGAT\nGGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGACTGTGCAGCGGCCAGGG\nCAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGTCCCCGACAGCTCCCACTGCCAG\nGTCCTCCTCTTACCACTGTTTGCTGAATGCCACAAGGTCCTGGCTCCAGCCACATTCTAT\nGCCATCTGCCAGCAGGACAGTTGCCACCAGGAGCAAGTGTGTGAGGTGATCGCCTCTTAT\nGCCCACCTCTGTCGGACCAACGGGGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCT\nATGTCATGCCCACCATCTCTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGT\nGATGGCAACGTGAGCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGAT\nAAAGTCATGTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAG\nGATGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAGATC\nTGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCCACGGCCAAA\nGCTCCCACGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAATGCAGACCAGTGCTGC\nCCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACCTGCCCCCAGTGCCTCACTGT\nGAACGTGGCCTCCAGCCCACACTGACCAACCCTGGCGAGTGCAGACCCAACTTCACCTGC\nGCCTGCAGGAAGGAGGAGTGCAAAAGAGTGTCCCCACCCTCCTGCCCCCCGCACCGTTTG\nCCCACCCTTCGGAAGACCCAGTGCTGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAAC\nTCCACAGTGAGCTGTCCCCTTGGGTACTTGGCCTCAACTGCCACCAATGACTGTGGCTGT\nACCACAACCACCTGCCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTG\nGGCCAGTTCTGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTG\nATGGGCCTCCGCGTGGCCCAGTGCTCCCAGAAGCCCTGTGAGGACAGCTGTCGGTCGGGC\nTTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTGCCTGTGAG\nGTGGTGACTGGCTCACCGCGGGGGGACTCCCAGTCTTCCTGGAAGAGTGTCGGCTCCCAG\nTGGGCCTCCCCGGAGAACCCCTGCCTCATCAATGAGTGTGTCCGAGTGAAGGAGGAGGTC\nTTTATACAACAAAGGAACGTCTCCTGCCCCCAGCTGGAGGTCCCTGTCTGCCCCTCGGGC\nTTTCAGCTGAGCTGTAAGACCTCAGCGTGCTGCCCAAGCTGTCGCTGTGAGCGCATGGAG\nGCCTGCATGCTCAATGGCACTGTCATTGGGCCCGGGAAGACTGTGATGATCGATGTGTGC\nACGACCTGCCGCTGCATGGTGCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGG\nAAGACCACCTGCAACCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGT\nTGTGGGAGATGTTTGCCTACGGCTTGCACCATTCAGCTAAGAGGAGGACAGATCATGACA\nCTGAAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATGAG\nAGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCCACCCTTTGATGAACACAAG\nTGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCTGTGACACATGTGAG\nGAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATGTCAAGGTGGGAAGCTGTAAG\nTCTGAAGTAGAGGTGGATATCCACTACTGCCAGGGCAAATGTGCCAGCAAAGCCATGTAC\nTCCATTGACATCAACGATGTGCAGGACCAGTGCTCCTGCTGCTCTCCGACACGGACGGAG\nCCCATGCAGGTGGCCCTGCACTGCACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAAT\nGCCATGGAGTGCAAATGCTCCCCCAGGAAGTGCAGCAAGTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00093",
                  "name": "VWC"
                },
                {
                  "identifier": "PF00092",
                  "name": "VWA"
                },
                {
                  "identifier": "PF00094",
                  "name": "VWD"
                },
                {
                  "identifier": "PF08742",
                  "name": "C8"
                },
                {
                  "identifier": "PF01826",
                  "name": "TIL"
                },
                {
                  "identifier": "PF16164",
                  "name": "VWA_N2"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "platelet alpha granule"
                },
                {
                  "category": "component",
                  "description": "Weibel-Palade body"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "proteinaceous extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "platelet alpha granule lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum"
                },
                {
                  "category": "function",
                  "description": "immunoglobulin binding"
                },
                {
                  "category": "function",
                  "description": "protease binding"
                },
                {
                  "category": "function",
                  "description": "protein homodimerization activity"
                },
                {
                  "category": "function",
                  "description": "collagen binding"
                },
                {
                  "category": "function",
                  "description": "identical protein binding"
                },
                {
                  "category": "function",
                  "description": "chaperone binding"
                },
                {
                  "category": "function",
                  "description": "glycoprotein binding"
                },
                {
                  "category": "function",
                  "description": "integrin binding"
                },
                {
                  "category": "function",
                  "description": "protein N-terminus binding"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, intrinsic pathway"
                },
                {
                  "category": "process",
                  "description": "cell-substrate adhesion"
                },
                {
                  "category": "process",
                  "description": "response to wounding"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "liver development"
                },
                {
                  "category": "process",
                  "description": "placenta development"
                },
                {
                  "category": "process",
                  "description": "protein homooligomerization"
                },
                {
                  "category": "process",
                  "description": "cell adhesion"
                },
                {
                  "category": "process",
                  "description": "hemostasis"
                },
                {
                  "category": "process",
                  "description": "extracellular matrix organization"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                }
              ]
            },
            "_id": "P04275",
            "_source": "Swiss-Prot"
          },
          "_position": "3"
        },
        {
          "id": "BE0002117",
          "name": "Phytanoyl-CoA dioxygenase, peroxisomal",
          "organism": "Human",
          "actions": {
            "action": "antagonist"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Chen C, Wang Q, Fang X, Xu Q, Chi C, Gu J: Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII. J Biol Chem. 2001 Dec 7;276(49):46340-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11574539",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Phytanoyl-CoA dioxygenase, peroxisomal",
            "general-function": "Phytanoyl-coa dioxygenase activity",
            "specific-function": "Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA.",
            "gene-name": "PHYH",
            "locus": "10pter-p11.2",
            "cellular-location": "Peroxisome",
            "transmembrane-regions": "",
            "signal-regions": "",
            "theoretical-pi": "8.65",
            "molecular-weight": "38538.065",
            "chromosome-location": "10",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:8940"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PHYH"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF023462"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "2564671"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "O14832"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PAHX_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "1.14.11.18",
                "PAHX",
                "PhyH",
                "Phytanic acid oxidase",
                "Phytanoyl-CoA alpha-hydroxylase"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004152|Phytanoyl-CoA dioxygenase, peroxisomal\nMEQLRAAARLQIVLGHLGRPSAGAVVAHPTSGTISSASFHPQQFQYTLDNNVLTLEQRKF\nYEENGFLVIKNLVPDADIQRFRNEFEKICRKEVKPLGLTVMRDVTISKSEYAPSEKMITK\nVQDFQEDKELFRYCTLPEILKYVECFTGPNIMAMHTMLINKPPDSGKKTSRHPLHQDLHY\nFPFRPSDLIVCAWTAMEHISRNNGCLVVLPGTHKGSLKPHDYPKWEGGVNKMFHGIQDYE\nENKARVHLVMEKGDTVFFHPLLIHGSGQNKTQGFRKAISCHFASADCHYIDVKGTSQENI\nEKEVVGIAHKFFGAENSVNLKDIWMFRARLVKGERTNL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016686|Phytanoyl-CoA dioxygenase, peroxisomal (PHYH)\nATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAG\nGTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTG\nAAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAAC\nAAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTAT\nTTCCCCTTCAGGCCCAGCGATCTCATCGTTTGCGCCTGGACGGCGATGGAGCACATCAGC\nCGGAACAACGGCTGTCTGGTTGTGCTCCCAGGCACACACAAGGGCTCCCTGAAGCCCCAC\nGATTACCCCAAGTGGGAGGGGGGAGTTAACAAAATGTTCCACGGGATCCAGGACTACGAG\nGAAAACAAGGCCCGGGTGCACCTGGTGATGGAGAAGGGCGACACTGTTTTCTTCCATCCT\nTTGCTCATCCACGGATCTGGTCAGAATAAAACCCAGGGATTCCGGAAGGCAATTTCCTGC\nCATTTCGCCAGTGCCGATTGCCACTACATTGACGTGAAGGGCACCAGTCAAGAAAACATC\nGAGAAGGAAGTTGTAGGAATAGCACATAAATTCTTTGGAGCTGAAAATAGCGTGAACTTG\nAAGGATATTTGGATGTTTCGAGCTCGACTTGTGAAAGGAGAAAGAACCAATCTTTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF05721",
                "name": "PhyH"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "peroxisomal matrix"
                },
                {
                  "category": "component",
                  "description": "mitochondrion"
                },
                {
                  "category": "component",
                  "description": "peroxisome"
                },
                {
                  "category": "function",
                  "description": "phytanoyl-CoA dioxygenase activity"
                },
                {
                  "category": "function",
                  "description": "cofactor binding"
                },
                {
                  "category": "function",
                  "description": "metal ion binding"
                },
                {
                  "category": "function",
                  "description": "L-ascorbic acid binding"
                },
                {
                  "category": "process",
                  "description": "cellular lipid metabolic process"
                },
                {
                  "category": "process",
                  "description": "fatty acid alpha-oxidation"
                },
                {
                  "category": "process",
                  "description": "isoprenoid metabolic process"
                },
                {
                  "category": "process",
                  "description": "methyl-branched fatty acid metabolic process"
                },
                {
                  "category": "process",
                  "description": "small molecule metabolic process"
                }
              ]
            },
            "_id": "O14832",
            "_source": "Swiss-Prot"
          },
          "_position": "4"
        },
        {
          "id": "BE0002118",
          "name": "Asialoglycoprotein receptor 2",
          "organism": "Human",
          "actions": {
            "action": "binder"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K: The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005 Jun;3(6):1257-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15946216",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Asialoglycoprotein receptor 2",
            "general-function": "Carbohydrate binding",
            "specific-function": "Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface.",
            "gene-name": "ASGR2",
            "locus": "17p",
            "cellular-location": "Membrane",
            "transmembrane-regions": "59-79",
            "signal-regions": "",
            "theoretical-pi": "6.34",
            "molecular-weight": "35092.04",
            "chromosome-location": "17",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:743"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "ASGR2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M11025"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "179081"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P07307"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "ASGR2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "ASGP-R 2",
                "C-type lectin domain family 4 member H2",
                "CLEC4H2",
                "Hepatic lectin H2",
                "HL-2"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037163|Asialoglycoprotein receptor 2\nMAKDFQDIQQLSSEENDHPFHQGEGPGTRRLNPRRGNPFLKGPPPAQPLAQRLCSMVCFS\nLLALSFNILLLVVICVTGSQSEGHGGAQLQAELRSLKEAFSNFSSSTLTEVQAISTHGGS\nVGDKITSLGAKLEKQQQDLKADHDALLFHLKHFPVDLRFVACQMELLHSNGSQRTCCPVN\nWVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDS\nDGSWKWVDGTDYRHNYKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVC\nEKRRNATGEVA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011535|Asialoglycoprotein receptor 2 (ASGR2)\nATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTC\nCATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTG\nAAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGT\nCTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAA\nAGTGAGGGTCACAGGGGTGCACAGCTGCAAGCCGAGCTGCGGAGCCTGAAGGAAGCTTTC\nAGCAACTTCTCCTCGAGCACCCTGACGGAGGTCCAGGCAATCAGCACCCACGGAGGCAGC\nGTGGGTGACAAGATCACATCCCTAGGAGCCAAGCTGGAGAAACAGCAGCAGGACCTGAAA\nGCAGATCACGATGCCCTGCTCTTCCATCTGAAGCACTTCCCCGTGGACCTGCGCTTCGTG\nGCCTGCCAGATGGAGCTCCTCCACAGCAACGGCTCCCAAAGGACCTGCTGCCCCGTCAAC\nTGGGTGGAGCACCAAGGCAGCTGCTACTGGTTCTCTCACTCCGGGAAGGCCTGGGCTGAG\nGCGGAGAAGTACTGCCAGCTGGAGAACGCACACCTGGTGGTCATCAACTCCTGGGAGGAG\nCAGAAATTCATTGTACAACACACGAACCCCTTCAATACCTGGATAGGTCTCACGGACAGT\nGATGGCTCTTGGAAATGGGTGGATGGCACAGACTATAGGCACAACTACAAGAACTGGGCT\nGTCACTCAGCCAGATAATTGGCACGGGCACGAGCTGGGTGGAAGTGAAGACTGTGTTGAA\nGTCCAGCCGGATGGCCGCTGGAACGATGACTTCTGCCTGCAGGTGTACCGCTGGGTGTGT\nGAGAAAAGGCGGAATGCCACCGGCGAGGTGGCCTGA"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00059",
                  "name": "Lectin_C"
                },
                {
                  "identifier": "PF03954",
                  "name": "Lectin_N"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "function",
                  "description": "asialoglycoprotein receptor activity"
                },
                {
                  "category": "function",
                  "description": "carbohydrate binding"
                },
                {
                  "category": "process",
                  "description": "regulation of protein stability"
                },
                {
                  "category": "process",
                  "description": "glycoprotein metabolic process"
                },
                {
                  "category": "process",
                  "description": "receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "bone mineralization"
                },
                {
                  "category": "process",
                  "description": "lipid homeostasis"
                }
              ]
            },
            "_id": "P07307",
            "_source": "Swiss-Prot"
          },
          "_position": "6"
        },
        {
          "id": "BE0001098",
          "name": "78 kDa glucose-regulated protein",
          "organism": "Human",
          "actions": {
            "action": "chaperone"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108",
          "known-action": "unknown",
          "polypeptide": {
            "name": "78 kDa glucose-regulated protein",
            "general-function": "Unfolded protein binding",
            "specific-function": "Probably plays a role in facilitating the assembly of multimeric protein complexes inside the endoplasmic reticulum. Involved in the correct folding of proteins and degradation of misfolded proteins via its interaction with DNAJC10, probably to facilitate the release of DNAJC10 from its substrate.",
            "gene-name": "HSPA5",
            "locus": "9q33-q34.1",
            "cellular-location": "Endoplasmic reticulum lumen",
            "transmembrane-regions": "",
            "signal-regions": "1-18",
            "theoretical-pi": "4.8",
            "molecular-weight": "72332.425",
            "chromosome-location": "9",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:5238"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "HSPA5"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M19645"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "386758"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P11021"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "GRP78_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "BiP",
                "Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78",
                "GRP-78",
                "GRP78",
                "Heat shock 70 kDa protein 5",
                "Immunoglobulin heavy chain-binding protein"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019062|78 kDa glucose-regulated protein\nMKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR\nITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV\nEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ\nRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG\nVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS\nSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV\nLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC\nPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG\nTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER\nMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE\nKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019063|78 kDa glucose-regulated protein (HSPA5)\nATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG\nGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCC\nTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC\nATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC\nAAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC\nCGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT\nGAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT\nGCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT\nTTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA\nCGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC\nGAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC\nCTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT\nGTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG\nCGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAA\nGACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAACGGGCCCTGTCT\nTCTCAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAG\nACCCTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAG\nCCCGTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTT\nCTTGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAAT\nGGCAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTC\nCAGGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGATGTATGT\nCCCCTTACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAACTGATTCCAAGGAAC\nACAGTGGTGCCTACCAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACT\nGTTACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGT\nACATTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACC\nTTTGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAAC\nAAAAATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGG\nATGGTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTCAAGGAGCGCATTGAT\nACTAGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAA\nAAGCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAA\nAAGATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAG\nAAGGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCT\nCCCCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00012",
                "name": "HSP70"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "myelin sheath"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "melanosome"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "component",
                  "description": "midbody"
                },
                {
                  "category": "component",
                  "description": "integral component of endoplasmic reticulum membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum chaperone complex"
                },
                {
                  "category": "component",
                  "description": "mitochondrion"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "smooth endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum-Golgi intermediate compartment"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "nucleus"
                },
                {
                  "category": "function",
                  "description": "misfolded protein binding"
                },
                {
                  "category": "function",
                  "description": "ATPase activity"
                },
                {
                  "category": "function",
                  "description": "glycoprotein binding"
                },
                {
                  "category": "function",
                  "description": "unfolded protein binding"
                },
                {
                  "category": "function",
                  "description": "protein domain specific binding"
                },
                {
                  "category": "function",
                  "description": "ubiquitin protein ligase binding"
                },
                {
                  "category": "function",
                  "description": "ATP binding"
                },
                {
                  "category": "function",
                  "description": "chaperone binding"
                },
                {
                  "category": "function",
                  "description": "enzyme binding"
                },
                {
                  "category": "function",
                  "description": "ribosome binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "process",
                  "description": "positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress"
                },
                {
                  "category": "process",
                  "description": "PERK-mediated unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "IRE1-mediated unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "regulation of protein folding in endoplasmic reticulum"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell migration"
                },
                {
                  "category": "process",
                  "description": "activation of signaling protein activity involved in unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "cellular response to interleukin-4"
                },
                {
                  "category": "process",
                  "description": "ER-associated ubiquitin-dependent protein catabolic process"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "cerebellum structural organization"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein ubiquitination"
                },
                {
                  "category": "process",
                  "description": "ER overload response"
                },
                {
                  "category": "process",
                  "description": "cerebellar Purkinje cell layer development"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "maintenance of protein localization in endoplasmic reticulum"
                },
                {
                  "category": "process",
                  "description": "substantia nigra development"
                },
                {
                  "category": "process",
                  "description": "ATF6-mediated unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "platelet degranulation"
                },
                {
                  "category": "process",
                  "description": "regulation of ATF6-mediated unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "protein folding in endoplasmic reticulum"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "toxin transport"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "cellular response to glucose starvation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of protein homodimerization activity"
                },
                {
                  "category": "process",
                  "description": "regulation of IRE1-mediated unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of transforming growth factor beta receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "endoplasmic reticulum unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "cellular response to antibiotic"
                },
                {
                  "category": "process",
                  "description": "regulation of PERK-mediated unfolded protein response"
                }
              ]
            },
            "_id": "P11021",
            "_source": "Swiss-Prot"
          },
          "_position": "7"
        },
        {
          "id": "BE0002109",
          "name": "Calreticulin",
          "organism": "Human",
          "actions": {
            "action": "chaperone"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9525969\r\n# Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2007 Sep 26;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17899080\r\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108\r\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Calreticulin",
            "general-function": "Zinc ion binding",
            "specific-function": "Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).",
            "gene-name": "CALR",
            "locus": "19p13.3-p13.2",
            "cellular-location": "Endoplasmic reticulum lumen",
            "transmembrane-regions": "",
            "signal-regions": "1-17",
            "theoretical-pi": "4.04",
            "molecular-weight": "48141.2",
            "chromosome-location": "19",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1455"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "CALR"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M32294"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "337487"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P27797"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "CALR_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Calregulin",
                "CRP55",
                "CRTC",
                "Endoplasmic reticulum resident protein 60",
                "ERp60",
                "grp60",
                "HACBP"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011528|Calreticulin\nMLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE\nEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT\nDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN\nTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE\nHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS\nPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK\nQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0011529|Calreticulin (CALR)\nATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCC\nGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC\nAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG\nGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT\nTTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG\nCAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA\nGACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC\nACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC\nATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC\nACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG\nGACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT\nGAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG\nCATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG\nTGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC\nGACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT\nCCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG\nGTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG\nGAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA\nCAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG\nGAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC\nAAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00262",
                "name": "Calreticulin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "cell surface"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "Golgi apparatus"
                },
                {
                  "category": "component",
                  "description": "endocytic vesicle lumen"
                },
                {
                  "category": "component",
                  "description": "smooth endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "nucleus"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "acrosomal vesicle"
                },
                {
                  "category": "component",
                  "description": "cytosol"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "integral component of lumenal side of endoplasmic reticulum membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "MHC class I peptide loading complex"
                },
                {
                  "category": "component",
                  "description": "perinuclear region of cytoplasm"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "polysome"
                },
                {
                  "category": "component",
                  "description": "sarcoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "external side of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "intracellular"
                },
                {
                  "category": "component",
                  "description": "proteinaceous extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "function",
                  "description": "ubiquitin protein ligase binding"
                },
                {
                  "category": "function",
                  "description": "DNA binding"
                },
                {
                  "category": "function",
                  "description": "glycoprotein binding"
                },
                {
                  "category": "function",
                  "description": "mRNA binding"
                },
                {
                  "category": "function",
                  "description": "androgen receptor binding"
                },
                {
                  "category": "function",
                  "description": "iron ion binding"
                },
                {
                  "category": "function",
                  "description": "hormone binding"
                },
                {
                  "category": "function",
                  "description": "chaperone binding"
                },
                {
                  "category": "function",
                  "description": "zinc ion binding"
                },
                {
                  "category": "function",
                  "description": "poly(A) RNA binding"
                },
                {
                  "category": "function",
                  "description": "integrin binding"
                },
                {
                  "category": "function",
                  "description": "carbohydrate binding"
                },
                {
                  "category": "function",
                  "description": "complement component C1q binding"
                },
                {
                  "category": "function",
                  "description": "peptide binding"
                },
                {
                  "category": "function",
                  "description": "protein binding involved in protein folding"
                },
                {
                  "category": "function",
                  "description": "unfolded protein binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "process",
                  "description": "protein folding in endoplasmic reticulum"
                },
                {
                  "category": "process",
                  "description": "negative regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "cellular senescence"
                },
                {
                  "category": "process",
                  "description": "response to estradiol"
                },
                {
                  "category": "process",
                  "description": "response to testosterone"
                },
                {
                  "category": "process",
                  "description": "sequestering of calcium ion"
                },
                {
                  "category": "process",
                  "description": "glucocorticoid receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "cellular calcium ion homeostasis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell cycle"
                },
                {
                  "category": "process",
                  "description": "positive regulation of substrate adhesion-dependent cell spreading"
                },
                {
                  "category": "process",
                  "description": "regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of retinoic acid receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "peptide antigen assembly with MHC class I protein complex"
                },
                {
                  "category": "process",
                  "description": "protein N-linked glycosylation via asparagine"
                },
                {
                  "category": "process",
                  "description": "endoplasmic reticulum unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent"
                },
                {
                  "category": "process",
                  "description": "positive regulation of dendritic cell chemotaxis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "response to drug"
                },
                {
                  "category": "process",
                  "description": "positive regulation of gene expression"
                },
                {
                  "category": "process",
                  "description": "negative regulation of neuron differentiation"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "protein export from nucleus"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "negative regulation of translation"
                },
                {
                  "category": "process",
                  "description": "regulation of transcription, DNA-templated"
                },
                {
                  "category": "process",
                  "description": "regulation of meiotic nuclear division"
                },
                {
                  "category": "process",
                  "description": "positive regulation of phagocytosis"
                },
                {
                  "category": "process",
                  "description": "protein stabilization"
                },
                {
                  "category": "process",
                  "description": "protein folding"
                },
                {
                  "category": "process",
                  "description": "cellular response to lithium ion"
                },
                {
                  "category": "process",
                  "description": "cortical actin cytoskeleton organization"
                },
                {
                  "category": "process",
                  "description": "cell cycle arrest"
                },
                {
                  "category": "process",
                  "description": "spermatogenesis"
                },
                {
                  "category": "process",
                  "description": "protein localization to nucleus"
                },
                {
                  "category": "process",
                  "description": "negative regulation of transcription from RNA polymerase II promoter"
                },
                {
                  "category": "process",
                  "description": "chaperone-mediated protein folding"
                },
                {
                  "category": "process",
                  "description": "ATF6-mediated unfolded protein response"
                },
                {
                  "category": "process",
                  "description": "negative regulation of intracellular steroid hormone receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "cardiac muscle cell differentiation"
                },
                {
                  "category": "process",
                  "description": "receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of DNA replication"
                },
                {
                  "category": "process",
                  "description": "protein maturation by protein folding"
                }
              ]
            },
            "_id": "P27797",
            "_source": "Swiss-Prot"
          },
          "_position": "7"
        },
        {
          "id": "BE0001011",
          "name": "Calnexin",
          "organism": "Human",
          "actions": {
            "action": "chaperone"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9525969\r\n# Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost. 2004 Jul;92(1):23-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15213841\r\n# Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2007 Sep 26;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17899080\r\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Calnexin",
            "general-function": "Poly(a) rna binding",
            "specific-function": "Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins. Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation. Additionally it may play a role in receptor-mediated endocytosis at the synapse.",
            "gene-name": "CANX",
            "locus": "5q35",
            "cellular-location": "Endoplasmic reticulum membrane",
            "transmembrane-regions": "482-502",
            "signal-regions": "1-20",
            "theoretical-pi": "4.21",
            "molecular-weight": "67567.695",
            "chromosome-location": "5",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:1473"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "CANX"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "L10284"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "186523"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P27824"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "CALX_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "IP90",
                "Major histocompatibility complex class I antigen-binding protein p88",
                "p90"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0002013|Calnexin\nMEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY\nKAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL\nVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH\nDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL\nILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK\nPDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC\nESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS\nAIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER\nPWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE\nEEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016282|Calnexin (CANX)\nATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT\nCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA\nGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC\nAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG\nTCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT\nGATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT\nGTGTTGATGTCTCGGGCCAAGCATCATGCCATCTCTGCTAAACTGAACAAGCCCTTCCTG\nTTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT\nGGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT\nGACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG\nCACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG\nAGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA\nATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA\nAATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA\nGACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG\nCCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC\nGAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG\nGATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT\nGAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA\nGGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG\nAAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT\nGCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT\nTGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT\nGCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC\nCCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC\nTTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT\nCAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG\nGAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT\nGGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG\nAACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF00262",
                "name": "Calreticulin"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "neuronal cell body"
                },
                {
                  "category": "component",
                  "description": "ER-mitochondrion membrane contact site"
                },
                {
                  "category": "component",
                  "description": "melanosome"
                },
                {
                  "category": "component",
                  "description": "integral component of lumenal side of endoplasmic reticulum membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "dendritic spine"
                },
                {
                  "category": "component",
                  "description": "myelin sheath"
                },
                {
                  "category": "component",
                  "description": "axon"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "rough endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "protein complex"
                },
                {
                  "category": "component",
                  "description": "smooth endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "ribosome"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum"
                },
                {
                  "category": "component",
                  "description": "dendrite cytoplasm"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "function",
                  "description": "carbohydrate binding"
                },
                {
                  "category": "function",
                  "description": "poly(A) RNA binding"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "process",
                  "description": "protein folding"
                },
                {
                  "category": "process",
                  "description": "protein folding in endoplasmic reticulum"
                },
                {
                  "category": "process",
                  "description": "aging"
                },
                {
                  "category": "process",
                  "description": "protein secretion"
                },
                {
                  "category": "process",
                  "description": "synaptic vesicle endocytosis"
                },
                {
                  "category": "process",
                  "description": "clathrin-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of peptide antigen via MHC class I"
                },
                {
                  "category": "process",
                  "description": "protein N-linked glycosylation via asparagine"
                },
                {
                  "category": "process",
                  "description": "chaperone-mediated protein folding"
                },
                {
                  "category": "process",
                  "description": "antigen processing and presentation of exogenous peptide antigen via MHC class II"
                }
              ]
            },
            "_id": "P27824",
            "_source": "Swiss-Prot"
          },
          "_position": "8"
        },
        {
          "id": "BE0002119",
          "name": "Protein ERGIC-53",
          "organism": "Human",
          "actions": {
            "action": "chaperone"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ: LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost. 2003 Nov;1(11):2360-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14629470\r\n# Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14726380",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Protein ERGIC-53",
            "general-function": "Unfolded protein binding",
            "specific-function": "Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or both. The LMAN1-MCFD2 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins.",
            "gene-name": "LMAN1",
            "locus": "18q21.3-q22",
            "cellular-location": "Endoplasmic reticulum-Golgi intermediate compartment membrane",
            "transmembrane-regions": "478-498",
            "signal-regions": "1-30",
            "theoretical-pi": "6.76",
            "molecular-weight": "57548.665",
            "chromosome-location": "18",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6631"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "LMAN1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X71661"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "433938"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P49257"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "LMAN1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "ER-Golgi intermediate compartment 53 kDa protein",
                "ERGIC53",
                "F5F8D",
                "Gp58",
                "Intracellular mannose-specific lectin MR60",
                "Lectin mannose-binding 1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019239|Protein ERGIC-53\nMAGSRQRGLRARVRPLFCALLLSLGRFVRGDGVGGDPAVALPHRRFEYKYSFKGPHLVQS\nDGTVPFWAHAGNAIPSSDQIRVAPSLKSQRGSVWTKTKAAFENWEVEVTFRVTGRGRIGA\nDGLAIWYAENQGLEGPVFGSADLWNGVGIFFDSFDNDGKKNNPAIVIIGNNGQIHYDHQN\nDGASQALASCQRDFRNKPYPVRAKITYYQNTLTVMINNGFTPDKNDYEFCAKVENMIIPA\nQGHFGISAATGGLADDHDVLSFLTFQLTEPGKEPPTPDKEISEKEKEKYQEEFEHFQQEL\nDKKKEEFQKGHPDLQGQPAEEIFESVGDRELRQVFEGQNRIHLEIKQLNRQLDMILDEQR\nRYVSSLTEEISKRGAGMPGQHGQITQQELDTVVKTQHEILRQVNEMKNSMSETVRLVSGM\nQHPGSAGGVYETTQHFIDIKEHLHIVKRDIDNLVQRNMPSNEKPKCPELPPFPSCLSTVH\nFIIFVVVQTVLFIGYIMYRSQQEAAAKKFF"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019240|Protein ERGIC-53 (LMAN1)\nATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTG\nCTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCG\nTTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGC\nGACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATT\nCGAGTAGCACCATCTTTAAAAAGCCAAAGAGGCTCAGTGTGGACAAAGACAAAAGCGGCC\nTTTGAGAACTGGGAAGTTGAGGTGACATTTCGAGTGACTGGAAGAGGTCGAATTGGAGCT\nGATGGCCTAGCAATTTGGTATGCAGAAAATCAAGGCTTGGAGGGCCCTGTGTTTGGATCA\nGCTGATCTGTGGAATGGTGTTGGAATATTTTTTGATTCTTTTGACAATGATGGAAAGAAA\nAATAATCCTGCTATAGTAATTATAGGCAACAATGGACAAATCCATTATGACCATCAAAAT\nGACGGGGCTAGTCAAGCTTTGGCAAGTTGCCAGAGGGACTTCCGCAACAAACCCTATCCT\nGTCCGAGCAAAGATTACCTATTACCAGAACACACTGACAGTAATGATCAATAATGGCTTT\nACACCAGATAAAAATGATTATGAATTTTGTGCCAAAGTGGAAAATATGATTATCCCTGCA\nCAAGGGCATTTTGGAATATCTGCTGCAACTGGAGGTCTTGCAGATGACCATGATGTCCTT\nTCTTTTCTGACTTTCCAGTTGACTGAACCTGGAAAAGAGCCGCCCACACCAGATAAAGAA\nATTTCGGAAAAGGAAAAAGAAAAGTATCAGGAGGAATTTGAGCACTTTCAACAAGAATTG\nGATAAAAAAAAAGAGGAATTCCAGAAGGGCCACCCCGACCTCCAAGGGCAGCCTGCGGAG\nGAAATATTTGAGAGTGTAGGAGATCGAGAGCTAAGACAAGTCTTTGAAGGACAGAATCGT\nATTCATCTTGAAATCAAGCAGCTGAACCGGCAGTTAGATATGATTCTTGATGAACAGAGA\nAGATATGTCTCTTCCTTAACAGAGGAAATCTCTAAAAGAGGAGCAGGAATGCCTGGGCAG\nCATGGGCAGATTACTCAACAAGAACTGGATACTGTTGTGAAAACTCAGCATGAGATTCTG\nAGACAAGTAAATGAAATGAAAAATTCCATGAGTGAAACCGTCAGACTGGTCAGTGGAATG\nCAGCACCCTGGCTCTGCTGGAGGCGTCTATGAGACAACACAGCACTTCATTGACATCAAA\nGAGCACCTGCACATAGTAAAGAGGGACATAGATAACTTAGTGCAGCGAAATATGCCATCA\nAATGAAAAGCCGAAATGCCCAGAACTACCACCATTTCCATCATGTTTGTCTACGGTCCAC\nTTCATTATATTTGTTGTGGTGCAAACTGTATTATTCATTGGTTATATCATGTATAGGTCT\nCAGCAAGAAGCAGCTGCCAAAAAATTCTTTTGA"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF03388",
                "name": "Lectin_leg-like"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "endoplasmic reticulum-Golgi intermediate compartment"
                },
                {
                  "category": "component",
                  "description": "integral component of membrane"
                },
                {
                  "category": "component",
                  "description": "ER to Golgi transport vesicle membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "host cell perinuclear region of cytoplasm"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum-Golgi intermediate compartment membrane"
                },
                {
                  "category": "component",
                  "description": "sarcomere"
                },
                {
                  "category": "component",
                  "description": "membrane"
                },
                {
                  "category": "component",
                  "description": "Golgi membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "function",
                  "description": "metal ion binding"
                },
                {
                  "category": "function",
                  "description": "mannose binding"
                },
                {
                  "category": "function",
                  "description": "unfolded protein binding"
                },
                {
                  "category": "process",
                  "description": "protein N-linked glycosylation via asparagine"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "Golgi organization"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "COPII vesicle coating"
                },
                {
                  "category": "process",
                  "description": "endoplasmic reticulum organization"
                },
                {
                  "category": "process",
                  "description": "protein transport"
                },
                {
                  "category": "process",
                  "description": "ER to Golgi vesicle-mediated transport"
                },
                {
                  "category": "process",
                  "description": "positive regulation of organelle organization"
                },
                {
                  "category": "process",
                  "description": "membrane organization"
                },
                {
                  "category": "process",
                  "description": "protein folding"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                }
              ]
            },
            "_id": "P49257",
            "_source": "Swiss-Prot"
          },
          "_position": "9"
        },
        {
          "id": "BE0002110",
          "name": "Prolow-density lipoprotein receptor-related protein 1",
          "organism": "Human",
          "actions": {
            "action": "modulator"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Franchini M, Montagnana M: Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011 Jun;49(6):967-70. Epub 2011 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21391865",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Prolow-density lipoprotein receptor-related protein 1",
            "general-function": "Receptor activity",
            "specific-function": "Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance of chylomicron remnants and activated LRPAP1 (alpha 2-macroglobulin), as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate cellular events, such as APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission.Functions as a receptor for Pseudomonas aeruginosa exotoxin A.",
            "gene-name": "LRP1",
            "locus": "12q13-q14",
            "cellular-location": "Cell membrane",
            "transmembrane-regions": "4420-4444",
            "signal-regions": "1-19",
            "theoretical-pi": "5.02",
            "molecular-weight": "504601.695",
            "chromosome-location": "12",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:6692"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "LRP1"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "X13916"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "34339"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q07954"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "LRP1_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "A2MR",
                "Alpha-2-macroglobulin receptor",
                "APOER",
                "Apolipoprotein E receptor",
                "APR",
                "LRP-1"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0037158|Prolow-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSQEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0019236|Prolow-density lipoprotein receptor-related protein 1 (LRP1)\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCAA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGACGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACTCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF07645",
                  "name": "EGF_CA"
                },
                {
                  "identifier": "PF00057",
                  "name": "Ldl_recept_a"
                },
                {
                  "identifier": "PF00058",
                  "name": "Ldl_recept_b"
                },
                {
                  "identifier": "PF12662",
                  "name": "cEGF"
                },
                {
                  "identifier": "PF16472",
                  "name": "DUF5050"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "clathrin-coated vesicle"
                },
                {
                  "category": "component",
                  "description": "nucleolus"
                },
                {
                  "category": "component",
                  "description": "endocytic vesicle membrane"
                },
                {
                  "category": "component",
                  "description": "lysosomal membrane"
                },
                {
                  "category": "component",
                  "description": "integral component of plasma membrane"
                },
                {
                  "category": "component",
                  "description": "focal adhesion"
                },
                {
                  "category": "component",
                  "description": "cytoplasm"
                },
                {
                  "category": "component",
                  "description": "dendrite"
                },
                {
                  "category": "component",
                  "description": "neuronal cell body"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "endosome"
                },
                {
                  "category": "component",
                  "description": "receptor complex"
                },
                {
                  "category": "component",
                  "description": "coated pit"
                },
                {
                  "category": "function",
                  "description": "apolipoprotein binding"
                },
                {
                  "category": "function",
                  "description": "lipoprotein transporter activity"
                },
                {
                  "category": "function",
                  "description": "protein complex binding"
                },
                {
                  "category": "function",
                  "description": "poly(A) RNA binding"
                },
                {
                  "category": "function",
                  "description": "receptor activity"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "lipoprotein particle receptor binding"
                },
                {
                  "category": "process",
                  "description": "negative regulation of neuron apoptotic process"
                },
                {
                  "category": "process",
                  "description": "lipoprotein metabolic process"
                },
                {
                  "category": "process",
                  "description": "cell proliferation"
                },
                {
                  "category": "process",
                  "description": "beta-amyloid clearance"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cholesterol efflux"
                },
                {
                  "category": "process",
                  "description": "apoptotic cell clearance"
                },
                {
                  "category": "process",
                  "description": "negative regulation of platelet-derived growth factor receptor-beta signaling pathway"
                },
                {
                  "category": "process",
                  "description": "regulation of actin cytoskeleton organization"
                },
                {
                  "category": "process",
                  "description": "regulation of phospholipase A2 activity"
                },
                {
                  "category": "process",
                  "description": "lipoprotein transport"
                },
                {
                  "category": "process",
                  "description": "positive regulation of lipid transport"
                },
                {
                  "category": "process",
                  "description": "receptor-mediated endocytosis"
                },
                {
                  "category": "process",
                  "description": "aorta morphogenesis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of Wnt signaling pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of neuron projection development"
                },
                {
                  "category": "process",
                  "description": "protein kinase C-activating G-protein coupled receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "negative regulation of smooth muscle cell migration"
                },
                {
                  "category": "process",
                  "description": "regulation of cholesterol transport"
                },
                {
                  "category": "process",
                  "description": "retinoid metabolic process"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein transport"
                },
                {
                  "category": "process",
                  "description": "phototransduction, visible light"
                },
                {
                  "category": "process",
                  "description": "aging"
                }
              ]
            },
            "_id": "Q07954",
            "_source": "Swiss-Prot"
          },
          "_position": "10"
        },
        {
          "id": "BE0002120",
          "name": "Multiple coagulation factor deficiency protein 2",
          "organism": "Human",
          "actions": {
            "action": "modulator"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# :   \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15886209",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Multiple coagulation factor deficiency protein 2",
            "general-function": "Calcium ion binding",
            "specific-function": "The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors.",
            "gene-name": "MCFD2",
            "locus": "2p21",
            "cellular-location": "Endoplasmic reticulum-Golgi intermediate compartment",
            "transmembrane-regions": "",
            "signal-regions": "1-26",
            "theoretical-pi": "4.25",
            "molecular-weight": "16390.175",
            "chromosome-location": "2",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:18451"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "MCFD2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "AF475284"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "20799383"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "Q8NI22"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "MCFD2_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "Neural stem cell-derived neuronal survival protein",
                "SDNSF"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0004158|Multiple coagulation factor deficiency protein 2\nMTMRSLLRTPFLCGLLWAFCAPGARAEEPAASFSQPGSMGLDKNTVHDQEHIMEHLEGVI\nNKPEAEMSPQELQLHYFKMHDYDGNNLLDGLELSTAITHVHKEEGSEQAPLMSEDELINI\nIDGVLRDDDKNNDGYIDYAEFAKSLQ"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016687|Multiple coagulation factor deficiency protein 2 (MCFD2)\nATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGT\nGCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGC\nCTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATC\nAACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCAT\nGATTATGATGGCAATAATTTGCTTGATGGCTTAGAACTCTCCACAGCCATCACTCATGTC\nCATAAGGAGGAAGGGAGTGAACAGGCACCACTAATGAGTGAAGATGAACTGATTAACATA\nATAGATGGTGTTTTGAGAGATGATGACAAGAACAATGATGGATACATTGACTATGCTGAA\nTTTGCAAAATCACTGCAGTAG"
            },
            "pfams": {
              "pfam": {
                "identifier": "PF13499",
                "name": "EF-hand_7"
              }
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "ER to Golgi transport vesicle membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum membrane"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum-Golgi intermediate compartment membrane"
                },
                {
                  "category": "component",
                  "description": "Golgi membrane"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "process",
                  "description": "COPII vesicle coating"
                },
                {
                  "category": "process",
                  "description": "ER to Golgi vesicle-mediated transport"
                },
                {
                  "category": "process",
                  "description": "membrane organization"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "protein N-linked glycosylation via asparagine"
                },
                {
                  "category": "process",
                  "description": "protein transport"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                }
              ]
            },
            "_id": "Q8NI22",
            "_source": "Swiss-Prot"
          },
          "_position": "11"
        }
      ]
    },
    "enzymes": {
      "enzyme": [
        {
          "id": "BE0000048",
          "name": "Prothrombin",
          "organism": "Human",
          "actions": {
            "action": "activator"
          },
          "references": "# Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL: Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000 Mar 1;95(5):1694-702. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10688826\r\n# Ratnoff OD, Lewis JH: Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). Blood. 1975 Aug;46(2):161-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1139038\r\n# Anderson DM, Shelley S, Crick N, Buraglio M: No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002 Dec;42(12):1358-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12463731\r\n# Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B: The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion. 1990 Sep;30(7):591-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2402772\r\n# Lazarchick J, Ashby MA, Lazarchick JJ, Sens DA: Mechanism of factor VIII inactivation by human antibodies. IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec;16(6):497-501. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3099625",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Prothrombin",
            "general-function": "Thrombospondin receptor activity",
            "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.",
            "gene-name": "F2",
            "locus": "11p11-q12",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-24",
            "theoretical-pi": "5.7",
            "molecular-weight": "70036.295",
            "chromosome-location": "11",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:3535"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "F2"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M17262"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "339641"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2362"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P00734"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "THRB_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.5",
                "Coagulation factor II"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00594",
                  "name": "Gla"
                },
                {
                  "identifier": "PF00051",
                  "name": "Kringle"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                },
                {
                  "identifier": "PF09396",
                  "name": "Thrombin_light"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "plasma membrane"
                },
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "blood microparticle"
                },
                {
                  "category": "component",
                  "description": "extracellular matrix"
                },
                {
                  "category": "component",
                  "description": "Golgi lumen"
                },
                {
                  "category": "component",
                  "description": "cytosol"
                },
                {
                  "category": "component",
                  "description": "extracellular exosome"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "function",
                  "description": "growth factor activity"
                },
                {
                  "category": "function",
                  "description": "receptor binding"
                },
                {
                  "category": "function",
                  "description": "thrombospondin receptor activity"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "cytosolic calcium ion homeostasis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of phosphatidylinositol 3-kinase signaling"
                },
                {
                  "category": "process",
                  "description": "cellular response to mechanical stimulus"
                },
                {
                  "category": "process",
                  "description": "fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "leukocyte migration"
                },
                {
                  "category": "process",
                  "description": "multicellular organismal development"
                },
                {
                  "category": "process",
                  "description": "positive regulation of reactive oxygen species metabolic process"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of astrocyte differentiation"
                },
                {
                  "category": "process",
                  "description": "peptidyl-glutamic acid carboxylation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of release of sequestered calcium ion into cytosol"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "negative regulation of fibrinolysis"
                },
                {
                  "category": "process",
                  "description": "regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of platelet activation"
                },
                {
                  "category": "process",
                  "description": "regulation of cell shape"
                },
                {
                  "category": "process",
                  "description": "regulation of gene expression"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of proteolysis"
                },
                {
                  "category": "process",
                  "description": "platelet activation"
                },
                {
                  "category": "process",
                  "description": "response to inactivity"
                },
                {
                  "category": "process",
                  "description": "positive regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "response to wounding"
                },
                {
                  "category": "process",
                  "description": "acute-phase response"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell growth"
                },
                {
                  "category": "process",
                  "description": "blood coagulation, intrinsic pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of cell proliferation"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "positive regulation of protein phosphorylation"
                },
                {
                  "category": "process",
                  "description": "cell surface receptor signaling pathway"
                },
                {
                  "category": "process",
                  "description": "positive regulation of collagen biosynthetic process"
                }
              ]
            },
            "_id": "P00734",
            "_source": "Swiss-Prot"
          },
          "inhibition-strength": "unknown",
          "induction-strength": "unknown",
          "_position": "12"
        },
        {
          "id": "BE0000380",
          "name": "Vitamin K-dependent protein C",
          "organism": "Human",
          "actions": {
            "action": "inactivator"
          },
          "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\r\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\r\n# Bereczky Z, Kovacs KB, Muszbek L: Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med. 2010 Dec;48 Suppl 1:S53-66. Epub 2010 Nov 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21054189",
          "known-action": "unknown",
          "polypeptide": {
            "name": "Vitamin K-dependent protein C",
            "general-function": "Serine-type endopeptidase activity",
            "specific-function": "Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts a protective effect on the endothelial cell barrier function (PubMed:25651845).",
            "gene-name": "PROC",
            "locus": "2q13-q14",
            "cellular-location": "Secreted",
            "transmembrane-regions": "",
            "signal-regions": "1-18",
            "theoretical-pi": "6.23",
            "molecular-weight": "52070.82",
            "chromosome-location": "2",
            "organism": {
              "_ncbi-taxonomy-id": "9606",
              "__text": "Human"
            },
            "external-identifiers": {
              "external-identifier": [
                {
                  "resource": "HUGO Gene Nomenclature Committee (HGNC)",
                  "identifier": "HGNC:9451"
                },
                {
                  "resource": "GenAtlas",
                  "identifier": "PROC"
                },
                {
                  "resource": "GenBank Gene Database",
                  "identifier": "M11228"
                },
                {
                  "resource": "GenBank Protein Database",
                  "identifier": "190334"
                },
                {
                  "resource": "Guide to Pharmacology",
                  "identifier": "2396"
                },
                {
                  "resource": "UniProtKB",
                  "identifier": "P04070"
                },
                {
                  "resource": "UniProt Accession",
                  "identifier": "PROC_HUMAN"
                }
              ]
            },
            "synonyms": {
              "synonym": [
                "3.4.21.69",
                "Anticoagulant protein C",
                "Autoprothrombin IIA",
                "Blood coagulation factor XIV"
              ]
            },
            "amino-acid-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0000757|Vitamin K-dependent protein C\nMWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECI\nEEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSC\nDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVK\nFPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGA\nVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDI\nALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVL\nNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLV\nSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP"
            },
            "gene-sequence": {
              "_format": "FASTA",
              "__text": ">lcl|BSEQ0020458|Vitamin K-dependent protein C (PROC)\nATGTGGCAGCTCACAAGCCTCCTGCTGTTCGTGGCCACCTGGGGAATTTCCGGCACACCA\nGCTCCTCTTGACTCAGTGTTCTCCAGCAGCGAGCGTGCCCACCAGGTGCTGCGGATCCGC\nAAACGTGCCAACTCCTTCCTGGAGGAGCTCCGTCACAGCAGCCTGGAGCGGGAGTGCATA\nGAGGAGATCTGTGACTTCGAGGAGGCCAAGGAAATTTTCCAAAATGTGGATGACACACTG\nGCCTTCTGGTCCAAGCACGTCGACGGTGACCAGTGCTTGGTCTTGCCCTTGGAGCACCCG\nTGCGCCAGCCTGTGCTGCGGGCACGGCACGTGCATCGACGGCATCGGCAGCTTCAGCTGC\nGACTGCCGCAGCGGCTGGGAGGGCCGCTTCTGCCAGCGCGAGGTGAGCTTCCTCAATTGC\nTCGCTGGACAACGGCGGCTGCACGCATTACTGCCTAGAGGAGGTGGGCTGGCGGCGCTGT\nAGCTGTGCGCCTGGCTACAAGCTGGGGGACGACCTCCTGCAGTGTCACCCCGCAGTGAAG\nTTCCCTTGTGGGAGGCCCTGGAAGCGGATGGAGAAGAAGCGCAGTCACCTGAAACGAGAC\nACAGAAGACCAAGAAGACCAAGTAGATCCGCGGCTCATTGATGGGAAGATGACCAGGCGG\nGGAGACAGCCCCTGGCAGGTGGTCCTGCTGGACTCAAAGAAGAAGCTGGCCTGCGGGGCA\nGTGCTCATCCACCCCTCCTGGGTGCTGACAGCGGCCCACTGCATGGATGAGTCCAAGAAG\nCTCCTTGTCAGGCTTGGAGAGTATGACCTGCGGCGCTGGGAGAAGTGGGAGCTGGACCTG\nGACATCAAGGAGGTCTTCGTCCACCCCAACTACAGCAAGAGCACCACCGACAATGACATC\nGCACTGCTGCACCTGGCCCAGCCCGCCACCCTCTCGCAGACCATAGTGCCCATCTGCCTC\nCCGGACAGCGGCCTTGCAGAGCGCGAGCTCAATCAGGCCGGCCAGGAGACCCTCGTGACG\nGGCTGGGGCTACCACAGCAGCCGAGAGAAGGAGGCCAAGAGAAACCGCACCTTCGTCCTC\nAACTTCATCAAGATTCCCGTGGTCCCGCACAATGAGTGCAGCGAGGTCATGAGCAACATG\nGTGTCTGAGAACATGCTGTGTGCGGGCATCCTCGGGGACCGGCAGGATGCCTGCGAGGGC\nGACAGTGGGGGGCCCATGGTCGCCTCCTTCCACGGCACCTGGTTCCTGGTGGGCCTGGTG\nAGCTGGGGTGAGGGCTGTGGGCTCCTTCACAACTACGGCGTTTACACCAAAGTCAGCCGC\nTACCTCGACTGGATCCATGGGCACATCAGAGACAAGGAAGCCCCCCAGAAGAGCTGGGCA\nCCTTAG"
            },
            "pfams": {
              "pfam": [
                {
                  "identifier": "PF00008",
                  "name": "EGF"
                },
                {
                  "identifier": "PF00594",
                  "name": "Gla"
                },
                {
                  "identifier": "PF00089",
                  "name": "Trypsin"
                }
              ]
            },
            "go-classifiers": {
              "go-classifier": [
                {
                  "category": "component",
                  "description": "extracellular space"
                },
                {
                  "category": "component",
                  "description": "Golgi apparatus"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum lumen"
                },
                {
                  "category": "component",
                  "description": "Golgi lumen"
                },
                {
                  "category": "component",
                  "description": "extracellular region"
                },
                {
                  "category": "component",
                  "description": "endoplasmic reticulum"
                },
                {
                  "category": "function",
                  "description": "calcium ion binding"
                },
                {
                  "category": "function",
                  "description": "serine-type endopeptidase activity"
                },
                {
                  "category": "process",
                  "description": "negative regulation of blood coagulation"
                },
                {
                  "category": "process",
                  "description": "peptidyl-glutamic acid carboxylation"
                },
                {
                  "category": "process",
                  "description": "negative regulation of coagulation"
                },
                {
                  "category": "process",
                  "description": "positive regulation of establishment of endothelial barrier"
                },
                {
                  "category": "process",
                  "description": "leukocyte migration"
                },
                {
                  "category": "process",
                  "description": "blood coagulation"
                },
                {
                  "category": "process",
                  "description": "cellular protein metabolic process"
                },
                {
                  "category": "process",
                  "description": "negative regulation of apoptotic process"
                },
                {
                  "category": "process",
                  "description": "post-translational protein modification"
                },
                {
                  "category": "process",
                  "description": "proteolysis"
                },
                {
                  "category": "process",
                  "description": "negative regulation of inflammatory response"
                }
              ]
            },
            "_id": "P04070",
            "_source": "Swiss-Prot"
          },
          "inhibition-strength": "unknown",
          "induction-strength": "unknown",
          "_position": "13"
        }
      ]
    },
    "carriers": "",
    "transporters": "",
    "_type": "biotech",
    "_created": "2005-06-13",
    "_updated": "2015-11-18"
  }
]